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Abstract 
 
IMPACTS OF BLACK BOX WARNING, NATIONAL COVERAGE DETERMINATION, 
AND RISK EVALUATION AND MITIGATION STRATEGIES ON THE INPATIENT 
ON-LABEL AND OFF-LABEL USE OF ERYTHROPOIESIS-STIMULATING AGENTS 
 
By Arpamas Seetasith, PhD 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2013 
 
Director: DAVID A. HOLDFORD, R.Ph., M.S., Ph.D., FAPhA 
Professor and Vice Chair of Graduate Education  
Department of Pharmacotherapy and Outcomes Science 
 
 
Background:  FDA black box warning, Risk Evaluation and Mitigation Strategies (REMS), and 
CMS national coverage determination (NCD) aim to reduce inappropriate use of erythropoiesis-
stimulating agents (ESAs) that are widely used in anemic patients.  Previous studies have not 
linked specific safety interventions to changes in ESA utilization patterns in the inpatient settings 
nor assessed such interventions on off-label use of the drugs.   Ineffectiveness of the intervention 
and lag time between such interventions and the observed change in clinical practice could lead 
to serious clinical outcomes.  In addition, such interventions may unintentionally reduce on-label 
and some off-label use of ESAs considered “appropriate” in patients who could otherwise 
benefit.  
Objectives:  The primary aim of the study is to quantify the impacts of the (1) addition of black 
box warning, (2) implementation of NCD, and (3) institution of REMS on ESA on-label and off-
  
  
xvii 
 
label utilization patterns of adult inpatients.  Demographic, clinical condition, physician, and 
hospital characteristics of ESAs users by their use category are also described in detail.   
Methods:  Electronic health records in Cerner Database from January 1, 2005 to June 30, 2011 
were used.  The use of the two erythropoietic drugs: epoetin alfa and darbepoetin alfa were 
categorized into three groups using ICD-9-CM diagnoses and procedures codes and patients’ 
medication information.  The three categories were (1) on-label use (approved by the FDA); (2) 
off-label use supported (use for the indications not approved by the FDA, but there is strong 
clinical evidence to support its use); and (3) off-label use unsupported (use for the indications not 
approved by the FDA and lacking clinical evidence).  The immediate and trend impacts of the 
interventions on the proportion of ESAs prescribed for each usage category between 2005 and 
2011 were assessed using an interrupted time series technique.  The likelihood of receiving ESAs 
among patients with on-label, off-label supported, off-label unsupported indications was assessed 
using a generalized estimating equation approach with binary logistic regression technique, 
clustering for hospitals and controlling for potential confounders such as patient characteristics, 
patient clinical conditions, physician specialty, and hospital characteristics. 
Results:  During the study period, there were 111,363 encounters of ESA use.  These encounters 
represented 86,763 patients admitted to Cerner health system between January 1, 2005 and June 
30, 2011.  Of these patients, 66,121 were prescribed epoetin alfa only (76.2%); 20,088 
darbepoetin alfa only (23.2%); and 554 were prescribed both epoetin alfa and darbepoetin alfa 
(0.6%).  Forty-nine percent of the patients used ESAs for the on-label indications, 8.6% for off-
label supported indications, and 42.7% for the off-label unsupported indications. The main uses 
of ESAs in our sample were for CKD (ONS, 41.1%) and chronic anemia (OFU, 31.8%). From 
2005 to 2010, the proportion of visits with ESA ONS and OFS use decreased 53.2% and 81.9%, 
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while ESA OFU increased 112.6%.  Results from binary logistic regression using GEE model 
showed overall decreasing trends in ESA use for the on-label and off-label supported indications, 
but not off-label unsupported indications.  REMS had no impact on the odds of receiving ESAs 
among patients with on-label and off-label conditions.  Black box warning reduced the odds of 
being prescribed with epoetin alfa in patients with off-label unsupported conditions by 40%.  It 
was also associated with 4% and 15% per month reduction in the odds of using darbepoetin alfa 
in patients with off-label supported and unsupported conditions.  Lastly, there was a significant 
decline in all categories of ESA use the month after Medicare national coverage determination 
was implemented.  The impact of NCD ranged from a 20% reduction in the odds of off-label 
supported use to a 37% reduction in on-label use.  Age, gender, race, source of payment, 
admission type, clinical complexity, discharge disposition, and hospital size were significant 
associated with ESA use on-label and off-label. 
Conclusion:  This study was the first to determine the impact of safety interventions on ESA on-
label and off-label utilization patterns in the inpatient settings using the Cerner database.  We 
demonstrated lag between the interventions and observed change in clinical practice, and the 
relative impacts of three types of safety interventions on on-label and off-label ESA use in the 
hospital settings.  The indirect impact of the reimbursement change was the potential unintended 
consequence of reducing the likelihood of receiving ESAs for a patient with indicated conditions 
who could have otherwise benefited from the drugs.   
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CHAPTER 1 
Introduction 
Overview of the document 
This dissertation was designed to assess the relative impacts of three events, the revision 
of product label to include a black box warning, restrictive reimbursement policy from the 
Center for Medicare and Medicaid Services for the National Coverage Determination (NCD), 
and implementation of the Risk Evaluation and Mitigation Strategies (REMS) program, on the 
on-label and off-label use of erythropoiesis-stimulating agents (ESAs) in the inpatient settings in 
the United States between January 2005 and December 2011. 
This introductory chapter provides an overview of the study, background information 
necessary for the understanding of study significance, conceptual frameworks, objectives, and 
clinical and political implications of this study.  The second chapter provides extensive 
background of related topics including potential confounding factors and systematically reviews 
existing literature.  Methodology and database used in this study are described in Chapter 3, 
followed by results in Chapter 4.  Discussions and comments are concluded in Chapter 5.   
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Background 
Anemia is a condition characterized by low hemoglobin (Hb) level or red blood cell 
volume.  According to the World Health Organization criteria, anemia is marked by the level of 
hemoglobin less than 12 g/dL for women and <13 g/dL for men.  This decrease in oxygen-
carrying capacity of the circulation system results in symptoms such as fatigue, faintness, chest 
pain or shortness of breath which may affect one’s ability to perform activities of daily living and 
also quality of life (QoL).
1 
 Anemia is second to tuberculosis as the world’s most prevalent health 
condition; it was estimated that anemia affects 1.62 billion people, one-quarter of the world 
population.
2 
 Numerous underlying pathologies that lead to anemia have been identified.  Causes 
of anemia range from blood loss, nutrition deficiency (iron, vitamin B12, and folic acid) 
morphologic abnormality of hemoglobin or red blood cells (beta-thalassemia and sickle cell 
anemia), and other chronic diseases such as inflammation, malignancy and chronic kidney 
disease (CKD).
2 
 
Anemia is common in patients with chronic kidney disease and a frequent side effect in 
cancer patients being treated with chemotherapy.  Approximately half of patients with cancer
3, 4 
or CKD
5
 suffer from anemia at some point in their disease course.  Severe anemia is linked to 
increased risks of comorbidities in the elderly such as falls, dementia, depression, and heart 
failure.
6 
  Severe anemia often requires blood transfusion, an event which carries its own risks.  
These risks include transmission of infectious agents, acute lung injury, and development of 
alloantibodies which reduce a patient’s ability to receive organ transplant.7   Acquisition and 
storage of blood for transfusion requires special procedures and is costly.  Apparently, anemia is 
economically burdensome to health care payers.  It has been estimated that anemic patients have 
a two-fold greater average annualized medical cost of that for non-anemic patients.
8 
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 The production of red blood cells, termed erythropoiesis, is regulated by the supply and 
demand for oxygen in the body.  In response to low tissue oxygen level, peritubular fibroblasts of 
the kidney increase their production of endogenous erythropoietin which in turn acts on the 
erythroid progenitors in the bone marrow to stimulate late differentiation and maturation of red 
blood cells.  Erythropoiesis-stimulating agents (ESAs) are a class of biological medications 
approved as an alternative to blood transfusions, the traditional treatment of anemia.  
Recombinant human erythropoietin possesses the same biological effects as endogenous 
erythropoietin.  Three drugs in this class are marketed for use in the United States: epoetin alfa 
(Procrit®, Johnson & Johnson’s Ortho Biotech Unit and Epogen®, Amgen), darbepoetin alfa 
(Aranesp®, Amgen), and methoxy polyethylene glycol-epoetin beta (Mircera®, Roche).   
Epoetin alfa, the first human recombinant ESA was first approved in 1989 for anemia 
associated with chronic kidney failure.
9
   The drug was later approved to treat chemotherapy-
induced anemia, treat zidovudine-related anemia in HIV infected patients, and use as a 
prophylaxis of allogeneic blood transfusion in non-cardiovascular surgeries.  Following in 2001, 
darbepoetin alfa was introduced into the market for treating anemia associated with chronic 
kidney failure and later for chemotherapy-induced anemia.
10 
  With an addition of N-
glycosylation at the two sites of epoetin alfa, darbepoetin possesses a three-fold longer half-life 
for erythropoietin receptors relative to erythropoietin alfa
11
,
 
implying greater potency and 
extended dosing interval that may improve patient compliance and better control anemia.   Two 
other ESAs not available in the US are methoxy polyethylene glycol-epoetin beta, Mircera
12 
and 
epoetin beta, NeoRecormon® (Roche).  
The use of erythropoietins as an alternative to red blood cell transfusion therapy 
represents a major advancement in anemia treatment and has been the mainstay of therapy in 
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anemia associated with chronic kidney failure since its approval.  Global sales of erythropoietin 
products dramatically increased 95% from 2004 to $12.3 billion in 2005.  In that same year, 
procrit and epogen, each with $3.0 billion US sales, ranked among the top 10 drug products in 
the United States according to sales.
13 
  Since the initial entry of ESAs onto the market, the drugs 
have found their place in the treatment of anemia outside their initial approved uses.   This broad 
array of use includes anemia of chronic heart failure, rheumatoid arthritis, and beta thalassemia.  
The use of ESAs off-label, the term which refers to the prescribing of medications in a manner 
different from that approved by the FDA, is common.
14 
  It was estimated that more than half of 
ESAs prescribed between 2001 and 2004 were for off-label purposes.
15
   Among those off-label 
prescriptions for ESAs, three-quarters were for indications supported by scientific evidence.
15 
 
Benefits of ESAs in anemia treatment have been extensively elaborated.  Correction of 
anemia with ESAs translates to a relief of its common symptoms like fatigue, improving one’s 
physical ability and quality of life.  The approval of epoetin alfa and darbepoetin, the two ESAs 
widely used in the United States by the FDA was based mainly by the evidence of reduced needs 
for blood transfusion in anemic patients.  The use of ESAs is thus a promising anemia treatment 
alternative to blood transfusion.  Benefits of ESAs extend beyond a simple reduction in 
transfusion requirements. ESA therapy in less severe CKD patients has been shown to delay time 
to dialysis.
16 
  In addition; a meta-analysis of 60 studies found that anemia is an independent risk 
factor of death in cancer patients
17 
and thus correcting it could improve survival.  
Despite their clinical benefits, ESAs have been associated with increased risks of adverse 
events such as cardiovascular complications, hypertension, and red cell aplasia.  In 1998, the 
Normal Hematocrit Cardiac Trial (NHCT), the first large randomized controlled trial (RCT) 
aimed at determining the outcomes of treating anemia with epoetin alfa in patients with cardiac 
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disease who were undergoing hemodialysis was published.  Patients who were randomized to 
receive high dose epoetin alfa to maintain high hematocrit level of 42 percent had 1.3 times 
higher risk of death or nonfatal myocardial infarction compared to those in the group targeted to 
lower hematocrit level of 30 percent though this finding was merely a near statistically 
significant one.
18 
  A tipping point in ESA therapy started in November 2006 when two RCTs, 
the correction of hemoglobin and outcomes in renal insufficiency (CHIOR) and cardiovascular 
risk reduction by early anemia treatment with epoetin beta (CREATE), were published.  CHIOR, 
the largest trial, showed that CKD patients treated with epoetin alfa dosed to a higher target 
hemoglobin concentration of 13.5 g/dL were at a significantly increased risk for serious 
cardiovascular events including thrombosis, congestive heart failure, and stroke compared to the 
treated patients whose hemoglobin was targeted at 11.3 g/dL.
19 
  Results from another large trial 
published at the same time showed no benefit or harm of early correction of anemia with epoetin 
beta in reducing the risk of cardiovascular events in anemic patients with CKD.
20 
 
Safety concerns of ESA use among patients with cancer were raised with the publication 
of the two pharmaceutical company-sponsored phase III randomized clinical trials.  Patients 
randomized to receive erythropoietin in the Breast Cancer Erythropoietin Survival Trial (BEST)
 
21 
and the Advanced Head-and-Neck Cancer Treated with Radiotherapy (ENHANCE)
 22 
showed 
significant worsening of overall survival and an increase in venous thromboembolic events.  A 
meta-analysis of 57 clinical trials evaluating the use of ESAs in certain types of cancer published 
in 2006 also pointed toward their negative effects on survival.
23 
  Similarly, the most recent 
Danish Head and Neck Cancer Study (DAHANCA 10), terminated early in October 2007, 
reported in their interim analysis that darbepoetin alfa had shown a low likelihood in improving 
patient outcomes.
24 
  Cancer progression acceleration was observed in several studies include the 
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ENHANCE trial of head and neck cancer, BEST trial of breast cancer, and EPO-CAN 20 of non-
small-cell lung cancer.
25 
  An exception was found in one study of 600 previously untreated 
patients with extensive-stage small-cell lung cancer where significant difference in progression-
free survival was not found.
26 
  While the mechanisms by which ESAs enhance tumor 
progression is unclear, it is plausible that the drug stimulates erythropoietin receptors commonly 
expressed in tumor cells, promoting tumor growth.  The results from 154 subjects in the 
ENHANCE trial support this hypothesis; ESAs were found to be harmful in two thirds of 
patients with erythropoietin receptor-positive tumors but beneficial in those with receptor-
negative tumors.
27
   
  As evidence pointed toward potential harm associated with the use of high dose ESAs, 
the FDA issued a series of public health advisories.
28 
  On November 16, 2006, the FDA issued a 
public health advisory alerting ESA prescribers to the results from CHIOR trial, emphasizing on 
maintaining the recommended target hemoglobin range of 10 to12 g/dL in all patients.
29 
  A 
combined effort came from Amgen, the manufacturer of epoetin alfa and darbepoetin alfa, 
sending out a series of dear doctor letters alerting physicians of the FDA updates.  In January 26, 
2007, Dear Healthcare Professional Letters were sent to highlight the results from recent clinical 
trials and recommend caution in the off-label use of darbepoetin alfa in cancer patients.  The 
letter specifically warned against the use of ESAs in non-chemotherapy cancer patients and its 
increased risk of death in this population.
30 
  These warnings were expected to alert prescribers of 
risks associated with the use of ESAs at high doses and their use in non-indicated populations.  
Two similar public health advisories were issued in March and November 2007. 
Finally, ESA labeling was revised to include a black box warning on March 9, 2007 to 
address these concerns.  The warning advised prescribers to use the lowest ESA dose possible 
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that gradually increases hemoglobin to sufficient levels to avoid blood transfusion.
31 
  An update 
of the black box warning on March 7, 2008
32, 33
 added the findings from two additional clinical 
studies, Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) in patients with breast 
cancer, and the National Cancer Institute Gynecologic Oncology Group (COG-19) in patients 
with cervical cancer.  These trials showed increased mortality and shortened time to tumor 
progression in cancers patients treated with Aranesp compared to those who did not receive 
ESAs.
34, 35
   
To supplement the black box warnings, the FDA required on March 24, 2010 that all 
ESA drugs be prescribed under the Risk Evaluation and Mitigation Strategies (REMS) 
program.
36, 37
   This REMS program requires physicians prescribing ESAs to cancer patients to 
complete and receive documentation of certification of the online ESA APPRISE Oncology 
Program Training. To complete such training, physicians must acknowledge that they understand 
the treatment recommendations and the specific risks associated with the use of ESAs.  Also, the 
program requires prescribers to counsel their patients regarding risks and benefits of ESAs prior 
to dispensing the medications.  More importantly, physicians not enrolled in the ESA APPRISE 
Oncology program are prohibited from prescribing ESAs for use in cancer patients.  The 
implementation of the ESA REMS program is designed to bring about high awareness of the 
warnings issued and risks associated with them and increase physician compliance with ESA 
guidelines.  The impact of REMS ESA inpatient prescribing remains unknown.      
Recombinant erythropoietin was first approved for Medicare outpatient reimbursement in 
June 1989
38 
when it was reimbursed for up to 80% of the allowed charge.
39 
  Since that time, 
ESA reimbursement in Medicare beneficiaries has been through many changes.  In January 
1991, the Medicare payment policy for ESA treatment of dialysis patients changed from a fixed 
  
  
8 
 
payment to a payment based on the doses of ESA administered
40 
to increase the use of ESAs in 
ESRD patients and to improve Hb levels.  In September 1997, the Hematocrit Measurement 
Audit (HMA) policy was implemented to halt reimbursement of ESAs if patient Hb level was 
greater than 12 g/dL
41 
as recommended by the NKF-DOQI clinical practice guidelines.
42 
  With 
the rise in ESA utilization, ESAs became Medicare’s largest pharmaceutical expense, at 
approximately $20 billion in 2004.
43 
  In April 2006, payments for ESA dosing was capped at 
500,000 IU/ month for dialysis patients and a 25% dose reduction was mandated for patients 
whose hemoglobin level exceeded 13 g/dL in the prior month.
44
  
National Coverage Determination (NCD) is a nationwide policy initiated by CMS to 
ensure that services and treatments provided to their beneficiaries are reasonable and necessary.
45 
  
NCD identifies the nationally covered indications for which Medicare will reimburse.  On July 
30, 2007, NCD restricted payment for ESAs in cancer-related anemia.  Nationally covered 
indications include ESA treatment for anemia secondary to myelosuppressive anti-cancer 
chemotherapy in solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia.  
However, CMS no longer pays for the use of ESAs in anemia due to radiotherapy; anemia of 
cancer not related to concurrent chemotherapy including anemia of bone marrow fibrosis; 
anemia resulted from the treatment of myelogenous leukemia, chronic myelogenous leukemia, or 
erythroid cancers; prophylactic use of chemotherapy-associated anemia; or use to reduce tumor 
hypoxia (which can inhibit radiotherapy and oxygen-dependent chemotherapy effectiveness).  
Reimbursement is not provided for patients with uncontrolled hypertension even when used to 
treat of anemia associated with chemotherapy.  Additionally, under NCD, Medicare does not 
reimburse ESA use in anemia due to folate, vitamin B12, and iron deficiencies; anemia of 
hemolysis; anemia of bleeding; and its use in patients with erythropoietin-type resistance due to 
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neutralizing antibodies.
46 
  In addition to indication restrictions, CMS restricted the use of ESAs 
exclusively to patients whose hemoglobin level is lower than 10 g/dL prior to ESA initiation or 
maintenance as such drugs “lacks adequate data to establish proof of no harm.”47   
Recommendations on dosing, dosage escalation and reduction, discontinuation, and treatment 
duration were also specified in the NCD.
48 
  However, NCD restrictions conflicted with FDA-
approved labeling and professional society guidelines on ESA initiation, dosage escalation, 
dosage reduction, and definition of response, creating confusion among health care providers.
49 
  
According to the letters written on behalf of professional societies to CMS, the decision was 
“inconsistent with available scientific evidence and national guideline on ESA use” and CMS 
was urged to reconsider “in order to avoid further confusion and harm to Medicare 
beneficiaries.”50   Despite criticisms from several professional associations that the decision could 
lead to greater chances for patients subjected to blood transfusion and endanger cancer patients, 
the NCD was officially implemented on April 7, 2008.   
NCD restrictions are not meant to impact ESA use for inpatient care because ESAs are 
included into the Diagnoses-Related Group (DRG) prospective payment system.  Under the 
DRG system, reimbursement is given for a patient's condition, not the drugs used to treat that 
condition. Thus, the change in the coverage determination would not affect the payment of ESAs 
in the hospital setting.  However, physicians who work in hospitals often work in outpatient 
settings where ESA coverage restrictions apply. Thus, the policy change may indirectly change 
prescribing in both setting.  Moreover, the restriction may influence prescribing patterns for non-
Medicare payer types because physicians typically treat more than just Medicare patients.  As a 
result, NCD policies may impact off-label use of ESAs outside of their intended purpose.  It is of 
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our interest to determine the impact of Medicare national coverage determination on ESA use in 
the inpatient settings where the determination does not directly apply.    
In summary, a timeline of significant events associated with ESA utilization since its 
approval is presented in Figure 1.1.  These include approval indications for ESA treatment, 
publications of scientific evidence from larger clinical trials, and interventions from 
manufacturers and government regulatory agencies. 
 
Figure 1.1 Timeline for ESA treatment, scientific evidence from clinical trials, and interventions from 
government regulatory agencies between 1989 and 2010 (adapted from Arbuckle et. al. 2008)
49
 
1989 1993 2001Pre-ESA Era 1991 1995 1997 1999
Epoetin alfa: 
Chronic Renal 
Failure -related 
anemia
Epoetin alfa: 
HIV
AZT-related anemia
Epoetin alfa: 
Chemotherapy-
related anemia
Darbepoetin alfa: 
Chemotherapy-
related anemia
Darbepoetin alfa: 
Chronic Renal 
Failure -related 
anemia
Epoetin alfa:
Pre-surgical prophylaxis 
of allogeneic blood 
transfusion
Blood transfusion, 
IV Iron therapy, 
Androgen therapy
1998
NHCT (CKD)
2006 20082003 2007 2009 2010 2011
November:
Public health advisories
March: 
1 st Black box warning
April:
Medicare NCD implemented
March:
REMS
20052004
July: 
Medicare NCD became effective
March & November: 
Black box warning updated
2003
ENHANCE (cancer)
2005
BEST (cancer)
2006
CHOIR (CKD), 
CREATE (CKD)
2007
DAHANCA 10 (cancer)
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Conceptual Framework 
This study is based on the diffusion of innovation of health care framework and an 
evidence-based medicine framework.  Diffusion of innovation refers to “the process by which an 
innovation is communicated through certain channels over time among the members of a social 
system.” 51  According to Everett Roger’s Diffusion of Innovation model, the spread of 
innovations follows a sigmoid pattern (the S-shaped curve), describing three stages of adoption: 
the early slow phase characterized with only the first few individual adopting the innovation, a 
rapid middle phase, and a slow third phase.  The model also illustrates five categories of adopters 
characterized by their relative rates of adoption of innovations: innovators, early adopters, early 
majority, late majority, and laggards.
51, 52 
  Rates of diffusion of innovation vary by various 
factors.  The main factor includes perceptions of the innovations viewed by stakeholders, which 
predict between 49% and 87% of the variance in the rates of spread of a change.  These 
perceptions include (1) the perceived benefit of the change; (2) compatibility of the innovation 
with the current values, belief, and needs of the individuals as well as their past history; (3) 
complexity of the proposed innovation; (4) trialability of the innovation without total 
commitment or minimal investment; and (5) the extent to which potential adopters observe the 
adoption by others (observability).
51
 
The process by which information is disseminated is similar to the diffusion of 
innovation.  Whether a prescriber will adjust their prescribing pattern to new information 
depends on several factors such as physician characteristics and the nature of the intervention of 
which knowledge is disseminated itself.  Since high doses of ESAs given to cancer patients or 
for its use for unsupported purposes could lead to serious adverse events including death, the 
stakes are significant for reducing the time lag between the interventions aiming at reducing 
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inappropriate use of ESAs in clinical practice.  It is therefore our interest to assess the relative 
impacts of the FDA black box warning, and FDA REMS, and National Coverage Determination 
on the rate of change in prescribing patterns.   
A systematic classification of indications for the three erythropoietic drugs into three 
drug use categories will be based on an evidence-based medicine (EBM) framework which 
provides objective evidence about the effectiveness of interventions through the use of research 
methods that minimize the risks of bias, such as randomized controlled trials.  Evidence 
synthesized in such manner is considered best to inform treatment decisions.
53
   
Objectives 
The proposed study aims to quantify the impacts of FDA interventions (adding a black 
box warning to drug labeling and the addition of a REMS program) and Medicare reimbursement 
restrictions established by the NCD on the on- and off-label use of ESAs among adult inpatients.  
The secondary objective is to investigate factors associated with the odds of being prescribed 
ESAs, controlling for the interventions and other confounding factors. 
Study Implications 
Correction of anemia is necessary as it has been shown to improve patients’ health status 
and quality of life.
54 
  Approximately 90% of hemodialysis patients in the US received an ESA
55 
to avoid blood transfusion.  The adoption of ESAs in clinical practice of anemia has alleviated 
some of the complications associated with blood transfusion and the issues of constrain blood 
limited supply.  However, concerns regarding serious risks of ESAs have led regulatory 
authorities to intervene with both regulatory communications and reimbursement changes.  
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These interventions can lead to have positive outcomes (reasonable and necessary drug use) or 
negative outcomes (reduced on-label use considered “appropriate” to patients who could 
otherwise benefit).  This study will quantify impacts of the communications from four sources: a 
public health advisory, an FDA black box warning on ESA labeling, ESA APPRISE Oncology 
program under REMS, and a reimbursement restriction under CMS National Coverage 
Determination for ESAs. We hope to demonstrate their relative immediate and trend impacts on 
ESA prescribing among patients admitted to the U.S. hospitals.    
Previous studies that investigated the impacts of FDA risk communications on ESA use 
did not link specific interventions to the level change in ESA use nor that for the off-label 
indications for patients treated in the inpatient settings.   The knowledge of relative impacts of 
the interventions would help policymakers make informed decision when designing risk 
communications and healthcare policies intending to shape prescribing patterns in the future.   
To our knowledge, no study has assessed the linkage between FDA risk communication 
including public health advisory, black box warning issuance, and REMS implementation, or the 
CMS National Coverage Determination on the prescribing patterns of erythropoiesis-stimulating 
agents in the inpatient settings.  More importantly, the impacts of such interventions on the off-
label use of ESAs have never been investigated.  Our proposed study quantified the immediate 
and trend impacts of both on on-label and off-label ESA prescribing and assess factors associated 
with ESA prescribing patterns in the inpatient settings between 2005 and 2011.    
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CHAPTER 2 
Literature Review 
This chapter has been divided into four parts: 1) an overview of ESA treatment of anemia 
for the on-label and off-label indications as classified by the evidence-based medicine 
framework; 2) regulatory risk communications and health policies shaping prescribing patterns; 
3) potential confounding factors associated with prescribing patterns and methods to control for 
confounding; and 4) a systematic review of existing studies.  This chapter concludes with a 
summary of literature gaps, research questions, research hypotheses, and specific aims 
formulated as a result of the literature evaluation. 
Erythropoiesis-stimulating agent treatment of anemia overview 
This section is further subdivided into two parts.  The first part provides an overview of 
an official compendium, Thomson Micromedex Drugdex®, the system adopted in this study to 
describe the classification of ESA use by indications.  The second part reviews treatment 
regimens, guidelines, and supporting evidence for the all ESA indications listed in DRUGDEX.  
Empirical studies of ESA off-label use in the United States are also summarized at this end of 
this section.  
1. Classification System 
Official compendia refer to nationally recognized sources of drug information including 
the US Pharmacopoeia (USP), National Formulary, or any supplements to them.  DRUGDEX 
system (Thomson Micromedex, Greenwood Village, CO) is recognized as a pharmaceutical 
compendium that provides reliable evidence-based evaluation for the on-label and off-label uses 
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of prescription drugs listed in the USP Dispensing Information.
56 
  Information on strength of 
scientific evidence supplied by DRUGDEX can be used to assess the level of medical evidence 
supporting the use of ESAs in an off-label manner.   
The three dimensions of drug use evaluated by DRUGDEX are efficacy, strength of 
recommendation, and strength of evidence.  Strength of recommendation is categorized into 4 
classes: Class I, IIa, IIb, III, and in-determinant.  Similar to that, strength of evidence as 
supported by clinical studies is presented in 4 levels: Category A, B, C, and no evidence.  Lastly, 
drug efficacy is subcategorizes into 4 groups: effective, evidence favors efficacy, evidence is 
inclusive, and ineffective.  The details of recommendation levels, strength of evidence scale and 
efficacy ratings defined by DRUGDEX are listed in Table 2.1, 2.2, and 2.3, respectively. 
Table 2.1 Strength of Recommendations specified by DRUGDEX 
Level Decision to recommend Definition 
Class I Recommended The given test or treatment has been proven to be 
useful, and should be performed or administered. 
Class IIa Recommended, 
In most cases 
The given test, or treatment is generally considered 
to be useful, and is indicated in most cases. 
Class IIb Recommended, 
In some cases 
The given test, or treatment may be useful, and is 
indicated in some, but not most, cases. 
Class III Not Recommended The given test, or treatment is not useful, and 
should be avoided. 
Class In-determinant Evidence Inconclusive - 
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Table 2.2 Strength of Evidence for use of a drug specified by DRUGDEX  
Level Definition 
Category A Evidence is based on data derived from: Meta-analyses of randomized controlled 
trials with homogeneity with regard to the directions and degrees of results between 
individual studies. Multiple, well-done randomized clinical trials involving large 
numbers of patients. 
Category B Evidence is based on data derived from: Meta-analyses of randomized controlled 
trials with conflicting conclusions with regard to the directions and degrees of results 
between individual studies. Randomized controlled trials that involved small 
numbers of patients or had significant methodological flaws (e.g., bias, drop-out 
rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-
control studies, observational studies). 
Category C Evidence is based on data derived from: Expert opinion or consensus, case reports 
or case series. 
No Evidence - 
 
Table 2.3 Efficacy ratings of a drug specified by DRUGDEX 
Efficacy rating Definition 
Effective Evidence and/or expert opinion suggests that a given drug treatment for a specific 
indication is effective 
Evidence favors 
efficacy 
Evidence and/or expert opinion is conflicting as to whether a given drug treatment for 
a specific indication is effective, but the weight of evidence and/or expert opinion 
favors efficacy. 
Evidence is 
inconclusive 
Evidence and/or expert opinion is conflicting as to whether a given drug treatment for 
a specific indication is effective, but the weight of evidence and/or expert opinion 
argues against efficacy. 
Ineffective Evidence and/or expert opinion suggests that a given drug treatment for a specific 
indication is ineffective. 
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2. ESA use in anemia treatment 
A review of clinical literature for all ESA indications listed in DRUGDEX is provided in 
the following section.  The review is based on clinical trials that support the FDA approval of 
such indications or scientific evidence reported in DRUGDEX.  Clinical guidelines and 
recommendations, if available, are also provided.  This review of anemia treatment is limited to 
adults only, as this population aligns with the study inclusion criteria.  A summary of 
DRUGDEX evaluation of scientific evidence ratings of such use of epoetin alfa and darbepoetin 
alfa is provided in Table 2.4 and 2.5, respectively.   
2.1 FDA-approved Indications  
Approved indications of ESAs are drug specific.  Epoetin alfa, the first erythropoietin in 
the market was approved for use in anemia of chronic kidney disease, chemotherapy induced 
anemia, zidovudine-related anemia in HIV infected patients, and prophylaxis of allogeneic blood 
transfusion in non-cardiovascular surgeries.  The second generation ESA, darbepoetin alfa is 
approved for two indications: anemia of chronic kidney disease and chemotherapy induced 
anemia.      
Anemia of Chronic Kidney Failure: epoetin alfa and darbepoetin alfa 
 Epoetin alfa has been shown to stimulate erythropoiesis and hence normalize Hb level in 
chronic kidney failure patients regardless of their dialysis requirement.
57 
  A meta-analysis of 
sixteen studies of 982 end-stage renal disease patients receiving epoetin alfa reported 87% 
effectiveness of the treatment defined as at least a 0.06 increase in hematocrit or a 2 g/dL 
increase in hemoglobin.
58 
  In a subsequent study, erythropoietin was proven to have no negative 
effect on blood pressure and be effective in correcting Hb values in adult with cardiac disease 
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and hemodialysis-dependent ESRD patients.
59 
  Similar improvement in Hb level was observed 
in non-dialysis patients.  In a large multi-center, open-label, single-arm, non-randomized trial, 
epoetin alfa dosed subcutaneously once weekly at 10,000 IU for 16 weeks significantly led to an 
increase in the mean Hb level of 2.7 g/dL.
60 
  Likewise, darbepoetin alfa, when given at 0.45 
mcg/kg once a week was proven to be as effective as 50 IU/kg epoetin alfa two to three times 
weekly in correcting anemia in epoetin-naïve dialysis and renal insufficiency patients.
61, 62 
   The 
drug was also able to maintain stable Hb concentration in CKD patients when given at an 
extended dosing interval once monthly.
63, 64
  Despite its efficacy, both erythropoietic drugs dosed 
to high target Hb level was shown to be associated with greater risk of all-cause mortality 
compared to that of lower Hb group in a meta-analysis of nine randomized controlled trials of 
5,143 patients with chronic kidney disease.
65 
 
The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI) published guidelines for the management of anemia in CKD patients in 2006.  After the 
2007 update of the target Hb concentration, no further change in the guidelines was made.  In 
dialysis and nondialysis patients with CKD receiving ESA therapy, a target Hb level between 
11.0 g/dL and 12.0 g/dL is recommended.  The KDOQI guidelines also emphasize the 
importance of not exceeding the target HB level beyond 13 g/dL.
66 
  Of note, this Hb target 
recommendation does not align with the darbepoetin alfa current labeling, revised in 2011, which 
suggests physicians to initiate ESA therapy only when Hb level falls below 10 g/dL.  As for the 
dose, an ESA starting dose often depends upon the initial and target Hb level of a patient
67 
 
though a starting dose of epoetin alfa at 50 to 100 units/kg three times weekly is 
recommended.
9,10
  In general, because of a longer half-life of darbepoetin alfa compared to 
epoetin alfa, darbepoetin alfa is recommended to be administered once weekly in patients who 
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are receiving epoetin alfa 2 to 3 times weekly and once every 2 weeks in once-weekly epoetin 
alfa patients.
68 
  It is important to halt the therapy once Hb level exceeds 10 g/dL for nondialysis 
and 11 g/dL for dialysis patients.
10
  On the other hand, if a patient’s Hb level has not increased 
by more than 1 g/dL after 4 weeks of the initiation of the therapy, ESA dose may be increased by 
25%.
10
 
Chemotherapy-Induced Anemia (CIA): epoetin alfa and darbepoetin alfa 
Several trials demonstrated efficacy of epoetin alfa and darbepoetin alfa in improving Hb 
levels and reducing the need for blood transfusion.
9,10
 Epoetin alfa dosed subcutaneously at 
40,000 IU once weekly led to a mean increase of 1.8 g/dL with a mean final Hb level of 11.3 
g/dL in patients receiving chemotherapy for nonmyeloid malignancies after the maximum of 16 
treatment weeks.
69 
  Results from a large community-based study also found a similar increase in 
Hb level of 2 g/dL and a progressive decline in the percentage of patients requiring transfusion 
during ESA treatment.
70 
   Similarly, darbepoetin alfa, both dosed weekly or at an extended-
dosing regimen every 3 weeks was more effective than placebo in increasing Hb values of 
anemic cancer patients receiving chemotherapy.
71-74
   Based on their clinical efficacy, epoetin 
alfa and darbepoetin alfa are used widely for the treatment of chemotherapy-induced anemia in 
nonmyeloid cancer patients.   
Three major guidelines are currently being used today in the ESA treatment of 
chemotherapy-induced anemia: the American Society of Clinical Oncology and the American 
Society of Hematology (ASCO/ASH), the European Organisation for Research and Treatment of 
Cancer (EORTC), and the National Comprehensive Cancer Network (NCCN).
75 
  In 2002 ASCO 
and ASH published their clinical practice guidelines for epoetin alfa using medical literature 
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published between 1985 and 1999.  The guideline suggests the use of epoetin alfa in CIA 
patients with Hb level < 10g/dL at 150U/kg, three times a week.  Epoetin alfa dose should be 
escalated to 300 U/kg three times a week if a patient fails to respond after 4 weeks.  The target 
Hb level is recommended at 12 g/dL, with the dose of epoetin alfa adjusted to maintain a 
patient’s Hb at this level.  Another reputable source of ESA treatment recommendation is the 
2004 EORTC guidelines which include evidence of both epoetin alfa and darbepoetin alfa 
between 1996 and 2003.  The EORTC guidelines recommend clinicians to initiate ESA treatment 
at Hb level of 9 to 11 g/dL, on the basis of anemia symptoms while targeting a patient’s Hb level 
at 12 to 13 g/dL.  Lastly, NCCN, an alliance of 19 major cancer centers in the United States, 
developed several guidelines in cancer treatment including supportive care.
6
  Updated in 2011 
the NCCN clinical practice guidelines suggest physicians to consider ESA treatment of anemia 
in cancer patients with chronic kidney disease, patients undergoing palliative treatment, and 
patients on myelosuppressive chemotherapy without identifiable cause of anemia.
76 
  ESAs 
should not be prescribed for a treatment of anemia in cancer patients under myelosuppressive 
chemotherapy with curative intent such as early stage breast cancer, Hodgkin lymphoma, non-
Hodgkin’s lymphoma, testicular cancer, and early stage non-small cell lung cancer.  
Additionally, co-administration of iron supplement is not required but should be considered with 
regard to a patient’s functional iron deficiency status. 
Anemia in zidovudine-treated HIV-infected Patients: epoetin alfa only 
Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI), is one of the most 
commonly used antiviral drugs for HIV infection.  Despite its effectiveness, the prevalence of 
zidovudine-induced anemia is high (5.42-9.62%).
77-79 
  Epoetin alfa is the only erythropoietic 
drug approved for treating anemia in zidovudine-treated HIV-infected patients; results from four 
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placebo-controlled trials suggest that it could significantly increase hematocrit and reduced blood 
transfusion requirements in the treatment group compared to the placebo group.
80-83 
  
Nonetheless, correcting anemia related to zidovudine use in HIV-infected patients with epoetin 
alfa is encouraged only in patients receiving zidovudine ≤ 4200 mg/week with endogenous 
erythropoietin level less than 500 mUnits/mL.  This is because patients with endogenous 
erythropoietin level greater than that appear to be nonresponsive to epoetin alfa therapy.  To treat 
anemia due to adverse reaction of zidovudine, epoetin alfa is recommended at 100 units per kg 
body weight, three times weekly.   
Prophylaxis of allogeneic blood transfusion in non-cardiovascular surgeries: epoetin alfa only 
 Epoetin alfa was approved for use as a prophylactic of allogeneic blood transfusion in 
patients with Hb level greater than but not exceeding 13 g/dL undergoing elective non-
cardiovascular surgeries that are at risk of perioperative blood loss, but are not willing to donate 
autologous blood.  In patients scheduled for major, elective orthopedic hip or knee surgery who 
were expected to require ≥ 2 units of blood, epoetin alfa dosed subcutaneously at 300 units/kg 10 
days before surgery, on the day of surgery, and for 4 days after surgery, significantly reduced the 
need for blood transfusion compared to the placebo group, only when pretreatment Hb level was 
greater than 10 but not more than 13 g/dL.
84
   
2.2 FDA-Unapproved Indication 
Several off-label uses of ESAs are documented in DRUGDEX.  These indications 
include the treatment anemia in cancer patients not currently on active chemotherapy, anemia of 
congestive heart failure, prematurity, puerperium, multiple myeloma, myelodysplastic syndrome, 
myelofibrosis, rheumatoid arthritis, beta thalassemia, anemia due to radiation, and anemia in 
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hepatitis C patients being treated with a combination of ribavirin and interferon alfa, and their 
use for blood unit collection for transfusion.  The following section review uses of ESAs for the 
unapproved indications and studies supporting their uses. 
Anemia of congestive heart failure 
 Anemia, a common complication of congestive heart failure (CHF), often leads to poorer 
cardiovascular outcomes and higher mortality.
85 
  The prevalence of anemia in CHF is estimated 
to be as high as 55 percent.
86 
  An uncontrolled study of ESAs therapy in anemic patients with 
CHF found that subcutaneous erythropoietin at an average dose of 5,227 units/week is associated 
with decreased hospitalization and improvement in several cardiovascular aspects including an 
increase in left ventricular ejection fraction and decline in the New York Heart Association 
(NYHA) class.
87 
  DRUGDEX recommends epoetin alfa to be used in some cases of CHF 
according to the moderate strength of evidence and efficacy report that favors efficacy for this 
indication. 
Anemia due to radiation 
 Anemia is widespread in cancer patients undergoing local radiotherapy.  An anemia 
prevalence study using Hb level < 12 g/dL as a cut-off point found that anemic patients increased 
from 41% at presentation to 54% by the end of radiation.
88 
  The majority of patients with almost 
all tumor types have developed anemia and the prevalence of anemia is found to be extremely 
high in patients with uterine-cervical tumor (75% and increased to 79% after radiation).  Epoetin 
alfa dosed at 200 units/kg/day for 5 consecutive days for up to 7 weeks during radiotherapy was 
found to significantly increase Hb level in anemic patients with lung, uterine-cervical, prostate, 
or breast cancer during a randomized, open-label trial of 48 patients.
89 
  As a result, DRUGDEX 
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recommends epoetin alfa to be used in certain cases of radiotherapy according to the moderate 
strength of evidence and efficacy report that favors efficacy for this indication. 
Anemia during Puerperium 
 Iron deficiency during pregnancy and acute blood loss at delivery constitutes a main 
cause of postpartum anemia.
90 
  The prevalence postpartum anemia is high in developing 
countries and was found to be as high as 80%.
91 
  In a randomized, placebo-controlled trial in 
which a mother lost an average of 806 mL of blood during delivery, a combination of IV 
erythropoietin at 300 units/kg/day and IV iron sucrose 200 mg/day given daily for 4 days after 
the delivery showed to be more effective than placebo or IV iron alone in correcting postpartum 
anemia.
92 
  DRUGDEX therefore recommends epoetin alfa to be used in certain cases of 
puerperium anemia according to the moderate strength of evidence and efficacy report that 
favors its efficacy. 
Anemia of ribavirin and interferon alfa use for treatment of Hepatitis C 
 Anemia is a common adverse effect observed in 10%-30% of hepatitis C patients 
receiving ribavirin and interferon alfa combination therapy.
93 
  This is due to the bone marrow 
suppression property of interferon and potential red blood cell hemolytic action of ribavirin.  
Criteria for initiating ESA therapy for hepatitis C treatment-related anemia have been provided 
based on medical evidence and clinical expert opinion.  Physicians may consider using 
subcutaneous injection of 40,000 IU epoetin alfa weekly (or darbepoetin alfa at 200 mcg weekly, 
though response is reported to be slower), together with ribavirin dose reduction, to increase Hb 
level of patients on ribavirin-interferon alfa combination therapy with Hb < 10 g/dL or < 11g/dL 
but with symptoms of anemia.  ESAs and/or ribavirin dosing should be adjusted based on a 
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patient’s Hb level and his response to ESA therapy.  Base on the moderate strength of evidence 
and favorable efficacy reports for this indication, DRUGDEX recommends epoetin alfa to be 
used in some cases of anemia associated with ribavirin and interferon alfa treatment of HCV-
infected patients.   
Anemia of multiple myeloma 
The cause of anemia observed in more than two thirds of patients with multiple myeloma 
(MM) is multi-factorial, ranging from the cancer itself, chemotherapy treatment, or deficiency of 
endogenous erythropoietin.
94 
  Several studies reported benefits of ESAs in myeloma-associated 
anemia.  A meta-analysis of 39 studies reported 40% effectiveness of erythropoietin in the 
treatment of anemia of multiple myeloma.
95 
  Another study shows that 85% of 13 multiple 
myeloma patients with baseline Hb less than 11.3 g/dL experienced an increase in Hb level of at 
least 2 g/dL after 5 weeks and a complete resolution of anemia symptoms after receiving 150 
units/kg ESAs three times weekly.
96 
  Recently, consensus guidelines for the management of 
anemia with ESAs in multiple myeloma were developed by the collaboration of MM specialists 
known as the International Myeloma Working Group.  Once other causes of anemia is ruled out, 
ESA therapy can be initiated in MM patients with HB level ≤ 10 g/dL and in those with higher 
Hb values but with symptoms of anemia.  The guidelines recommend starting epoetin alfa at 40 
IU once weekly or 10 IU three times weekly, or darbepoetin alfa 150 mcg once weekly or 500 
mcg every 3 weeks.  Dose increment is allowable if a patient does not respond but the therapy in 
non-responding patients should be discontinued within 6-8 weeks.
97 
  DRUGDEX recommends 
epoetin alfa to be used in some cases of multiple myeloma according to the moderate strength of 
evidence and efficacy report that favors efficacy for this indication. 
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Anemia of myelodysplastic syndrome 
Anemia is the most common comorbid condition of myelodysplastic syndrome (MDS), a 
group of diseases characterized by the malfunction of bone marrow.  An MDS patient 
experiences anemia because of the damaged bone marrow becoming unable to producing 
sufficient blood cells and approximately 50% of MDS high-risk patients progress to having acute 
leukemia within 5 years.  Risk factors of MDS include certain kinds of cancer treatment such as 
mechlorethamine and procarbazine, genetic mutation, and smoking.  Stem cell transplant is the 
only curative for MSD but patients are more commonly treated with chemotherapy and/or 
growth factors including ESAs.
98 
  Despite significant improvement in Hb level observed in 
several clinical trials, results show similar rates of overall survival and progression to acute 
myeloid leukemia
99
, and conflicting evidence of transfusion requirement and quality of life 
associated with ESA treatment.
100 
  Given as a monotherapy, epoetin alfa subcutaneous treatment 
of 150 IU/kg three times weekly or 40,000 IU once weekly for 24-26 weeks was found to be 
associated with 37-68 % erythroid response defined as an increase in Hb or reduction in 
transfusion requirement in low-risk MDS patients.
101-103 
  Positive response was also observed 
with a combination therapy of ESAs and granulocyte colony-stimulating factor (G-CSF).
96, 97
  
Likewise, the benefit of darbepoetin alfa is also evidenced in a clinical trial of anemic patients 
with low-risk MDS.
104 
  As the results of several trials pointed toward favorable erythroid 
response to erythropoietin in this population, the American Society of clinical 
Oncology/American Society of Hematology Clinical Practice Guidelines recommend the use of 
ESAs in low-risk MDS patients whose Hb values approaches 10 g/dL to avoid blood transfusion.
 
105 
  In line with ASCO/ASH guidelines, DRUGDEX recommends epoetin alfa to be used in 
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some cases of myelodysplastic syndrome due to the moderate strength of evidence and efficacy 
report that favors efficacy for this indication. 
Anemia of myelofibrosis 
Myelofibrosis refers to the condition by which bone marrow tissues are replaced with 
fibrous tissue, hindering blood cell productions and resulting in anemia.
106 
  Profound anemia 
associated with myelofibrosis is usually treated with transfusion therapy but several small, open-
label studies of 7-20 patients suggest the condition occasionally responds to ESAs.
107-111 
  
Epoetin alfa given subcutaneously at 10,000 IU three times weekly was found to be well-
tolerated and effective in reducing transfusion requirement and increasing Hb level in 
myelofibrosis patients with myeloid metaplasia
112 
 and chronic idiopathic myelofibrosis (CIMF).
 
113 
  Due to the small sample size of the trials, DRUGDEX recommends epoetin alfa to be used in 
some cases of myelofibrosis according to the moderate strength of evidence and efficacy report 
that favors efficacy for this indication. 
Anemia of rheumatoid arthritis 
Anemia prevalence in rheumatoid arthritis (RA) is high.  A systematic literature review 
of anemia in RA reveals that between 33% and 60% of RA patients experience mild anemia.
114 
  
More than 60% of anemia cases in RA are classified under anemia of chronic disease in which 
the increased production of inflammatory cytokines characterized rheumatoid arthritis reduces 
the response of bone marrow to erythropoietin.
115 
   A report of two patients with anemia of 
rheumatoid arthritis showed that erythropoietin dosed at 100 units/kg administered three times 
weekly for 8 weeks resulted in positive hematologic response but with no change in RA 
outcomes over a five-month period.
 116 
  According to similar results from other studies, 
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DRUGDEX recommends epoetin alfa to be used in some cases of RA.  The strength of evidence 
is moderate and favors efficacy for its use in this indication. 
Beta Thalassemia 
Beta thalassemia is a genetic disorder of beta globin protein that makes up red blood 
cells.  The disease is most common in persons with Mediterranean, Asian, or African origins.  
Defects in hemoglobin lead to destruction of red blood cells and hence anemia symptoms that 
can be corrected with blood transfusion.
117 
  Results from an open-label clinical trial of 10 
patients with beta thalassemia suggest potential use of epoetin alfa for this indication.  
Subcutaneous administration of epoetin alfa at 150 units/kg three times weekly for at least 12 
weeks successfully reduced the median blood transfusion units though no significant change in 
Hb level was found.
118 
  In addition, a combination of ESAs (200 units/kg/day) and iron (300 
mg/day) therapy from week 30 of pregnancy to week 4 of delivery may alleviate the requirement 
for blood transfusion in pregnant women with beta thalassemia though a larger clinical trial is 
needed to warrant such findings.
119 
  DRUGDEX recommends epoetin alfa to be used in some 
cases of beta thalassemia according to the moderate strength of evidence and efficacy report that 
favors efficacy for this indication. 
Blood unit collection of autotransfusion 
As noted earlier, epoetin alfa was approved for use as a prophylactic of allogeneic blood 
transfusion only in patients who are not willing to donate autologous blood before undergoing 
elective surgeries.  If a patient is willing to donate, erythropoietin may be used off-label to 
increase capacity donation.  DRUGDEX recommends epoetin alfa to be used in some cases of 
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transfusion prior to elective surgery according to the moderate strength of evidence and efficacy 
report that favors efficacy for this indication. 
Anemia in traumatic, postsurgical patients 
The use of erythropoietic drugs as an alternative to blood transfusion is potentially 
beneficial in a case where a patient of traumatic or surgical blood loss denies blood products due 
to his religious belief.
120 
  It was evident from many case reports and case series that epoetin alfa 
could successfully reverse life-threatening anemia due to trauma, burns, and surgical procedures 
in Jehovah’s Witness patients refusing blood transfusion.121-123   For example, erythropoietin 
given IV or SC at 300 IU/kg daily until a patient achieved a suitable response, then reduced to 
150 U/kg every other day has resulted in 5% increases in Hb level.
124 
  DRUGDEX recommends 
epoetin alfa to be used in some cases despite inconclusive evidence of efficacy and only 
moderate strength of evidence present to support the use of ESAs in the treatment of anemia in 
traumatic, postsurgical patients. 
Anemia in critical illness 
The use of ESAs to treat anemia in critically ill patients shows positive effects in term 
increasing hematocrit values and reducing the need for blood transfusion.  In two randomized, 
double-blind, placebo-controlled trials of 1,302 and 86 adult ICU patients, weekly subcutaneous 
administration of 40,000 IU epoetin alfa shows to increase Hb level and reduce the need for 
blood transfusion
125, 126 
and no significant difference in mortality or adverse events was found 
between the treatment and placebo groups in two trials.  Another small study of 36 patients also 
shows significant between-group differences of Hb values after five doses of subcutaneous 
erythropoietin at 300 units/kg was given every other day to anemic patients in the intensive care 
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unit.
127 
  In contrast, results from a large multi-center randomized double-blind placebo-
controlled clinical trial indicate that erythropoietin is ineffective in reducing the need for blood 
transfusion in this specific group of patients and its use was in fact was associated with greater 
risk of thrombotic vascular events.
128 
  The use of erythropoietin in anemia of some critical 
illness cases is recommended in some cases by DRUGDEX (Class IIb) despite the inconclusive 
evidence of efficacy and moderate strength of evidence. 
Anemia of malignancy - not due to chemotherapy 
 Causes of cancer-related anemia are multifaceted, ranging from the direct effect of the 
neoplasm to the products of the cancer.  Almost all of cancer patients suffer from anemia over 
the course of the disease.
3, 4
   Improvements in hematologic profile are demonstrated in various 
cancer trials though the treatment has failed to benefit quality of life or cancer outcome.
129, 130 
  In 
fact, the use of ESAs was associated with increased mortality.
 131 
  Epoetin alfa dosed 
subcutaneously at 40,000 IU once weekly for 12 weeks was found to be associated with lower 
median survival in the treatment arm that remains significant after adjusting for baseline 
characteristics (68 versus 131 days).
128
  Similar to epoetin alfa, darbepoetin alfa successfully 
increases Hb level of cancer patients not on active chemotherapy in spite of conflicting evidence 
on transfusion requirement and quality of life improvement
132-135  
but is also associated with an 
increased incidence of cardiovascular and thromboembolic events though no difference in 
serious or fatal adverse events was observed.  As a result, the ASCO/ASH guidelines caution 
against the use of ESAs in cancer patients not currently receiving chemotherapy
102
 and 
DRUGDEX does not recommend the use of ESAs in anemia of malignancy not due to 
chemotherapy in any cases due to its negative effect on survival despite the moderate strength of 
evidence and evidence that favors efficacy. 
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Anemia of Porphyria cutanea tarda 
Porphyria cutanea tarda (PCT) is the most common type of porphyria,
 136 
a rare disorder 
of liver enzyme uroporphyrinogen decarboxylase deficiency which is diagnosed in 
approximately 1 in 10,000 individuals.
137 
   Inefficiency of the enzyme causes porphyrin to 
accumulated in the liver, transported to the skin, and resulted in skin damage.  About 20% of 
PCT diagnosed is hereditary, resulting from a genetic mutation, while majority of causes may be 
due to use of alcohol, estrogens, smoking, chronic hepatitis C, or HIV infection.
138 
  A reduction 
of serum iron through a removal of blood termed phlebotomy is a preferred treatment of PCT.  In 
patients with advance kidney disease, PCT can be extremely severe and a combined ESA therapy 
and phlebotomy may be beneficial.  Two case reports pointed out that ESAs can help manage 
anemia of porphyria cutanea tarda and hepatoerythrpoietic porphyria.  A remission was achieved 
in a woman with porphyria cutanea tarda after undergoing ESA therapy at 150 units/kg for 4 
months.
139 
  Similarly, subcutaneous administration of erythropoietin at 600 units/kg/week for 1 
year partially corrected severe anemia in a 68-year-old male with chronic hepatoerythropoietic 
porphyria.
140 
   DRUGDEX recommends epoetin alfa to be used in some cases of anemia of 
porphyria cutanea tarda though the strength of evidence is low and efficacy evidence is still 
inconclusive.  
Athletic performance enhancement 
Abusive use of ESAs in sport is well-recognized.  An alternative to blood transfusion, 
erythropoietin is used to increase the number of red blood cells, oxygen uptake, and hence 
player’s endurance.  Risks of erythropoietin use in athletic performance enhancement were 
widely reported
141 
 resulting in the prohibition of its use by the International Olympic Committee 
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and other sport authorities.
142 
  Similarly, the use of erythropoietin for this indication is not 
recommended by DRUGDEX because of an inconclusive evidence of efficacy.   
Iron-overloaded – Transfusion 
Iron overload, an excessive state of tissue iron, may result from repeated blood 
transfusion or over-absorption of iron from the gastrointestinal tract.  Deposition of iron in 
various organs leads to dysfunctionality of the heart, endocrine system and death.
143 
  A 
combination of 150 units/kg erythropoietin therapy and phlebotomy in 5 transfusion-dependent 
hemodialysis patients was found associated with a reduction mean serum ferritin at the end of the 
18-week study period.
144 
  DRUGDEX therefore recommends the use of epoetin alfa as an 
alternative to deferoxemine therapy in some cases of transfusional iron overload.  Evidence of 
ESA use for this indication favors efficacy though the strength of evidence is low. 
Sexual Dysfunction 
Erythropoietin may enhance sexual function in male patients undergoing dialysis by 
directly affecting the endocrine or by increasing patient Hb level and blood viscosity.  
Improvement in sexual function was reported in 4 of 7 males undergoing hemodialysis after 
initiating ESA therapy.  Moreover, 5 of 9 dialysis female patients reported a restoration of 
menstruation during the treatment.
145 
   Because of inconclusive evidence on efficacy and low 
strength of evidence, DRUGDEX recommend the use of ESAs for the treatment of sexual 
dysfunction only in selected cases. 
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Table 2.4 Use of Epoetin alfa and DRUGDEX ratings  
FDA Approval Therapeutic use Level of Evidence 
Strength of 
Recommendation 
Strength of 
Evidence 
Efficacy 
Rating 
Yes 
Anemia - Chronic renal failure IIa B Effective 
Anemia - Due to chemotherapy - 
Neoplastic diseases, Non-myeloid, 
metastatic 
IIa B Effective 
Anemia - Zidovudine adverse reaction IIa B Favors efficacy 
Surgical procedure - Transfusion of 
blood product, Allogeneic; Prophylaxis 
IIa B Effective 
No 
Anemia - Congestive heart failure IIb B Favors efficacy 
Anemia - Due to radiation IIb B Favors efficacy 
Anemia - During the puerperium IIb B Favors efficacy 
Anemia - Hepatitis C, In patients 
being treated with a combination of 
ribavirin and interferon alfa or ribavirin 
and peginterferon alfa 
IIb 
 
B Favors efficacy 
Anemia - Multiple myeloma IIb B Favors efficacy 
Anemia - Myelodysplastic syndrome IIb B Favors efficacy 
Anemia – Myelofibrosis IIb B Favors efficacy 
Anemia – Prematurity 
(pediatric) 
IIb B Favors efficacy 
Anemia - Rheumatoid arthritis IIb B Favors efficacy 
Beta Thalassemia IIb B Favors efficacy 
Blood unit collection for 
autotransfusion 
IIb B Favors efficacy 
Anemia - Traumatic or postsurgical IIb B Inconclusive 
Anemia - Critical illness IIb B Inconclusive 
Anemia - Not due to chemotherapy - 
Neoplastic disease 
III B Favors efficacy 
Epidermolysis bullosa (pediatric) IIb C Inconclusive 
Anemia - Porphyria cutanea tarda IIb C Inconclusive 
Athletic performance enhancement III B Inconclusive 
Cancer III B Inconclusive 
Iron overload – Transfusion IIb C Favors efficacy 
Sexual dysfunction IIb C Inconclusive 
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Table 2. 5 Use of Darbepoetin alfa and DRUGDEX ratings 
FDA Approval Therapeutic use Level of Evidence 
Strength of 
Recommendation 
Strength of 
Evidence 
Efficacy 
Rating 
Yes 
Anemia - Chronic renal failure IIa A Effective 
Anemia - Due to 
chemotherapy - Neoplastic 
diseases, Non-myeloid, 
metastatic 
IIa 
 
B Effective 
No 
Anemia - Not due to 
chemotherapy - Neoplastic 
disease 
III B Inconclusive 
Anemia - Myelodysplastic 
syndrome 
IIb B Favors efficacy 
 
Table 2. 6 Use of ESAs for conditions not supported by scientific evidence and DRUGDEX ratings 
Therapeutic use Level of Evidence 
Strength of 
Recommendation 
Strength of 
Evidence 
Efficacy 
Rating 
Anemia due to trauma, postsurgical, 
and critical illness 
IIb B Inconclusive 
Anemia in neoplastic disease not due to 
chemotherapy 
III 
 
B Favors efficacy 
Anemia in porphyria cutanea tarda IIb C Inconclusive 
Sexual dysfunction IIb C Inconclusive 
Sickle cell anemia IIb C Inconclusive 
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Empirical studies of ESA Off-label Use 
  The use of erythropoiesis-stimulating agents in the hospital settings is extensive and 
involving multiple hospital units and various indications.  A study reports that over a 6-month 
study period, 120 physicians in a large medical center prescribed approximately 17 million units 
of erythropoietin, translating into a direct drug cost of $172,390.
146 
  Hemodialysis and renal 
indications were found to be the most common indications of ESA use though oncologists 
accounted for the highest units of ESA use.  Off-label prescribing of ESAs is prevalent in 
inpatient settings.  The same study found that 49% of ESAs prescribed for 248 inpatients 
between February and June 2000 were for off-label indications.  Off-label indications of ESAs 
included bone marrow transplantation and hematologic malignancy (13%), neonatal care (10%), 
and their use in neurosurgical procedure (8.2%).   
Similar patterns of ESA prescribing were observed in a study entailing nearly half a 
million ESA users in 515 hospitals nationwide.
15
   Chronic kidney disease and cancer were the 
most common reason for ESA use in the hospitals between January 2002 and June 2004.  During 
this period, inpatient off-label prescribing of ESAs was found to be 52%.  Interestingly, one-
quarters of such off-label use were prescribed for the indications not supported by strong 
scientific evidence including cardiovascular (3.7%) and pulmonary (3.8%) disorders.  This study 
offers further insight into inpatient off-label prescribing of ESAs patterns.  For example, off-
label prescribing was more common in teaching hospitals compared to the community ones; 
surgeons were more likely to prescribed ESA off-label compared to specialists and generalists.  
Regional variations and patient characteristics such as age, gender, race, insurance status, and 
hospital length of stay were also found to be associated with off-label prescribing of ESAs.    
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Efforts of regulatory risk communications and health policies to influence prescribing 
patterns 
  The first part of this section describes risk communication approaches undertaken by the 
FDA to ensure safety use of a medication while the final part summarizes a systematic review of 
the impact of FDA drug risk communications on health care utilization and health behaviors.   
The United States Food and Drug Administration (FDA) takes responsibility in 
protecting public health, one of which by ensuring that the drug products are safe and 
effective.
147 
  At the same time, there is pressure on the FDA’s Center for Drug Evaluation and 
Research (CDER) to put the new drug onto the market as quickly as possible causing the period 
of premarketing surveillance period of adverse events to be significantly reduced.
148 
  As a result, 
the burden of drug safety monitoring relies heavily upon post-marketing surveillance.   The 
primary mechanism for post-marketing surveillance is FDA's MEDWATCH program, which 
relies on health professionals to spontaneously and voluntarily report drug adverse events.  Based 
upon MEDWATCH adverse event reports, the FDA’s CDER and its an advisory committee 
analyzes drug risk and communicates them to patients and providers.  The FDA channels of risk 
communication of medical products include safety alerts or public health advisories, Dear 
Healthcare Professional Letters, labeling revisions including black box warnings, and 
implementation of Risk Evaluation and Mitigation Strategies (REMS).
149 
 
Safety alert or public health advisory is often the FDA's first step in communicating drug 
risks to the public.  When the evidence of risk accumulates the addition of a black box warning 
on the drug labeling is often warranted.  Sometimes a black box warning occurs soon after a 
public advisory.  An ESA public health advisory was first issued to the general public in 
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November 2006, highlighting the increased cardiovascular risk associated with epoetin alfa use 
in CKD patients not on dialysis.  This was quickly followed by a black box warning in March 
2007.  Following that, a second public health advisory was issued which emphasized the black 
box warning and highlighted additional risks of death in cancer-ESA treatment and blood clot in 
major surgery.   A third advisory was issued in November 2007 which warned that ESAs may 
shorten time to survival in cancer patients and emphasized maintaining Hb levels at 10-12 g/dL 
in CKD patients. 
Black box warning is a frequently used risk communication tool of the FDA.  The name 
“black box” refers to a prominent section outlined by a black border on the labeling of a drug, of 
which clinical or animal toxicity data indicate the use of serious adverse reactions.
150 
  The 
warning highlights risks associated with and warns prescribers against the use of the drug for 
certain indications and/or in some population.  The use of black box warning, the strongest safety 
warning issued by the FDA,
 151 is limited to “the most serious warnings necessary to ensure the 
continued safe use of the product.”   The popularity of black box warnings has been noted in a 
study that found approximately 8.2% of the 548 new drugs approved between 1975 and 1999 had 
at least one black box warning.
152   Among all drugs listed in the 1995 Physicians Desk 
Reference (PDR), 206 carried a black box warning.
153   
The most frequent warning found was for 
the identification of use in high-risk patients, followed by information on dosing and drug 
interaction, and the need for special training or use in special settings.  Nearly 14% of all 
labeling revisions between 2005 and 2008 were due to black box warnings.
154 
   In March 2007, a 
black box warning was added to the label of epoetin alfa and darbepoetin alfa to reflect increased 
risks associated with ESAs use in cancer and CKD patients reported in many large clinical trials.  
The boxed warning was later updated in March 2008 to include results from recent trials. 
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  In addition to the public advisories and black box warnings, the FDA also 
communicates with prescribers using a Dear Health Care Professional letter (DHCP), or Dear 
Doctor/Dear Health Care Provider letter.  DHCP letter is a paper or electronic mailing from the 
manufacturer, distributor of drugs or biologics, or the FDA to health care providers about the 
new information concerning a drug.  DHCP letters can be of three types: “important drug 
warning letter”, “important prescribing information letter”, and “important correction of drug 
information letter.”  The “important drug warning letter” alerts health care providers of the safety 
issue hazardous to patient health such as life-threatening adverse reactions or a subpopulation in 
which the drug is contraindicated.  The “important prescribing information letter” indicates 
changes in the prescribing information other than those in important drug warning letter type.  
Such important prescribing information includes a change in the indication, dosage, and route of 
administration intended to minimize risk or optimize effectiveness of the drug.  The “important 
correction of drug information letter” emphasizes corrections of misleading information in 
prescription drug advertisements or other forms of promotion.  A DHCP letter may either be 
requested by the FDA or initiated by drug manufacturers according to one of the reasons noted 
above but is normally done by the manufacturer.  Information on DHCP letters can typically be 
found on the MedWatch website.  In the case of ESAs, an important drug warning DHCP letter 
was sent by Amgen, a manufacturer of erythropoietin, in January 2007 to alert physicians of 
results from major clinical trials regarding risks associated with ESAs use.  The letter 
specifically warned against the use of ESAs in non-chemotherapy cancer patients and the 
potential for increased risk of death in this population.  In addition, physicians were 
recommended to use the lowest does of erythropoietin possible to maintain patient Hb at the 
level sufficient to avoid blood transfusion.    
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Under the FDA Amendment Act of 2007, the risk evaluation and mitigation strategies 
(REMS) surveillance system was developed.  The FDA is now empowered with the authority to 
order manufacturer of a drug to provide REMS.  The scope of REMS varies by drugs and the 
risks they carry.  For example, REMS of a drug with relatively low risk may require nothing but 
an addition of package insert.  However, because of the apparent risk associated with ESA use in 
cancer treatment, REMS for ESAs requires physicians prescribing ESA drugs to cancer patients 
to complete and receive documentation of certification of the online ESA APPRISE Oncology 
Program Training.  Physicians must be enrolled in the ESA APPRISE Oncology program in 
order to be able to prescribe ESAs for use in patients with cancer.   
Before the implementation of Risk Evaluation and Mitigation Strategies programs, no 
formal system exists to document physician adherence to FDA warnings; adherence to the 
warning is purely voluntary.  One study found that 0.7% of prescriptions violate at least one 
aspect of the warning, though less than 1% actually resulted in adverse drug events.
155 
  
Moreover, a national survey found the physician knowledge of the FDA-approved indications 
and evidence base for prescription drugs to be low.
 156 
  The problem of risk communication has 
not been resolved with the REMS program.    
Dusetzina et al. systematically reviewed the impact of FDA drug risk communications on 
health care utilization and health behaviors from the studies published between January 1990 and 
November 2010 listed in MEDLINE and Web of Sciences.
157 
  Among 16 therapeutic classes 
investigated in the forty-nine studies included in the review, antidepressants were the most 
common therapeutic class (31%) assessed for the impact of risk interventions, followed by 
glitazones (13%), cisapride (8%), terfenadine (8%), long-acting β2- agonist (6%), droperidol 
(6%), and antipsychotics (6%).  Black box warnings were the most frequent risk communication 
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tool (51%), followed by public health advisory or safety alert (47%) and dear healthcare provider 
letters (29%).  None of the studies included in this review investigated the impact of FDA risk 
communication on prescribing patterns of ESAs.   
Nearly all studies of drug risk communications investigate their effect on changes in the 
level of targeted drug utilization. Drug risk communications fell  into four recommendation 
types: 1) increase patient monitoring; 2) avoid co-prescribing of drugs that may have adverse 
interaction; 3) avoid use of a drug among subpopulations; and 4) provide general caution of a 
drug product.  Of note, recommendations regarding increased clinical monitoring appeared to 
have little or no effect on clinical practice.  In addition, the effect of the recommendations failed 
to be sustained in the short term, although physicians appeared to decrease inappropriate 
prescribing over time.  The effect of risk communication also appeared to vary considerably by 
therapeutic classes.  Lastly, spillover effects of the regulatory risk communication messages to 
non-target user population were assessed in a few studies. A drop in antidepressant use was 
observed in adult populations even though the communications only warned against its use in 
youth.
158
   
This study seeks to add to the literature in the following ways. This will be the first to 
assess the impact of safety warnings and funding changes on the use of erythropoietin.  It will be 
one of the few studies that look at the impact of REMS on any type of drug on patient-level 
changes in utilization.  It is also the first to examine the relative impact of safety warnings and 
funding decisions on on-label and off-label drug use of any type when examined at the patient 
level.   
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The following section extensively review potential confounders needed to be considered 
in the analysis of patient-level data.  Lastly, systematic literature review of public interventions 
on ESA utilization that leads to the formulation of research question concludes the final section 
of this chapter. 
Potential confounding factors associated with prescribing patterns    
The diffusion of innovation of health care framework clearly defines factors influencing 
the decision to adopt an innovation including perceived benefit of the change, compatibility of 
the innovation with the current values, belief, and needs of the individuals, complexity of the 
proposed innovation, trialability of the innovation, and the extent to which potential adopters 
observe the adoption by others.  In parallel to the diffusion of innovation theory, influencing 
factors of prescribing have been extensively studied.  Prescribing decisions are a complex and 
intertwining process where changes in physician’s prescribing patterns are a variety of factors.  
Such influencing factors may be categorized into 3 groups: patient, physician, and external 
factors.
 159
   
1. Patient Factors 
Patient clinical conditions (admission type, severity of illness, length of hospital stay) 
Patient clinical conditions are major influencing factors of treatment patterns.  The 
relationship holds true for ESA use in specific; the likelihood of the off-label use of ESAs 
showed a positive relationship with patient’s length of hospital stay.15 Similar results were found 
in oncology where a drug use report indicated that the use of drugs for off-label purposes is more 
prevalent in patients with advance cancer stages compared to the initial stages.
160 
  Admission 
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status, severity of illness calculated using a combined comorbidity score, and length of hospital 
stay available in electronic medical records can serve as proxies for patient clinical conditions in 
this study.   
Patient characteristics (age, race, gender) 
Off-label prescribing is a concern as the drugs tested in adult participants may not work 
as safely or effectively in the elderly and children because of differences in body composition 
and pharmacokinetics.
161, 162 
   In addition, treatment patterns in the older elderly patients may 
differ from the younger ones.  Physician could be more reluctant to prescribe a drug with some 
risks to older patients who are frailer and the goals of therapy may shift from increasing 
longevity to improving quality of life.  Also, as an individual draw closer to death, health care 
utilization increases and thus adjusting for patient age in the analyses is essential.
163  
 Racial disparities in ambulatory care and pharmacotherapy are well-documented.  
African-American and other minorities were less likely to be prescribed with medications for 
certain chronic disease conditions such as diabetes and mental disorders compared to their White 
counterparts.
164, 165 
  Even though the association between patient race and off-label prescribing 
has rarely been assessed, it is crucial to control for potential confounding effect of patient race on 
ESA prescribing in this study. 
 Despite evidence suggesting that women are greater users of health care resources than 
men, gender disparities in the treatment of life-threatening diseases were apparent in the medical 
literature.
166 
  Researchers have rigorously examined gender as a predictor of the extent of 
therapeutic intervention provision in various health conditions.  For example, gender differences 
were found to be correlated with the likelihood of receiving dialysis or a kidney transplant 
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among patients with kidney diseases.
167-169 
  It is therefore important to include patient gender 
into the model to avoid its potential confounding effects on ESAs prescribing. 
Primary Payer of Health Insurance 
 Health insurance has been long identified as enabling factor of healthcare encounter.
170
   
A study found that physicians also incorporate patient’s health insurance in their prescribing 
decision where participating physicians reported to change their therapeutic treatment due to 
insurance issues in approximately 16% of the sampled visits.
171 
  Additionally, this change is 
most likely to occur when the patients was uninsured.  The impact of health insurance on 
prescribing patterns in the inpatient settings is largely unknown and deserved further 
investigation. 
2. Physician Factors 
Physician specialty 
Existing literature have identified that specialists and generalists may be different in their 
treatment intensity.  Research has found, for example, that endocrinologists and cardiologists 
may have been more resource-intensive than generalists in the treatment of diabetes.
172 
  Another 
Canadian study also found that early prescribers of celecoxib, a specific cox-2 inhibitor 
analgesic, were more likely than majority of prescribers to be general practitioners.
173 
  A 
possible explanation of such differences may lie in the extent of medical journal use or training.  
As the literature suggests possible differences in prescribing patterns between physician 
specialties, it is important to include information on physician specialty in the model.  
Information on physician specialty is readily available in Cerner data.   
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3. Hospital Specific Factors 
Hospital characteristics (bed size, teaching status, geographic region) 
Hospital characteristics including size, teaching status, and geographic region may 
influence prescribing patterns.  Larger hospitals are better equipped with prescribing decision 
support system that leads to quality prescribing.  A study of new drug adoption found that Dutch 
general practitioners who used a prescribing decision support system were less likely to prescribe 
angiotensin II receptor blockers (ARBs), an expensive anti-hypertensive medication, compared 
to those who worked in single-handed practices or in rural areas where decision support system 
is less likely to exist.
174 
   In addition, knowledge dissemination may happen at a faster rate in a 
larger hospital where thought leaders reside.  One study found that key opinion leader physicians 
and those who are socially well connected with their peers will also be one of first to react 
compared to “patient-oriented” physicians.175   Though a study of ESA off-label prescribing 
found no association between hospital bed size and ESA off-label prescribing, it is still important 
to control for hospital size in this study.  Hospital size in this study is measured through the 
number of beds in a hospital and categorized into 5 groups: <99, 100-199, 200-299, 300-499, 
500 or more beds, based on a categorization of the American Hospital Association (AHA).
176 
 
Small area variation (SAV) is evident in medical practices.  For clinical conditions where 
alternative treatments are available or in the absence of well-defined guidelines, practice styles 
vary across physicians depending on their preferences.  Economists believe that SAV mainly 
stems from physician’s uncertainty and lack of knowledge as a result of inadequate diffusion of 
medical information.
177, 178 
  Regional variations were seen in off-label prescribing of ESAs such 
that hospitals in the northeast and western portions of the country being more likely to prescribe 
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ESAs for off-label unsupported indications than other regions.  Information on geographical 
region is available in our database and will be categorized into Northeast, South, Midwest, and 
West. 
Teaching status of the hospital may be associated with prescribing patterns.  Diffusion of 
innovation and the uptake of technologies usually occur faster in a larger practice
179, 180
 and it is 
possible that physicians who work in a group practice and those in teaching hospitals would be 
more likely to follow the warning compared to those in solo practice and nonteaching hospitals. 
Previous study has identified that off-label use of ESAs occurred more in teaching hospitals than 
nonteaching hospitals.
15
   
To conclude, it is evident from the literature that patient characteristics and their clinical 
conditions, primary payer of health insurance, physician and hospital characteristics, to a certain 
extent affect one’s decision to prescribe for on-label and off-label purposes.  Outside influences 
including safety issues speculate around the prescribing environment could likewise influence 
prescribing patterns.  Since effects of safety interventions on the ESA prescribing can be masked 
by these characteristics, it is essential to include them in the analytical model. 
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Systematic literature review 
The systematic review of existing literature is subdivided into four parts: methods, 
results, discussion, and conclusion.  The objectives of this literature search was to summarize 
existing knowledge on FDA and Medicare actions on ESA use patterns, namely the proportion of 
patients treated, dose, and duration of ESA treatment.  Findings from this review are used to 
identify gaps in the literature and formulate research questions, research hypotheses, and specific 
aims that are described at the end of this chapter. 
Methods 
Three databases were used for this search: MEDLINE, CINAHL, and Web-of-Sciences.  
First, MEDLINE was searched via PubMed for relevant studies from a combination search of 3 
search strings that comprised of MeSH terms and keywords.  CINAHL database via EBSCO host 
and Web-of-Science were searched using a combination search of similar keywords to identify 
additional articles.  Reference lists of selected studies and relevant review articles were also 
searched.  To keep such search at a manageable level, keyword search was applied to title and 
abstract [tiab] in PubMed.  Web-of-Science search was limited to topic field and studies based in 
the United States only while no search field was specified in CINAHL.  
Inclusion criteria are English language articles studies that analyzed empirical data on the 
impact of interventions of interest on ESA use patterns.  This review excluded letters to editors, 
commentaries, news articles, and meeting abstracts.  Review articles were included only for 
reference mining.  The search was limited to English language articles published between 2007 
and May 2012.  The year 2007 was chosen because the scope of this study focuses interventions 
that took place only between 2006 and 2010.  To be included in this review, a study must have 
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investigated at least one of the following outcomes during the period of study: proportion of 
patients treated with ESAs, ESA dose, and treatment duration.  Abstracts produced from initial 
search strategies were reviewed for possible inclusion and exclusion.  The corresponding full 
articles of qualifying abstracts were then retrieved through Virginia Commonwealth University 
and inclusion and exclusion criteria were then confirmed.  Search strings used in for PubMed 
search are described below.  For Web-of-Science and CINAHL, MeSH terms were substituted 
with exact or similar keywords.   
String #1:  
“Erythropoiesis-Stimulating Agents” [MeSH] OR “Erythropoietin” [MeSH] OR 
“Erythropoiesis” [MeSH] OR “ESA” [tiab] OR “Erythropoietic” [tiab] 
String #2: 
“safety” [tiab] OR “warning” [tiab] OR “black box” [tiab] OR “public health” [tiab] OR 
“advisory” [tiab] OR “alert” [tiab] OR “dear doctor” [tiab]  OR “dear healthcare professional” 
[tiab] OR “dear healthcare provider” [tiab]  OR “letter” [tiab] OR “risk communication” [tiab] 
OR “risk evaluation and mitigation strategies” [tiab] OR “REMS” [tiab] OR “drug labeling” 
[MeSH] OR “Food and Drug Administration” [tiab] OR “FDA”[tiab] OR “regulatory” [tiab] OR 
“United States Food and Drug Administration” [MeSH] OR “National Coverage Determination” 
[tiab] OR “NCD” [tiab] OR “reimbursement” [tiab] OR “restrict” [tiab] OR “payment” [tiab] OR 
“policy” [tiab] OR Medicare [MeSH] OR “United States Centers for Medicare and Medicaid 
Services” [MeSH] 
  
  
  
47 
 
String #3:  
“Physician's Practice Patterns" [MeSH] OR "Drug Prescriptions" [MeSH] OR "Drug Utilization" 
[MeSH] OR “prescribing” [tiab] OR “impact” [tiab] OR “effect” [tiab] OR “change” [tiab] OR 
“outcome” [tiab] OR “consequence” [tiab] OR “results” [tiab] OR “trend” [tiab]  
Results 
PubMed search (string #1 AND string #2 AND string #3) identified 477 articles 
published between 2007 and 2012, ninety-five of which were review articles.  After applying 
exclusion criteria, abstracts were selected for full text assessment for eligibility. Eight original 
research article of a qualitative analysis of empirical data was identified.  Reference mining of 
original studies and review articles did not yield additional relevant study.  Likewise, no 
additional eligible studies were found from CINAHL (247 studies) and Web-of-Science (339 
studies) search.  Thus, a total of eight studies are used for this review. 
Studies of impact of regulatory safety warnings and reimbursement restriction through 
the national coverage determination cover a variety of outcomes.  The primary outcomes 
commonly identified are the proportion of patients treated with ESAs, dose, treatment duration, 
Hb level, and requirement for blood transfusion.  Two studies assessed the change in ESA use in 
CKD patients while the other six studies investigated such change in cancer patients.  Study 
methods, results, and conclusion are summarized in Table 2.7 and 2.8. 
An increasing trend in mean ESA dose was observed among hemodialysis patients 
internationally between1996 and 2008.
181 
  MaFarlane and his colleagues analyzed the trend in 
ESA use and their Hb levels among patients treated in selected dialysis units in 12 countries (US, 
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Canada, France, Germany, Italy Spain, Belgium, Sweden, the UK, Australia, New Zealand, and 
Japan) using data from a three-phase large prospective observation study, Dialysis Outcomes and 
Practice Pattern Study (DOPPS). The study found an increasing trend in mean ESA doses 
between the DOPPS study phases (1996-2001, 2002-2004, and 2005-2008) in all participating 
countries but Belgium.  An increase in Hb levels was observed in all countries but Sweden. 
Contradicting results were reported among CKD patients not on dialysis in the United 
States between 2005 and 2009.
182 
  ESA use in this population treated in free-standing US 
nephrology clinics decline from 60% to 46% during this period with the largest drop in 2007 and 
2008 (the study did not test for statistical significance in this difference).  A significant decline in 
the proportion of patients with Hb level > 12 g/dL and an increase in the proportion of patients 
with Hb within 10-12 g/dL range were observed in 2007.  This change was parallel with a 
decline in ESA dose that began in early 2007 (a 21% drop throughout the 4 years period).   
Nonetheless, the drop in ESA dose and Hb level was not statistically significant after adjusting 
for patient case-mix.   
A consistent decline in ESA use in cancer treatment was noted in all studies.  Vadhan-Raj 
et al. assessed usage patterns of ESAs and transfusion among patients on active treatment at a 
cancer center between January 2006 and December 2008 to determine whether changes in the 
level of ESA use correspond with changes in the safety concerns and reimbursement strategy 
during the study period.
183 
  Active treatment was defined as inpatient admission, emergency 
center visit, blood transfusion, surgery, chemotherapy, radiation therapy, and other therapy for 
cancer.  Compared with 2006, the proportion of patients receiving ESAs decreased by 26% in 
2007, and by 61% in 2008.  A non-significant increasing trend of 8% in the proportion of 
patients receiving transfusions was observed during the investigational period.  A significant 
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reduction in Hb values at ESA initiation was also found among ESA-naïve patients such that the 
proportion of patients first receiving ESAs at Hb level ≤ 10 g/dL increased from 60.6% in 2006 
to 88.9% in 2008.  Additionally, the proportion of ESA-naïve patients receiving transfusion 
before any ESA use increased from 26.4% in 2006 to 40.7% in 2008.  Moreover, the study used 
piecewise linear models to detect changes in the numbers of patients treated at the center, ESA 
units dispensed, blood units transfused, mean Hb values on the day of transfusion and at the 
initiation of ESAs, proportions of ESA use among transfused patients, and proportions of ESA-
receiving patients undergoing transfusion.  A significant reduction in ESA units dispensed was 
observed at 9.8 months (October 2006) and ESA units dispensed reduced by 77% during the 
three years study period.  In the same period, no significant changes in the number of patients 
treated at the center, RBC units transfused, or mean Hb values on the day of transfusion were 
found.  The greatest reduction in ESA use was in the hematologic services (28%) though this 
decrease was observed across all services.  Finally, after adjusting for patient and clinical 
characteristics, the authors found that though ESA use decreased, transfusion did not increase 
significantly.  Despite a large number of outcomes studied the study did not investigated 
differences in such outcomes between patients on and off-chemotherapy.   
The impact of the reimbursement change on the level ESA utilization in cancer patients 
receiving chemotherapy in multiple oncology clinics was first observed in a study by Hess et 
al.
184 
  ESAs were used in 41.3% of all episode of chemotherapy care before the implementation 
of national coverage determination (NCD).  In the post-NCD period, only 30.4% of the 
chemotherapy episodes were associated with ESA use, translating into 26.4% reduction in ESA 
use.  Concurrently, a significant increase in the episodes with blood transfusion was observed 
(17% relative reduction) while the mean minimum Hb values during the episodes were 
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significantly lower after NCD (10.7 g/dL vs. 10.9 g/dL).  The impact of NCD seemed to be 
different between the two groups of patients such that more prominent changes in ESA use, 
blood transfusion, and Hb values were found in patients older than 65 years old (29.1% relative 
reduction in ESA use and a 31% increase in blood transfusion).  In contrast, though ESA use 
decreased significantly by 24% among those younger than 65 years old, no significant increase 
in blood transfusion was found. 
A study by Henry and his colleagues determined the impact of NCD on utilization of 
ESAs among Medicare patients with colorectal, lung, and breast cancer patients on concomitant 
chemotherapy.
185 
  Information of patients with chemotherapy-induced anemia (Hb values < 11 
g/dL while receiving chemotherapy or within 60 days of the last chemotherapy dose) from 49 
community oncology clinics with was derived from electronic medical records to assess blood 
transfusion (proportion of patients receiving transfusion and transfusion units), ESA use, time, 
and dosing, Hb values, and hospitalization.  The proportion of CIA patients receiving ESAs 
decreased in the post-NCD compared to the pre-NCD period (56% vs. 88%).  Duration of ESA 
use decreased significantly from 48 days to 32 days and doses reduced from 4.6 to 2.9 units.  
Adjusting for patient demographics, clinical characteristics, tumor types, and chemotherapy 
treatment, the likelihood of receiving transfusion was found to be 41% greater after NCD.  
Parallel with this increase, a significant rise in the proportion of patients with Hb < 10 g/dL, 
mean number of transfusion per patient and mean number of units transfused was found post-
NCD period.  Nonetheless, no significant differences in the rate of hospitalization between the 
two periods were observed.  In spite of reporting a crude reduction in the proportion of cancer 
patients receiving ESAs after the implementation of NCD, the study did not assess the likelihood 
of receiving ESAs, adjusting for covariate.    
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Hemoglobin trends and anemia treatment among chemotherapy-treated patients with 
cancer between 2006 and 2009 were assessed by Feinberg and colleagues.
186 
   Overall, the 
proportion of chemotherapy episodes in community oncology clinics in which ESA was 
prescribed decreased significantly from 45.4% to in 2006 to 11.5% in 2009.  This change aligned 
with an increase in chemotherapy episodes with no anemia treatment (44.6% to 77.8%), episodes 
with transfusion services only (3.4% to 8.73%), and a decrease in episodes with both transfusion 
and ESA treatment (6.6% to 2.0%).  For episodes with ESA treatment, patients showed 
decreased in mean Hb values.  The study implied that over time, initiation of ESAs after 
chemotherapy was delayed (from 29.4 days in 2006 to 39.0 days in 2009) and patients seemed to 
be initiated with any anemia treatments at a lower Hb values.   
Arneson et al. assessed the impact of NCD on ESA and transfusion use in chemotherapy-
treated Medicare beneficiaries with cancer using a nationally representative Medicare claims 
data between 2005 and 2007.
187 
  The proportion of ESA use among patients aged 66 or older 
who had lung, breast, or colorectal cancer, or lymphomas, and initiated chemotherapy in the 
outpatient settings decreased significantly from 35.0% pre-NCD to 15.2% in post-NCD period, 
adjusting for patient demographic and clinical variables.  Though an increasing trend was found 
in the proportion of patients receiving transfusion or transfusion event rate, a statistical 
difference could not be detected pre- and post-NCD implementation (9.3% vs 10.4% of patients 
and 19.0 to 21.8 transfusion events per 100 patient-quarters).  The findings were similar across 
the four types of cancer.   
Lastly, appropriateness of ESA use at National Cancer Centre in Singapore was assessed 
by Chan and Chan.
188 
  The release of safety advisories appeared to be associated with 
appropriate ESA prescribing measured through Hb initiation level and target level achieved, but 
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ESA treatment duration remained unchanged.  Furthermore, a smaller proportion of patients 
required more blood transfusion after ESA therapy was observed after the warnings compared to 
the pre-warning period.  Nonetheless, the study did not statistically compare the proportion of 
patients using ESA before and after the release of safety advisories considered useful to answer 
our research questions. 
Discussion and Conclusion 
ESA use in all patients except those receiving hemodialysis decreased after 2006.  
Among the six studies of ESA use in cancer patients, a consistent reduction in use was observed 
over time.  The greatest decline in use (number, dose, duration of therapy) occurred between late 
2006 and early 2007, corresponding to the release of negative results from clinical trials, black 
box warning, and restriction in Medicare reimbursement.  Though impact of NCD was most 
prominent among Medicare beneficiaries, studies observed a spillover effect in the younger 
population.  Consistent with safety warnings, patient Hb levels at the initiation of ESA treatment 
seemed to lower over time.  The reduction in ESA prescribing was associated with increases in 
the use of transfusion services in many, but not all studies.  No study examined the impact of 
safety warnings on off-label prescribing of ESAs.   
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Table 2.7 Results of systematic literature review: summary of study methods 
Author, pub year Study Design Study Sample Data Source Time period Intervention Unit of Analysis 
Chronic Kidney Disease 
McFarlane et al., 
2010 
Descriptive Hemodialysis 
patients in 12 
countries 
DOPPS 
database 
1996-2008 None Patient 
Regidor et al., 
2010 
Pre-post 
comparison 
CKD non-dialysis 
patients at free-
standing nephrology 
clinics  
N = 15,836 
Electronic 
medical 
records 
Mar 05-Jul 09 All possible 
between the study 
period 
Patient 
Cancer 
Vadhan-Raj et al., 
2010 
Time-series Cancer patients on 
active treatment at 
one cancer center  
N = 83,399 
Electronic 
medical 
records 
Jan 06-Dec 08 All possible 
between the study 
(black box warning 
and NCD) 
Patient 
Hess et al., 2010 Pre-post 
comparison 
Cancer patients with 
chemotherapy-
induced anemia at 
52 oncology clinics 
N Pre-NCD = 4,784 
N Post-NCD = 5,605 
Electronic 
medical 
records 
Jun 06-Mar 08 NCD Episode of 
chemotherapy care 
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Author, pub year Study Design Study Sample Data Source Time period Intervention Unit of Analysis 
Cancer 
Henry et al., 2011 Pre-post 
comparison 
Adult Medicare 
patients with 
colorectal, lung, or 
breast cancer who 
were treated at 
community oncology 
clinics and 
developed 
chemotherapy-
induced anemia 
 
N = 800 pre-NCD 
(Jan 00 – Jul 07) 
N = 994 post-NCD 
(Aug 07 – Jan 09) 
Electronic 
medical 
records 
January 2000 – 
January 2009 
NCD Patient 
Feinber et al., 
2012 
Pre-post 
comparison 
Cancer patients at an 
oncology private 
practice 
N =4,021 patients 
(4,864 episodes of 
chemotherapy care) 
Electronic 
medical 
records 
Jan 06-Aug 09 All possible 
between the study 
period with focus 
on NCD 
Episode of 
chemotherapy care 
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Arneson et al., 
2012 
Pre-post 
comparison 
66 years old 
Medicare 
beneficiaries who 
had lung, breast, 
colorectal cancer, or 
lymphomas, and 
initiated 
chemotherapy in 
outpatient settings 
 
N = 1,897 pre-NCD 
N = 1,877 post-NCD 
 
 
Medicare 5% 
sample  
September 
2006-
November 
2007 
NCD Patient 
Author, pub year Study Design Study Sample Data Source Time period Intervention Unit of Analysis 
Cancer 
Chan, 2010 Pre-post 
comparison 
Patients who 
received at least one 
dose of ESAs at a 
cancer center in 
Singapore 
N = 91pre-NCD 
N = 48 post-NCD 
 
Pharmacy 
electronic 
dispensing 
records 
January 2005 – 
December 
2009 
FDA safety 
warnings 
Patient 
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Table 2. 8 Results of systematic literature review: summary of study results 
Author, 
pub year 
Outcomes Measure Statistical 
Approach  
Results Conclusion Limitations/Gaps 
in literature 
Chronic Kidney Disease 
McFarlane et al., 
2010 
Trend in mean Hb level 
and ESA dose 
Linear regression 
analysis adjusting 
for clustering by 
facility 
Mean Hb level and percentage 
of patients with Hb level ≥ 12 
g/dL, in the US increased 
significantly. 
 
Mean ESA doses increased 
from 15,959 U/week in DOPPS 
Phase I to 21,386 U/week in 
DOPPS Phase III (p < 0.001). 
Percentage of patients with a 
mean ESA dose greater than 
35,000 U/week also increased 
significantly.  
ESA use in the 
kidney disease in 
the US increased 
despite safety 
warning and 
reimbursement 
change 
Crude estimates of 
outcomes change 
that are loosely tied 
to an intervention 
since the study 
compares Hb level 
and ESA dose 
between phases of 
DOPPS.  
Regidor et al., 
2010 
Proportion of patients 
treated with ESAs 
 
ESA dosing in 
mcg/month and mean 
Hb level 
Mantel-Haenszel 
chi-square test 
and ANOVA  for 
biavariate 
analysis 
 
Multiple linear 
regression of 
trends in ESA 
dosing and Hb 
level over the 
study period 
ESA use declined from 60% in 
2005 to 46% in 2009 with largest 
decline (20.5%) between 2007 
and 2008 
 
Mean dose declined from 176 to 
136 mcg/month with the largest 
decline observed at the 
beginning of 2007.  Mean Hb 
level declined significantly. 
A decline in ESA 
use between 2005 
and 2008 was 
observed and may 
be associated with 
safety warnings, 
change in clinical 
practice guidelines, 
and reimbursement 
restriction 
Did not test for 
statistical difference 
in ESA use between 
years 
 
Did not adjust for 
patient 
characteristics 
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Author, 
pub year 
Outcomes Measure Statistical 
Approach  
Results Conclusion Limitations/Gaps 
in literature 
Cancer 
Vadhan-Raj et 
al., 2010 
Proportion of patients 
receiving chemotherapy, 
ESAs, or transfusion 
 
Change point during 36-
month period and 
differences in slopes 
before and after change 
point for: 
- ESA use: total ESA 
unit dispensed and 
total number of 
patients treated during 
the period 
 
- Transfusion: Total 
number of transfusion, 
proportion of ESA-
receiving patient 
requiring a 
transfusion, proportion 
of transfused patients 
receiving ESAs 
 
- Hb profile: mean Hb 
level on the day of 
transfusion (implies 
transfusion threshold), 
mean Hb at initiation 
of ESAs in ESA-naïve 
patients (implies 
threshold for initiating 
Chi-square test 
for proportion 
 
Piecewise linear 
model to assess 
change points 
 
Wald test to 
assess change in 
slope 
 
Multiple logistic 
regression 
ESA use 
Compared to 2006, number of 
patients who received ESAs 
decreased by 26% in 2007, 61% 
in 2008. 
 
Total number of standardized 
ESA units dispensed decreased 
by 29% in 2007, and by 80% in 
2008.  Change point occurred at 
9.8 months (October 2006), 
slope before = 31.58 ESA 
units/month, slope after = -91.38 
units/month (p<0.0001).  
 
Blood transfusion 
Total number of transfusion 
increased by 2% in 2007, by 8% 
by 2008. Number of patients 
received transfusion increased 
by 6% in 2007, 8% by 2008 (p = 
0.003). However, no statistically 
significant change point was 
detected.   
 
Subgroup analysis of those 
receiving chemotherapy 
Proportion of patients receiving 
ESAs decreased from 26.5% in 
2006 to 9.4% in 2008, p < 
0.0001). No change in the 
proportion of patient receiving 
Safety concerns and 
reimbursement 
change were 
associated with a 
decrease in ESA 
use among cancer 
patients, both 
receiving and 
receiving 
concomitant 
chemotherapy. 
- 
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ESAs) 
 
Change in ESA use and 
transfusion use over 
time, adjusting for 
patient demographic and 
clinical characteristics. 
transfusion was observed. 
 
Hb value at transfusion 
No change was found in Hb 
values at transfusion and in 
proportion of patients with Hb 
level < 10 g/dL on day of 
transfusion 
 
Hb value at initiation of ESAs 
Proportion of patients who 
started ESAs at Hb ≤ 10 g/dL 
increased from 60.6% in 2006 to 
88.9% in 2008 (P < 0.0001).   
Hess et al., 2010 Proportion of patients 
administered with ESAs 
 
Proportion of patients 
required blood 
transfusion 
 
Frequency of 
myelosuppressive 
chemotherapy treatment 
Chi-square tests 
and t-tests 
All patients: 26.4% relative 
decrease (p < 0.001) 
 
Aged ≥65: 29.1% relative 
decrease (p < 0.001) 
 
Blood transfusion increased 
significantly (17.1% for all 
patients and 31.3% in elderly) 
NCD reimbursement 
restriction was 
associated with the 
reduction in ESA 
use among cancer 
patients treated at 
oncology clinics 
The study did not 
adjust for patient 
characteristics when 
testing for the 
difference in ESA 
use. 
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Author, 
pub year 
Outcomes Measure Statistical 
Approach  
Results Conclusion Limitations/Gaps 
in literature 
Cancer 
Henry et al., 
2011 
Proportion of patients 
receiving transfusion 
during chemotherapy-
induced anemia episode 
 
Mean number of units of 
blood transfused 
 
Patient hematologic 
status (mean Hb) 
 
Frequency and duration 
of ESA use  
 
Hospitalization 
Bivariate analysis 
comparing pre-
post outcomes of 
interest 
 
Logistic 
regression to 
evaluate the 
likelihood of 
receiving a 
transfusion and 
negative binomial 
regression to 
estimate the 
number of units 
transfused 
Proportion of patients receiving 
ESAs before and during CIA 
episode decreased significantly 
pre-post NCD (88% vs 56%, p < 
0.0001).  ESA doses and 
duration of treatment decrease 
significantly (48 vs. 32 days and 
4.6 vs. 2.9 doses, p < 0.0001). 
 
NCD is associated with lower Hb 
level, 41% increase in the odds 
of receiving a transfusion, and 
53% increase in blood 
utilization. 
 
No significant difference in the 
rate of hospitalization was 
found. 
NCD was 
associated with 
decreased 
frequency and 
duration of ESA 
treatment in cancer 
patients receiving 
chemotherapy, a 
modest increase in 
blood transfusion, 
and a decreased Hb 
level, but was not 
associated with an 
increase in 
hospitalization. 
The study did not 
look at the likelihood 
of receiving ESAs 
before and after 
NCD. 
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Author, 
pub year 
Outcomes Measure Statistical 
Approach  
Results Conclusion Limitations/Gaps 
in literature 
Cancer 
Feinberg et al., 
2012 
Number of episodic 
cohorts (stratified by Hb 
at anemia treatment 
initiation < 10 g/dL) with: 
1. No anemia 
treatment 
2. ESA use only 
3. Transfusion only 
4. ESA+transfusion 
 
Mean Hb values, 
stratified by episodic 
cohorts at: 
1. Initiation of 
anemia treatment 
2. Up to 6 weeks 
before treatment 
3. Up to 6 weeks 
after anemia 
treatment 
 
Average number of days 
from chemotherapy 
initiation to Hb < 10 g/dL 
and average number of 
days from Hb < 10 g/dL 
to anemia treatment 
initiation 
Bivariate analysis 
using chi-square 
(number of 
episodic cohorts) 
and t-test (mean 
Hb values, time 
from 
chemotherapy to 
Hb < 10 g/dL and 
to treatment 
initiation) 
 
Comparing yearly 
number of 
episodic 
outcomes, using 
2006 as 
comparator 
Chemotherapy episodes with 
ESA treatment decreased 
significantly from 45.42% in 
2006 to 11.47% in 2009, with 
significant all year-to-year trends 
(p < 0.05). 
 
Mean Hb values at initiation of 
ESA-anemia treatment 
decreased from 10.8 g/dL in 
2006 to 8.9 g/dL in 2009 (p < 
0.001). 
 
Average number of days 
between chemotherapy and 
anemia treatment initiation with 
ESAs increased each year from 
21.2 days in 2006 to 39.0 days 
in 2009 (p < 0.001) 
Between 2006 and 
2009, there was a 
decreased use of 
ESAs, delayed in 
ESA-anemia 
treatment, and a 
decrease in Hb level 
at time of treatment 
initiation among 
cancer patients 
receiving 
chemotherapy at a 
private oncology 
clinic. 
The study did not 
adjust for patient 
characteristics when 
testing for the 
difference in ESA 
use. 
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Author, 
pub year 
Outcomes Measure Statistical 
Approach  
Results Conclusion Limitations/Gaps 
in literature 
Cancer 
Arneson et al., 
2012 
Proportion of patient with 
ESA use 
 
Proportion of patients 
requiring ≥ 1 blood 
transfusion and 
transfusion event rates 
Logistic 
regression 
comparing pre-
post proportion 
and poisson 
regression 
comparing pre-
post event rates 
ESA use in Medicare cancer 
patients receiving chemotherapy 
decrease from 35.0% to 15.2%.  
After adjusting for covariates, 
NCD was associated with 67% 
reduction in the odds of ESA 
use (OR = 0.33, p < 0.0001)  
 
No significant change in the 
adjusted transfusion use and 
transfusion event rates was 
found 
NCD was 
associated with a 
reduction in ESA 
use among 
Medicare cancer 
patients receiving 
chemotherapy, but 
was not associated 
with transfusion use 
- 
Chan 2010 “Appropriateness” of 
ESA prescribing 
measured through Hb 
initiation and targeted  
levels, ESA dose 
adjustment, treatment of 
duration and presence of 
concomitant iron 
supplement 
 
“Appropriateness” of 
ESA efficacy and toxicity 
monitoring measured 
through the number of 
blood transfusion 
needed before and after 
ESA therapy and other 
indicators 
Chi-square tests 
and t-tests 
Mean Hb level at treatment 
initiation was significantly lower 
(8.52 g/dL vs. 8.95 g/dL, p = 
0.032), but the duration of 
treatment remained unchanged 
(17 days vs. 20 days, p = 0.844). 
 
A significantly smaller proportion 
of patients requiring more blood 
transfusion after ESA therapy 
was observed (44.8% vs. 7.1%, 
p = 0.016). 
 
Safety guidelines 
were associated 
with lower Hb level 
at the time of 
treatment initiation 
and fewer blood 
transfusions after 
ESA treatment 
among patients with 
cancer in 
Singapore.  No 
change in duration 
of ESA treatment 
was seen. 
The study did not 
test for a 
significance 
difference in the 
proportion of 
patients receiving 
ESAs pre- and post-
warning period and 
did not adjust for 
covariates for other 
statistical testing.  
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Gaps in the Literature 
Existing literature has provided concrete evidence of changes in ESA prescribing in the 
outpatient settings from 2005 to 2009.  However, the literature is lacking on prescribing patterns 
of ESAs among hospitalized patients since 2004.  Among studies exploring changes in ESA 
outpatient utilization over time, none of them has attempted to link specific safety interventions 
to prescribing patterns of ESA.  In addition, the effect of REMS, the FDA’s most recent risk 
communication tool implemented in 2010, on ESA use has never been assessed.  Finally, the 
relative impacts of various safety interventions on the on-label and off-label use of ESAs has not 
been explored.   
This study contributes to the literature in the following ways.  First, it provides update on 
the on-label and off-label use of ESAs in the inpatient settings - last studied in 2004.  Second, it 
quantifies relative immediate and trend impacts of various regulatory interventions on inpatient 
ESA use between November 2006 and November 2010.  The study further compares impacts of 
such interventions across the.  Third, this study explores how these interventions might influence 
three types of ESA prescribing (on-label, off-label supported, and off-label unsupported 
indications)   differently.  Finally, the study determines factors associated with the likelihood of 
receiving ESAs in the inpatient settings between 2005 and 2011.    
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Research Questions, Specific Aims, and Hypotheses 
Descriptive Study: Specific Aim 1  
No hypotheses were formulated for the descriptive study. 
Research Question 1a 
 Do differences in demographic characteristics, clinical conditions, insurance status, 
hospital characteristics, and physician characteristics exist between users of epoetin alfa and that 
of darbepoetin alfa? 
Specific Aim 1a 
To compare demographic characteristics, clinical conditions, insurance status, hospital 
characteristics, and physician characteristics between epoetin alfa users and darbepoetin alfa 
users. 
Research Question 1b 
 Do differences in demographic characteristics, clinical conditions, insurance status, 
hospital characteristics, and physician exist among ESA users of on-label, off-label supported, 
and off-label unsupported indications in the inpatient settings? 
Specific Aim 1b 
 To compare demographic characteristics, clinical conditions, insurance status, hospital 
characteristics, and physician characteristics among ESA users of on-label, off-label supported, 
and off-label unsupported indications in the inpatient settings. 
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Inferential Study: Specific Aim 2 and 3 
Specific Aim 2: Impact of Black box warning, NCD, and REMS on the proportions of visits with 
on-label, off-label supported, and off-label unsupported ESA use 
Research Question 2 
What are the immediate and trend impacts of 1) black box warning, 2) national coverage 
determination, and 3) REMS on utilization patterns of ESAs and for the on-label, off-label 
supported, and off-label unsupported indications?  
Specific Aim 2 
To quantify the immediate and trend impacts of black box warning, NCD, and REMS on 
the proportion of visits where a patient was prescribed ESAs for on-label, off-label supported, 
and off-label unsupported indications  
Hypothesis for Question 2 
Each of the interventions is associated with a significant change in the immediate and 
trend of the proportion of ESA use in the three use categories.  
H0-2-a : There exists no significant immediate and trend change in the proportion of visits 
where a patient was prescribed ESAs for a) on-label, b) off-label supported, or c) off-label 
unsupported indications in the hospital settings after the issuance of black box warning  
H0-2-b : There exists no significant immediate and trend change in the proportion of visits 
where a patient was prescribed ESAs for a) on-label, b) off-label supported, or c) off-label 
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unsupported indications in the hospital settings after the implementation of national coverage 
determination. 
H0-2-c : There exists no significant immediate and trend change in the proportion of visits 
where a patient was prescribed ESAs for a) on-label, b) off-label supported, or c) off-label 
unsupported indications in the hospital settings after the implementation of REMS. 
Specific Aim 3: Impact of Black box warning, NCD, and REMS on the odds of a patient being 
prescribed ESAs for the on-label, off-label supported, and off-label unsupported indications  
Research Question 3a 
What are the immediate and trend impacts of 1) black box warning, 2) national coverage 
determination, and 3) REMS on the odds of receiving ESA among patients with a) on-label and 
b) off-label supported indications, adjusting for patient & hospital characteristics?  This question 
is formulated to find out whether the three interventions have an unintended effect on ESA use in 
the hospital settings.  Specifically, we would like to know if there is a decrease in the likelihood 
of receiving ESAs among patients who could benefit from the on-label and off-label supported 
indications of ESAs after the interventions.  
Hypothesis for Question 3a 
Each of the interventions is associated with significant unintended change in the 
immediate and trend in the odds of receiving ESAs in patients with the on-label and off-label 
unsupported indications, adjusting for individual patient characteristics, hospital characteristics, 
and physician specialty.   
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H0-3a-a: There exists no significant immediate and trend change in the odds of receiving 
ESAs in patients with the on-label or off-label supported indications in the hospital settings after 
the issuance of black box warning.  
H0-3a-b : There exists no significant immediate and trend change in the odds of receiving 
ESAs in patients with the on-label or off-label supported indications in the hospital settings after 
the implementation of NCD. 
H0-3a-b : There exists no significant immediate and trend change in the odds of receiving 
ESAs in patients with the on-label or off-label supported indications in the hospital settings after 
the implementation of REMS. 
Specific Aim 3a 
To quantify the immediate and trend unintended impacts of black box warning, NCD, 
and REMS on the odds of receiving ESAs among the following patients in the hospital settings, 
adjusting for individual patient characteristics, hospital characteristics, and physician specialty: 
1. Those with diagnoses related to the on-label indications of ESA use in the absence of 
observable contraindications. 
2. Those with diagnoses related to the off-label supported indications of ESA use in the 
absence of observable contraindications. 
3. Those with diagnoses related to the documented off-label unsupported indications of ESA 
use in the absence of observable contraindications. 
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Specific Aim 3b: Association between patient characteristics, clinical conditions, hospital 
characteristics, and admitting physician medical specialties on the odds of being prescribed 
ESAs for the on-label, off-label supported, and off-label unsupported indications 
Research Question 3b 
What are the associations between patient demographic and clinical characteristics, 
hospital characteristics, or physician specialty and the odds of receiving ESAs between January 
2005 and June 2011 among patients with a) on-label and b) off-label supported indications, and 
c) documented off-label unsupported indications, other things constant? 
Hypotheses for Question 3b 
We hypothesize that patient demographic, clinical characteristics, hospital characteristics, 
and ordering physician specialties are associated with the odds of receiving ESAs among patients 
with a) on-label, b) off-label supported indications, and c) documented off-label unsupported 
indications.  
Patient characteristics (age, race, gender, primary payer of health insurance) 
H0-3b-a : There exists no significant association between patient’s age and the odds of 
receiving ESAs in the hospital settings among the three patient populations.  
H0-3b-b : There exists no significant association between patient’s race and the odds of 
receiving ESAs in the hospital settings among the three patient populations. 
H0-3b-c : There exists no significant association between patient’s gender and the odds of 
receiving ESAs in the hospital settings among the three patient populations. 
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H0-3b-d : There exists no significant association between patient’s primary payer of health 
insurance and the odds of receiving ESAs in the hospital settings among the three patient 
populations. 
Patient clinical conditions (admission status, severity of illness, discharge disposition) 
H0-3b-e : There exists no significant association between patient’s admission status and the 
odds of receiving ESAs in the hospital settings among the three patient populations. 
H0-3b-f: There exists no significant association between patient’s severity of illness and the 
odds of receiving ESAs in the hospital settings among the three patient populations. 
H0-3b-g : There exists no significant association between patient’s place of discharge and 
the odds of receiving ESAs in the hospital settings among the three patient populations. 
Hospital characteristics (teaching status, bed size, geographic region)  
H0-3b-h : There exists no significant association between teaching status and the odds of 
receiving ESAs in the hospital settings among the three patient populations. 
H0-3b-i : There exists no significant association between hospital size and the odds of 
receiving ESAs in the hospital settings among the three patient populations. 
H0-3b-j : There exists no significant association between geographic region and the odds of 
receiving ESAs in the hospital settings among the three patient populations. 
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Physician specialty 
H0-3b-m: There exists no significant association between physician specialties and the odds 
of receiving ESAs in the hospital settings among the three patient populations. 
Specific Aim 3b 
To determine if association exist between patient characteristics, clinical conditions, 
physician specialty, and hospital characteristics and odds of receiving ESAs among patients with 
a) on-label, b) off-label supported indications, and c) documented off-label unsupported 
indications. 
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CHAPTER 3 
Methodology 
This chapter describes the study methodology used to assess the relative effect of safety 
regulations on the inpatient on-label and off-label ESA use between January 1, 2005 and June 
30, 2011.  The chapter is divided into five parts including 1) information regarding the data and 
subject selection, 2) classification of ESA use, 3) variable measurements, 4) statistical analysis 
and testing of hypotheses, and 5) data privacy. 
Study Design and Data Collection 
  This was a retrospective time-series study of patients within a multi-hospital database.  
The data for this retrospective cohort study came from Cerner Millennium and was provided 
through the Center for Clinical and Translational Research (CCTR) at Virginia Commonwealth 
University.
a
  The Cerner HealthFacts® database provides de-identified, HIPAA-compliant, 
longitudinal collection of patient information generated from the Cerner
®
 electronic medical 
record (EMR)  from over one hundred community and academic hospitals in the United States.  
The data  
The Cerner HealthFacts® database contained detailed information on inpatient care such 
as procedure and diagnoses-specific data (in International Classification of Diseases, 9
th 
Revision, Clinical Modification (ICD-9-CM) format) from discharge abstract summaries and 
                                                          
a
 The project described was supported by CTSA award No. UL1TR000058 from the National Center for Advancing 
Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent 
official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. 
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inpatient medication orders.  Database elements also included patient (age, gender, race, 
admission date, discharge date and length of stay), hospital (bed size, geographic region), drug 
(medication started dates), and ordering physician (medical specialty) information.  
Study Population 
Eligible visits/patients were adult individuals who were admitted to Cerner hospitals with 
predefined diagnoses codes (on-label, off-label supported, or known off-label unsupported) or 
received at least one order of erythropoietin during the period of January 1, 2005 and June 30, 
2011. 
Inclusion and Exclusion Criteria 
This study included all visits of adult patients (≥ 18 years of age) who were admitted to 
Cerner hospitals and received erythropoietin (epoetin alfa or darbepoetin alfa) at least once 
during their stay.  Visits with no recorded information on ICD-9-CM diagnoses codes were 
excluded.  In addition, all visits of adult patients with predefined ICD-9-CM for on-label and off-
label indications of ESAs were included in the analysis.  Visits without any drug records were 
excluded from the analyses.  Children and adolescence were excluded from all analyses as the 
indications and level of evidence supporting use of ESAs were different by age within the 
pediatric population themselves and also between the two populations.  A list of pre-specified 
ICD-9-CM codes used to define on-label, off-label supported, and documented off-label 
unsupported uses are described in Table 3.1 – 3.4 and detail use categorization is described in the 
later part.   
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Classification of ESA use 
Use of ESAs was classified into three categories using ICD-9-CM diagnoses codes, 
procedures codes, and/or their medication use, into (1) on-label use, ONS (approved by the 
FDA); (2) off-label use supported, OFS (use for the indications not approved by the FDA, but 
there is strong clinical evidence to support its use); and (3) off-label use unsupported, OFU (use 
for the indications not approved by the FDA and lacking clinical evidence).  The DRUGDEX 
system is described in detail in Section 1 of Chapter 2.  
First, the list of all FDA-approved indications provided in the drug’s package inserts was 
compared with the FDA-approved indication listed by DRUGDEX.  Conditions that matched 
with the indications stated in the drug’s package insert and confirmed by DRUGDEX were 
identified as on-label (ONS).  Discrepancies existing between the two sources were resolved by 
consulting with the clinical expert, Dr. Donald F. Brophy, Pharm.D., M.Sc., FCCP, FASN, 
BCPS.  ICD-9-CM diagnoses codes, ICD-9-CM procedures codes, and certain use of 
medications related to the conditions were used to identify patients with ONS conditions.  The 
ONS conditions for epoetin alfa and darbepoetin alfa included anemia of chronic kidney disease, 
chemotherapy-induced anemia, zidovudine-induced anemia, and an indication of a patient 
undergoing a major, non-cardiovascular surgery that may result in loss of significant amount of 
blood.   
The categorization of a specific off-label indication using the strength of evidence, level 
of recommendation, and treatment effectiveness provided by DRUGDEX were proposed by 
Walton et al.
 189  
 In their study, off-label use was categorized into three groups: evidence-based 
off-label use, uncertain evidence for off-label use, and inadequate evidence for off-label use.  
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However, to avoid classifying off-label as uncertain, we categorized off-label use into two 
groups: supported and unsupported, as suggested by other off-label studies.
15, 190 
  A use of a drug 
for a condition was off-label supported (OFS) if its use in such condition was recommended by 
the compendium (Class I-IIb) and/or supported by published clinical evidence (Category A, B).  
On the other hand, the use was classified as off-label unsupported (OFU) if it was for a condition 
not recommended by DRUGDEX (Class III or In-determinant) and minimal evidence regarding 
such use was present (Category C or No evidence).
56
 An indication receiving an efficacy rating 
of “effective” and “evidence favors efficacy” was classified as off-label supported use while that 
with “inconclusive evidence” and “ineffective” was labeled off-label unsupported.56  Should 
conflicts between these three drug evaluation dimensions arise; a conservative approach was 
taken; an indication was categorized into the group that the least favorable level of evidence 
indicates.  For example, if a use falls under Class IIb, Category C, with an evidence that favors 
efficacy, it was classified as off-label unsupported, not off-label supported, based on its strength 
of evidence (Category C). 
In a similar fashion to ONS, ICD-9-CM diagnoses codes, ICD-9-CM procedures codes, 
and certain use of medications related to the conditions were use to identify visits of a patient 
with OFS conditions.  Examples of OFS conditions for ESAs were non-chronic kidney diseases, 
anemia due to adverse effect of ribavirin and interferon alfa in hepatitis C patients, congestive 
heart failure, and rheumatoid arthritis.   
Listed OFU use included treatment of anemia in cancer patients not undergoing 
concurrent chemotherapy, anemia in traumatic patients, porphyria cutanea tarda, and sickle cell 
anemia.  Additional unsupported off-label uses of ESAs were identified from the published off-
label literature.
15
 Examples of such use included the treatment of anemia of chronic diseases, 
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hemorrhage, and cardiac surgery.  The algorithmic categorization used in this study is described 
in Figure 3.1 and complete list of ICD-9-CM diagnoses/procedure codes and drug orders used to 
identify the ONS, OFS, and OFU cohorts can be found in Table A.1, A.2, and A.3, respectively.  
 
 
Figure 3.1 Schematic algorithm of categorizing ESA use 
Despite the fact that darbepoetin alfa was only approved for the treatment of chronic 
kidney disease and chemotherapy-induced anemia, hospitals may choose to include solely 
darbepoetin alfa in their formulary and the drug can be used solely in place of epoetin alfa be 
used on-label and off-label.  As a result, this study did not distinguish the two erythropoietins for 
on-label or off-label indications.   
Does the condition match any of the indications listed in package inserts?
Is there a strong evidence supporting such use?
Off-label use, supported (OFS)
Appropriate Use
Off-label use, unsupported (OFU)
Potentially Inappropriate Use
- Class I, IIa, or IIb
- Category A or B
- Effective or Evidence 
favors efficacy
- Class III or In-determinant
- Category C or No evidence
- Evidence inconclusive or 
Ineffective
On-label use (ONS)
Appropriate Use
Off-label use
YES
YES
NO
NO
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Table 3.1 ICD-9-CM procedures and diagnoses codes used to identify on-label use of ESAs 
Therapeutic use of 
epoetin alfa 
Selection criteria 
(ICD-9-CM diagnoses & 
procedure codes and drug 
use) 
ICD-9-CM descriptions 
On-label indications (ONS) 
1.  Anemia of 
chronic renal failure 
285.21 Anemia in chronic kidney disease 
585 Chronic kidney disease (CKD) 
403 Hypertensive kidney disease 
404 Hypertensive heart and kidney disease 
753.0 Congenital anomalies of urinary system -  Renal 
agenesis and dysgenesis 
753.3 Other specified anomalies of kidney 
996.73 Other complications of internal (biological) 
(synthetic) prosthetic device, implant, and graft - 
Due to renal dialysis device, implant, and graft 
996.81 Complications of kidney transplant 
V42 Kidney transplant 
V45.1 Renal dialysis status 
V45.73 Acquired absence of kidney 
V56.0 Aftercare involving extracorporeal dialysis 
V56.1 Fitting and adjustment of extracorporeal dialysis 
catheter 
V56.2 Fitting and adjustment of peritoneal dialysis 
catheter 
V56.3 Encounter for adequacy testing for hemodialysis 
or peritoneal dialysis 
V 56.8 Aftercare involving other dialysis 
38.95 Venous catheterization for renal dialysis 
39.27 Ateriovenostomy for renal dialysis 
39.95 Hemodialysis 
54.98 Peritoneal dialysis 
2.  Anemia due to 
chemotherapy in 
patients with 
metastatic, non-
myeloid 
malignancies  
285.22 combined with any of 
the following codes or 
chemotherapeutic agents 
(see chemotherapeutic 
agents list) 
Anemia in neoplastic disease 
V58.1 Encounter for antineoplastic chemotherapy and 
immunotherapy 
E933.1 Antineoplastic and immunosuppressive drugs 
causing adverse effects in therapeutic use 
V66.2 Convalescence following chemotherapy 
V67.2 Follow-up examination following chemotherapy 
00.10 Implantation Of Chemotherapeutic Agent 
99.25 Injection Or Infusion Of Cancer 
Chemotherapeutic Substance 
3.  Anemia due to 042 Human immunodeficiency virus (HIV) disease 
  
  
76 
 
zidovudine adverse 
reaction 
Any order of zidovudine Zidovudine, abacavir/lamivudine/zidovudine, or 
lamivudine-zidovudine 
E931.7 Antiviral drugs causing adverse effects in 
therapeutic use 
4.  Prophylaxis of 
blood transfusion 
before and during 
surgical procedure 
Any of the following V codes or major surgical procedure codes (see Table X in 
Appendix) with codes for injury, cardiac dx/surgeries, or procedural bleeding (see 
lists of injury diagnoses and procedural bleeding codes in Table 3.3)  
 V54.0 Aftercare involving internal fixation device 
 V54.9 Unspecified orthopedic aftercare 
 V58.4 Other aftercare following surgery 
 V58.7 Aftercare following surgery to specified body 
systems not elsewhere classified 
 V66.0 Convalescence following surgery 
 
Generic names of chemotherapy agents used as inclusion criteria of on-label use of ESAs 
were specified below: 
Arsenic trioxide, azacitidine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, 
cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, 
daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, 
gemcitabine, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, 
mercaptopurine, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, 
pemetrexed, procarbazine, streptozocin, teniposide, thioguanine, thitepa, topotecan, 
vinblastine, vincristine, and vinorelbine
191 
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Table 3.2 ICD-9-CM procedures and diagnoses codes used to identify off-label supported use of ESAs 
Therapeutic use of 
epoetin alfa 
Selection criteria 
(ICD-9-CM diagnoses & 
procedure codes and drug 
use) 
ICD-9-CM descriptions 
Off-label Supported indications (OFS) 
1. Non-chronic 
kidney disease 
581 Nephrotic syndrome 
582 Chronic glomerulonephritis 
583 Nephritis and nephropathy not specified as acute 
or chronic 
 584 Acute kidney failure 
 586 Renal failure unspecified 
 587 Renal sclerosis unspecified 
 588.89 Other specified disorders resulting from impaired 
renal function 
 593.0 Nephroptosis 
 593.1 Hypertrophy of kidney 
 593.2 Cyst of kidney acquired 
 593.6 Postural proteinuria 
 593.8 Other specified disorders of kidney and ureter 
 593.9 Unspecified disorder of kidney and ureter 
 753.1 Cystic kidney disease 
 794.4 Nonspecific abnormal results of function study of 
kidney 
2. Anemia in patients 
with hepatitis C 
being treated with a 
combination of 
ribavirin and 
interferon alfa or 
ribavirin and 
peginterferon alfa 
070.41 Acute hepatitis c with hepatic coma 
070.44 Chronic hepatitis c with hepatic coma 
070.51 Acute hepatitis c without hepatic coma 
070.54 Chronic hepatitis c without hepatic coma 
070.70 Unspecified viral hepatitis c without hepatic coma 
070.71 Unspecified viral hepatitis c with hepatic coma 
Any order of ribavirin and 
interferon alfa 
interferon alfa-2a, interferon alfa-2b, interferon 
alfacon-1, interferon alfa-n1, interferon alfa-n3, 
interferon alfa-2b-ribavirin, or ribavirin 
3.  Anemia due to 
congestive heart 
failure 
398.91 Rheumatic heart failure (congestive) 
402.91 Unspecified hypertensive heart disease with 
heart failure 
428 Heart failure 
4.  Anemia due to 
radiation 
V58.0 Encounter for radiotherapy 
V66.1 Convalescence following radiotherapy 
V67.1 Follow-up examination following radiotherapy 
990 Effects of radiation unspecified 
E879.2 Radiological procedure and radiotherapy as the 
cause of abnormal reaction of patient or of later 
complication without misadventure at time of 
procedure 
E926.3 Exposure to x-rays and other electromagnetic 
ionizing radiation 
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E926.5 Exposure to radioactive isotopes 
92.2 Therapeutic Radiology And Nuclear Medicine 
5.  Anemia during 
the puerperium 
641 Antepartum hemorrhage abruptio placentae and 
placenta previa 
646 Other complications of pregnancy not elsewhere 
classified 
 648 Other current conditions in the mother classifiable 
elsewhere but complicating pregnancy childbirth 
or the puerperium 
 664 Trauma to perineum and vulva during delivery 
 666 Postpartum hemorrhage 
 674 Other and unspecified complications of the 
puerperium not elsewhere classified 
 677 Late effect of complication of pregnancy childbirth 
the puerperium 
 72 Forceps, Vacuum, And Breech Delivery 
 73 Other Procedures Inducing Or Assisting Delivery 
 74 Cesarean Section And Removal Of Fetus 
 75 Other Obstetric Operations 
6.  Anemia due to 
multiple myeloma 
203.0 Multiple myeloma and immunoproliferative 
neoplasms 
7. Anemia due to 
myelodysplastic 
syndrome 
238.72 Low grade myelodysplastic syndrome lesions 
 238.73 High grade myelodysplastic syndrome lesions 
 238.74 Myelodysplastic syndrome with 5q deletion 
 238.75 Myelodysplastic syndrome, unspecified 
8. Anemia due to 
myelofibrosis 
238.76 Myelofibrosis with myeloid metaplasia 
 289.83 Myelofibrosis  
9. Anemia due to 
rheumatoid arthritis 
714 Rheumatoid arthritis and other inflammatory 
polyarthropathies 
10. Beta 
Thalassemia 
282.49 Other thalassemia 
 
11. Blood unit 
collection for 
autotransfusion 
99.02 Transfusion of previously collected autologous 
Blood 
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Table 3.3 ICD-9-CM procedures and diagnoses codes used to identify documented off-label unsupported 
use of ESAs 
Therapeutic use of 
epoetin alfa 
Selection criteria 
(ICD-9-CM diagnoses & 
procedure codes and 
drug use) 
ICD-9-CM descriptions 
Known Off-label Unsupported Indications (OFU Known) 
1. Cancer with no 
indication of 
chemotherapy 
285.22 Anemia in neoplastic disease  
141-239 Various types of neoplasm 
V10 Personal history of malignant neoplasm 
2. Anemia of chronic 
disease 
280 Iron deficiency anemias 
281 Other deficiency anemias 
282 Hereditary hemolytic anemias 
283 Acquired hemolytic anemias 
284 Aplastic anemia 
285 Other and unspecified anemias 
286 Coagulation defects 
287 Purpura and other hemorrhagic conditions 
289 Other diseases of blood and blood-forming 
organs 
3. Hemorrhage 430 Other diseases of blood and blood-forming 
organs 
 431 Intracerebral hemorrhage 
 432 Other and unspecified intracranial hemorrhage 
 456.20 Esophageal varices in diseases classified 
elsewhere with bleeding (bleeding) 
 455.2 Internal hemorrhoids with other complication 
 455.5 External hemorrhoids with other complication 
(bleeding) 
 455.8 Unspecified hemorrhoids with other 
complication (bleeding) 
 459 Other disorders of circulatory system 
 511.8 Other specified forms of pleural effusion 
except tuberculous 
 530.21 Ulcer of esophagus with bleeding 
 530.82 Esophageal hemorrhage 
 530.0 Acute gastric ulcer with hemorrhage 
 531.1 Acute gastric ulcer with perforation 
 531.2 Acute gastric ulcer with hemorrhage and 
perforation 
 531.4 Chronic or unspecified gastric ulcer with 
hemorrhage 
 531.5 Chronic or unspecified gastric ulcer with 
perforation 
 531.6 Chronic or unspecified gastric ulcer with 
hemorrhage and perforation 
 532.1 Acute duodenal ulcer with perforation 
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 532.4 Chronic or unspecified duodenal ulcer with 
hemorrhage 
 532.5 Chronic or unspecified duodenal ulcer with 
perforation 
 532.6 Chronic or unspecified duodenal ulcer with 
hemorrhage and perforation 
 533.4 Chronic or unspecified peptic ulcer of 
unspecified site with hemorrhage without 
obstruction 
 534.4 Chronic or unspecified gastrojejunal ulcer with 
hemorrhage  
 534.9 Gastrojejunal ulcer unspecified as acute or 
chronic without hemorrhage or perforation  
 535.01 Acute gastritis with hemorrhage 
 535.11 Atrophic gastritis with hemorrhage 
 535.41 Other specified gastritis with hemorrhage 
 535.51 Unspecified gastritis and gastroduodenitis with 
hemorrhage 
 535.61 Duodenitis with hemorrhage 
 535.71 Eosinophilic gastritis with hemorrhage 
 537.83 Angiodysplasia of stomach and duodenum 
with hemorrhage 
 537.84 Dieulafoy lesion (hemorrhagic) of stomach and 
duodenum 
 562.12 Diverticulosis of colon with hemorrhage 
 562.13 Diverticulitis of colon with hemorrhage 
 568.81 Hemoperitoneum (nontraumatic) 
 569.3 Hemorrhage of rectum and anus 
 569.85 Angiodysplasia of intestine with hemorrhage 
 569.86 Dieulafoy lesion (hemorrhagic) of intestine 
 578 Gastrointestinal hemorrhage 
 635.11 Legally induced abortion incomplete 
complicated by delayed or excessive 
hemorrhage 
 640.03 Threatened abortion antepartum 
 729.92 Nontraumatic hematoma of soft tissue 
 784.7 Epistaxis 
 786.3 Hemoptysis 
 790.92 Abnormal coagulation profile 
 998.11 Hemorrhage complicating a procedure 
 998.12 Hematoma complicating a procedure 
 E870.0 Accidental cut puncture perforation or 
hemorrhage during surgical operation 
 28.7 Control Of Hemorrhage After Tonsillectomy 
And Adenoidectomy 
 44.4 Control Of Hemorrhage And Suture Of Ulcer 
Of Stomach Or Duodenum 
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 49.95 Control Of (Postoperative) Hemorrhage Of 
Anus 
 57.93 Control Of (Postoperative) Hemorrhage Of 
Bladder 
 60.94 Control Of (Postoperative) Hemorrhage Of 
Prostate 
4. Cardiac surgery V72.81 Pre-operative cardiovascular examination 
 00.4 Adjunct Vascular System Procedures 
 00.5 Other Cardiovascular Procedures 
 00.6 Procedures On Blood Vessels 
 17.5 Additional Cardiovascular Procedures 
 35 Operations On Valves And Septa Of Heart 
 36 Operations On Vessels Of Heart 
 37 Other Operations On Heart And Pericardium 
 38 Incision, Excision, And Occlusion Of Vessels 
 39 Other Operations On Vessels 
5. Acute use in critical 
care/injury/trauma/fracture 
733.1 Pathologic fracture 
733.8 Malunion and nonunion of fracture 
733.93-733.98 Stress fracture of bones (various sites) 
800-829 Fracture (various sites) 
850-854 Intracranial Injury, Excluding Those With Skull 
Fracture 
860-869 Internal Injury Of Chest, Abdomen, And Pelvis 
870-879 Open Wound Of Head, Neck, And Trunk 
880-887 Open Wound Of Upper Limb 
890-897 Open Wound Of Lower Limb 
900-904 Injury To Blood Vessels 
905-909 Late Effects Of Injuries, Poisonings, Toxic 
Effects, And Other External Causes 
910-919 Superficial Injury 
920-924 Contusion With Intact Skin Surface 
925-929 Crushing Injury 
958 Certain early complications of trauma 
959 Injury other and unspecified 
E887 Fracture cause unspecified 
V54.1 Aftercare for healing traumatic fracture 
V54.2 Aftercare for healing pathologic fracture 
16.89  
6. Other known off-label 
use 
277.1 Anemia in porphyria cutanea tarda 
282.6 Sickle-cell disease 
410 Acute myocardial infarction 
411 Other acute and subacute forms of ischemic 
heart disease 
412 Old myocardial infarction 
555 Regional enteritis 
556 Ulcerative enterocolitis 
607.84 Sexual dysfunction 
 99.0 Blood transfusion 
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Table 3.4 ICD-9-CM procedures codes of major surgeries used to identify on-label use of ESAs 
Therapeutic use of epoetin alfa ICD-9-CM procedure  ICD-9-CM descriptions 
Prophylaxis of blood transfusion 
before and during surgical 
procedure* 
00.7 Other Hip Procedures 
00.8 Other Knee Procedures 
01-05 Operations On The Nervous System 
06-07 Operations On The Endocrine System 
30-34  Operations On The Respiratory System 
40-41 Operations On The Hemic And Lymphatic 
System 
42-54 Operations On The Digestive System 
55-59 Operations On The Urinary System 
60-64 Operations On The Male Genital Organs 
65-71 Operations On The Female Genital Organs 
72-75 Obstetrical Procedures 
76-84 Operations On The Musculoskeletal 
System 
85-86 Operations On The Integumentary System 
*Codes related to diagnostic procedures were not included 
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Variable Measurements for Inferential Statistics 
Independent variables 
Independent variables of the multivariable regression models assessing the impact of 
safety interventions on ESA prescribing patterns were the three events of the safety 
interventions.  During the six years period, five types of interventions had occurred, namely the 
issuance of a public health advisory (November 2006), Dear Health Care Professional Letter 
(January 2007), FDA black box warning (March 2007), reimbursement restriction (July 2007 and 
April 2008), and REMS (March 2010).  Interventions that occurred very close to one another 
were consolidated because time-series study design suggested at least 10-12 time points between 
each segment to accurately assess seasonality and trend impact.
 192 
  As a result of event 
consolidation, three specific events were chosen to represent interventions at three time points.  
These events were the addition of black box warning in March 2007; the official implementation 
of NCD in April 2008; and the implementation of REMS in March 2010.  In the first period 
between January 2005 and April 2008, three events had occurred: the issuance of the first public 
health advisory (November 2006), Dear Health Care Professional Letter (January 2007), labeling 
revision to include a black box warning (March 2007), and the announcement of NCD effective 
(July 2007).  The addition of a black box warning was chosen as a main intervention during this 
nine months period.  Black box warning was chosen over a public health advisory because we 
believe that black box warning was more publicized and would have a more prominent effect on 
ESA utilization than an advisory.   We did not choose July 2007, the month which NCD first was 
announced effective as the first intervention because the change in reimbursement policy was not 
directly applicable to the inpatient setting and should have little effect in our sample.  Moreover, 
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little effect of the NCD during this period was anticipated because the announcement was only 
made public in the CMS website and without any press release.   
The second period of this analysis was between April 2008 and March 2010.  During this 
period, two events occurred: the official implementation of NCD on April 7, 2008 and the 
revision of the black box warning on March 14, 2008.  The official implementation of NCD was 
chosen as a main event in this period because we believed that the official implementation of the 
reimbursement restriction would have created a greater impact of the level of drug use, compared 
to a revision of a black box warning already in place.   
The third and final period of the analysis lasted between March 2010 and June 2011.  The 
implementation of REMS in March 2010 was the only event considered significant enough to 
influence ESA prescribing.   
Table 3.5 Independent variables for Specific Aim 2 and 3 
Event Time period 
First Intervention  
   Public health advisory  November 2006 
   Dear Healthcare Provider letter  January 2007 
   Black box warning  March, 2007 
   National Coverage Determination announced effective July 2007 
   Black box warning update November 2007 
Second Intervention  
   Black box warning update March 2008 
   National Coverage Determination Implemented April 2008 
Third Intervention  
   REMS initial approval February 2010 
   REMS Implementation March 2010 
*Bolded event and time period indicate the event and time of the intervention used in this study 
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Dependent variables  
Specific Aim 2 
Monthly aggregated proportions of visits with ESA use for on-label, off-label supported, 
and off-label unsupported indications were dependent variables for the time-series analysis.  
Definitions for ONS, OFS, and OFU proportions used as dependent variables were provided 
below. 
1. On-label proportion  
The proportion of encounters which ESAs were prescribed for on-label indications was 
defined as the number of encounters with diagnoses codes that matched with on-label indications 
for ESA use and had one order of ESAs (A), divided by the total number of encounters with 
those diagnoses codes (1), in a given time period. 
2. Off-label supported proportion 
The proportion of encounters being prescribed ESAs for the off-label supported 
indication was defined as the number of encounters with diagnoses codes that matched with on-
label indications for ESA use and had one order of ESAs (B), divided by the total number of 
encounters with those diagnoses codes (2), in a given time period. 
3. Off-label unsupported proportion 
Since the total number of eligible encounters for ESA off-label unsupported indications 
could not feasibly be obtained from the database, the proportion of visits with ESAs prescribed 
for the off-label unsupported indication was calculated by dividing the number of encounters 
with ESAs, but did not have diagnoses codes that matched with on-label or off-label supported 
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indications of ESA use (C) + (D) by the total number of encounters with known OFU (3), in a 
given time period.   
 
 
Figure 3.2 Proportion of ESA use as dependent variables for Specific Aim 2 
ONS: On-label supported indications, OFS: Off-label supported indications, OFU: Off-label unsupported 
indications.   
First, all inpatient visits of patients aged 18 and above who had at least one record of 
ESAs (epoetin alfa or darbepoetin alfa) were identified in the database.  Two separate cohorts of 
epoetin alfa and darbepoetin alfa were formed.  Each user’s diagnoses, procedures, and 
medications records were searched to categorize use of ESAs into ONS, OFS, or OFU using the 
algorithm shown in Figure 3.2.  The number of visits which ESAs were for prescribed for ONS, 
OFS, and OFU indications in a month was calculated as respective numerator cohorts.   
Encounters with
ONS diagnoses
Encounters with
ONS diagnoses
& ESA
Encounters with
OFS diagnoses
Encounters with OFS 
diagnoses & ESA
Encounters 
with OFU 
diagnoses & 
ESA
4
1
3
2
5
All ESA encounters 2005-2011
Encounters with 
known OFU 
diagnoses
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7
Unidentif ied OFU 
use of  ESAs
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Figure 3.3 Schematic algorithm defining numerator cohorts for Specific Aim 2 
Next, the monthly number of admissions eligible for receiving ESAs was calculated as 
denominator cohorts.  All visits of adult patients admitted to the inpatient settings during the 
study period with diagnoses, procedure codes, and drug use of interest were included in the 
sample and categorized into the ONS, OFS, or OFU cohorts using a hierarchy categorization 
approach.  First, diagnoses, procedures, and medication records of all admissions were searched 
for ONS indications, if none of their diagnoses matched the ONS indications, the same sets of 
records were searched for OFS indications and OFU accordingly.  If diagnoses did not match 
ONS, OFS, or documented OFU indications, such encounters were excluded from this part of the 
analysis.  It is important to note that the OFU denominator cohort only included visits with 
conditions known to be treated with ESAs off-label identified earlier in Table 3.3.  This approach 
of using documented OFU conditions was taken because it was almost impossible to identify 
encounters with all possible off-label unsupported use of ESAs.  Examples of documented OFU 
indications used in this study included its use in anemia of neoplastic disease not due to 
All ESA use in adult patients seen in the inpatient settings without missing information on ICD-9-CM codes
Do their diagnoses match any of the ONS indications?
Off-label use, supported 
(OFS) numerator cohort
On-label use
(ONS) numerator cohort
YESYES
NO
NO
Do their diagnoses match any of the OFS indications?
Off-label use, unsupported
(OFU) numerator cohort
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chemotherapy, anemia due to trauma, bleeding, and other chronic anemia.  Categorization of 
denominator cohorts followed the algorithm is shown in Figure 3.4. 
 
Figure 3.4 Schematic algorithm defining denominator cohorts for Specific Aim 2 
 
  
All adult patients seen in the inpatient settings with complete information on DX/procedures/drugs
Do their diagnoses match any of the ONS indications?
Off-label use, supported
(OFS) denominator cohort
Documented Off-label use, 
unsupported (OFU) 
denominator cohort
On-label use (ONS) 
denominator cohort
YES
YES
NO
Do their diagnoses match any of the OFS indications?
YES
Excluded
NO
Do their diagnoses match any of the documented OFU indications?
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Specific Aim 3  
Dependent variable was ESA use, defined as whether or not an eligible patient received 
ESAs in a given month.   
 To assess the impact of the intervention on ESA prescribing patterns for the on-label, 
off-label supported, and off-label unsupported indications, three population proportions which 
were used as dependent variables were identified as following.  
1. On-label: Proportion of patients with on-label conditions that were prescribed ESAs. 
2. Off-label supported use:  Proportion of patients with off-label supported conditions 
that were prescribed ESAs. 
3. Off-label unsupported use: Proportion of patients with off-label unsupported 
conditions that were prescribed ESAs. 
Similar steps were taken to identify the three cohorts: ONS, OFS, and documented OFU.  
Once the three cohorts were identified, drug records of these eligible patients were searched to 
determine if ESAs (epoetin alfa or darbepoetin alfa) were prescribed during a hospital stay.  If a 
record of ESAs was found, that patient was classified as a user (ESA use = 1).  Without a record 
of ESAs, that patient was a non-user (ESA use = 0).  Schematic algorithm used to identify 
patient cohorts for the analysis is shown in Figure 3.5. 
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Figure 3.5 Schematic algorithm selecting study sample for Specific Aim 3 
  
All adult patients seen in the inpatient settings without missing information on drug records
Do their diagnoses match any of the ONS indications?
Off-label use, supported
(OFS) Cohort
Documented
Off-label use, unsupported
(OFU) Cohort
On-label use
(ONS) Cohort
YES
YES
NO
Do their diagnoses match any of the OFS indications?
YES
Excluded
NO
Do their diagnoses match any of the documented OFU indications?
ESA = 1:
Received ESAs
ESA = 0:
Did not receive ESAs
ESA = 1: 
Received ESAs
ESA = 0:
Did not receive ESAs
ESA = 1: 
Received ESAs
ESA = 0:
Did not receive ESAs
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Covariates 
 Covariates included in the multivariable model used in Specific Aim 3 were patient 
demographics of age, gender, and race; primary payer of the hospital services; patient clinical 
conditions described by the proxies of admission type, discharge disposition, length of stay, 
Combined Comorbidity Index; hospital characteristics including teaching status, bed size, and 
geographic region, and physician specialty classified as specialist and non-specialist.  We did not 
differentiate between the rural and urban status because very few hospitals in our sample were 
identified as rural hospitals.  Due to small number of patients in the ‘other’ group of the 
admission type and discharge disposition, the other ‘group’ was combined with ‘missing’ group 
to obtain reliable estimates.  Relevant studies identifying the aforementioned covariates as 
predictors of drug use were described in detail under Section 3 of Chapter 2.  Table 3.6 describes 
the categorization of covariates used in the analytical models. 
Table 3.6 Categorization of Covariates used in Specific Aim 3 
Variable  Variable Name Description 
Patient Characteristics   
Demographics   
   Age age_in_years regrouped to 
age_cat 
18-30 = 1 
31-50 = 6 
51-64 = 2 
65-74 = 3 
75-84 = 4 
85 and above = 5 
   Race race regrouped to race_cat Missing = 0 
African American = 1 
Other = 2 
Caucasian = 3  
   Gender Gender recoded to gender_cat Female = 0 
Male = 1 
Clinical Conditions   
   Admission type admission_type_code 
regrouped to admission_ cat 
Missing/Other = 0  
Urgent = 1 
 Elective = 2 
 Emergency = 3 
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   Charlson Comorbidity Index cci  Calculated from ICD-9-CM codes 
   Length of Stay  hos_los  Continuous, number of days from 
admission date to discharge date 
   Discharge status discharge_disposition_key 
regrouped to discharge_cat 
Missing/Other = 0 
Expired = 1 
Discharged to Hospice = 2 
Discharged/transferred to 
institutionalized care = 3 
Discharged/transferred to 
noninstitutionalized care = 4 
Discharged to home/self care = 5 
Payer Type   
   Source of Payment payer_id regrouped to payer_ 
cat 
Missing = 0 
Medicaid = 1 
Commercial/Private/HMO 
Managed Care = 2 
Self-pay = 3 
Other = 4   
Medicare = 5 
Hospital Characteristics   
   Geographic region census_region regrouped to 
region_cat 
Midwest = 1 
South = 2 
West = 3  
Northeast = 4 
   Bed size bed_size_range recoded to 
bed_cat 
≤ 99 = 1 
100-199 = 2 
200-299 = 5 
300-499 = 3 
≥500 = 4 
   Teaching status teaching_facility_ind recoded to 
teaching 
Teaching = 0 
 Non-teaching = 1 
Physician and Care Characteristics 
   Physician Specialty medical_specialty regrouped to 
medical_specialty_cat 
Missing = 0 
Specialist = 1 
Non-specialist = 2 
*Bolding indicates reference group. Reference group was coded into the last order for convenience  
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Data Integration 
 Encounter information was captured in four main SAS datasets including patient, 
diagnoses, procedure, and medication files containing patient demographic information, ICD-9-
CM codes, procedure codes, and medications used, respectively.  Specific information including 
dosing unit, diagnoses type, care setting, admission type, physician specialty, payer, and hospital 
information are also provided in separate SAS files.  Two master datasets were built by 
integrating the files using the selection criteria specified above. The first dataset was used for 
descriptive analysis of ESA users (patient level) and as numerator cohorts for aggregated time-
series analysis (visit level).  The second dataset was used for the patient level analysis of the 
impacts of safety interventions (Aim 3).  
Descriptive analysis of ESA users and numerator cohorts for aggregated time-series analysis 
 Encounters with any order of epoetin alfa or darbepoetin alfa were first identified in the 
medication dataset.  This medication dataset contained medication information like generic 
name, medication entered date, started date, and stopped date, care setting where medications 
were ordered and dispensed, dose quantity, frequency, and route of administration.  Visits which 
ESAs were prescribed were linked to the two datasets containing diagnoses and procedure 
information, and encounters file which comprised of patient’s age, admitted and discharged 
dates, patient type, admission source, discharge disposition, primary payer information, patient 
ID, and hospital ID.  Only encounters of adult patients (18 years and above) admitted and 
received medication on January 1, 2005 onward were retained in the sample.  Lastly, the file was 
merged with hospital and patient dataset for hospital and patient demographic information.  For 
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the patient level analysis (descriptive analyses), in such case that the same patients had more than 
one encounter with the health system, only the first records were used in the study.   
Outpatient encounters (hospital outpatient department, day surgical services, clinic, 
dialysis centers, laboratory, and emergency department and observational units) constituted 
22.0% of our overall sample.  Visits to outpatient settings, institution, nursing home, and home 
health services were excluded.  The final inpatient cohort of 86,763 patients consisted of patients 
who were admitted to a hospital (inpatient), pre-admitted patient, patients in an obstetrics 
department, hospice, and skilled nursing facility (SNF).   Hospice and SNF patients were 
included in the inpatient group because of similarity in insurance reimbursement toward the 
services (covered by Medicare Part A).  The details of ESA use in each patient type reported in 
Cerner database are shown in Table 3.6 and 3.7.   
The integrated data contained information of 111,363 encounters (86,763 unique patients) 
with at least one order of ESAs during their visit to the health system.  Of these 111,363 
encounters, 83,876 received epoetin alfa only (75.3%); 26,772 received darbepoetin alfa only 
(24.0%); and 715 (0.64%) received both epoetin alfa and darbepoetin alfa during that single visit.  
These encounters translated into 66,121 patients with epoetin alfa only (76.2%); 20,088 patients 
with darbepoetin alfa only (23.2%); and 554 patients with both use of epoetin alfa and 
darbepoetin alfa (0.6%)).  Data integration steps used to identify ESA users (for descriptive 
analysis numerator in Specific Aim 2a) are described in Figure 3.6. 
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Table 3.7 ESA inpatient users (encounter level) identified in Cerner database 
Care settings N Encounters (column %) 
Any ESAs Epo Darbe Epo & Darbe 
Inpatient     
   Hospice 7 (0.01) 5 (0.01) 2 (0.01) 0 (0.00) 
   Inpatient 110,880 (99.57) 83,441 (99.48) 26,731 (99.85) 708 (99.02) 
   Obstetrics 2 (0.00) 2 (0.00) 0 (0.00) 0 (0.00) 
   Preadmit 121 (0.11) 101 (0.12) 19 (0.07) 1 (0.00) 
   Skilled Nursing Facility 353 (0.32) 327 (0.39) 20 (0.07) 6 (0.84) 
   Total (row %) 111,363 (100.00) 83,876 (75.32) 26,772 (24.04) 715 (0.64) 
 
Table 3.8 ESA inpatient users (patient level) identified in Cerner database 
Care settings N Patient (column %) 
Any ESAs Epo Darbe Epo & Darbe 
Inpatient     
   Hospice 5 (0.01) 3 (0.01) 2 (0.01) 0 (0.00) 
   Inpatient 86,429 (99.62) 65,825 (99.55) 20,056 (99.84) 548 (98.92) 
   Obstetrics 3 (0.00) 3 (0.00) 0 (0.00) 0 (0.00) 
   Preadmit 82 (0.09) 65 (0.10) 16 (0.08) 1 (0.00) 
   Skilled Nursing Facility 244 (0.28) 225 (0.34) 14 (0.07) 5 (0.90) 
   Total (row %) 86,763 (100.00) 66,121 (76.21) 20,088 (23.15) 554 (0.64) 
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Figure 3.6 Data integration step of ESA users 
  
Medication file
Encounters with at least one medication order 
given after Jan 05.  Contains medication 
start/enter/stop dates, generic names,  and 
variables that can be linked to ordering 
physicians, care setting where medications were 
requested 
Encounter file
Adult encounters admitted after Jan 05. Contains 
admitted/discharged dates, age, and variables that can 
be linked to information on hospital type, patient type, 
admission type, discharge disposition, and payers
Diagnosis file
Contains  variables that can be linked 
to ICD-9-CM diagnoses codes 
Procedure file
Contains  variables that can be linked 
to ICD-9-CM procedures codes 
-Diagnosis lookup file contains 
information on  ICD-9-CM 
diagnosis codes, description, and 
diagnosis priority
- Hospital lookup file contains information on  
census region, bed size, teaching status, 
urban status,  and hospital type status
- Patient type lookup file
- Admission type lookup file
- Discharge disposition lookup file
- Care setting lookup file
- Physician lookup file contains medical 
specialty information of physicians
- Procedure lookup file 
contains information on ICD-9-
CM procedure codes and 
description
Excluded encounters to the outpatient settings 
Excluded Epoetin alfa
AND
Darbepoetin alfa users 
N encounters = 715 
N patients = 554
N encounters = 111,363 
N patients = 86,763 
Unique encounters /patients of adult patients admitted (Jan 05- Jun 11) to the 
inpatient settings with at least one order of epoetin alfa or darbepoetin alfa
given between Jan 05 and Jun 11, with diagnosis and encounter information
Encounters of adult patients admitted (Jan 05- Jun 11) with at least one order of epoetin alfa or 
darbepoetin alfa given between Jan 05 and Jun 11, with diagnosis and encounter information
Epoetin alfa users only
N = 83,876 encounters 
N = 66,121 patients
Epo - ONS
N encounters = 40,449
N patients = 31,333  
Epo - OFS
N encounters = 6,901
N patients = 5,834 
Epo - OFU
N encounters = 36,526
N patients= 28,954  
Darb - ONS
N encounters = 14,650
N patients = 10,598 
Darb - OFS
N encounters = 1,981
N patients =1,586 
Darb - OFU
N encounters = 10,141
N patients =7,904 
Descriptive analysis of Epo/Darb users (patient level) (Aim 1) and numerator cohorts (visit level) for  aggregated time series (Aim 2) analyses 
ONS
N encounters = 55,482
N patients = 42,218 
OFS
N encounters = 8,958
N patients = 7,477 
OFU
N encounters = 46,923
N patients  = 37,068  
*Using approved indications for epoetinalfa
*Using approved indications for epoetinalfa
1
32
Darbepoetin alfa users only 
N = 26,772 encounters
N = 20,088 patients
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Denominator cohorts for aggregated time-series analysis (Aim 2) and Specific Aim 3 
 The denominator cohort for Specific Aim 2 and analytic cohort for Specific Aim3 
consisted of any visits (or patients – Aim 3) with diagnoses of interest (See Table 3.1-3.4).  For 
consistency, we identified only visits from same hospitals as the ESA users that contributed 
medication records into Cerner database.  The dataset included inpatient visits (inpatient, pre-
admitted, obstetrics, hospice, and skilled nursing facility (SNF) encounters) in 128 unique 
hospitals.  The initial cohort included a total of 2,170,654 unique visits (1,815,028 patients) with 
at least one condition specified as ONS, OFS, or documented OFU. 
Of 2,170,654 encounters (1,815,028 patients), 912,141 encounters (750,321 patients) had 
diagnoses that made them eligible for ESA approved treatments.  These visits (or patients) were 
classified as ONS cohort. 595,193 encounters (505,694 patients) had OFS diagnoses (OFS 
cohort), and 663,320 encounters (559,031 patients) had documented OFU diagnoses (OFU 
cohort).  Data integration steps adopted in identifying all eligible cohorts for Specific Aim 2 and 
3 are shown in Figure 3.7. 
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Figure 3.7 Data integration steps of all eligible admissions 
 
Patient Risk Adjustment 
 This study made use of a combined comorbidity score developed to appraise a patient’s 
mortality risk based on his ICD-9-CM diagnoses codes
193 to model patient’s clinical complexity.   
The combined score of the Charlson Index with the Romano modification and van Walraven’s 
adaptation of the Elixhauser system was developed by the Division of Pharmacoepidemiology 
and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard 
Medical School to improve upon existing scores in predicting 1-year mortality in older adults. 
SAS codes we adapted to calculate validated combined comorbidity scores for this study were 
provided by the developers.
194 
  The use of the combined comorbidity score was justifiable in our 
study as our population of users consisted largely of older adults.  Since no specific 
comorbidities were suggested by the literature as predictors of ESA prescribing, we did not 
include specific cormobid conditions in the multivariable models but instead the combined 
Encounter file
Adult encounters admitted after Jan 05. 
Contains admitted/discharged dates, age, and 
variables that can be linked to information on 
hospital type, patient type, admission type, 
discharge disposition, and payers
Diagnosis file
Encounters with ONS, OFS, 
and documented OFU 
diagnoses codes predefined 
for ESA use.
Contains  variables that can 
be linked to ICD-9-CM 
diagnoses codes 
Procedure file
Encounters with ONS, OFS, 
and documented OFU 
procedure codes predefined 
for ESA use.
Contains  variables that can 
be linked to ICD-9-CM 
procedures codes 
-Diagnosis lookup file 
contains information on  
ICD-9-CM diagnosis 
codes, description, and 
diagnosis priority
- Hospital lookup file contains 
information on  census region, bed size, 
teaching status, urban status,  and 
hospital type status
- Patient type lookup file
- Admission type lookup file
- Discharge disposition lookup file
- Procedure lookup file 
contains information on 
ICD-9-CM procedure 
codes and description
N Encounters = 2,170,654
N Patients = 1,815,028 
Unique encounters of adult patients admitted (Jan 05- Jun 11) 
with any predefined dx/proc/meds between Jan 05 and Jun 11
Medication file
Encounters with at least order of 
chemotherapeutic agents, HIV zidovudine, 
hepatitis C ribavirin/interferon alfa
medications, which were given after Jan 05..  
Contains medication start/enter/stop dates, 
generic names,  and variables that can be 
linked to ordering physicians, care setting 
where medications were requested 
- Care setting lookup file
- Physician lookup file contains medical 
specialty information of physicians
ONS 
N Encounters = 912,141
N  Patients = 750,321 
OFS 
N Encounters = 595,193
N patients = 505,694 
Documented OFU 
N Encounters = 663,320
N Patients = 559,013
Denominator cohorts for  aggregated time series (Aim 2) and analytic cohort for Aim 3 
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comorbidity score to avoid multicollinearity between a set of comorbidities and comorbidity 
score.   
Statistical Analysis 
To understand the prevalence of ESA therapy in patients admitted to Cerner hospitals, 
descriptive analysis was performed.  Patient demographics, clinical conditions, hospital 
characteristics, and ordering physician specialties of patients receiving epoetin alfa or 
darbepoetin alfa were aggregated over the study period of six and a half year and described with 
means, standard deviations, and column percentages.  The differences in these variables among 
the two user groups were tested with chi-squares and t- statistics.  Similarly, aggregated 
characteristics of ONS, OFS, and OFU users were also tested with chi-squares and t- statistics. 
The inferential analyses were based on two techniques: segmented regression modeling 
for interrupted time-series (Aim 2), and generalized estimating equation (GEE) approach with 
binary logistic regression technique (Aim 3a and 3b).   
Segmented Times Series (Aim 2) 
Segmented time series study design provided the strongest quasi-experimental approach 
for investigating the longitudinal effect of the intervention.  The lack of random assignment and 
a control group accustomed in observational studies hindered the true estimation of an exposure 
(intervention) on the outcomes.  Internal validity of such study was therefore questionable 
because systematic differences in observed and unobserved characteristics of the treatment and 
non-treatment group were not accounted for.  The time-series approach allowed for both visual 
statistical assessment of how much the intervention affects the outcomes immediately and over 
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time, transiently or permanently.  The use of a control group was not necessarily with this study 
design because each segment served as a control for the preceding segments.  In this study, 
monthly aggregate proportions of visits at which a patient received ESAs for a specific group of 
indications (ONS, OFS, or OFU) were a unit of analysis.  ONS proportion was defined as the 
proportion of visits at which a patient was prescribed with ESAs for the indications approved by 
the FDA (ONS), over the total number of visits at which a patients had clinical conditions 
eligible for receiving ESAs on-label, the a given month.  OFS and OFU proportions were 
classified in a similar manner.  Ordinary least square was chosen as the distribution of the data 
was approximately continuous i.e. the data did not consists of a mass at the limits (zero and/or 
one).  First-differencing and suitable number of lags was included in the model to correct for 
autocorrelation of each observation in the series and to obtain accurate standard errors of the 
estimates. 
Generalized Estimating Equations (Aim 3) 
Previous studies identified hospital level differences in practices where patient’s 
responses, though homogeneous within hospitals, may not be so across hospitals.  In the 
presence of clustered data and in the situation where consecutive observation was not 
independent, the use of generalized estimating equations (GEE) approach was most appropriate.  
Clustered GEE model improved inferences as accounting of correlation structure between 
repeated observations provides unbiased and more efficient estimates of standard errors 
compared to the falsely small standard errors in the un-clustering model.
195, 196 
  In GEE, 
correlation structure that adequately described the known or suspected correlations between 
repeated observations was specified.   The types of correlation structures commonly adopted 
included exchangeable, autoregressive, dependent, independent and unstructured.  The choice of 
  
  
101 
 
correlation structure relied on the nature of the data.  This study specified an exchangeable 
correlation structure as such type of correlation structure was the only one appropriate for 
clustered data with no natural ordering of the subjects with the cluster.
197 
 
We chose binary logistic regression method as it allows for non-normal distribution of 
the data.  The binomial distribution and logit link function were specified to model with a 
dichotomous outcome variable.  An outcome variable in the binary logistic regression model is 
defined as whether a patient with on-label, off-label supported, or off-label unsupported 
conditions received ESAs in that given month.  To obtain robust standard errors of the estimates, 
we adjust for hospital level differences using hospital ID as a cluster variable.  
A two-sided alpha of 0.05 is considered statistically significant for all analyses.  SAS 
(version 9.3 for Windows; SAS Institute, Cary, NC) and Stata (Stata 11; Stata Corp, College 
Station, TX) was used for all analyses in this study. 
Statistical Models 
Specific Aim 2  
To quantify the immediate and trend impact of the black box warning, NCD policy, and 
REMS on the change in the proportion of visits which a patient was treated with ESAs, three 
separate ordinary least square regressions for on-label, off-label supported, and off-label 
unsupported ESA use were fit.  Impacts of black box warning, NCD, and REMS on the level of 
ESA use for the on-label and off-label indications were specified in the models shown below.  A 
set of month indicators was included in the model to adjust for monthly seasonality. 
  
  
102 
 
 
Figure 3.8 Segmented regressions modeling interrupted time-series used in assessing the impact of the 
interventions on ESA prescribing 
YONSt : Proportion of ESA use among eligible visits 
Coefficients: β0 Baseline proportion of ESA on-label use at t = 0;  β1 Change in proportion of ESA on-label use (Yt) that occurs with 
each month before the first intervention; β2 Level change in proportion of ESA on-label use immediately after the first intervention; β3 
Change in the trend in proportion of ESA on-label use after the first intervention 
Independent variables: intervention1 = Black Box Warning; intervention2 = National Coverage Determination; intervention3 = REMS  
Time variable: t = number of month of the study period (1-78); t1 = number of month since the occurrence of the first intervention 
(Mar 07) till the end of the study period (t1 =1-52); t2 = number of month since the occurrence of the second intervention (April 08) 
(t1 = 1-39); t3 = number of month since the occurrence of the third intervention (Mar10) (t1 = 1- 16) 
M: a set of month indicator variable to control for monthly seasonal effect; 
A similar interpretation was applied for all three models.  For the purpose of presentation 
simplicity, only interpretation of Model 1 was given below. 
In Specific Aim 2, Y
ONSt 
was the monthly proportion of visits at which a patient was 
prescribed with ESAs for on-label purposes over the total number of eligible visits in that month.  
Variable t was a continuous variable indicating the number of month since the beginning of the 
Model 1: On-label (ONS)
YONSt= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+ 
β7 intervention3 × t3 + M + et
Model 2: Off-label Supported (OFS)
YOFSt= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+ 
β7 intervention3 × t3 + M + et
Model 3: Off-label Unsupported (OFU)
YOFUt= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + β6intervention3+ 
β7 intervention3 × t3 + M + et
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study takes on values from 1 to 78.  Intervention 1 was a dichotomous variable indicating the 
issuance of black box warning;  t1 equaled 0 for the months prior to that issuance and took the 
values 1 to 51 indicating the numbers of months since issuance (March 2007; t1 = 1 in March 
2007) to the end of the study period.  Intervention 2 was a dichotomous variable indicating the 
official implementation of NCD; t2 equaled 0 for the months prior to that when NCD was release 
and took the values 1 to 39 indicating the numbers of months since the implementation (April 
2008; t2 = 1 in April 2008) to end of the study period.  Intervention 3 was a final dichotomous 
variable marking the point in time when REMS was implemented; t3 takes a value of 0 for the 
months prior to the third intervention and 1 through 15 indicating the numbers of months since 
the implementation of REMS (March 2010; t3 = 1 in March 2010) until the end of the study 
period.   
The coefficients in the model can be interpreted as followed: β
0 
represents baseline 
proportion of ESA use at t = 0; β
1
 was the change in proportion of ESA use (Y
t
) that occurred 
with each month before the release of black box warning (Intervention 1); β
2 
level change in 
proportion of ESA use immediately after the black box labeling change; β
3
 change in the trend in 
the proportion of ESA use after black box warning.  Similarly, β
4
, and β
6
 represented level 
change in the dependent variables immediately after the release of NCD (Intervention 2) and the 
implementation of REMS (Intervention 3), respectively.  Finally, β
5
, and β
7
 represented changes 
in the trend in the Y variables after the occurrence of each intervention, respectively. 
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Specific Aim 3a and 3b 
Three models using the same set of independent variables and covariates were fit 
separately to determine the impacts of the interventions on the odds of an ESA being prescribed 
to a patient with 1) on-label, 2) off-label supported, and 3) documented OFU conditions.  Figure 
3.3 specifies the models that were fit to examine the trend and immediate effects of the three 
interventions on the odds of an ESA being prescribed to a patient.   
 
DEM = a vector of patient demographic variables; HEALTH = a vector of clinical conditions; HOS = hospital characteristics; PHYS = 
physician specialty.  
 
Figure 3.9 Models used to assess the impact of interventions on odds of being prescribed with ESAs for a 
patient with on-label and off-label supported indications. 
 Again, since similar interpretation was applied for all three models.  For the purpose of 
presentation simplicity, only interpretation of Model 1 was given below. 
In Model 1, logit (ESA=1) represented the odds of receiving ESAs in a patient with an 
on-label conditions.  All other independent variables were the same as specified under Specific 
Model 1: On-label (ONS)
Logit(ESA=1)= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + 
β6intervention3+ β7 intervention3 × t3 + DEM + HEALTH + HOS + PHYS + et
Model 2: Off-label Supported (OFS)
Logit(ESA=1)= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + 
β6intervention3+ β7 intervention3 × t3 + DEM + HEALTH + HOS + PHYS + et
Model 3: Documented Off-label Unsupported (Known OFU)
Logit(ESA=1)= β0 + β1t + β2intervention1 + β3intervention1 × t1 + β4intervention2 + β5intervention2 × t2 + 
β6intervention3+ β7 intervention3 × t3 + DEM + HEALTH + HOS + PHYS + et
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Aim 1.  DEM denotes a vector of patient demographic variables which included age (18-30, 31-
50, 51-60, 61-64, 65-74, 75-84, and 85 and above years old), gender (Male and Female), and 
race (Caucasian, African-American, Hispanic, Other); Payer was specified as the primary payer 
of the hospital services (Medicare, Medicaid, Private, Self-pay, and Other); HEALTH was a 
vector of patient clinical conditions including admission status (Elective, Emergency, Urgent, 
Other), length of stay, Comorbidity Index, and discharge status (Expired, Discharged to home, 
Hospice, Institutionalized care, Non-institutionalized care, Other); HOS include hospital 
characteristics variables such as geographic region (Northeast, Midwest, South, West), teaching 
status (Teaching, Non-teaching), and bed size (<99, 100-199, 200-299, 300-499, 500 or more).  
Lastly PHYS denotes physician specialty as non-specialist and specialist.  Due to a large number 
of observations with missing information, we created a category ‘Missing’ for the race, payer, 
admission type, discharge status, and physician specialty variables.  
The coefficients in the model can be interpreted as followed: β0 is the intercept presenting 
baseline odds of receiving ESAs among patients with on-label indications when the effects of all 
independent variables in the model were turned off; β1 represented the time trend prior to the first 
intervention, the black box warning.  β2 estimated the immediate effects of the first intervention 
(black box warning). In a similar manner, β4 and β6 estimated the immediate effects of NCD and 
REMS, respectively.  β3 estimated the change in time trend after the issuance of black box 
warning.  β5 and β7  represented the change in time trends after the implementation of NCD and 
REMS, respectively.  Finally, et was the error term represents the variability not explained by the 
model.   
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Human subjects’ protection and data privacy 
 Cerner data are encrypted in such a way that no patient will be identified in order to 
ensure minimal confidentiality risks to the patients.  Access to the dataset was restricted to 
individuals listed in the protocol.  The data were maintained in a password-protected 
environment.  The study proposal was submitted to the Institution Review Board (IRB) at 
Virginia Commonwealth University for an exemption 45 CFR 46.101(b)(4).
198 
  The approval 
number was HM 14257. 
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CHAPTER 4 
Results 
Research results are presented in this chapter.  The results are summarized into five 
following sections: 
1. Data Description 
- Study cohort for each specific aims 
- Overall prevalence and trend in ESA use from 2005 to 2011 by use category 
2. Specific Aim 1 
- Descriptive summary of patient, hospital, and physician characteristics of ESA users 
- Descriptive summary of patient, hospital, and physician characteristics of epoetin alfa 
and darbepoetin alfa by use category 
- Specific indications of ESAs in ONS, OFS, and OFU use category 
3. Specific Aim 2 
- Trend in ESA On-label, off-label supported, and off-label unsupported therapy 
- Outlier Identification and Data manipulation 
- Time-series model selection 
- Impacts of black box warning, NCD, and REMS on proportion of visits with ESA use 
4. Specific Aim 3 
- Outlier Identification and Data manipulation 
- Bivariate analysis of ESA users 
- GEE model selection 
- Impacts of black box warning, NCD, and REMS on odds of being prescribed with ESAs 
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- Associations of demographic, clinical, and hospital characteristics and the odds of being 
prescribed with ESAs. 
Data Description 
Study cohorts for each specific aim 
A total of 166,741 unique visits of 108,489 unique patients were reported to Cerner 
health system, and received at least one order of any ESAs between January 1, 2005 and June 30, 
2011.  Among them, 111,363 encounters (66.8%) were admitted to the inpatient health system 
while the rest were seen in the outpatient settings and excluded accordingly.  Approximately 
75.3% of the total inpatient encounters (n = 83,876 encounters: 66,121 patients) were prescribed 
epoetin alfa only, and 24.0% (n = 26,772 encounters: 20,088 patients) were prescribed 
darbepoetin alfa only.  Less than one percent of them were prescribed both epoetin alfa and 
darbepoetin alfa during the same visit (0.8%, n = 715 encounters: 554 patients).  A total of 128 
unique hospitals reported using any ESAs during the study period.  Epoetin alfa was used in 124 
hospitals in our sample while darbepoetin alfa was used in 91 hospitals.  Sixty-four hospitals 
reported the use of both epoetin alfa and darbepoetin alfa during the study period.  The number 
of reporting hospitals increased from 37 hospitals in the first year to 71 hospitals in the last year 
of the study period.  On average, the report of any use of ESAs came from approximately 50 
hospitals per month.   Lastly, during the 6.5-year study period, a total of 112 unique hospitals 
reported ESA ONS use while 89 and 127 unique hospitals reported OFS and OFU use of ESAs, 
respectively.  
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The proportion of visits with ESA use for the ONS, OFS, and OFU indications was set up 
from 111,363 unique visits with at least one ESA orders and 2,170,654 eligible admissions to 
assess the impact of the interventions on ESA prescribing patterns (Specific Aim 2).   
Finally, in order to assess the impacts of the interventions on the odds of receiving ESAs 
in patients with specific on-label and off-label supported conditions and the associations of 
demographic, clinical, and hospital characteristics on such likelihood (Specific Aim 3), a patient 
is used as a unit of analysis.  This analysis consisted of a total of 1,815,028 patients (750,321 
ONS, 505,694 OFS, and 559,013 documented OFU).   
Overall prevalence and trend in ESA use 
ESA utilization patterns over time measured through the number of visits with any use of 
erythropoietic drugs (epoetin alfa or darbepoetin alfa) per reporting hospital during the study 
period is shown in Table 4.1 (annually) and Figure 4.1 (monthly).   
Number of cases which an ESA was prescribed increased 44% from 240 per hospital in 
2005 to 346 cases in 2006.  ESA use decreased 13% to 302 cases in 2007; then utilization level 
went up 9% to 328 cases in 2008.  The largest reduction in use was in 2009 when there was a 
50% reduction from 2008.  ESA utilization level remained low from then through 2010.  Overall, 
ESA use in our sample decreased 33% from 2005 to 2010. 
Epoetin alfa use increased 47% from approximately 211 cases per reporting hospital in 
2005 to 310 cases in 2006.  This increase was followed by a 27% drop in 2007 and a 15% 
increase in epoetin alfa use in the following year.  The number of visits which epoetin alfa was 
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prescribed per hospital declined 54% in 2009, but increase again to 131 cases per hospital in 
2010 (10% increase from 2009).  Overall, epoetin alfa use decreased 38% from 2005 to 2010. 
Overall use of darbepoetin alfa, however, increased 20% from 63 cases in 2005 to 76 
cases in 2010.  A year by year analysis showed that its use also increased in 2006 (44%).  
However, in contrary to epoetin alfa, the number of visits which darbepoetin alfa was prescribed 
per hospital continued to increase in 2007 (66% increase from 2006).  After 2007, the level of 
darbepoetin alfa use decreased every year until the end of the study period. 
Table 4.1 Overall annual trend in the number of visits with ESA use per reporting hospital* 
Drug Number of visits with ESA use per reporting hospital 
2005 2006 2007 2008 2009 2010 %∆ (2005-2010) 
Total (any ESAs) 239.7 345.8 302.0 327.9 163.1 161.6  
∆ from preceding year - +44.0% -12.6% +8.6% -50.3% -0.9% -32.6% 
Epoetin alfa 211.0 310.4 225.9 259.0 118.6 131.0  
∆ from preceding year - +47.1% -27.2% +14.6% -54.2% +10.5% -37.9% 
Darbepoetin alfa 63.3 91.1 151.0 131.1 103.6 75.7  
∆ from preceding year - +44.0% +65.7% -13.2% -21.0% -26.9% +19.7% 
*Only years with full-year reports were included 
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To compare the trends in epoetin alfa and darbepoetin alfa over time, a graphical 
representation of monthly drug use is shown in Figure 4.1.  Any use of ESAs (epoetin alfa or 
darbepotin alfa) is marked with -○- symbol while the use of epoetin alfa or darbepoetin alfa 
alone is portrayed with -×- and -◊-, respectively.  In general, changes in the level of darbepoetin 
alfa use were delayed and fluctuated at a lesser extent compared to that of epoetin alfa. 
 
Figure 4.1 Monthly trend in use of ESAs, epoetin alfa, and darbepoetin alfa from January 2005 to June 
2011 expressed in term of number of visits with ESA use per hospital 
 
The number of visits which at least one ESA order was prescribed in a month in a 
hospital increased steadily from 24 visits at the beginning of the study period to 32 visits per 
Black box warning 
begins 
NCD 
 begins 
REMS 
 begins 
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hospital per month in April 2006.  After that, a sharp rise in the average number of visits with 
ESAs was observed.  There were close to 50 visits at which ESAs were ordered per hospital per 
month during that period.  However, beginning in October 2006, use of ESAs in our sample 
started to show a declining trend that continued until the end of the study period.  In the last 
month of the study, there were as few as 16 visits per hospital which patients were prescribed 
ESAs.  The trend in overall ESA use in our sample was likely to be caused by epoetin alfa 
because darbepoetin alfa utilization level, on the other hand, did not drop after October 2006 but 
instead remained relatively stable at approximately 20 visits per hospital per month until April 
2010.  After April 2010, darbepoetin alfa use decreased to about 10 cases per hospital monthly 
until the end of the study period. 
ONS, OFS, and OFU use per hospital 
The use of ESAs per hospital for the on-label, off-label supported, and off-label 
unsupported indications is shown in Table 4.2 (annually) and Figure 4.2 (monthly).  
Between 2005 and 2010, the number of visits with ESA on-label (ONS) use decreased 
63% from 196 cases to 72 cases.  The decline in ESA ONS use was observed starting in 2007 
(21% reduction from 2006) with the largest decline seen in 2009 (57% reduction from 2008).  A 
similar trend was observed with ESA OFS use.  ESA OFS use decreased 78.2% from 53 cases 
per hospital in 2005 to only 11.6 cases in 2010, with the largest decline in 2009 (57%).  ESA 
OFU use, on the other hand, increased 80% from 57 cases to 102 cases.  The largest increase in 
ESA OFU use was in 2006.  During that year, the number of visits with ESA OFU use per 
hospital increased 78%. 
Table 4.2 Annual trend in the number of visits with ESA use per reporting hospital by use category* 
  
  
113 
 
Use Category Number of visits with ESA use per reporting hospital 
2005 2006 2007 2008 2009 2010 %∆ (2005-2010) 
Total (any ESAs)        
ONS 195.9 245.8 194.6 202.5 86.6 72.2  
∆ from preceding year - +25.5% -20.8% +4.1% -57.3% -16.7% -63.2% 
OFS 53.3 44.3 46.1 36.8 15.8 11.6  
∆ from preceding year - -16.8% 3.9% -20.2% -57.1% 26.3% -78.2% 
OFU 56.7 100.9 114.7 128.6 95.9 102.0  
∆ from preceding year - +78.0% +13.7% +12.1% -25.4% +6.4% +80.0% 
*Only years with full-year reports are shown 
Monthly trends in ESA use on-label and off-label (supported and unsupported) is shown 
in Figure 4.2.   On-label use of ESA is outlined with a long-dashed line while off-label supported 
and off-label unsupported use are marked with solid and dotted lines, respectively.  
On-label use of ESAs in our sample increased steadily from 20 visits per hospital per 
month in January 2005 to 32 cases in November 2006.  After than month, ESA on-label use 
declined sharply.  During the last months of the study, a hospital on average approximately 
prescribed ESA in less than 10 visits per month.  On the other hand, no fluctuation of level of 
ESA use for off-label supported indications was observed in our sample; there was a slight 
downward trending in the off-label supported use of ESAs throughout the study period.  ESA 
OFS use decreased from 7 visits per hospital per month to only one to two visits in the later 
months.  In contrast to ESA ONS and OFS use, ESA use for the unsupported indications (OFU) 
increased from 6 visits in 2005 to 19 visits December 2006.  This OFU use remained high, with a 
slight increasing trend throughout the study period.   
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Figure 4.2 Monthly trend in ESA use for the on-label, off-label supported, and off-label unsupported 
indications from January 2005 to June 2011 expressed in term of number of visits with ESA use per 
hospital 
The annual trends in ESA use were broken down by drug.  Changes in epoetin alfa and 
darbepoetin alfa use per hospital per year for the on-label, off-label supported, and off-label 
unsupported indications are shown Table 4.3.   
The observed trends in ESA use described in the previous section were likely to be 
contributed by the use of epoetin alfa which made up more than 75% of all ESA use in our 
sample.  Epoetin alfa ONS use increased 23% in the first year of the study period, but decreased 
thereafter.  Overall, similar to ESAs, epoetin alfa ONS use decreased 67% between 2005 and 
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2010, with the largest decline in 2009 (-65%).  Epoetin alfa OFS use also declined throughout 
the whole study period (75%, 2005-2010), with the largest drop of 61% in 2009.  Lastly, epoetin 
alfa OFU use increase 93% over six years.  The largest increase in epoetin alfa OFU use was 
observed in 2006 where its use was almost doubled (99%).   
In contrast to epoetin alfa, darbepoetin alfa ONS use did not decrease after 2005.  Instead, 
its use continued to increase until 2007, and decreased thereafter.  There was also an increase of 
73% and 71% in darbepoetin alfa OFS and OFU use in our sample in that year (2007), 
respectively.  At the end of the study period, darbepoetin alfa OFS use decreased 45% while 
OFU use increased more than 111%. 
Table 4.3 Annual trend in the number of visits with epoetin alfa and darbepoetin alfa use per reporting 
hospital by use category* 
Use Category Number of visits with ESA use per reporting hospital 
2005 2006 2007 2008 2009 2010 %∆ (2005-2010) 
Epoetin alfa         
ONS 179.6 220.8 141.1 156.4 54.8 60.0  
∆ from preceding year - +22.9% -36.1% +10.8% -64.9% +9.4% -66.6% 
OFS 48.5 44.6 35.7 33.1 12.8 11.9  
∆ from preceding year - -8.0% -20.1% -7.3% -61.2% -7.0% -75.4% 
OFU 45.9 91.1 95.3 116.2 82.4 88.4  
∆ from preceding year - +98.5% +4.6% +21.9% -29.1% +7.3% +92.6% 
Darbepoetin alfa        
ONS 52.8 68.9 112.4 98.5 82.8 48.6  
∆ from preceding year - +30.5% +63.1% -12.3% -16.0% -41.3% -8.0% 
OFS 14.1 13.7 23.8 20.7 14.7 7.8  
∆ from preceding year - -2.6% +73.3% -12.8% -28.9% -47.2% -44.7% 
OFU 23.6 29.1 49.7 45.9 51.4 50.0  
∆ from preceding year - +23.4% +70.5% -7.6% +12.0% -2.7% +111.8% 
*Only years with full-year reports are shown 
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Figure 4.3 and 4.4 show monthly trend in epoetin alfa and darbepoetin alfa use per 
hospital, respectively.  In general, ONS and OFS use in our sample decreased while OFU use 
increased drastically after April 2006.   
 
Figure 4.3 Monthly trend in epoetin alfa use for the on-label, off-label supported, and off-label 
unsupported indications from January 2005 to June 2011 expressed in term of number of visits with ESA 
use per hospital 
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Figure 4.4 Monthly trend in darbepoetin alfa use for the on-label, off-label supported, and off-label 
unsupported indications from January 2005 to June 2011 expressed in term of number of visits with ESA 
use per hospital 
The graphic representation shown in Figure 4.4 confirmed that the decline in the use of 
darbepoetin alfa for the on-label indications was delayed compared to that in epoetin alfa ONS 
use.  Instead of a declining trend at the end of 2006, darbepoetin alfa ONS use continued to rise 
until mid-2006, after which it remained relatively stable until early 2010.  Darbepoetin alfa ONS 
use then dropped drastically toward the end of the study period.  In contrast to epoetin alfa OFS 
use which trended downward throughout the study period, OFS use of darbepoetin alfa in fact 
increased at first, and then leveled off after 2008.  Finally, similarly to epoetin alfa, the use of 
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darbepoetin alfa for the off-label unsupported indications rose after 2006, and remained 
relatively stable until the end of the study period. 
Specific Aim 1 
Descriptive Statistics  
Descriptive statistics were divided into three parts.  The first part describes and compares 
demographic data (age, race, sex, admission type, comorbidity, length of stay, and discharge 
status), source of payment and hospital and physician characteristics between epoetin alfa (EPO) 
and darbepoetin alfa (DARB) users.  The EPO+DARB user group was not included in the 
analysis due to its small sample size (554 patients).  In the second part, differences in patient 
demographic and clinical characteristics, and hospital and physician characteristics between ESA 
users of each category (ONS, OFS, and OFU) were tested separately for each drug.  Actual use 
of ESA for specific ONS, OFS, and OFU indications was described under the final section.   
Descriptive statistical analysis of demographic information of patients prescribed with 
epoetin alfa or darbepoetin alfa only 
Demographic data for patients who received only epoetin alfa or only darbepoetin alfa 
were tested for statistically significant differences.  Bivariates results are shown in Table 4.4.  
The age of patients ranged from 18 to 85 years old, with the average age being 66 years old.  The 
late middle aged (51-64 years), young old (65-74 years), and older old (75-84 years) comprised 
the largest group of ESA users.  Slightly more female than male patients received ESAs.  
Majority of ESA users in our sample were white (62.4%), had Medicare as their primary payer, 
were admitted as emergency cases, and discharged home.  The average length of stay was 12 
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days (0 to 1,362 days) and on average, an ESA user had a comorbidity score of 1.6.  Majority of 
ESA users in this study were admitted to the hospitals located in the Northeast and the South 
with more than 300 beds.  Most of the hospitals were teaching hospitals (74.8%).   Lastly, among 
users without missing information on physician specialty, 61.1% of them were prescribed by a 
specialist.  It is important to note that though age, gender, race, discharge disposition, and 
hospital characteristics were well captured in Cerner data, more than half of the payer 
information of ESA users, and as high as 30-40% of the admission type and ordering physician 
specialty were missing from the records.   
There were significant differences between the EPO and DARB users with respect to 
patient demographic characteristics, clinical characteristics, physician characteristics and hospital 
characteristics.  Overall, compared with those prescribed with epoetin alfa, those prescribed with 
darbepoetin alfa were significantly younger (40.5% vs 46.9% non-elderly), and consisted of 
slightly more male and Caucasians. Greater proportion of DARB users, compared to EPO users, 
had Medicare as their primary payer.  Fewer DARB users were admitted as emergency cases 
compared to EPO users.  Discharge status of both users was similar. However, drug utilization 
was drastically different across the census regions.  Patients admitted to the hospitals located in 
the Midwest and the northeast received darbepoetin alfa to a greater extent compared to patients 
in any other regions.  On the other hand, epoetin alfa was used mostly in the hospitals located in 
the Northeast and the South.  Drug utilization was quite similar across hospital bed size, teaching 
status, and ordering physician specialty categories.   
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Table 4.4 Descriptive statistics for patients admitted to inpatient settings and had at least one order of 
ESAs between January 01, 2005 and June 30, 2011 
Variable N Patients 2005- 2011 (column %) Chi-sq,  
p-value  Any ESAs Epo Darb 
Patient Characteristics     
Demographics     
Age     
   18-30 2,273 (2.64) 1,580 (2.39) 693 (3.45) 389.15 
   31-50 12,362 (14.34) 8,912 (13.48) 3,450 (17.17) p < 0.0001 
   51-64 21,686 (25.16) 16,350 (24.73) 5,336 (26.56)  
   65-74 19,430 (22.54) 15,035 (22.74) 4,395 (21.88)  
   75-84 20,811 (24.14) 16,470 (24.91) 4,341 (21.61)  
   85+ 9,647 (11.19) 7,774 (11.76) 1,873 (9.32)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Average age (SD) 66.1 (15.81) 66.7 (15.62) 64.1 (16.28) p < 0.0001 
Gender*      
   Male 41,564 (48.22) 31,583 (47.77)  9,981 (49.70) 22.91 
   Female 44,636 (51.78)  34,533 (52.23) 10,103 (50.30) p < 0.0001 
   Total (row %) 86,200 (100)  66,116 (76.70) 20,084 (23.30)  
Race     
   Caucasian 53,799 (62.41) 40,517 (62.28) 13,282 (66.12) 783.95 
   African-American 24,473 (28.39) 19,332 (29.24) 5,141 (25.59) p < 0.0001 
   Other 6,149 (7.13) 5,254 (7.95) 895 (4.46)  
   Not recorded 1,788 (2.07) 1,018 (1.54) 770 (3.83)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Primary Payer     
Source of Payment     
   Medicare  24,548 (60.35) 17,666 (58.50) 6,882 (65.67) 888.47 
   Medicaid 3,471 (8.53) 2,541 (8.41) 930 (8.87) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
5,839 (14.35) 4,338 (14.36) 1,501 (14.32)  
   Self-pay 1,700 (4.18) 1,162 (3.85) 538 (5.13)  
   Other 5,120 (12.59) 4,492 (14.87) 628 (5.99)  
   Not recorded 45,531 (52.81) 35,922 (54.33) 9,609 (47.83)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Clinical Conditions     
Admission type     
   Emergency 38,243 (64.09) 29,639 (64.90) 8,604 (61.44) 648.90 
   Urgent 10,598 (17.76) 8,675 (19.00) 1,923 (13.73) p < 0.0001 
   Elective 10,694 (17.92) 7,249 (15.87) 3,445 (24.60)  
   Other 137 (0.23) 106 (0.23) 31 (0.22)  
   Not recorded 26,537 (30.78) 20,452 (30.93) 6,085 (30.29)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Average CCI (SD) 1.62 (1.991), 
-1 to 13 
1.56 (1.967), 
-1 to 13 
1.80 (2.058) 
-1 to 13 
p < 0.0001 
Average LOS (SD), range 12.4 (18.72), 
0 – 1,362 
12.1 (18.85), 
0 - 1,362 
13.4 (18.24),  
0 - 540 
p < 0.0001 
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Discharge status     
   Expired  5,974 (7.24) 4,615 (7.29) 1,359 (7.07) 41.55 
   Discharged to home/ 
self care 
37,211 (45.08) 28,465 (44.95) 8,746 (45.49) p < 0.0001 
   Discharged to Hospice 1,769 (2.17) 1,367 (2.16) 425 (2.22)  
   Discharged/transferred to 
institutionalized care 
24,014 (29.09) 18,216 (28.77) 5,798 (30.15)  
   Discharged/transferred to 
noninstitutionalized care 
12,942 (15.68) 10,163 (16.05) 2,779 (14.45)  
   Other 617 (0.75) 498 (0.79) 119 (0.62)  
   Not recorded 3,657 (4.24) 2,797 (4.23) 860 (4.28)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Hospital Characteristics     
Geographic region     
   Northeast 35,167 (40.79) 27,914 (42.22) 7,253 (36.11) 13384.40 
   Midwest 18,197 (21.11) 8,406 (12.71) 9,791 (48.74) p < 0.0001 
   South 26,628 (30.89) 23,793 (35.98) 2,835 (14.11)  
   West 6,217 (7.21) 6,008 (9.09) 209 (1.04)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Bed size     
   ≤ 99 2,358 (2.74) 1,889 (2.86) 469 (2.33) 1174.51 
   100-199 7,823 (9.07) 5,324 (8.22) 2,390 (11.90) p < 0.0001 
   200-299 15,864 (18.40) 10,919 (16.51) 4,945 (24.62)  
   300-499 26,270 (30.47) 21,419 (32.39) 4,851 (24.15)  
   ≥500 33,894 (39.32) 26,461 (40.02) 7,433 (37.00)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Teaching status     
   Teaching 64,455 (74.77) 49,660 (75.10) 14,795 (73.65) 17.26 
   Non-teaching 21,754 (25.23) 16,461 (24.90) 5,293 (26. 53) p < 0.0001 
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 13,577 (15.75) 11,317 (17.12) 2,260 (11.25) 1550.28 
   Surgeon 5197 (6.03) 3,253 (4.92) 1,944 (9.68) p < 0.0001 
   Specialist 29,535 (34.26) 21,208 (32.07) 8,327 (41.45)  
   Not recorded 37,900 (43.96) 30,343 (45.89) 3,557 (37.62)  
   Total (row %) 86,209 (100.00) 66,121 (76.70) 20,088 (23.30)  
*Nine patients with missing gender information were not tested. 
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Descriptive statistical analysis of demographic information of patients prescribed with 
epoetin alfa and darbepoetin alfa by use category 
This part of the descriptive analysis examined characteristics of the ESA users by their 
use category.  Majority of ESA use in our sample was for on-label indications (48.7%), followed 
by off-label unsupported (42.7%), and off-label supported indications (8.6%).  
There were significant differences in the utilization of epoetin alfa and darbepoetin alfa 
with respect to use categories. Darbepoetin alfa was used to a larger extent for on-label 
indications compared to epoetin alfa; of 20,008 darbepoetin alfa users, 52.8% were for on-label 
indications compared to 47.4% ONS of epoetin alfa users.  Unsupported use of both drugs 
constituted about 83.2% of all off-label use of the drugs.  Table 4.5 summarizes percentages of 
patients with epoetin alfa and darbepoetin alfa use by indication category. 
Table 4.5 Number of ESA users in the inpatient settings by use categories 
Use category N Patients (column %) Chi-sq, 
p-value All ESA users Epo only Darbe only 
ONS 42,218 (48.66) 31,333 (47.39) 10,598 (52.76) 177.90 
OFS 7477 (8.62) 5,834 (8.82) 1,586 (7.90) p < 0.0001 
OFU 37,068 (42.72) 28,954 (43.79) 7,904 (39.35)  
Total (row %) 86,763 66,121 (76.70)  20,088 (23.30)  
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Part 2.1: Any ESAs 
There were statistically significant differences between users of ESAs for ONS, OFS, and 
OFU indications with respect to all variables: age, gender, race, insurance status, admission type, 
comorbidity index, length of stay, discharge disposition, geographic region, hospital size, 
teaching status, and physician specialty.  ESAs, regardless of their indications, were also for a 
greater extent prescribed off-label to female.  ESA utilization patterns were similar across 
geographic regions, hospital bed size, teaching status, and ordering physician specialty 
categories.   
Compared with ONS and OFU users, there was greater proportion of older patients in the 
OFS group. The average age of ESA-OFS group was 70 years old while that of ESA-ONS and 
ESA-OFU groups were 65 and 66 years old, respectively. Greater proportion of ESA-OFS users 
died in the hospital or was discharged to institutionalized care.  There were fewer White and 
Medicare patients in the OFU group compared to the other two groups.  Also, admission type of 
the OFU patients was, to the highest extent, not recorded in the database (60.3% compared 8.8% 
and 11.1% of the ONS and OFS groups, respectively).  However, among those with recorded 
information, admission type did not vary across the three user groups.  We found that the 
majority of ESA patients in our sample were admitted to the hospitals as emergency cases.  
Hospital length-of-stay was longest in the OFS group (14.7 days), followed by OFU (12.9 days), 
while ONS patients stayed in the hospital for 11.8 days on average.  Lastly, OFU patients had 
much lower comorbidity index compared to the ONS and OFS patients (0.3 vs. 2.7 and 2.0).  
Average age, L-O-S, and comorbidity indices of ESA drug recipients are illustrated in Figure 4.5 
and 4.6, respectively.  Descriptive statistics of ESA users by use category was shown in Table 
4.6. 
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Figure 4.5 Average age of ESA drug recipients 
 
Figure 4.6 Average L-O-S and Average CCI of ESA drug recipients 
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Table 4.6 Descriptive statistics for ESA users in the inpatient settings by use categories 
Variable N Patients by Use Category 2005-2011 (column %) Chi-sq, 
p-value  Any indications ONS OFS OFU 
Patient Characteristics 
Demographics      
Age      
   18-30 2,286 (2.63) 1,078 (2.55) 164 (2.19) 1,044 (2.82) 870.35 
   31-50 12,432 (14.33) 6,473 (15.33) 640 (8.56) 5,319 (14.35) p < 0.0001 
   51-64 21,836 (25.17) 11,253 (26.65) 1,404 (18.78) 9,179 (24.76)   
   65-74 19,553 (22.54) 9,461 (22.41) 1,688 (22.58) 8,404 (22.67)  
   75-84 20,952 (24.15) 9,863 (23.36) 2,266 (30.31) 8,823 (23.80)  
   85+ 9,704 (11.18) 4,090 (9.69) 1,315 (17.59) 4,299 (11.60)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Average age (SD) 66.1 (15.81) 65.3 (15.64) 70.5 (15.07) 66.0 (16.00) p < 0.0001 
Gender*      
   Male 41,837 (48.22) 21,229 (50.29) 3,501 (46.82) 17,107 (46.16) 140.94 
   Female 44,917 (51.78) 20,988 (49.71) 3,976 (53.18) 19,953 (53.84) p < 0.0001 
   Total (row %) 86,754 (100.00) 42,217 (48.66) 7,477 (8.62) 37,060 (42.72)  
Race      
   Caucasian 54,172 (64.44) 26,636 (63.09) 5,799 (77.56) 21,737 (58.64) 1046.09 
   African-American 24,608 (28.36) 12,105 (28.67) 1,220 (16.32) 11,283 (30.44) p < 0.0001 
   Other 6,179 (7.12) 2,720 (6.44) 334 (4.47) 3,125 (8.43)  
   Not recorded 1,804 (2.08) 757 (1.79) 124 (1.66) 923 (2.94)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Primary Payer      
Source of Payment      
   Medicare  24,689 (28.46) 1,4550 (34.46) 2,910 (38.92) 7,229 (19.50) 4907.39 
   Medicaid 3,486 (4.02) 1,902 (4.51) 345 (4.61) 1,239 (3.34) p < 0.0001 
  Commercial/ 
Private/ HMO 
Managed Care 
5,886 (6.78) 3,008 (7.12) 623 (8.33) 2,255 (6.08)  
   Self-pay 1,702 (1.96) 855 (2.03) 192 (2.57) 655 (1.77)  
   Other 5,152 (5.94) 3,424 (8.11) 482 (6.45) 1,245 (3.36)  
   Not recorded 45,848 (52.84) 18,478 (43.77) 2,925 (39.12) 24,445 (65.95)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Clinical Conditions      
Admission type      
   Emergency 38,475 (44.34) 24,791 (58.72) 4,231 (56.59) 9,453 (25.50) 26164.05 
   Urgent 10,665 (12.29) 6,445 (15.27) 1,376 (18.40) 2,844 (7.67) p < 0.0001 
   Elective 10,755 (12.40) 7,288 (17.26) 1,038 (13.88) 2,429 (6.55)  
   Other/Not 
recorded 
26,868 (30.97) 3,694 (8.75) 832 (11.13) 22,342 (60.27)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Average CCI (SD) 1.62 (1.991), 
-1 to 13 
2.72 (1.909), 
-1 to 13 
2.00 (1.844), 
0 to 11 
0.29 (1.116), 
0 to 9 
p < 0.0001 
Average LOS (SD), 
range 
12.5 (18.97), 
0 to 1362 
11.8 (16.42), 
0 to 1029 
14.7 (17.99), 
0 to 340 
12.9 (21.64), 
0 to 1362 
p < 0.0001 
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Discharge status      
   Expired  6,031 (6.95) 2,794 (6.62) 872 (11.66) 2,365 (6.07) 5502.15 
   Discharged to 
home/self care 
37,362 (43.06) 17,708 (41.94) 2,011 (26.90) 17,643 (47.60) p < 0.0001 
   Discharged to 
Hospice 
1,809 (2.08) 940 (2.23) 258 (3.45) 611 (1.65)  
   Discharged/ 
transferred to 
institutionalized care 
24,243 (27.94) 12,394 (29.36) 2,873 (38.42) 8,976 (24.21)  
   Discharged/ 
transferred to 
noninstitutionalized 
care 
13,006 (14.99) 7,772 (18.41) 1,397 (18.68) 3,837 (10.35)  
   Other/Not 
recorded 
4,312 (4.97) 610 (1.44)  66 (0.88) 3,636 (9.81)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Hospital Characteristics 
Geographic region      
   Northeast  35,513 (40.93) 16,422 (38.90) 3,415 (45.67) 15,676 (42.29) 1207.08 
   Midwest 18,300 (21.09) 10,700 (25.34) 1,488 (19.90) 6,112 (16.49)  p < 0.0001 
   South 26,712 (30.79) 12,607 (29.86) 2,192 (29.32) 11,913 (32.14)  
   West 6,238 (7.19)  2,489 (5.90) 382 (5.11) 3,367 (9.08)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Bed size      
   ≤ 99 2,374 (2.74) 962 (2.28) 240 (3.21) 1,172 (3.16) 1,360.49 
   100-199 7,886 (9.09) 4,400 (10.42) 659 (8.81) 2,827 (7.63) p < 0.0001 
   200-299 16,053 (18.50) 7,711 (18.26) 1,668 (22.31) 6,678 (18.00)  
   300-499 26,371 (30.39) 13,878 (32.87) 2,789 (37.30) 9,704 (26.18)  
   ≥500 34,079 (39.28) 15,267 (36.16) 2,121 (28.37) 16,691 (45.03)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Teaching status      
   Teaching 64,819 (74.71) 32,051 (75.92) 5,406 (72.30) 27,362 (73.82) 71.23 
   Non-teaching 21,944 (25.29) 10,167 (24.08) 2,071 (27.70) 9,706 (26.18) p < 0.0001 
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
Physician Characteristics     
Ordering Physician Specialty    
   Non-specialist 13,632 (15.71) 5,855 (13.87) 1,324 (17.71) 6,453 (17.41) 692.13 
   Surgeon 5,229 (6.03) 2,835 (6.72) 464 (6.21) 1,930 (5.21) p < 0.0001 
   Specialist 29,669 (34.20) 15,698 (37.18) 2,748 (36.75) 11,223 (30.28)  
   Not recorded 38,233 (44.07) 17,830 (42.23) 2,941 (39.33) 17,462 (47.11)  
   Total (row %) 86,763 (100.00) 42,218 (48.66) 7,477 (8.62) 37,068 (42.72)  
*Nine patients with missing gender information were not tested. 
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Part 2.2: Use of Epoetin alfa Darbepoetin alfa 
 Descriptive analysis of patient characteristics, clinical conditions, hospital characteristics, 
and physician specialty were done separately for epoetin alfa and darbepoetin alfa.  Bivariate 
results for epoetin alfa and darbepoetin alfa are described in Table 4.7 and 4.8, respectively. 
Significant differences between the ONS, OFS, and OFU users of epoetin alfa and darbepoetin 
with respect to patient demographic characteristics, clinical characteristics, physician 
characteristics and hospital characteristics were comparable to those described above in the ESA 
section.  For example, those who used the drug for off-label supported indications were the 
oldest, mostly White female, had higher hospital mortality, and were transferred to other 
institutionalized care settings to a greater extent compared to patients in the other two groups.   
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Table 4.7 Epoetin alfa by use category in the inpatient settings 
Variable N Patients by Use Category 2005-2011 (column %) Chi-sq, 
p-value  Any indications ONS OFS OFU 
Patient Characteristics 
Demographics      
Age      
   18-30 1,580 (2.39) 715 (2.28) 108 (1.85) 757 (2.61) 719.96 
   31-50 8,691 (13.48) 4,494 (14.34) 457 (7.83) 3,961 (13.68) p < 0.0001 
   51-64 16,350 (24.73) 8,198 (26.16) 1,024 (17.55) 7,128 (24.62)  
   65-74 15,035 (22.74) 7,102 (22.67) 1,326 (22.73) 6,607 (22.82)  
   75-84 16,470 (24.91) 7,609 (24.28) 1,837 (31.49) 7,024 (24.26)  
   85+ 7,774 (11.76) 3,215 (10.26) 1,082 (18.55) 3,477 (12.01)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Average age (SD) 66.6 (15.62) 65.9 (15.43) 71.3 (14.70) 66.5 (15.84)  
Gender*      
   Male 31,583 (47.77) 15,633 (49.89) 2,698 (46.25) 13,252 (45.78) 108.12 
   Female 34,533 (52.23) 15,700 (50.11) 3,136 (53.75) 15,697 (54.22) p < 0.0001 
   Total (row %) 66,116 (100.00) 31,333 (47.39) 5,834 (8.82) 28,949 (43.79)  
Race      
   Caucasian 40,517 (61.28) 19,471 (62.14) 4,486 (76.89) 16,560 (57.19) 911.14 
   African-American 19,332 (29.24) 9,266 (29.57) 995 (17.04) 9,072 (31.33) p < 0.0001 
   Other 5,254 (7.95) 2,225 (7.10) 275 (4.71) 2,754 (9.51)  
   Not recorded 1,018 (1.54) 371 (1.18) 79 (1.35) 568 (1.96)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Primary Payer      
Source of Payment      
   Medicare  17,666 (26.72) 10,058 (32.10) 2,305 (39.51) 5,303 (18.32) 4551.74 
   Medicaid 2,541 (3.84) 1,354 (4.32) 258 (4.42) 929 (3.21) p < 0.0001 
  Commercial/ 
Private/ HMO 
Managed Care 
4,338 (6.56) 2,079 (6.64) 443 (7.59) 1,816 (6.27)  
   Self-pay 1,162 (1.76) 472 (1.51) 143 (2.45) 547 (1.89)  
   Other 4,492 (6.79) 3,247 (10.36) 448 (7.68) 797 (2.75)  
   Not recorded 35,922 (54.33) 14,123 (45.07) 2,237 (38.34) 19,562 (67.56)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Clinical Conditions      
Admission type      
   Emergency 29,639 (44.83) 18,950 (60.48) 3,449 (59.12) 7,240 (61.06) 21689.07 
   Urgent 8,675 (13.12) 5,259 (16.78) 1,206 (20.67) 2,210 (25.01) p < 0.0001 
   Elective 7,249 (10.96) 4,719 (15.06) 704 (12.07) 1,826 (7.63)  
   Other/Not 
recorded 
20,558 (31.09) 2,405 (7.68) 475 (8.14) 17,678 (61.06)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Average CCI (SD) 1.56 (1.967), 
-1 to 13 
2.66 (1.911), 
-1 to 13 
2.00 (1.823), 
0 to 11 
0.29 (1.128), 
0 to 9 
 
Average LOS (SD), 
range 
12.1 (18.85), 
0 to 1362 
11.3 (15.91), 
0 to 1029 
13.8 (16.49), 
0 to 329 
12.7 (21.94), 
0 to 1362 
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Discharge status      
   Expired  4,615 (6.98) 2,037 (6.50) 665 (11.40) 1,913 (6.61) 4041.55 
   Discharged to 
home/self care 
28,465 (43.05) 12,952 (41.34) 1,573 (26.96) 13,940 (48.15) p < 0.0001 
   Discharged to 
Hospice 
1,367 (2.07) 715 (2.28) 207 (3.55) 445 (1.54)  
   Discharged/ 
transferred to 
institutionalized care 
18,216 (27.55) 9,084 (28.99) 2,185 (37.45) 6,947 (23.99)  
   Discharged/ 
transferred to 
noninstitutionalized 
care 
10,163 (15.37) 6,025 (19.23) 1,143 (19.59) 2,995 (10.34)  
   Other/Not 
recorded 
3,295 (4.98) 520 (1.66) 61 (1.05) 2,714 (9.37)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Hospital Characteristics 
Geographic region      
   Northeast  27,914 (42.22) 12,618 (40.27) 2,688 (46.07) 12,608 (43.54) 713.65 
   Midwest 8,406 (12.71) 4,763 (15.20) 759 (13.01) 2,884 (9.96) p < 0.0001 
   South 23,793 (35.98) 11,597 (37.01) 2,030 (34.80) 10,166 (35.11)  
   West 6,008 (9.09) 2,355 (7.52) 357 (6.12) 3,296 (11.38)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Bed size      
   ≤ 99 1,889 (2.86) 675 (2.15) 184 (3.15) 1,030 (3.56) 1947.62 
   100-199 5,433 (8.22) 3,251 (10.38) 490 (8.40) 1,692 (5.84) p < 0.0001 
   200-299 10,919 (16.51) 5,429 (17.33) 1,107 (18.97) 4,383 (15.14)  
   300-499 21,419 (32.39) 11,036 (35.22) 2,466 (42.27) 7,917 (27.34)  
   ≥500 26,461 (40.02) 10,942 (34.92) 1,587 (27.20) 13,932 (48.12)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Teaching status      
   Teaching 49,660 (75.10) 23,625 (75.40) 4,379 (75.06) 21,656 (74.79) 2.96 
   Non-teaching 16,461 (24.90) 7,708 (24.60) 1,455 (24.94) 7,298 (25.21) p = 0.2282 
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
Physician Characteristics     
Ordering Physician Specialty    
   Non-specialist 11,317 (17.12) 4,699 (15.00) 1,127 (19.32) 5,491 (18.96) 729.28  
   Surgeon 3,253 (4.92) 1,740 5.55) 277 (4.75) 1,236 (4.27) p < 0.0001 
   Specialist 21,208 (32.07) 11,123 (35.50) 2,158 (36.99) 7,927 (27.38)  
   Not recorded 30,343 (45.89) 13,771 (43.95) 2,272 (38.94) 14,300 (49.39)  
   Total (row %) 66,121 (100.00) 31,333 (47.39) 5,834 (8.82) 28,954 (43.79)  
*Five patients with missing gender information were not tested. 
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Table 4.8 Darbepoetin alfa by use category in the inpatient settings 
Variable N Patients by Use Category 2005-2011 (column %) Chi-sq, 
p-value  Any indications ONS OFS OFU 
Patient Characteristics 
Demographics      
Age      
   18-30 693 (3.45) 356 (3.36) 54 (3.40) 283 (3.58) 146.21 
   31-50 3,450 (17.17) 1,734 (18.25) 180 (11.35) 1,336 (16.90) p < 0.0001 
   51-64 5,336 (26.56) 2,982 (28.14) 367 (23.14) 1,987 (25.14)  
   65-74 4,395 (21.88) 2,295 (21.66) 350 (22.07) 1,750 (22.14)  
   75-84 4,341 (21.61) 2,182 (20.59) 412 (25.98) 1,747 (22.10)  
   85+ 1,873 (9.32) 849 (8.01) 223 (14.06) 801 (10.13)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Average age (SD) 64.10 (16.28) 63.3 (16.08) 67.6 (16.01) 64.4 (16.51)  
Gender*      
   Male 9,981 (49.70) 5,452 (51.45) 776 (48.93) 3,753 (47.50) 28.63 
   Female 10,103 (50.30) 5,145 (48.55) 810 (51.07) 4,148 (52.50) p < 0.0001 
   Total (row %) 20,084 (100.00) 10,597 (52.76) 1,586 (7.90) 7,901 (39.34)  
Race      
   Caucasian 13,282 (66.12) 6,959 (64.56) 1,274 (79.46) 5,049 (63.88) 172.85 
   African-American 5,141 (25.59) 2,778 (27.14) 212 (14.29) 2,151 (27.21) p < 0.0001 
   Other 895 (4.46) 480 (4.60) 57 (3.65) 358 (4.53)  
   Not recorded 770 (3.83) 381 (3.60) 43 (2.71) 346 (4.38)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Primary Payer      
Source of Payment      
   Medicare  6,682 (34.26) 4,403 (41.55) 592 (37.33) 1,887 (23.87) 1245.31 
   Medicaid 930 (4.63) 540 (5.10) 84 (5.30) 306 (3.87) p < 0.0001 
  Commercial/ 
Private/ HMO 
Managed Care 
1,501 (7.47) 907 (8.56) 173 (10.91) 421 (5.33)  
   Self-pay 538 (2.68) 383 (3.61) 48 (3.03) 107 (1.35)  
   Other 628 (3.13) 168 (1.59) 32 (2.02) 428 (5.41)  
   Not recorded 9,609 (47.83) 4,197 (39.60) 657 (41.42) 4,755 (60.16)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Clinical Conditions      
Admission type      
   Emergency 8,604 (42.83) 5,701 (55.38) 753 (43.47) 2,150 (27.20) 4707.65 
   Urgent 1,923 (9.57) 1,141 (10.78) 166 (10.51) 616 (7.79) p < 0.0001 
   Elective 3,445 (17.15) 2,529 (23.32) 326 (23.86) 590 (7.46)  
   Other/Not 
recorded 
6,116 (30.45) 1,227 (11.58) 341 (21.50) 4,548 (57.54)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Average CCI (SD) 1.80 (2.058) 
-1 to 13 
2.92 (1.888) 
-1 to 13 
2.01 (1.938) 
0 to 11 
0.26 (1.078) 
0 to 9 
 
Average LOS (SD), 
range 
13.4 (18.34) 
0 to 540 
12.9 (17.06) 
0 to 398 
17.45 (20.84) 
0 to 340 
13.3 (19.07) 
0 to 540 
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Discharge status      
   Expired  1,359 (6.77) 724 (6.83) 200 (12.61) 435 (5.50) 1550.59 
   Discharged to 
home/self care 
8,746 (43.54) 4,677 (44.13) 426 (26.86) 3,643 (46.09) p < 0.0001 
   Discharged to 
Hospice 
427 (2.13) 216 (2.04) 51 (3.22) 160 (2.02)  
   Discharged/ 
transferred to 
institutionalized care 
5,798 (28.86) 3,185 (30.15) 659 (41.55) 1,954 (24.72)  
   Discharged/ 
transferred to 
noninstitutionalized 
care 
2,779 (13.83) 1,709 (16.13) 245 (15.45) 825 (11.44)  
   Other/Not 
recorded 
979 (4.87) 87 (0.82) 5 (0.32) 887 (11.22)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Hospital Characteristics 
Geographic region      
   Northeast  7,253 (36.11) 3,610 (34.06) 691 (43.57) 2,952 (37.35) 800.45 
   Midwest 9,791 (48.74) 5,892 (55.60) 719 (45.33) 3,180 (40.23) p < 0.0001 
   South 2,835 (14.11) 969 (9.14) 154 (9.71) 1,712 (21.66)  
   West 209 (1.04) 127 (1.20) 22 (1.39) 60 (0.76)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Bed size      
   ≤ 99 469 (2.33) 281 (2.65) 56 (3.53) 132 (1.67) 347.01 
   100-199 2,390 (11.90) 1,118 (10.55) 163 (10.28) 1,109 (14.03) p < 0.0001 
   200-299 4,945 (24.62) 2,176 (20.53) 535 (33.73) 2,234 (28.26)  
   300-499 4,851 (24.15) 2,790 (26.33) 315 (19.86) 1,746 (22.09)  
   ≥500 7,433 (37.00) 4,233 (39.94) 517 (32.60) 2,683 (33.94)  
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Teaching status      
   Teaching 14,795 (73.65) 8,229 (77.65) 994 (62.67) 5,572 (70.50) 226.22 
   Non-teaching 5,293 (26.35) 2,369 (22.35) 592 (37.33) 2,332 (29.50) p < 0.0001 
   Total (row %) 20,088 (100.00) 10,598 (52.76) 1,586 (7.90) 7,904 (39.35)  
Physician Characteristics     
Ordering Physician Specialty    
   Non-specialist 2,260 (11.25) 1,130 (10.66) 195 (12.30) 935 (11.83) 46.21 
   Surgeon 1,944 (9.68) 1,086 (10.25) 183 (11.54) 675 (8.54) p < 0.0001 
   Specialist 8,327 (41.45) 4,506 (42.52) 580 (36.57) 3,241 (41.00)  
   Not recorded 7,557 (37.62) 3,876 (36.57) 628 (39.60) 3,053 (38.63)  
   Total (row %) 12,531 (100.00) 6,722 (53.64) 958 (7.65) 4,851 (38.71)  
*Four patients with missing gender information were not tested. 
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Specific indications of ESAs in ONS and OFU use category 
Uses of epoetin alfa and darbepoetin alfa were further analyzed into individual 
indications.  Specific on-label uses of all ESAs, epoetin alfa, and darbepoetin alfa are described 
in Table 4.9, 4.10, and 4.11 respectively). Chronic kidney disease (CKD) presented the highest 
use of on-label ESA use (84.4%).  On-label utilization pattern of epoetin alfa was similar to that 
of the overall ESAs.  As expected, the use of darbepoetin alfa on-label was prominent in CKD 
while few HIV, anemic patients received darbepoetin alfa as this indication was not officially 
approved for darbepoetin alfa by the FDA. 
Part 3.1 On-label use of ESAs 
Over the period of 6.5 years, the use of ESAs in CKD, among other on-label indications 
increased from 78.6% in 2005 to 91.5% in 2011.  ESA use in chemotherapy-induced anemia 
remained relatively stable, while its use in HIV and surgical procedure fluctuated greatly 
throughout the study period.  Approximately 14% of ONS drug use was for patients undergoing 
major elective surgery.  Less than 10% of ESA ONS use was to treat anemia due to 
chemotherapy.  ESA drug use for zidovudine-induced anemia constituted less than 2% of on-
label drug use.   
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Table 4.9 ONS use of ESA (either Epoetin alfa or Darbepoetin alfa, or both) indications within a category 
are not mutually exclusive 
ONS 
conditions 
Year 
2005 2006 2007 2008 2009 2010 2011 Total 
CKD 4,731 
(78.61)  
6,947 
(81.26) 
6,881 
(86.01) 
7,734 
(84.41) 
4,204 
(87.78) 
4,104 
(89.96) 
1,041 
(91.48) 
35,642 
(84.42) 
CIA 420 
(6.98) 
660 
(7.72) 
538 
(6.73) 
524 
(5.72) 
309 
(6.45) 
281 
(6.16) 
78  
(6.85) 
2,810 
(6.66) 
HIV 90 
(1.50) 
159 
(1.86) 
143 
(1.79) 
185 
(2.02) 
84 
(1.75) 
60 
(1.32) 
13 
(1.14) 
734 
(1.74) 
Surgery 350 
(5.82) 
1,732 
(20.26) 
1,090 
(13.63) 
1,620 
(17.68) 
652 
(13.61) 
478 
(10.48) 
105 
(9.23) 
6,027 
(14.28) 
Any ONS 6,018 8,549 8,000 9,162 4,789 4,562 1,138 45,213 
 
Table 4.10 ONS use of Epoetin alfa only, indications within a category are not mutually exclusive 
ONS 
conditions 
Year 
2005 2006 2007 2008 2009 2010 2011 Total 
CKD 4,049 
(77.49) 
5,672 
(81.19) 
4,708 
(86.64) 
5,481 
(84.09) 
2,628 
(86.70) 
2,941 
(89.72) 
786 
(91.29) 
26,265 
(83.83) 
CIA 375 
(7.18) 
518 
(7.41) 
361 
(6.64) 
318 
(4.88) 
189 
(6.24) 
196 
(5.98) 
60 
(6.97) 
2,017 
(6.44) 
HIV 87 
(1.67) 
142 
(2.03) 
92  
(1.69) 
149 
(2.29) 
57  
(1.88) 
45 
(1.37) 
11 
(1.28) 
583 
(1.86) 
Surgery 1,203 
(23.02) 
1,385 
(19.83) 
704 
(12.96) 
1,186 
(18.20) 
411 
(13.56) 
326 
(9.95) 
88 
(10.22) 
5,303 
(16.92) 
Any ONS 5,225 6,986 5,434 6,518 3,031 3,278 861 31,333 
 
Table 4. 11 ONS use of Darbepoetin alfa only, indications within a category are not mutually exclusive 
ONS 
conditions 
Year 
2005 2006 2007 2008 2009 2010 2011 Total 
CKD 604 
(94.08) 
1,214 
(91.48) 
2,128 
(93.83) 
2,221 
(93.36) 
1,562 
(95.89) 
1,147 
(95.03) 
252 
(94.03) 
9,128 
(93.91) 
CIA 40  
(6.23) 
135 
(10.17) 
173 
(7.63) 
202 
(8.49) 
117 
(7.18) 
84  
(6.96) 
17  
(6.34) 
768 
(7.90) 
HIV 3  
(0.47) 
16  
(1.21) 
51  
(2.25) 
36  
(1.51) 
27  
(1.66) 
13  
(1.08) 
2  
(0.75) 
148 
(1.52) 
Surgery 135 
(21.03) 
331 
(24.94) 
380 
(16.75) 
427 
(17.95) 
241 
(14.79) 
151 
(12.51) 
17 
(6.34) 
1,682 
(17.30) 
Any ONS 642 1,327 2,268 2,379 1,629 1,207 268 9,720 
*Epo indications for HIV and surgery 
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Separate analyses of use for epoetin alfa and darbepoetin alfa showed that chronic kidney 
disease was the main use of both drugs in our sample.  Approximately 83% and 93% of epoetin 
alfa and darbepoetin alfa, respectively, in the ONS cohort, used the drugs to treat anemia of 
CKD.  Approximately 17% of the on-label use was for patients undergoing major surgeries.  
Chemotherapy-induced anemia and zidovudine-induced anemia was responsible for 
approximately 7% and 1.5% of ONS use in the sample.  Comparison of ONS use of epoetin alfa 
and darbepoetin alfa between 2005 and 2011 in the inpatient settings is illustrated in Figure 4.7. 
 
Figure 4.7 ONS use of ESAs, epoetin alfa, and darbepoetin alfa from 2005-2011 
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Part 3.2 Off-label supported use of ESAs 
Among the eleven off-label indications with strong supporting scientific evidence (OFS), 
acute kidney disease contributed the highest use of ESAs (4,514 patients, 60.4%), epoetin alfa 
only (3,436 patients, 58.9%), and darbepoetin alfa only (1,369 patients, 55.6%) – data not shown.  
Due to the relatively small sample size and large number of indications in this category, off-label 
supported use of ESAs was not further subcategorized into individual conditions.   
Part 3.3 Off-label unsupported use of ESAs 
We were able to identified specific use of approximately 18% of the total off-label 
unsupported use of ESAs in the dataset.  The majority of identifiable OFU patients (60%) used 
ESAs for chronic anemia conditions such as iron deficient-related anemia.  The second largest 
use of ESAs for identifiable off-label unsupported indications included anemia of neoplastic 
disease in those not receiving concomitant chemotherapy, cardiac surgery, fractures and other 
injuries, and various GI bleeding.  Identifiable indications of ESAs neither approved nor 
supported by scientific evidence are summarized in Table 4.12-4.14, and compared in Figure 4.8.  
We additionally found that approximately four percent (1,072 patients) of epoetin alfa users with 
OFU conditions had blood transfusion while 328 (4.1%) darbepoetin alfa users with OFU 
conditions had blood transfusion.   
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Figure 4.8 Documented OFU use of ESAs, epoetin alfa, and darbepoetin alfa from 2005-2011 
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Table 4.12 Defined OFU use of any ESAs, indications within a category are not mutually exclusive 
ONS 
conditions 
Year 
2005 2006 2007 2008 2009 2010 2011 Total 
Chronic 
Anemia 
675 
(30.36)  
1,000 
(24.33)  
865 
(15.12)  
648 
(10.34) 
395 
(7.16)  
241 
(3.19)  
31  
(0.55) 
3,855 
(10.40)  
Cancer 510 
(22.94)  
727 
(17.69)  
611 
(10.68)  
386 
(6.16)  
212 
(3.84)  
132 
(1.75)  
15  
(0.26)  
2,593 
(7.00)  
Bleeding 194 
(8.73)  
268 
(6.52) 
260 
(4.54) 
206 
(3.29) 
112 
(2.03) 
85  
(1.12) 
8 
 (0.14) 
1,133 
(3.06) 
Injury 177 
(7.96)  
279 
(6.79)  
334 
(5.84)  
166 
(2.65)  
102 
(1.85)  
57 
 (0.75)  
4  
(0.07)   
1,119 
(3.02) 
Cardiac 
surgery 
350 
(15.74) 
504 
(12.26) 
333 
(5.82) 
494 
(7.88) 
225 
(4.08) 
156 
(2.06) 
12  
(0.21) 
2,074 
(5.60) 
Blood 
transfusion 
284 
(12.78)  
355 
(8.64)  
224 
(3.91)  
288 
(4.60)  
125 
(2.26)  
122 
(1.61) 
13  
(0.23)  
1,411 
(3.81) 
Other known 
OFU 
19 
(0.85)  
25  
(0.61)  
32 
(0.56)  
50 
(0.80)  
20  
(0.36)  
13  
(0.17)  
2  
(0.04)  
161 
(0.43) 
Defined OFU 1,127 
(50.70)  
1,584 
(38.54)  
1,464 
(25.59)  
1,116 
(17.81)  
581 
(10.53) 
440 
(5.82) 
45  
(0.79)  
6,357 
(17.15) 
Any OFU 2,223 4,110 5,722 6,267 5,520 7,563 5,663 37,068 
 
Table 4.13 Defined OFU use of epoetin alfa only, indications within a category are not mutually exclusive 
ONS 
conditions 
Year 
2005 2006 2007 2008 2009 2010 2011 Total 
Chronic 
Anemia 
629 
(35.48) 
850 
(24.42) 
604 
(13.46) 
489 
(9.85) 
316 
(7.25) 
188 
(3.22) 
27  
(0.67) 
3,103 
(10.72) 
Cancer 471 
(26.57) 
611 
(17.55) 
465 
(10.36) 
304 
(6.13) 
164 
(3.76) 
100 
(1.71) 
13  
(0.32) 
2,128 
(7.35) 
Bleeding 180 
(10.15) 
227 
(6.52) 
194 
(4.32) 
151 
(3.04) 
92  
(2.11) 
69  
(1.18) 
8  
(0.20) 
921 
(3.18) 
Injury 165 
(9.31) 
242 
(6.95) 
177 
(3.94)  
114 
(2.30) 
88  
(2.02) 
52  
(0.89) 
4  
(0.10) 
842 
(2.91) 
Cardiac 
surgery 
328 
(18.50) 
427 
(12.27) 
209 
(4.66) 
402 
(8.10) 
188 
(4.31) 
135 
(2.31) 
10  
(0.25) 
1,699 
(5.87) 
Blood 
transfusion 
256 
(14.44) 
280 
(8.04) 
125 
(2.79) 
206 
(4.15) 
91  
(2.09) 
101 
(1.73) 
13  
(0.32) 
1072 
(3.70) 
Other known 
OFU 
18 
(1.02) 
22  
(0.63) 
28 
(0.62) 
44 
(0.89) 
17  
(0.39) 
13  
(0.22) 
1  
(0.02) 
143 
(0.49) 
Defined OFU 1,051 
(59.28) 
1,347 
(38.70) 
991 
(22.09) 
869 
(17.51) 
477 
(10.94) 
368 
(6.30) 
40 
(0.99) 
5,143 
(17.76) 
Any OFU 1,773 3,481 4,487 4,962 4,360 5,839 4,052 28,954 
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Table 4.14 Defined OFU use of darbepoetin alfa only, indications within a category are not mutually 
exclusive 
ONS 
conditions 
Year 
2005 2006 2007 2008 2009 2010 2011 Total 
Chronic 
Anemia 
44 
(10.30)  
144 
(24.00)  
252 
(20.79)  
158 
(12.35)  
78  
(6.83)  
52  
(3.09)  
4 (0.26)  
 (0.13) 
732 
(9.26)  
Cancer 38 
(8.90)  
112 
(18.67)  
143 
(11.80)  
82 
(6.41)  
47  
(4.12)  
32  
(1.90) 
2  
(0.00) 
456 
(5.77)  
Bleeding 13 
(3.04) 
39  
(6.50) 
65 
(5.36) 
54 
(4.22) 
20 
(1.75) 
16 
(0.95) 
0 
 (0.00) 
207 
(2.62) 
Injury 9  
(2.11)  
35  
(5.83)  
155 
(12.79)  
49  
(3.83)  
14  
(1.23) 
5  
(0.30)  
0  
(0.00) 
267 
(3.38)  
Cardiac 
surgery 
18  
(4.22)  
74 
(12.33) 
117 
(9.65) 
91 
(7.11) 
36  
(3.15) 
20  
(1.19) 
2  
(0.13) 
358 
(4.53) 
Blood 
transfusion 
25 
(5.85) 
73 
(12.17) 
94 
(7.76) 
82 
(6.41) 
33 
 (2.89) 
21  
(1.25) 
0 
 (0.00) 
328 
(4.15) 
Other known 
OFU 
1  
(0.23)  
 3  
(0.50)  
4  
(0.33)  
6  
(0.47)  
3  
(0.26) 
0  
(0.00) 
1  
(0.06) 
18 
(0.23)  
Defined OFU 69 
(16.16)  
226  
(37.67)  
459 
(37.87)  
244 
(19.08)  
103 
(9.02)  
70  
(4.16) 
5  
(0.32) 
1176 
(14.88)  
Any OFU 427 600 1212 1279 1142 1684 1560 7904 
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Specific Aim 2: Estimating the impacts of black box warning, NCD, and REMS on the on 
proportion of visits with ESA use 
Trends in ESA On-label, off-label supported, and off-label unsupported therapy 
 Annual trends in ESA ONS, OFS, and OFU use from 2005 to 2010 are shown in Table 
4.15.  These trends were measured in term of the proportion of visits which the drug was 
prescribed over the total number of eligible admissions.  Only full-year data was used to describe 
the annual trends.  In general, the proportions of epoetin alfa and darbepoetin alfa use for on-
label (ONS) and off-label supported (OFS) indications decreased from 2005 to 2011, while that 
for off-label unsupported use (OFU) increase drastically.   
Epoetin alfa ONS use increased 57% from 6.0% (2005) to 7.3% (2006) to 7.4% (2007).  
At the same time, Darbepoetin alfa ONS use increased 250% from 1.0% (2005) to 1.7% (2006) 
to 3.5% (2007).  In 2008, ONS use of both drug started to decline.  Epoetin alfa ONS use 
decreased 76% from 7.4% (2007) to 5.0% (2008) to 1.8% (2009), after which its use increased 
again slightly in 2010 (+1.3%).  Darbepoetin alfa ONS use decreased 71% from 3.5% (2007) to 
2.1% (2008) to 1.4% (2009), and to 1.0% (2010).  Overall, in 6 years, epoetin alfa ONS use 
declined 53% while the level of darbepoetin alfa ONS use remained the same. 
We observed a continual reduction in the proportion of visits which epoetin alfa was used 
in patients with OFS conditions.  In contrast, darbepoetin alfa OFS use increased at the 
beginning of the study period from 0.3% (2005) to 08% (2007) before it started to decreased. 
Overall, epoetin alfa and darbepoetin alfa OFS use declined 85% and 54%, respectively.  
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Similar to ONS use, we found that the OFU proportions increased at the beginning of the 
study period (from 2005 to 2007), but reduced in 2008 and 2009.  OFU use then surged in 2010.  
These annual trends resulted in the overall increase in OFU use of 103% and 147% for epoetin 
alfa and darbepoetin alfa between 2005 and 2011, respectively.  
Table 4.15 Annual trend in the proportion of ESA use by use category* 
Use Category Percent of visits with ESA use (%) 
2005 2006 2007 2008 2009 2010 %∆  
(2005-2010) 
Total (any ESAs)        
ONS 6.9 8.9 10.8 7.1 3.2 3.2  
∆ from preceding year - +29.4% +21.2% -34.6% -55.0% +1.3% -53.2% 
OFS 2.8 2.4 2.4 1.7 0.6 0.5  
∆ from preceding year - -11.3% -2.5% -28.9% -65.1% -15.4% -81.9% 
OFU 3.7 6.3 7.0 7.0 5.2 7.8  
∆ from preceding year - +71.9% +11.3% -1.0% -24.6% +48.8% +112.6% 
Epoetin alfa         
ONS 6.0 7.3 7.4 5.0 1.8 2.2  
∆ from preceding year - +22.0% +1.4% -32.3% -63.5% +21.9% -62.7% 
OFS 2.5 2.0 1.6 1.3 0.4 0.4  
∆ from preceding year - -19.1% -19.2% -23.1% -67.8% -7.4% -85.0% 
OFU 3.0 5.4 5.6 5.5 4.1 6.0  
∆ from preceding year - +80.6% +3.8% -0.6% -26.8% +48.8% +103.0% 
Darbepoetin alfa        
ONS 1.0 1.7 3.5 2.1 1.4 1.0  
∆ from preceding year - +68.5% +105.1% -40.1% -34.3% -26.3% +.03% 
OFS 0.3 0.5 0.8 0.4 0.2 0.1  
∆ from preceding year - +67.6% +68.5% -42.4% -57.2% -33.3% -53.5% 
OFU 0.7 1.0 1.5 1.4 1.2 1.8  
∆ from preceding year - +34.0% +50.3% -2.0% -16.7% +50.2% +147.0% 
*Only years with full-year reports are shown 
 
  
  
141 
 
The proportions of visits with ESA use for the on-label, off-label supported, and off-label 
unsupported were plotted against time to illustrate monthly trends in ESA use.  In Figure 4.5, 
monthly proportions of visits with ESA use for on-label indications are marked with -○- symbol 
while that for off-label supported and off-label unsupported are marked with -×- and  
-□-, respectively.   
ESA use for on-label indication showed an increasing trend from 5.5% at month 1 
(January 2005) to 10.3% at month 22 (October 2006), after which its use leveled off slightly to 
7.7% in June 2007.  A sudden increase in the percent of visits with ESA use was observed at 
month 31 (July 2007).  ESA on-label use level remained high for six months at approximately 
18%.  After that, a rapid drop to 7.9% at month 37 (January 2008) was observed.  Off-label 
supported use of ESAs (OFS) remained relative stable from 2005 to early 2008, and declined 
slightly afterward.  OFU use, however, began to increase from an average of 3.6% in 2005 to 
6.4% (2006-September 2008).  After October 2008, OFU use started to rise sharply (> 500%).  
Similar trends were observed when use was broken down by drug.  Monthly trends for each use 
category of epoetin alfa and darbepoetin alfa are illustrated in Figure 4.9 and 4.11, respectively.   
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Figure 4.9 Monthly trend in ESA use for the on-label, off-label supported, and off-label unsupported 
indications from January 2005 to June 2011 expressed in term of proportion of visits with ESA use over 
total number of eligible visits 
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Figure 4.10  Monthly trend in epoetin alfa use for the on-label, off-label supported, and off-label 
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with 
ESA use over total number of eligible visits 
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Figure 4.11 Monthly trend in darbepoetin use for the on-label, off-label supported, and off-label 
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with 
ESA use over total number of eligible visits 
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Outlier Identification and Data Manipulation 
Outliers or wild data points referred to spurious observations that were highly 
inconsistent with the rest of the series.  An outlier was usually dealt with by checking the original 
data for errors, replacing the observation with imputed values, or deleting such observations.
189
 
Outliers oftentimes make the inference unreliable or even invalid and thus it was important to 
detect and remove such outliers.   
Two possible set of outliers were detected in our data.  In the ONS series, we observed a 
drastic increase in the percent of visits after month 30.  ONS utilization level remained high for 
six month then dropped off suddenly at month 37.  Secondly, possible outliers were detected in 
the all OFU series after month 70 when the proportion increased sharply.  We did not believe 
that such extreme changes in the series were caused by any external interventions, but such 
sudden changes were likely to cause by errors in data collection and reporting of the eligible 
admissions that could not be corrected.  At month 31-36, we found that even though the number 
of visits which a drug was prescribed remained relatively stable, the number of ONS eligible 
admission changed suspiciously.  During those six months, the number of admissions with ONS 
conditions was halved from that at month 30 and resumed to normal level at month 37.  
Likewise, at month 70, there was a rise in the number of visits with ESA OFU use and a drop in 
the number admissions with known OFU conditions, leading to an extreme shift on the OFU 
proportion after month 70.  Similar outliers were also detected for both EPO and DARB series.   
To account for these spurious data points before modeling interrupted time-series 
(Specific Aim 2), values during the outlier months were imputed using time-series forecasting 
method.  A series that minimized root mean square errors was fit to generate predicted y values 
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that were to be used in the subsequent analysis.  Forecasting assumes that the trend in proportion 
continued from month 30 into month 31 to 36 as if the ONS series was left to continue without 
any interventions.  The same approach was used from month 71 onward for the OFU series.  The 
adjusted series with imputed values replacing the outliers are shown in Figure 4.12-4.14.  These 
series were used in the subsequent interrupted time-series analysis.    
 
Figure 4.12 Monthly trend in ESA use for the on-label, off-label supported, and off-label unsupported 
indications from January 2005 to June 2011 expressed in term of proportion of visits with ESA use over 
total number of eligible visits after data manipulation 
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Figure 4.13 Monthly trend in epoetin alfa use for the on-label, off-label supported, and off-label 
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with 
ESA use over total number of eligible visits after data manipulation 
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Figure 4.14 Monthly trend in darbepoetin alfa use for the on-label, off-label supported, and off-label 
unsupported indications from January 2005 to June 2011 expressed in term of proportion of visits with 
ESA use over total number of eligible visits after data manipulation 
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Time-Series Model selection 
 The application of time series to model ESA prescribing patterns and the effects of the 
intervention on the utilization patterns relied on several statistical assumptions.  In order to 
obtain unbiased OLS estimation, it was important to assume that the error terms and all 
explanatory variables were uncorrelated for all time periods.  More importantly, serial correlation 
(autocorrelation) must not be present in the data.  Serial correlation referred to the existence of 
the correlations between the observations’ errors terms in different periods.  The existence of 
serial correlation implied heteroskedasticity of the variance over time resulting in falsely 
estimation of the standard errors.  Only once the assumption of having no serial correlation was 
fulfilled that the OLS estimator became the best linear unbiased estimator (BLUE). 
 In an attempt to fit the best time-series model for our data, several approaches were 
taken to attenuate serial correlations and produce stationary series.  First, autocorrelation patterns 
at different lags were assessed.  Serial correlation was virtually detected with the sample 
autocorrelation function plot (ACF) generated by -proc arima- with identify statement.  The slow 
decay in the ACF plot shown in Panel B of Figure 4.15, 4.16, and 4.17 indicated that correlation 
exists between the dependent variable (proportion of visits with ESA use) and the value in the 
previous period for all three models (ONS, OFS, and OFU).   This slow decay in the ACF plots 
also implied that the series was nonstationary.  Second, white noise test, which intended to test a 
hypothesis that none of the autocorrelations were significantly different from zero, confirmed the 
existence of autocorrelation as the null hypothesis was rejected strongly for all possible lag 
values (p < 0.0001).   Autocorrelations were tested in epoetin alfa and darbepoetin alfa model 
and similar results of strong autocorrelation were observed (data not shown).   
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 Figure 4.15 Diagnostic of autocorrelation in the ESA-ONS series 
 
 
Figure 4.16 Diagnostic of autocorrelation in the ESA-OFS series 
A B 
C D 
A B 
C D 
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Figure 4.17 Diagnostic of autocorrelation in the ESA-OFU series 
To eliminate serial correlation, the use of first-differencing method of the series was 
suggested.
199, 200
   First-differencing referred to a transformation on a time series constructed by 
taking the difference of adjacent time period, where the earlier time period was subtracted from 
the later time period.
201 
   First differencing of the data resolved the issue of serial correlation in 
the ONS and OFU models (all white noise test p-values > 0.05, data not shown).  However, the 
white noise test revealed the remaining of serial correlations in the OFS model (all p-value < 
0.05, data not shown).  First-differencing series and autocorrelation plots after first-differencing 
of the ESA- ONS, ESA-OFS, and ESA-OFU series are shown in Figure 4.18, 4.19, and 4.20. 
A B 
C D 
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Figure 4.18 Diagnostic of autocorrelation in the ESA-ONS series after first-differencing 
 
Figure 4.19 Diagnostic of autocorrelation in the ESA-OFS series after first-differencing 
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Figure 4.20 Diagnostic of autocorrelation in the ESA-OFU series after first-differencing 
As mentioned earlier, the presence of autocorrelation in the model resulted in inaccuracy 
of standard errors even when the coefficients were estimated in an unbiased manner.  To correct 
for autocorrelation remained in the OFS series and to obtain accurate standard errors of the 
estimates, Newey-West’s serial correlation-robust estimation was applied to all models.  Newey 
and West suggested the integer part of 
2( )
94( )
100
n
 as the number of lags in the model if no 
specific theory can otherwise be specified.
201
   This approach corrected for autocorrelation 
remained in the first-differencing OFS series and was also a more conservative approach of 
correcting for any autocorrelation that may still remain undetected in the ONS and OFU series.  
Figure 4.21 – 4.23 show the residual plots of the first-differencing ONS, OFS, and OFU when 
the series were re-estimated with a lag of four (as calculated with Newey-West’s method).  The 
residuals for all three series appeared to follow a normal distribution. 
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Figure 4.21 Residual normality diagnostic of first-differenced ESA-ONS series with a lag of four 
 
Figure 4.22 Residual normality diagnostic of first-differenced ESA-OFS series with a lag of four 
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Figure 4.23 Residual normality diagnostic of first-differenced ESA-OFU series with a lag of four 
The interventions were tested with segmented ordinary least-square regressions once that 
the endogeneous pattern in the series was reduced to random through transformation and 
modeling. Using the estimating equations specified in Chapter 3: Y
t
= β
0 
+ β
1
t + β
2
intervention1 + 
β
3
intervention1 × t
1
 + β
4
intervention2 + β
5
intervention2 × t
2
  + β
6
intervention3+ β
7 
intervention3 
× t
3
 + M2-M12 + e
t
, the final model included first-differencing of all variables and Newey-
West’s serial correlation-robust estimation with the lag of four time periods.  Since the 
aggregated time series was monthly, a set of 11 months variables (M2-M12) were included in the 
model to account of seasonal cycles.   
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Impacts of Safety interventions on the proportion of visits with ESA use 
The aim of this analysis was to determine if the three safety interventions: black box 
warning (BBW), national coverage determination (NCD), and risk evaluation and mitigation 
strategies program (REMS) were associated with change in ESA on-label, off-label supported, 
and off-label unsupported use.  The parameters estimated from the time-series analysis are given 
in Table 4.16, 4.17, and 4.18 for overall ESAs, epoetin alfa, and darbepoetin alfa, respectively.  
On-label use of ESAs (ONS) 
From the beginning of our study period in January 2005 to the issuance of a black box 
warning there was a non-significant, increasing trend in ESA on-label use (0.1% increase in the 
use proportion per month, p = 0.1360).  The addition of a black box warning onto ESA label in 
March 2007 was associated with a significant 1.2 percentage point drop in the proportion of 
visits with ESA on-label use to all ONS eligible visits (95% CI -1.979, -0.358, p = 0.0050).  The 
use of ESAs for the on-label indications continued in a decreasing trend after the first 
intervention (β = -0.142, p = 0.1970).  No other statistical significant reduction in the proportion 
was found though NCD and REMS resulted in non-significant decreased in the level of ONS 
prescribing (β NCD = -0.608, p = 0.1340; β REMS = -0.738, p = 0.0730).  
Off-label supported use of ESAs (OFS) 
Black box warning issuance did not significantly lead to a significant reduction in ESA 
on-label supported use (OFS) like the change in reimbursement policy National Coverage 
Determination did in April 2008.  NCD was the only significant intervention for OFS use.  There 
was a significant 0.3 percentage point drop in the proportion of visits with ESA-OFS use after 
the coverage change in April 2008 (95% CI -0.447, -0.182, p < 0.0001).  Finally, REMS did not 
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have any significant impact on the level of ESA use for OFS indications (β REMS = -0.017, p = 
0.7720).  
Off-label unsupported use of ESAs (OFU) 
None of the intervention appeared to have an effect on the utilization patterns of ESAs 
for the off-label unsupported indications (OFU). 
Epoetin alfa 
The analysis was re-performed by specific drug: epoetin alfa (Table 4.17) and 
darbepoetin alfa (Table 4.18).  Black box warning appeared to have no significant effect on the 
level of epoetin alfa use, for any indications (all p-values > 0.5).  NCD resulted in a 0.3% 
immediate drop in the proportion of OFS-EPO use in at the first month after the intervention was 
implemented (95% CI -0.437, -0.170, p < 0.0001) and non-significant decreasing trends 
afterward.  REMS, on the other hand, did not have any significant impact of epoetin alfa 
utilization patterns.  
Darbepoetin alfa 
Black box warning reduced level of darbepoetin alfa on-label use significantly - 
darbepoetin alfa use drop 0.6% after the intervention took place (95% CI -0.670, 0.433, p < 
0.0001).  In our sample, the reversed effect of black box warning was observed in the off-label 
use.  Black box warning resulted in a significant rise in off-label supported and unsupported use 
of darbepoetin alfa in April 2007 (02% and 0.9% increase for OFS and OFU darb use, 
respectively).  National coverage determination led to a significant increase in on-label use only 
(0.4% point reduction, 95% CI -0.466, -0.256, p < 0.0001).  Finally, the use of darbepoetin alfa 
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was most affected by REMS.  There was a significant 0.5% percentage point drop in the 
proportion of visits which darbepoetin alfa was used on-label (95% CI -0.637, -0.443, p < 
0.0001) and also for off-label unsupported indications (95% CI -0.805, -0.223, p < 0.0010) in 
April 2010, one month after the implementation of REMS. 
None of the intervention effect appeared to be permanent. No significant changes in the 
trend of use continued after the implementation of the interventions though non-significantly 
decreasing trends were observed.  
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Table 4.16 Relative Impacts of Interventions on proportion of ESA use by use category 
Variable Parameters 
 β Newey-
West SE 
95 % Confidence 
Interval 
t-statistics p-value 
Model 1: ONS      
      Time 0.131 0.0867 [-0.042, 0.305] 1.51 0.1360 
   BBW      
      Immediate -1.169* 0.4052 [-1.979, - 0.358] -2.88 0.0050 
      Level Change -0.142 0.1090 [-0.360, 0.076] -1.30 0.1970 
   NCD      
      Immediate -0.608 0.4001 [-1.409, 0.192] -1.52 0.1340 
      Level Change -0.101 0.1791 [-0.459, 0.257] -0.56 0.5750 
   REMS      
      Immediate -0.738 0.4035 [-1.545, 0.070] -1.83 0.0730 
      Level Change 0.076 0.2369 [-0.398, 0.550] 0.32 0.7490 
Model 2: OFS      
      Time -0.005 0.0634 [-0.132, 0.121] -0.08 0.9330 
   BBW      
      Immediate 0.167 0.0876 [-0.008, 0.343] 1.91 0.0610 
      Level Change -0.023 0.0889 [-0.201, 0.155] -0.26 0.7940 
   NCD      
      Immediate -0.315* 0.0661 [-0.447, -0.182] -4.76 < 0.0001 
      Level Change -0.014 0.0732 [-0.160, 0.133] -0.19 0.8520 
   REMS      
      Immediate -0.017 0.0597 [-0.137, 0.102] -0.29 0.7720 
      Level Change 0.011 0.0537 [-0.097, 0.118] 0.20 0.8420 
Model 3: OFU      
     Time 0.134 0.1578 [-0.182, 0.450] 0.85 0.3980 
   BBW      
      Immediate 0.597 0.4455 [-0.295, 1.488] 1.34 0.1860 
      Level Change -0.202 0.1900 [-0.582, 0.178] -1.06 0.2920 
   NCD      
      Immediate 0.205 0.4205 [-0.637. 1.046] 0.49 0.6280 
      Level Change 0.078 0.1651 [-0.252, 0.409] 0.47 0.6370 
   REMS      
      Immediate -0.434 0.4667 [-1.368, 0.500] -0.93 0.3560 
      Level Change -0.047 0.1647 [-0.377, 0.282] -0.29 0.7760 
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Table 4.17 Relative Impacts of Interventions on proportion of epoetin alfa use by use category 
Variable Parameter 
 β Newey-
West SE 
95 % Confidence 
Interval 
t-statistics p-value 
Model 1: ONS      
      Time 0.046 0.0927 [-0.140, 0.232] 0.50 0.6220 
   BBW      
      Immediate -0.596 0.4294 [-1.456, 0.263] -1.39 0.1700 
      Level Change -0.063 0.1594 [-0.382, 0.255] -0.40 0.6920 
   NCD      
      Immediate -0.177 0.4048 [-0.987, 0.633] -0.44 0.6630 
      Level Change -0.078 0.1976 [-0.474, 0.317] -0.40 0.6930 
   REMS      
      Immediate -0.138 0.4058 [0.0950, 0.674] -0.34 0.7340 
      Level Change 0.070 0.2090 [-0.348, 0.488] 0.33 0.7390 
Model 2: OFS      
      Time -0.026 0.0520 [-0.130, 0.079] -0.49 0.6250 
   BBW      
      Immediate 0.021 0.0770 [-0.133, 0.175] 0.27 0.7880 
      Level Change 0.014 0.0691 [-0.124, 0.152] 0.20 0.8390 
   NCD      
      Immediate -0.303* 0.0669 [-0.437, -0.170] -4.54 < 0.0001 
      Level Change -0.015 0.0563 [-0.128, 0.097] -0.27 0.7870 
   REMS      
      Immediate 0.043 0.0585 [-0.074, 0.160] 0.73 0.4660 
      Level Change 0.001 0.0467 [-0.092, 0.095] 0.03 0.9750 
Model 3: OFU      
     Time 0.117 0.1150 [-0.113, 0.347] 1.02 0.3120 
   BBW      
      Immediate -0.117 0.2737 [-0664, 0.431] -0.43 0.6710 
      Level Change -0.114 0.1465 [-0.407, 0.179] -0.78 0.4410 
   NCD      
      Immediate -0.014 0.2653 [-0.545, 0.517] -0.05 0.9580 
      Level Change -0.016 0.1288 [-0.273, 0.242] -0.12 0.9040 
   REMS      
      Immediate 0.221 0.2941 [-0.367, 0.810] 0.75 0.4550 
      Level Change -0.044 0.1393 [-0.323, 0.235] -0.32 0.7540 
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Table 4.18 Relative Impacts of Interventions on proportion of darbepoetin alfa use by use category 
Variable Parameter 
 β Newey-
West SE 
95 % Confidence 
Interval 
t-statistics p-value 
Model 1: ONS      
      Time 0.088 0.0437 [0.000, 0.175] 2.00 0.0500 
   BBW      
      Immediate -0.552* 0.0591 [-0.670, -0.433] -9.34 < 0.0001 
      Level Change -0.084 0.0564 [-0.197, 0.028] -1.50 0.1400 
   NCD      
      Immediate -0.361* 0.0524 [-0.466, -0.256] -6.90 < 0.0001 
      Level Change -0.021 0.0498 [-0.121, 0.078] -0.43 0.6700 
   REMS      
      Immediate -0.540* 0.0485 [-0.637, -0.443] -11.13 < 0.0001 
      Level Change 0.007 0.0429 [-0.079, 0.093] 0.17 0.8650 
Model 2: OFS      
      Time 0.020 0.0163 [-0.013, 0.053] 1.22 0.2260 
   BBW      
      Immediate 0.158* 0.0533 [0.052, 0.265] 2.97 0.0040 
      Level Change -0.038 0.0533 [-0.098, 0.022] -1.26 0.2140 
   NCD      
      Immediate 0.011 0.0485 [-0.086, 0.108] 0.23 0.8160 
      Level Change 0.002 0.0286 [-0.056, 0.059] 0.06 0.9540 
   REMS      
      Immediate -0.049 0.0471 [-0.143, 0.046] -1.03 0.3080 
      Level Change 0.010 0.0170 [-0.024, 0.044] 0.59 0.5540 
Model 3: OFU      
     Time 0.018 0.0652 [-0.113, 0.148] 0.27 0.7880 
   BBW      
      Immediate 0.870* 0.1775 [0.515, 1.255] 4.90 < 0.0001 
      Level Change -0.102 0.0786 [-0.259, 0.056] -1.29 0.2010 
   NCD      
      Immediate 0.361* 0.1625 [0.036, 0.686] 2.22 0.0300 
      Level Change 0.101 0.0604 [-0.020, 0.222] 1.68 0.0990 
   REMS      
      Immediate -0.537* 0.1568 [-0.850, -0.223] -3.42 0.0010 
      Level Change -0.007 0.0515 [-0.110, 0.096] -0.14 0.8900 
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Specific Aim 3: Estimating the impact of of black box warning, NCD, and REMS on odds 
of a patient being prescribed with ESAs 
Outlier identification and Data manipulation 
Similar to the visit level analysis in the previous section, we observed a sudden drop in 
the number of patients admitted to Cerner hospitals with ONS conditions at month 31-36.  This 
reduction was similar to that in the denominator cohort of eligible visits used for a time-series 
analysis and was likely to cause by errors in data recording.  Since it was not possible to impute 
the number of eligible patients, we decided to drop observations at month 31-36 completely from 
the analysis.  No other possible outliers were found in other use cohorts and all patients with 
OFS and OFU indications were retained in the subsequent analysis.  
As demonstrated in the descriptive analysis of ESA users, missing information on race, 
admission type, discharge disposition, primary payer, and medical specialty was common in our 
data.  To retain as many subjects as possible in our final analytical cohort, we opted to conctruct 
a ‘Missing’ category to be in the analytical models.  This approach was adopted for all variables 
with vast number of missing values.  However, due to a small number of observations with 
missing gender information (N = 174 patients), these observations were excluded completely 
from the analysis.  
The ONS cohort consisted of 730,412 patients with ONS conditions.  Among them, 
33,004 patients (15.6%) received ESAs (N epoetin alfa = 25,494 (77.2%) and N darbepoetin = 
7,724 alfa (23.4%)).  The OFS cohort consisted of 505,658 patients with OFS conditions, 5,140 
(1.0%) of which were prescribed with ESAs (N epoetin alfa = 4,093 (%), N darbepoetin alfa = 
1,089 (%)).  The OFU cohort consisted of 559,917 patients with documented OFU conditions, 
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4,491 (0.80%) of which received ESAs (N epoetin alfa = 3,736 (83.1%), N darbepoetin alfa = 
780 (17.4%)).  Number of epoetin alfa and darbepoetin alfa users did not sum to the total number 
of ESA users as some patients received both drugs during the same visit.   
Bivariate analysis 
Patients with ONS conditions 
Bivariate chi-square tests showed statistically significant differences for all demographic, 
hospital characteristic, and physician characteristic variables between ONS+ESA users and ONS 
patients who did not use ESAs.  Compared to patients with ONS conditions who did not receive 
the drug, ESA users appeared to older (mean age 65.4 (SD 15.61) vs. 58.4 (SD 18.52)), consisted 
of greater proportion of male, African-American, and had Medicare as their primary payer.  ESA 
users were more complex than the non-users as they had greater comorbidity score (CCI 2.64 
(SD 1.917) vs. CCI 1.19 (1.804)) and tended to stay in the hospital for a longer period of time 
(LOS 11.6 (SD 15.63) vs. 4.3 (6.42)).  Greater proportion of ESA users was admitted as 
emergency cases, but fewer were discharged home.  To a larger extent, ESA ONS users were 
discharged to hospice, institutionalized and non-institutionalized care, or died in the hospital 
compared to the non-users with the same indications.  Patients admitted to larger hospitals with 
greater than 300 beds, and teaching hospitals received ESAs to a greater extent than patients in 
seen in non-teaching, and small hospitals.  Finally, greater proportion of ESA users were 
admitted by non-specialists compared to the ONS patients who did not receive the drug.  Similar 
results were observed in the separate analyses of epoetin alfa and darbepoetin alfa.  Descriptive 
results are shown in Table 4.19, 4.20, and 4.21 for ESA, epoetin alfa, and darbepoetin alfa users, 
respectively). 
  
  
164 
 
Table 4.19 Descriptive analysis of users and non-users of ESAs with ONS conditions 
Variable N Patients with ONS conditions (column %) Chi-sq,  
p-value  Total ESA Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 62,556 (8.56) 831 (2.52) 61,725 (8.85) 4652.73 
   31-50 180,601 (24.73) 4,969 (15.06) 175,632 (25.19) p < 0.0001 
   51-64 184,676 (25.28) 8,777 (26.59) 175,899 (25.22)  
   65-74 129,368 (17.71) 7,432 (22.52) 121,936 (17.48)  
   75-84 117,046 (16.02) 7,722 (23.40) 109,324 (15.68)  
   85+ 56,165 (7.69) 3,273 (9.92) 52,892 (7.58)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Average age (SD) 58.8 (18.45) 65.4 (15.61) 58.4 (18.52) p < 0.0001 
Gender      
   Male 302,245 (41.38) 16,525 (50.07) 285,720 (40.97) 1076.00 
   Female 428,167 (58.62) 16,479 (49.93) 411,688 (59.03) p < 0.0001 
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Race     
   Caucasian 561,384 (76.86) 20,571 (62.33) 540,813 (77.55) 5195.68 
   African-American 115,395 (15.80) 9,622 (29.15) 105,773 (15.17) p < 0.0001 
   Other 34,898 (4.78) 2,212 (6.70) 32,686 (4.69)  
   Not recorded 18,735 (2.56) 599 (1.81) 18,136 (2.60)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Primary Payer     
Source of Payment     
   Medicare  163,596 (22.40) 10,970 (33.24) 152,626 (21.88) 6044.95 
   Medicaid 40,052 (5.48) 1,462 (4.43) 38,590 (5.53) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
134,077 (18.36) 2,246 (6.81) 131,831 (18.90)  
   Self-pay 23,582 (3.23) 676 (2.05) 22,906 (3.28)  
   Other 105,115 (14.39) 2,865 (8.68) 102,250 (14.66)  
   Not recorded 263,990 (36.14) 14,785 (44.80) 249,205 (35.73)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Clinical Conditions     
Admission type     
   Emergency 256734 (35.15) 19962 (60.48) 236772 (33.68) 12650.48 
   Urgent 81658 (11.18) 5145 (15.59) 76513 (10.97) p < 0.0001 
   Elective 290265 (39.74) 5487 (16.63) 284778 (40.83)  
   Other/ Not recorded 101,755 (13.93) 2,410 (7.30) 99,345 (14.24)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Average CCI (SD) 1.26 (1.834), 
-1 to 14 
2.64 (1.917), 
-1 to 13 
1.19 (1.804), 
-1 to 14 
p < 0.0001 
Average LOS (SD), range 4.6 (7.25), 
0 to 814 
11.6 (15.63), 
0 to 588 
4.3 (6.42), 
0 to 814 
p < 0.0001 
Discharge status     
   Expired  16,526 (2.26) 2,285 (6.92) 14,241 (2.04) 14167.57 
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   Discharged to home/ 
self care 
428,180 (58.62) 13,729 (41.60) 414,451 (59.43) p < 0.0001 
   Discharged to Hospice 8,356 (1.14) 753 (2.28) 7,603 (1.09)  
   Discharged/transferred to 
institutionalized care 
106,950 (14.64) 9,820 (29.75) 97,130 (13.93)  
   Discharged/transferred to 
noninstitutionalized care 
95,472 (13.07) 5,978 (18.11) 89,494 (12.83)  
   Other/Not recorded 74,928 (10.26) 439 (1.33) 74,489 (10.68)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Hospital Characteristics     
Geographic region     
   Northeast 331,785 (45.42) 12,578 (38.11) 319,207 (45.77) 768.88 
   Midwest 153,858 (21.06) 8,157 (24.72) 145,701 (20.89) p < 0.0001 
   South 202,856 (27.77) 10,084 (30.55) 192,772 (27.64)  
   West 41,913 (5.74) 2,185 (6.62) 39,728 (5.70)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Bed size     
   ≤ 99 43,083 (5.90) 756 (2.29) 42,327 (6.07) 2424.64 
   100-199 107,679 (14.74) 3,582 (10.85) 104,097 (14.93) p < 0.0001 
   200-299 146,974 (20.12) 5,953 (18.04) 141,021 (20.22)  
   300-499 178,578 (24.45) 11,150 (33.78) 167,428 (24.01)  
   ≥500 254,098 (34.79) 11,563 (35.04) 242,535 (34.78)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Teaching status     
   Teaching 523,350 (71.65) 24,799 (75.14) 498,551 (71.49) 207.04 
   Non-teaching 207,062  (28.35) 8,205 (24.86) 198,857 (28.51) p < 0.0001 
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 73,589 (10.07) 4,765 (14.44) 68,824 (9.87)  988.76 
   Specialist 288,084 (39.44) 11,032 (33.43) 277,052 (39.73) p < 0.0001 
   Not recorded 368,739 (50.48) 17,207 (52.14) 351,532 (50.41)  
   Total (row %) 730,412 (100.00) 33,004 (4.52) 697,408 (95.48)  
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Table 4.20 Descriptive analysis of users and non-users of epoetin alfa with ONS conditions 
Variable N Patients with ONS conditions (column %) Chi-sq,  
p-value  Total Epo Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 62,556 (8.56) 584 (2.29) 61,972 (8.79) 4079.00 
   31-50 180,601 (24.73) 3,656 (14.34) 176,945 (25.10) p < 0.0001 
   51-64 184,676 (25.28) 6,668 (26.16) 178,008 (25.25)  
   65-74 129,368 (17.71) 5,785 (22.69) 123,583 (17.53)  
   75-84 117,046 (16.02) 6,155 (24.14) 110,891 (15.73)  
   85+ 56,165 (7.69) 2,646 (10.38) 53,519 (7.59)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Average age (SD) 58.5 (18.50) 66.0 (15.45) 58.8 (18.45) p < 0.0001 
Gender     
   Male 302,245 (41.38) 12,643 (49.59) 289,602 (41.08)  734.39 
   Female 428,167 (58.62) 12,851 (50.41) 415,316 (58.92) p < 0.0001 
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Race     
   Caucasian 561,384 (76.86) 15,593 (61.16) 545,791 (77.43) 4904.77 
   African-American 115,395 (15.80) 7,721 (30.29) 107,674 (15.27) p < 0.0001 
   Other 34,898 (4.78) 1,870 (7.34) 33,028 (4.69)  
   Not recorded 18,735 (2.56) 310 (1.22) 18,425 (2.61)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Primary Payer     
Source of Payment     
   Medicare  163,596 (22.40) 7,899 (30.98) 155,697 (22.09) 4064.66 
   Medicaid 40,052 (5.48) 1,128 (4.42) 38,924 (5.52) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
134,077 (18.36) 1,672 (6.56) 132,405 (18.78)  
   Self-pay 23,582 (3.23) 390 (1.53) 23,192 (3.29)  
   Other 105,115 (14.39) 2,756 (10.81) 102,359 (14.52)  
   Not recorded 263,990 (36.14) 11,649 (45.69) 252,341 (35.80)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Clinical Conditions     
Admission type     
   Emergency 256,734 (35.15) 15,736 (61.72) 240,998 (34.19) 11220.11 
   Urgent 81,658 (11.18) 4,295 (16.85) 77,363 (10.97) p < 0.0001 
   Elective 290,265 (39.74) 3,739 (14.67) 286,526 (40.65)  
   Other/ Not recorded 101,755 (13.93) 1,724 (6.76) 100,031 (14.19)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Average CCI (SD) 1.26 (1.834), 
-1 to 14 
2.58 (1.913), 
-1 to 13  
1.21 (1.813),  
-1 to 14 
p < 0.0001 
Average LOS (SD), range 4.6 (7.25), 
0 to 814 
11.1 (15.4), 
0 to 588 
4.4 (6.69), 
0 to 814 
p < 0.0001 
Discharge status     
   Expired  16,526 (2.26) 1,728 (6.78) 14,798 (2.10) 10584.91 
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   Discharged to home/ 
self care 
428,180 (58.62) 10,505 (41.21) 417,675 (59.25) p < 0.0001 
   Discharged to Hospice 8,356 (1.14) 598 (2.35) 7,758 (1.10)  
   Discharged/transferred to 
institutionalized care 
106,950 (14.64) 7,450 (29.22) 99,500 (14.12)  
   Discharged/transferred to 
noninstitutionalized care 
95,472 (13.07) 4,829 (18.94) 90,643 (12.86)  
   Other/Not recorded 74,928 (10.26) 384 (1.51) 74,544 (10.57)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Hospital Characteristics     
Geographic region     
   Northeast 331,784 (45.42) 9,860 (38.68) 321,925 (45.67) 1794.34 
   Midwest 153,858 (21.06) 4,000 (15.69) 149,858 (21.26) p < 0.0001 
   South 202,856 (27.77) 9,541 (37.42) 193,315 (27.42)  
   West 41,913 (5.74) 2,093 (8.21) 39,820 (5.65)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Bed size     
   ≤ 99 43,083 (5.90) 540 (2.12) 42,543 (6.04) 2634.36 
   100-199 107,679 (14.74) 2,714 (10.65) 104,965 (14.89) p < 0.0001 
   200-299 146,974 (20.12) 4,386 (17.20) 142,588 (20.23)  
   300-499 178,578 (24.45) 9,306 (36.50) 169,272 (24.01)  
   ≥500 254,098 (34.79) 8,548 (33.53) 245,550 (34.83)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Teaching status     
   Teaching 523,350 (71.65) 18,930 (74.25) 504,420 (71.56) 88.01 
   Non-teaching 207,062 (28.35) 6,564 (25.75) 200,498 (28.44) p < 0.0001 
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 73,589 (10.07) 3,993 (15.66) 69,596 (9.87) 992.29 
   Specialist 288,084 (39.44) 8,762 (34.37) 279,322 (39.62) p < 0.0001 
   Not recorded 368,739 (50.48) 12,739 (49.97) 356,000 (50.50)  
   Total (row %) 730,412 (100.00) 25,494 (3.49) 704,918 (96.51)  
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Table 4.21 Descriptive analysis of users and non-users of darbepoetin alfa with ONS conditions 
Variable N Patients with ONS conditions (column %) Chi-sq,  
p-value  Total Darb Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 62,556 (8.56) 251 (3.25) 62,305 (8.62) 653.79 
   31-50 180,601 (24.73) 1,348 (17.45) 179,253 (24.80) p < 0.0001 
   51-64 184,676 (25.28) 2,154 (27.89) 182,522 (25.26)  
   65-74 129,368 (17.71) 1,701 (22.02) 127,667 (17.67)  
   75-84 117,046 (16.02) 1,624 (21.03) 115,422 (15.97)  
   85+ 56,165 (7.69) 646 (8.36) 55,519 (7.68)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Average age (SD) 58.8 (18.46) 63.7 (16.01) 58.7 (18.47) p < 0.0001 
Gender     
   Male 302,245 (41.38) 3,983 (51.57) 298,262 (41.27) 333.94 
   Female 428,167 (58.62) 3,741 (48.43) 424,426 (58.73) p < 0.0001 
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Race     
   Caucasian 561,384 (76.86) 5,133 (66.46) 556,251 (76.97) 598.96 
   African-American 115,395 (15.80) 1,949 (25.23) 113,446 (15.70) p < 0.0001 
   Other 34,898 (4.78) 347 (4.49) 34,551 (4.78)  
   Not recorded 18,735 (2.56) 295 (3.82) 18,440 (2.55)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Primary Payer     
Source of Payment     
   Medicare  163,596 (22.40) 3,133 (40.56) 160,463 (22.20) 2651.50 
   Medicaid 40,052 (5.48) 340 (4.40) 39,712 (5.50) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
134,077 (18.36) 583 (7.55) 133,494 (18.47)  
   Self-pay 23,582 (3.23) 287 (3.72) 23,295 (3.22)  
   Other 105,115 (14.39) 116 (1.50) 104,999 (14.53)  
   Not recorded 263,990 (36.14) 3,265 (42.27) 260,725 (36.08)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Clinical Conditions     
Admission type     
   Emergency 256,734 (35.15) 4,336 (56.14) 252,398 (34.92) 1643.67 
   Urgent 81,658 (11.18) 884 (11.44) 80,774 (11.18) p < 0.0001 
   Elective 290,265 (39.74) 1,775 (22.98) 288,490 (39.92)  
   Other/ Not recorded 101,755 (13.93) 729 (9.44) 101,026 (19.98)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Average CCI (SD) 1.26 (1.834), 
-1 to 14 
2.83 (1.916), 
-1 to 13 
1.24 (1.826), 
-1 to 14 
p < 0.0001 
Average LOS (SD), range 4.6 (7.25), 
0 to 814 
13.4 (17.71), 
0 to 398 
4.6 (7.00), 
0 to 814 
p < 0.0001 
Discharge status     
   Expired  16,526 (2.26) 582 (7.53) 15,944 (2.21) 3682.14 
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   Discharged to home/ 
self care 
428,180 (58.62) 3,277 (42.43) 424,903 (58.79) p < 0.0001 
   Discharged to Hospice 8,356 (1.14) 162 (2.10) 8,194 (1.13)  
   Discharged/transferred to 
institutionalized care 
106,950 (14.64) 2,465 (31.91) 104,485 (14.46)  
   Discharged/transferred to 
noninstitutionalized care 
95,472 (13.07) 1,182 (15.30) 94,290 (13.05)  
   Other/Not recorded 74,928 (10.26) 56 (0.73) 74,872 (10.36)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Hospital Characteristics     
Geographic region     
   Northeast 331,785 (45.42) 2,879 (37.27) 328,906 (45.51) 5622.26 
   Midwest 153,858 (21.06) 4,183 (54.16) 149,675 (20.71) p < 0.0001 
   South 202,856 (27.77) 566 (7.33) 202,290 (27.99)  
   West 41,913 (5.74) 96 (1.24) 41,817 (5.79)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Bed size     
   ≤ 99 43,083 (5.90) 220 (2.85) 42,863 (5.93) 246.02 
   100-199 107,679 (14.74) 886 (11.47) 106,793 (14.78) p < 0.0001 
   200-299 146,974 (20.12) 1,648 (21.34) 145,326 (20.11)  
   300-499 178,578 (24.45) 1,882 (34.37) 176,696 (24.45)  
   ≥500 254,098 (34.79) 3,088 (39.98) 251,010 (34.73)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Teaching status     
   Teaching 523,350 (71.65) 6,016 (77.89) 517,334 (71.58) 149.44 
   Non-teaching 207,062 (28.35) 1,708 (22.11) 205,354 (28.42) p < 0.0001 
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 73,589 (10.07) 816 (10.56) 72,773 (10.07) 308.29 
   Specialist 288,084 (39.44) 2,310 (29.91) 285,774 (39.54) p < 0.0001 
   Not recorded 368,739 (50.48) 4,598 (59.53) 364,141 (50.39)  
   Total (row %) 730,412 (100.00) 7,724 (1.06) 722,688 (98.94)  
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Patients with OFS conditions 
Bivariate chi-square tests showed statistically significant differences between OFS+ESA 
users and OFS patients for all demographic, hospital characteristic, and physician characteristic 
variables with an exception of teaching status and darbepoein alfa ESA-OFS use. 
Overall OFS patients consisted of relatively young population (average age 49.5 (SD 
24.14)) who were largely women (75.4%).  Interestingly, OFS+ESA group consisted of much 
older patients than the non-users population (average age 70.1 (SD 15.40)).  Due to the nature of 
conditions defined as eligible OFS conditions such as postpartum anemia, only 25% of the OFS 
cohort was men.  However, almost 50% of ESA-OFS users were male.  More than half of ESA 
users had Medicare as their primary payer compared to the non-users (38% vs 17% Medicare 
patients).  ESA users with OFS conditions were also sicker than the non-users (CCI 1.94 (SD 
1.823) vs. CCI 1.02 (1.443)), stayed in the hospital much longer, (L-O-S 15.7 (SD 19.48) vs. 4.2 
(6.67)), more frequently were admitted as emergency cases (57.2%), discharged to hospice, 
institutionalized and non-institutionalized care, or died in the hospital.  Results from bivariate 
analysis of the OFS cohort showed a similar pattern in patient and hospital characteristics of 
ESA users compared to the ONS cohort.  For instance, erythropoietins were used to a much 
higher extent in large and teaching hospitals.  Descriptive results are shown in Table 4.22, 4.23, 
and 4.24 for ESA, epoetin alfa, and darbepoetin alfa users, respectively). 
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Table 4.22 Descriptive analysis of users and non-users of ESAs with OFS conditions 
Variable N Patients with OFS conditions (column %) Chi-sq,  
p-value  Total ESA Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 171,290 (33.87) 132 (2.57) 171,158 (34.20) 4081.87 
   31-50 104,642 (20.69) 464 (9.03) 104,178 (20.81) p < 0.0001 
   51-64 57,998 (11.47) 976 (18.99) 57,022 (11.39)  
   65-74 52,212 (10.33) 1,177 (22.90) 51,035 (10.200  
   75-84 69,200 (13.69) 1,488 (28.95) 67,712 (13.53)  
   85+ 50,316 (9.95) 903 (17.57) 49,413 (9.87)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Average age (SD) 49.5 (24.14) 70.1 (15.40) 49.2 (24.13) p < 0.0001 
Gender     
   Male 124,431 (24.61) 2,408 (49.85) 122,023 (24.38) 1384.49 
   Female 381,227 (75.39) 2,732 (53.15) 378,495 (75.62) p < 0.0001 
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Race     
   Caucasian 359,136 (71.02) 3,901 (75.89) 355,235 (70.97) 142.80 
   African-American 83,978 (16.61) 877 (17.06) 83,101 (16.60) p < 0.0001 
   Other 48,549 (9.60) 256 (4.98) 48,293 (9.65)  
   Not recorded 13,995 (2.77) 106 (2.06) 13,889 (2.77)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Primary Payer     
Source of Payment     
   Medicare  89,213 (17.64) 1,954 (38.02) 87,259 (17.43) 1925.67 
   Medicaid 68,541 (13.55) 250 (4.86) 68,291 (13.64) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
85,682 (16.94) 441 (8.58) 85,241 (17.03)  
   Self-pay 17,817 (3.52) 124 (2.41) 17,693 (3.53)  
   Other 63,645 (12.59) 328 (6.38) 6,3317 (12.65)  
   Not recorded 180,760 (35.75) 2,043 (39.75) 178,717 (35.71)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Clinical Conditions     
Admission type     
   Emergency 190,791 (37.73) 2,938 (57.16) 187,853 (37.53) 1107.60 
   Urgent 115,098 (22.76) 953 (18.54) 114,145 (22.81) p < 0.0001 
   Elective 160,897 (31.82) 729 (14.18) 160,168 (32.00)  
   Other/ Not recorded 38,872 (7.69) 520 (10.12) 38,352 (7.66)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Average CCI (SD) 1.03 (1.450), 
0 to 13 
1.94 (1.823), 
0 to 11 
1.02 (1.443), 
0 to 13 
p < 0.0001 
Average LOS (SD), range 4.3 (7.02), 
0 to 1354 
15.7 (19.48), 
0 to 340 
4.2 (6.67), 
0 to 1354 
p < 0.0001 
Discharge status     
   Expired  16,428 (3.25) 682 (13.27) 15,746 (3.15) 6930.42 
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   Discharged to home/ 
self care 
358,259 (70.85) 1,284 (24.98) 356,975 (71.32) p < 0.0001 
   Discharged to Hospice 6,327 (1.25) 185 (3.60) 6,142 (1.23)  
   Discharged/transferred to 
institutionalized care 
62,864 (12.43) 2014 (39.18) 60850 (12.16)  
   Discharged/transferred to 
noninstitutionalized care 
45,160 (8.93) 926 (18.02) 44,234 (8.84)  
   Other/Not recorded 16,620 (3.29) 49 (0.95) 16,571 (3.31)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Hospital Characteristics     
Geographic region     
   Northeast 206,082 (40.76) 2,148 (41.79) 203,934 (40.74) 50.48 
   Midwest 116,911 (23.12) 1,105 (21.50) 115,806 (23.14) p < 0.0001 
   South 143,890 (28.46) 1,601 (31.15) 142,289 (28.43)  
   West 38,775 (7.67) 286 (5.56) 38,489 (7.69)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Bed size     
   ≤ 99 51,918 (10.27) 152 (2.96) 51,766 (10.34) 977.44 
   100-199 73,374 (14.51) 385 (7.49) 72,989 (14.58) p < 0.0001 
   200-299 130,516 (25.81) 1,015 (19.75) 129,501 (25.87)  
   300-499 135,871 (26.87) 2,062 (40.12) 133,809 (26.73)  
   ≥500 113,979 (22.54) 1,526 (29.69) 112,453 (22.47)  
   Total (row %) 505,658 (100.00)  5,140 (1.02) 500,518 (98.98)  
Teaching status     
   Teaching 345,003 (68.23) 3,828 (74.47) 341,175 (68.16) 93.46 
   Non-teaching 160,655 (31.77) 1312 (25.53) 159,343 (31.84) p < 0.0001 
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 56,927 (11.26) 850 (16.54) 56,077 (11.20) 151.16 
   Specialist 206,183 (40.78) 1,887 (36.71) 204,296 (40.82) p < 0.0001 
   Not recorded 242,548 (47.97) 2,403 (46.75) 240,145 (47.98)  
   Total (row %) 505,658 (100.00) 5,140 (1.02) 500,518 (98.98)  
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Table 4.23 Descriptive analysis of users and non-users of epoetin alfa with OFS conditions 
Variable N Patients with OFS conditions (column %) Chi-sq,  
p-value  Total Epo Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 171,290 (33.87) 93 (2.27) 171,197 (33.87) 3455.82 
   31-50 104,642 (20.69) 331 (8.09) 104,311 (20.69) p < 0.0001 
   51-64 57,998 (11.47) 726 (17.74) 57,272 (11.47)  
   65-74 52,212 (10.33) 939 (22.94) 51,273 (10.33)  
   75-84 69,200 (13.69) 1,237 (30.22) 67,963 (13.69)  
   85+ 50,316 (9.95) 767 (18.74) 49,549 (9.95)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Average age (SD) 49.5 (24.14) 70.9 (15.07) 49.3 (24.13) p < 0.0001 
Gender     
   Male 124,431 (24.61) 1,882 (45.98) 122,549 (24.43) 1016.04 
   Female 381,227 (75.39) 2,211 (54.02) 379,016 (75.57) p < 0.0001 
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Race     
   Caucasian 359,136 (71.02) 3,072 (75.05) 356,064 (70.99) 106.89 
   African-American 83,978 (16.61) 731 (17.86) 83,247 (16.60) p < 0.0001 
   Other 48,549 (9.60) 219 (5.53) 48,330 (9.64)  
   Not recorded 13,995 (2.77) 71 (1.73) 13924 (2.78)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Primary Payer     
Source of Payment     
   Medicare  89,213 (17.64) 1,539 (37.60) 87,674 (17.48) 1499.30 
   Medicaid 68,541 (13.55) 187 (4.57) 68,354 (13.63) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
85,682 (16.94) 327 (7.99) 85,355 (17.02)  
   Self-pay 17,817 (3.52) 90 (2.20) 17,727 (3.53)  
   Other 63,645 (12.59) 308 (7.53) 63,337 (12.63)  
   Not recorded 180,760 (35.75) 1,642 (40.12) 179,118 (35.71)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Clinical Conditions     
Admission type     
   Emergency 190,791 (37.73) 2,437 (59.54) 188,354 (37.55) 1038.18 
   Urgent 115,098 (22.76) 826 (20.18) 114,272 (22.78) p < 0.0001 
   Elective 160,897 (31.82) 495 (12.09) 160,402 (31.98)  
   Other/ Not recorded 38,872 (7.69) 335 (8.18) 38,537 (7.68)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Average CCI (SD) 1.03 (1.450), 
0 to 13 
1.94 (1.801), 
0 to 11 
1.02 (1.445),  
0 to 13 
p < 0.0001 
Average LOS (SD), range 4.3 (7.02) 
0 to 1354 
14.8 (18.24), 
0 to 329 
4.3 (6.78), 
0 to 1354 
p < 0.0001 
Discharge status     
   Expired  16,428 (3.25) 533 (13.02) 15,895 (3.17) 5382.59 
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   Discharged to home/ 
self care 
358,259 (70.85) 1,019 (24.90) 357,240 (71.23) p < 0.0001 
   Discharged to Hospice 6,327 (1.25) 154 (3.76) 6,173 (1.23)  
   Discharged/transferred to 
institutionalized care 
62,864 (12.43) 1,564 (38.21) 61300 (12.22)  
   Discharged/transferred to 
noninstitutionalized care 
45,160 (8.93) 777 (18.98) 44,383 (8.85)  
   Other/Not recorded 16,620 (3.29) 46 (1.12) 16,574 (3.30)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Hospital Characteristics     
Geographic region     
   Northeast 206,082 (40.76) 1,740 (42.51) 204,342 (40.74) 243.69 
   Midwest 116,911 (23.12) 585 (14.29) 116,326 (23.19) p < 0.0001 
   South 143,890 (28.46) 1,497 (36.57) 142,393 (28.39)  
   West 38,775 (7.67) 271 (6.62) 38,504 (7.68)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Bed size     
   ≤ 99 51,918 (10.27) 121 (2.96) 51,797 (10.33) 1023.39 
   100-199 73,374 (14.51) 285 (6.96) 73,089 (14.57) p < 0.0001 
   200-299 130,516 (25.81) 722 (17.64) 129,794 (25.88)  
   300-499 135,871 (26.87) 1,832 (44.76) 134,039 (26.72)  
   ≥500 113,979 (22.54) 1,133 (27.68) 112,846 (22.50)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Teaching status     
   Teaching 345,003 (68.23) 3,113 (76.06) 341,890 (68.16) 116.65 
   Non-teaching 160,655 (31.77) 980 (23.94) 159,675 (31.84) p < 0.0001 
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 56,927 (11.26) 764 (18.67) 56,163 (11.20) 227.39 
   Specialist 206,183 (40.78) 1,555 (37.99) 204,628 (48.00) p < 0.0001 
   Not recorded 242,548 (47.97) 1,774 (0.81) 240,774 (40.80)  
   Total (row %) 505,658 (100.00) 4,093 (0.81) 501,565 (99.19)  
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Patients with OFU conditions 
In contrary to the ONS and OFS cohort, small differences in the average age of ESA 
users and non-users were observed in patients with OFU indications (average age OFU+ESAs 
64.8 vs 61.6 for OFU group).  Slightly greater proportion of female and African American OFU 
patients received ESAs (17% vs 12%).  Medicare remained as the major payer of ESA in the 
OFU population but the differences between the users and non-users were less obvious compared 
to that in the ONS and OFS cohorts.  ESA users with OFU conditions were sicker, stayed in the 
hospital longer, more frequently discharged to institutionalized and non-institutionalized care.  
Finally, the use of ESAs for OFU indications was higher in medium to large hospitals (300-499 
beds).  Descriptive results are shown in Table 4.24, 4.25, and 4.26 for ESA, epoetin alfa, and 
darbepoetin alfa users, respectively). 
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Table 4.24 Descriptive analysis of users and non-users of darbepoetin alfa with OFS conditions 
Variable N Patients with OFS conditions (column %) Chi-sq,  
p-value  Total Darb Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 171,290 (33.87) 40 (3.67) 171,250 (33.94) 736.48 
   31-50 104,642 (20.69) 136 (12.49) 104,506 (20.71) p < 0.0001 
   51-64 57,998 (11.47) 260 (23.88) 57,738 (11.44)  
   65-74 52,212 (10.33) 248 (22.77) 51,964 (10.30)  
   75-84 69,200 (13.69) 262 (24.06) 68,938 (13.66)  
   85+ 50,316 (9.95) 143 (13.13) 50,173 (9.94)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Average age (SD) 49.5 (24.14) 66.8 (16.12)  49.4 (24.15) p < 0.0001 
Gender     
   Male 124,431 (24.61) 546 (50.14) 123,885 (24.55) 383.41 
   Female 381,227 (75.39) 543 (49.86) 380,684 (75.45) p < 0.0001 
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Race     
   Caucasian 359,136 (71.02) 859 (78.88) 358,277 (71.01) 56.51 
   African-American 83,978 (16.61) 156 (14.33) 83,822 (16.61) p < 0.0001 
   Other 48,549 (9.60) 38 (3.49) 48,511 (9.61)  
   Not recorded 13,995 (2.77) 36 (3.31) 13,959 (2.77)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Primary Payer     
Source of Payment     
   Medicare  89,213 (17.64) 425 (39.03) 88,788 (17.60) 452.61 
   Medicaid 68,541 (13.55) 66 (6.06) 68,475 (13.57) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
85,682 (16.94) 120 (11.02) 85,562 (16.96)  
   Self-pay 17,817 (3.52) 34 (3.12) 17,783 (3.52)  
   Other 63,645 (12.59) 21 (1.93) 63,624 (12.61)  
   Not recorded 180,760 (35.75) 423 (38.84) 180,337 (35.74)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Clinical Conditions     
Admission type     
   Emergency 190,791 (37.73) 525 (48.21) 190,266 (37.71) 263.10 
   Urgent 115,098 (22.76) 130 (11.94) 114,968 (22.79) p < 0.0001 
   Elective 160,897 (31.82) 241 (22.13) 160,656 (31.84)  
   Other/ Not recorded 38,872 (7.69) 193 (17.72) 38,679 (7.67)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Average CCI (SD) 1.03 (1.450), 
0 to 13 
1.90 (1.885), 
0 to 10 
1.03 (1.449), 
0 to 13 
p < 0.0001 
Average LOS (SD), range 4.3 (7.02), 
0 to 1354 
20.4 (25.06), 
0 to 340 
4.3 (6.89), 
0 to 1354 
p < 0.0001 
Discharge status     
   Expired  16,428 (3.25) 154 (14.14) 16,274 (3.23) 1650.54 
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   Discharged to home/ 
self care 
358,259 (70.85) 272 (24.98) 357,987 (70.95) p < 0.0001 
   Discharged to Hospice 6,327 (1.25) 31 (2.85) 6,296 (1.25)  
   Discharged/transferred to 
institutionalized care 
62,864 (12.43) 472 (43.34) 62,392 (12.37)  
   Discharged/transferred to 
noninstitutionalized care 
45,160 (8.93) 157 (14.42) 45,003 (8.92)  
   Other/Not recorded 16,620 (3.29) 3 (0.28) 16,617 (3.29)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Hospital Characteristics     
Geographic region     
   Northeast 206,082 940.76) 433 (39.76) 205,649 (40.76) 481.16 
   Midwest 116,911 (23.12) 527 (48.39) 116,384 (23.07) p < 0.0001 
   South 143,890 (28.46) 111 (10.19) 143,779 (28.50)  
   West 38,775 (7.67) 18 (1.65) 38,757 (7.68)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Bed size     
   ≤ 99 51,918 (10.27) 31 (2.85) 51,887 (10.28) 197.97 
   100-199 73,374 (14.51) 105 (9.64) 73,269 (14.52) p < 0.0001 
   200-299 130,516 (25.81) 309 (28.37) 130,207 (25.81)  
   300-499 135,871 (26.87) 236 (21.67) 135,635 (26.88)  
   ≥500 113,979 (22.54) 408 (37.47) 113,571 (22.51)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Teaching status     
   Teaching 345,003 (68.23) 744 (68.32) 344,259 (68.23) 0.0042 
   Non-teaching 160,655 (31.77) 345 (31.68) 160,310 (31.77) p = 0.9485 
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 56,927 (11.26) 93 (8.54) 56,834 (11.26)  67.88 
   Specialist 206,183 (40.78) 341 (31.31) 205,842 (40.80)  p < 0.0001 
   Not recorded 242,548 (47.97) 655 (60.15) 241,893(47.94)  
   Total (row %) 505,658 (100.00) 1,089 (0.22) 504,569 (99.78)  
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Table 4.25 Descriptive analysis of users and non-users of ESAs with documented OFU conditions 
Variable N Patients with OFU conditions (column %) Chi-sq,  
p-value  Total ESA Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 37,399 (6.69) 215 (4.79) 37,184 (6.71) 165.33 
   31-50 110,811 (19.83) 688 (15.32) 110,123 (19.86) p < 0.0001 
   51-64 145,430 (26.02) 1,057 (23.54) 144,373 (26.04)  
   65-74 107,065 (19.16) 969 (21.58) 106,096 (19.14)  
   75-84 104,715 (18.74) 1,062 (23.65) 103,653 (18.70)  
   85+ 53,497 (9.57) 500 (11.13) 52,997 (9.56)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Average age (SD) 61.7 (17.94) 64.8 (17.19) 61.6 (17.95) p < 0.0001 
Gender     
   Male 275,478 949.29) 1,922 (42.80) 273,556 (49.34) 76.32 
   Female 283,439 (50.71) 2,569 (57.20) 280,870 (50.66) p < 0.0001 
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Race     
   Caucasian 452,164 (80.900 3,358 (74.77) 448,806 (80.95) 182.33 
   African-American 69,234 (12.390 773 (17.21) 68,461 (12.35) p < 0.0001 
   Other 22,491 (4.02) 284 (6.32) 22207 (4.01)  
   Not recorded 15,028 (2.69) 76 (1.69) 14,952 (2.70)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Primary Payer     
Source of Payment     
   Medicare  137,606 (24.62) 1,254 (27.92) 136,352 (24.59)  321.63 
   Medicaid 25,966 (4.65) 234 (5.21) 25,732 (4.64) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
88,676 (15.87) 586 (13.05) 88,090 (15.89)  
   Self-pay 26,006 (4.65) 126 (2.81) 25,880 (4.67)  
   Other 83,757 (14.99) 347 (7.73) 83,410 (15.04)  
   Not recorded 196,906 (35.23) 1,944 (43.29) 194,962 (35.16)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Clinical Conditions     
Admission type     
   Emergency 302,620 (54.14) 2,201 (49.01) 300,419 (54.19) 292.36 
   Urgent 75,339 (13.48) 860 (19.15) 74,479 (13.43) p < 0.0001 
   Elective 121,033 (21.65) 729 (16.23) 120,304 (21.70)  
   Other/ Not recorded 59,925 (10.72) 701 (15.61) 59,224 (10.68)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Average CCI (SD) 0.65 (1.373), 
0 to 11 
1.48 (2.164), 
0 to 9 
0.64 (1.363), 
0 to 11 
p < 0.0001 
Average LOS (SD), range 4.6 (7.96),  
0 to 1430 
14.4 (19.02),  
0 to 369 
4.5 (7.75),  
0 to 1430 
p < 0.0001 
Discharge status     
   Expired  13,947 (2.50) 280 (6.23) 13,667 (2.47)  2570.57 
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   Discharged to home/ 
self care 
340,227 (60.87) 1,524 (33.93) 338,703 (61.09) p < 0.0001 
   Discharged to Hospice 7,457 (1.33) 144 (3.21) 7,313 (1.32)  
   Discharged/transferred to 
institutionalized care 
92,573 (16.56) 1,658 (36.92) 90,915 (16.40)  
   Discharged/transferred to 
noninstitutionalized care 
60,531 (10.83) 838 (18.66) 59,693 (10.77)  
   Other/Not recorded 44,182 (7.90) 47 (1.05) 44,135 (7.96)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Hospital Characteristics     
Geographic region     
   Northeast 242,258 (43.34) 1,778 (39.59) 240,480 (43.37) 122.56 
   Midwest 114,295 (20.45) 769 (17.12) 113,526 (20.48) p < 0.0001 
   South 173,037 (30.96) 1,598 (35.58)  171,439 (30.92)  
   West 29,327 (5.25) 346 (7.70) 28,981 (5.23)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Bed size     
   ≤ 99 27,733 (4.96) 79 (1.76) 27,654 (4.99) 786.64 
   100-199 76,368 (13.660 291 (6.48) 76,077 (13.72) p < 0.0001 
   200-299 109,642 (19.620 841 (18.73) 108,801 (19.62)  
   300-499 148,829 (26.630 1,951 (43.44) 146,878 (26.49)  
   ≥500 196,345 (35.13) 1,329 (29.59) 195,016 (35.17)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Teaching status     
   Teaching 405,948 (72.63) 3,349 (74.57) 402,599 (72.62) 8.57 
   Non-teaching 152,969 (27.37) 1,142 (25.43) 151,827 (27.38) p = 0.0034 
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 77,760 (13.91) 799 (17.79) 76,961 (13.88) 62.84 
   Specialist 193,374 (34.600 1,558 (34.69) 191,816 (34.60) p < 0.0001 
   Not recorded 287,783 (51.49) 2,134 (47.52) 285,649 (51.52)  
   Total (row %) 558,917 (100.00) 4,491 (0.80) 554,426 (99.20)  
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Table 4.26 Descriptive analysis of users and non-users of epoetin alfa with documented OFU conditions 
Variable N Patients with OFU conditions (column %) Chi-sq,  
p-value  Total Epo Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 37,399 (6.69) 145 (3.88) 37,254 (6.71) 174.31 
   31-50 110,811 (19.83) 563 (15.07) 110,248 (19.86) p < 0.0001 
   51-64 145,430 (26.02) 897 (24.01) 144,533 (26.03)  
   65-74 107,065 (19.16) 813 (21.76) 106,252 (19.14)  
   75-84 104,715 (18.74) 900 (24.09) 103,815 (18.70)  
   85+ 53,497 (9.57) 418 (11.19) 53,079 (9.56)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Average age (SD) 61.7 (17.94) 65.3 (16.70) 61.6 (17.95) p < 0.0001 
Gender     
   Male 275,478 (49.29) 1,599 (42.80) 273,879 (49.33) 63.34 
   Female 283,439 (50.71) 2,137 (57.20) 281,302 (50.67) p < 0.0001 
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Race     
   Caucasian 452,164 (80.90) 2,782 (74.46) 449,382 (80.94) 181.29 
   African-American 69,234 (12.39) 646 (17.29) 68,588 (12.35) p < 0.0001 
   Other 22,491 (4.02) 252 (6.75) 22,239 (4.01)  
   Not recorded 15,028 (2.69) 56 (1.50) 14,972 (2.70)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Primary Payer     
Source of Payment     
   Medicare  137,606 (24.62) 1,027 (27.49) 136,579 (24.60) 277.47 
   Medicaid 25,966 (4.65) 196 (5.25) 25,770 (4.64) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
88,676 (15.87) 473 (12.66) 88,203 (15.89)  
   Self-pay 26,006 (4.65) 87 (2.33) 25,919 (4.67)  
   Other 83,757 (14.99) 310 (8.30) 83,447 (15.03)  
   Not recorded 196,906 (43.98) 1,643 (43.98) 195,263 (35.17)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Clinical Conditions     
Admission type     
   Emergency 302,620 (54.14) 1,898 (50.80) 300,722 (54.17) 219.66 
   Urgent 75,339 (13.48) 787 (21.07) 74,552 (13.43) p < 0.0001 
   Elective 121,033 (21.65) 613 (16.41) 120,420 (21.69)  
   Other/ Not recorded 59,925 (10.72) 438 (11.72) 59,487 (10.71)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Average CCI (SD) 0.65 (1.373), 
0 to 11 
1.50 (2.17), 
0 to 9 
0.64 (1.365), 
0 to 11 
p < 0.0001 
Average LOS (SD), range 4.6  (7.96), 
0 to 1430 
14.1  (19.06), 
0 to 369 
4.5  (7.79), 
0 to 1430 
p < 0.0001 
Discharge status     
   Expired  13,947 (2.50) 230 (6.16) 13,717 (2.47) 2077.96 
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   Discharged to home/ 
self care 
340,227 (60.87) 1,284 (34.37) 338,943 (61.05) p < 0.0001 
   Discharged to Hospice 7,457 (1.33) 132 93.53) 7,325 (1.32)  
   Discharged/transferred to 
institutionalized care 
92,573 (16.56) 1,353 (36.22) 91,220 (16.43)  
   Discharged/transferred to 
noninstitutionalized care 
60,531 (10.83) 695 (18.60) 59,836 (10.78)  
   Other/Not recorded 44,182 (7.90) 42 (1.12) 44,140 (7.95)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Hospital Characteristics     
Geographic region     
   Northeast 242,258 (43.34) 1,405 (37.61) 240,853 (43.38) 284.76 
   Midwest 114,295 (20.45) 531 (14.21) 113,764 (20.49) p < 0.0001 
   South 173,037 (30.96) 1,462 (39.13) 171,575 (30.90)  
   West 29,327 (5.25) 338 (9.05) 28,989 (5.22)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Bed size     
   ≤ 99 27,733 (4.96) 69 (1.85) 27,664 (4.98) 1022.68 
   100-199 76,368 (13.66) 216 (5.78) 76,152 (13.72) p < 0.0001 
   200-299 109,642 (19.62) 570 (15.26) 109,072 (19.65)  
   300-499 148,829 (26.63) 1,822 (48.77) 147,007 (26.48)  
   ≥500 196,345 (35.13) 1,059 (28.35) 195,286 (35.18)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
Teaching status     
   Teaching 405,948 (72.63) 2,881 (77.11) 403,067 (72.60) 38.03 
   Non-teaching 152,969 (27.37) 855 (22.89) 152,114 (27.40) p < 0.0001 
   Total (row %) 555,181 (100.00) 3736 (0.67) 558,917 (99.33)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 77,760 (13.91) 666 (17.83) 77,094 (13.89) 72.97 
   Specialist 193,374 (34.60) 1,372 (36.72) 192,002 (34.58) p < 0.0001 
   Not recorded 287,783 (51.49) 1,698 (45.45) 286,085 (51.53)  
   Total (row %) 555,181 (100.00) 3,736 (0.67) 558,917 (99.33)  
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Table 4.27 Descriptive analysis of users and non-users of darbepoetin alfa with documented OFU 
conditions 
Variable N Patients with OFU conditions (column %) Chi-sq,  
p-value  Total Darb Users Non-users 
Patient Characteristics     
Demographics     
Age     
   18-30 37,399 (6.69) 71 (9.10) 37,328 (6.690 24.22 
   31-50 110,811 (19.83) 129 (16.54) 110,682 (19.83) p = 0.0002 
   51-64 145,430 (26.02) 165 (21.15) 145,265 (26.03)  
   65-74 107,065 (19.16) 161 (20.64) 106,904 (19.15)  
   75-84 104,715 (18.74) 171 (21.92) 104,544 (18.73)  
   85+ 53,497 (9.57) 83 (10.64) 53,414 (9.57)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Average age (SD) 61.66 (17.94) 62.3 (19.17) 61.7 (17.94) p < 0.0001 
Gender     
   Male 275,478 (49.29) 335 (42.95) 275,143 (49.30) 12.56 
   Female 283,439 (50.71) 445 (57.05) 282,994 (50.70) p = 0.0004 
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Race     
   Caucasian 452,164 (80.90) 595 (76.28) 451,569 (80.91) 14.57 
   African-American 69,234 (12.39) 131 (16.79) 69,103 (12.38) p = 0.0022 
   Other 22,491 (4.02) 34 (4.36) 22,457 (4.02)  
   Not recorded 15,028 (2.69) 20 (2.56) 15,008 (2.69)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Primary Payer     
Source of Payment     
   Medicare  137,606 (24.62) 234 (30.00) 137,372 (24.61) 70.82 
   Medicaid 25,966 (4.65) 38 (4.87) 25,928 (4.65) p < 0.0001 
  Commercial/Private/HMO 
Managed Care 
88,676 (15.87) 116 (14.87) 88,560 (15.87)  
   Self-pay 26,006 (4.650 39 (5.00) 25,967 (4.65)  
   Other 83,757 (14.99) 37 (4.74) 83,720 (15.00)  
   Not recorded 196,906 (35.23) 316 (40.51)  196,590 (35.22)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Clinical Conditions     
Admission type     
   Emergency 302,620 (54.14) 312 (40.00) 302,308 (54.16) 481.11 
   Urgent 75,339 (13.48) 75 (9.62) 75,264 (13.48) p < 0.0001 
   Elective 121,033 (21.65) 120 (15.38) 120,913 (21.66)  
   Other/ Not recorded 59,925 (10.72) 273 (35.00) 59,652 (10.69)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Average CCI (SD) 0.65 (1.373), 
0 to 11 
1.39 (2.113), 
0 to 9 
0.65 (1.372), 
0 to 11 
p < 0.0001 
Average LOS (SD), range 4.6 (7.96), 
0 to 1,430 
16.4 (19.22), 
1 to 141 
4.6 (7.92), 
0 to 1,430 
p < 0.0001 
Discharge status     
   Expired  13,947 (2.50) 51 (6.54) 13,896 (2.49) 537.65 
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   Discharged to home/ 
self care 
340,227 (60.87) 246 (31.54) 339,981 (60.91) p < 0.0001 
   Discharged to Hospice 7,457 (1.33) 14 (1.79)  7,443 (1.33)  
   Discharged/transferred to 
institutionalized care 
92,573 (16.56) 319 (40.90) 92,254 (16.53)  
   Discharged/transferred to 
noninstitutionalized care 
60,531 (10.83) 145 (18.59) 60,386 (10.82)  
   Other/Not recorded 44,182 (7.90) 5 (0.64) 44,177 (7.92)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Hospital Characteristics     
Geographic region     
   Northeast 242,258 (43.34) 388 (49.74) 241,870 (43.34) 120.70 
   Midwest 114,295 (20.45) 244 (31.28) 114,051 (20.43) p < 0.0001 
   South 173,037 (30.96) 139 (17.82) 172,898 (30.98)  
   West 29,327 (5.25) 9 (1.15) 29,318 (5.25)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Bed size     
   ≤ 99 27,733 (4.96) 10 (1.28) 27,723 (4.97) 171.94 
   100-199 76,368 (13.66) 77 (9.87) 76,291 (13.67) p < 0.0001 
   200-299 109,642 (19.62) 285 (36.54) 109,357 (19.59)  
   300-499 148,829 (26.63) 131 (16.790 148,698 (26.64)  
   ≥500 196,345 (35.13) 277 (35.51) 196,068 (35.13)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Teaching status     
   Teaching 405,948 (72.63) 481 (61.67) 405,467 (72.65) 47.24 
   Non-teaching 152,969 (27.37) 299 (38.33) 152,670 (27.35) p < 0.0001 
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
Physician Characteristics     
Ordering Physician Specialty 
   Non-specialist 77,760 (13.91) 134 (17.18) 77,626 (13.91) 37.90 
   Specialist 193,374 (34.60) 189 (24.23) 193,185 (34.61) p < 0.0001 
   Not recorded 287,783 (51.49) 457 (58.59 287,326 (51.48)  
   Total (row %) 558,917 (100.00) 780 (0.14) 558,137 (99.86)  
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GEE Model Selection 
The objective of this specific aim was to determine the impacts of safety interventions on 
ESA utilization patterns and associations of patient demographics, clinical characteristics, 
hospital characteristics, and physician characteristics with ESA on-label and off-label 
prescribing.  These variables were selected a priori based on the literature review described in 
Chapter 2.   
In order to obtain reliable estimates of the parameter, it was important to identify whether 
multicollinearity existed.  Multicollinearity referred to linear correlations among explanatory 
variables in the estimating which can result in bias estimation of coefficients. A diagnostics of 
multicollinearity was done using OLS estimation because such test was not possible in logistic 
regression.  Multicollinearity was not detected (VIF
b
 values < 4 for all time-constant explanatory 
variables, data not shown).  The final model included all variables used in the bivariate analysis 
except for hospital length of stay because its inclusion caused failure in the convergence of the 
correlation matrix and iteration process of standard errors of the GEE models.  
The GEE models were specified using a binomial distribution and a logit link. The link 
and distribution was appropriate in modeling categorical dependent variable, ESA use, in this 
case.  Exchangeable correlation structure was selected because of the non-ordering nature of 
patients within the hospital clusters.
197
 An alternative to exchangeable correlation structure is 
unstructured matrix.  However, this choice was not selected because of the large number of time 
                                                          
b
 Variance Inflation Factor (VIF) value represents the inflation of the variance of an estimated coefficient beyond 
what would have resulted if there was no collinearity.  VIF less than 4 implies acceptable level of correlation among 
explanatory variables in the models.   
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points in our data.  All correlations at all time points must be estimated if unstructured 
correlation matrix were specified.  If unstructured matrix were to be used instead of the 
exchangeable matrix, we were likely to have encountered a computation constraint, reduction of 
power of statistical tests, and non-convergence issues of the estimates. 
The variables included in the model came from five main domains: intervention and time 
variables, patient demographic characteristics, patient clinical characteristics, hospital 
characteristics, and physician characteristics.  The selected binary logistic regression model can 
be specified as followed: Logit(ESA=1) = β
0 
+ β
1
t + β
2
intervention1 + β
3
intervention1 × t
1
 + 
β
4
intervention2 + β
5
intervention2 × t
2
  + β
6
intervention3+ β
7 
intervention3 × t
3 
+ DEM + 
HEALTH + HOS + PHYS + e
t
  
Intervention variables: Three indicator variables: black box warning (BBW), NCD, and REMS, 
were included in the model. The intervention indicator variable indicated the immediate month 
after which the intervention was implemented.  The interaction terms of intervention indicator 
variable and time indicated the monthly time trend after the intervention. 
Patient demographic variables (DEM): Patient demographics included were age, race, gender, 
and primary payer.  The variable age was categorized into six different age groups: young adult 
(18-30 years), middle-aged (31-50 years), late middle-age (51-64 years), young old (65-74 
years), older old (75-84 years), and oldest old (85 years and above).  The reference group used 
for age group was adult aged between 31 and 50 years old.  The gender reference group was 
male.  The race variables included Caucasian, African-American, Other, and Missing.  Caucasian 
group was used as a reference.  The primary payer variable included Medicare, Medicaid, 
Private, Self-pay, Other, and Missing.  Medicare was the reference category. 
  
  
186 
 
Patient clinical characteristics (HEALTH): Clinical variables included admission type, 
comorbidity index, and discharge disposition.  Variable indicating hospital length-of-stay was 
dropped from the final model because addition of this variable created convergence issue of the 
estimate: Admission type was categorized into Emergency, Urgent, Elective, and Other/Missing, 
and admission through an emergency department was used as the reference category. 
Comorbidity index was added into the model as a continuous variable.  Finally, discharge type 
was categorized into Discharged to home, Expired, Discharged to hospice, Discharged to 
institutionalized care, Discharged to non-institutionalized care, and Other/Missing.  Discharged 
to home category was use as a reference group. 
Hospital characteristics (HOS): These variables included census region where the hospital was 
located: Northeast, Midwest, South, and West, where the Northeast region was use as a 
reference, teaching status, where non-teaching hospital group was used as a reference category, 
and hospital size (number of beds), Bed size variable was categorized in less than 99 beds, 100-
199 beds, 200-299 beds (reference), 300-499 beds, and more than 500 beds.   
Physician characteristics (PHY): The only physician characteristic used in the analytical model 
was physician specialty.  Medical specialty of admitting physicians were categorized into Non-
specialist, Specialist, and Missing, with Non-specialist as the reference category. 
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Aim 3a: Impacts of black box warning, NCD, and REMS on odds of being prescribed ESAs 
Impacts of the interventions on ESA utilization patterns 
Impact of black box warning, NCD, and REMS on the odds of being prescribed ESAs for 
the on-label, off-label supported, and off-label unsupported indications are summarized in Table 
4.28, 4.29, and 4.30, respectively. 
Addition of a black box warning onto ESA labels did not significantly affect the odds of a 
patient receiving the drug for any indications.  However, there was a marginally insignificant 
decrease in the odds of receiving ESAs among patients with ONS indications (OR 0.870, 95% CI 
0.750, 1.008, p = 0.0645).  National coverage determination (NCD), on the other hand, was 
associated with significant reduction in the odds of using the drugs once implemented. The 
impact of NCD was observed across three use categories. Patients with ONS, OFS, and OFU 
conditions were 0.13 times (95% CI 0.760, 0.986, p = 0.0299), 0.20 times (95% CI 0.716, 0.891, 
p < 0.0001), and 0.38 times (95% 0.474, 0.817, p < 0.0006), respectively, less likely to receive 
ESAs after the change in reimbursement policy.  Moreover, patients with on-label and off-label 
supported conditions were 0.046 times (95% CI 0.931, 0.977, p = 0.000) and 0.06 times (95% 
0.902, 0.974, p = 0.0009) less likely to use the drugs, with every month after NCD.  No 
significant impact of REMS was found on the on-label and off-label use of ESAs.   
Impacts of the interventions on epoetin alfa utilization patterns 
The impact of safety interventions on individual erythropoietic drugs were assessed using 
the binary logistic regression models with the same set of independent variables. In the epoetin 
alfa mode, the impact of black box warning was observed in off-label unsupported prescribing 
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only.  A patient with off-label unsupported indications admitted in April 2007 was 0.394 times 
less likely to received epoetin alfa, compared to than those admitted in before that month.  NCD, 
on the other hand, significantly reduced the odds of a patient receiving epoetin alfa off-label 
immediately after its implementation.  A patient admitted to the hospital with off-label supported 
indication and off-label unsupported indications in April 2008 was 0.20 times (95% CI 0.691, 
0.921, p = 0.0021) and 0.47 times (95% 0.383, 0.729, p = 0.0001) less likely to be prescribed 
with epoetin alfa, compared than similar patients admitted before that month.  Moreover, after 
the NCD, the odds of a patient with off-label supported indication in receiving the drug was 
reduced by 0.07 times per month (95% CI 0.879, 0.975, p = 0.0032).  Finally, the 
implementation of REMS was not associated with any change in the odds of receiving epoetin 
alfa. 
Impacts of the interventions on darbepoetin alfa utilization patterns 
 There appeared to be small but statistically significant increases in the off-label 
unsupported use of darbepoetin alfa during the study period (OR 1.079, 95% CI 1.038, 1.122, p 
<0.0001).  While we observed neither the impact of black box warning nor REMS on the on-
label use of darbepoetin alfa, NCD was associated with significant reduction in the odds of 
receiving darbepoetin alfa on-label.  A patient with ONS conditions was 9.6% less likely to use 
darbepoetin alfa after the change in reimbursement policy was put in place. There were small but 
statistically significant decreases in the use of darbepoetin alfa for OFS and OFU conditions after 
the issuance of a black box warning (OR 0.957, 95% CI 0.918, 0.998, p = 0.0410, and OR 0.848, 
95% CI 0.75, 0.958, p = 0.0079).  Similarly, we found small but statistically significant 
decreases in the use of darbepoetin alfa associated with NCD implementation in patients with the 
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conditions for OFS indications.  Risk Evaluation and Mitigation Strategy program (REMS) did 
not have any significant impacts on the use of darbepoetin for any indications. 
Table 4.28 Relative Impacts of Interventions on the odds of receiving any ESA therapy by Use Category 
Variable Parameter 
 β Exp (β) SE of 
Exp (β) 
95% Confidence 
Interval 
Chi-
Square 
p-value 
Model 1: ONS       
      Time -0.04 0.967 0.0024 [0.992, 1.001] 2.06 0.1516 
   BBW       
      Immediate -0.140 0.870 0.0657 [0.750, 1.008] 3.42 0.0645 
      Level Change 0.005 1.005 0.0067 [0.992, 1.019] 0.61 0.4354 
   NCD       
      Immediate -0.143* 0.867* 0.0572 [0.762, 0.986] 4.71 0.0299 
      Level Change -0.047* 0.954* 0.0120 [0.931, 0.977] 14.28 0.0002 
   REMS       
      Immediate 0.097 1.102 0.1163 [0.896, 1.355] 0.84 0.3594 
      Level Change 0.027 1.028 0.0257 [0.979, 1.079] 1.19 0.2748 
Model 2: OFS       
      Time 0.0004 1.000 0.0071 [0.987, 1.014] < 0.01 0.9554 
   BBW       
      Immediate -0.101 0.904 0.0922 [0.740, 1.104] 0.99 0.3208 
      Level Change 0.007 1.007 0.0115 [0.985, 1.030] 0.42 0.5170 
   NCD       
      Immediate -0.225* 0.799* 0.0445 [0.716, 0.891] 16.26 <0.0001 
      Level Change -0.065* 0.937* 0.0184 [0.902, 0.974] 10.97 0.0009 
   REMS       
      Immediate 0.197 1.218 0.1557 [0.948, 1.565] 2.38 0.1231 
      Level Change 0.008 1.008 0.0310 [0.949, 1.071] 0.07 0.7890 
  Model 3: Documented OFU 
     Time 0.012* 1.011* 0.0049 [1.002, 1.021] 5.66 0.0173 
   BBW       
      Immediate -0.245 0.783 0.1407 [0.550, 1.114] 1.85 0.1734 
      Level Change -0.029 0.971 0.0196 [0.934, 1.011] 2.08 0.1495 
   NCD       
      Immediate -0.474* 0.622* 0.0865 [0.474, 0.817] 11.63 0.0006 
      Level Change -0.008 0.992 0.0279 [0.939, 1.049] 0.08 0.7835 
   REMS       
      Immediate -0.079 0.924 0.1839 [0.626, 1.365] 0.16 0.6926 
      Level Change -0.010 0.991 0.0274 [0.938, 1.046] 0.12 0.7309 
*Statistically significance at α = 0.05 
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Table 4.29 Relative Impacts of Interventions on odds of receiving epoetin alfa therapy by Use Category 
Variable Parameter 
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Model 1: ONS       
      Time -0.006 0.995 0.0043 [0.986, 1.003] 1.65 0.1991 
   BBW       
      Immediate -0.184 0.832 0.0931 [0.668, 1.036] 2.70 0.1004 
      Level Change 0.004 1.004 0.0107 [0.983, 1.025] 0.13 0.7133 
   NCD       
      Immediate -0.159 0.853 0.0861 [0.700, 1.040] 2.47 0.1159 
      Level Change 0.051* 0.950* 0.0177 [0.916, 0.986] 7.47 0.0063 
   REMS       
      Immediate 0.236 1.266 0.1642 [0.982, 1.633] 3.31 0.0687 
      Level Change 0.044 1.045 0.0323 [0.983, 1.110] 2.01 0.1561 
Model 2: OFS       
      Time -0.006 0.994 0.0085 [0.978, 1.011] 0.47 0.4926 
   BBW       
      Immediate -0.202 0.817 0.1195 [0.613, 1.088] 1.91 0.1667 
      Level Change 0.022 1.022 0.0157 [0.992, 1.053] 2.02 0.1548 
   NCD       
      Immediate -0.226* 0.798* 0.0585 [0.691, 0.921] 9.49 0.0021 
      Level Change -0.077* 0.926* 0.0243 [0.879, 0.975] 8.68 0.0032 
   REMS       
      Immediate 0.223 1.250 0.2215 [0.883, 1.769] 1.59 0.2077 
      Level Change 0.026 1.026 0.0392 0.952, 1.106 0.46 0.4990 
Model 3: Documented OFU 
     Time 0.004 1.004 0.0054 [0.993, 1.014] 0.48 0.4879 
   BBW       
      Immediate -0.502* 0.606* 0.1130 [0.420, 0.873] 7.23 0.0072 
      Level Change 0.009 1.009 0.0184 [0.974, 1.046] 0.25 0.6187 
   NCD       
      Immediate -0.638* 0.528* 0.0868 [0.383, 0.729] 15.08 0.0001 
      Level Change -0.031 0.970 0.0285 [0.915, 1.027] 1.10 0.2949 
   REMS       
      Immediate -0.116 0.891 0.2054 [0.567, 1.400] 0.25 0.6153 
      Level Change -0.010 0.991 0.0310 [0.932, 1.053] 0.09 0.7607 
*Statistically significance at α = 0.05 
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Table 4.30 Relative Impacts of Interventions on odds of receiving darbepoetin alfa therapy by Use 
Category 
Variable Parameter 
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Model 1: ONS       
      Time 0.005 1.001 0.0067 [0.992, 1.018]  0.55 0.4575 
   BBW       
      Immediate -0.046 0.955 0.1043 [0.771, 1.183] 0.18 0.6713 
      Level Change 0.008 1.008 0.0138 [0.981, 1.035] 0.34 0.5602       
   NCD       
      Immediate -0.101* 0.904* 0.0272 [0.852, 0.959] 11.29 0.0008 
      Level Change -0.047* 0.955* 0.0128 [0.930, 0.980] 11.98 0.0005 
   REMS       
      Immediate -0.261 0.770 0.1367 [0.544, 1.091] 2.17 0.1410 
      Level Change 0.003 1.003 0.0426 [0.923, 1.090] < 0.01 0.9504 
Model 2: OFS       
      Time 0.039 1.039 0.0122 [1.016, 1.064] 10.80 0.0010 
   BBW       
      Immediate -0.007 0.993 0.1197 [0.784, 1.258] 0.00 0.9559 
      Level Change -0.044* 0.957* 0.0205 [0.918, 0.998] 4.17 0.0410 
   NCD       
      Immediate -0.205 0.814 0.0923 [0.652, 1.017] 3.28 0.0700 
      Level Change -0.046* 0.955* 0.0170 [0.923, 0.989] 6.59 0.0103 
   REMS       
      Immediate 0.164 1.178 0.1738 [0.883, 1.573] 1.24 0.2658 
      Level Change -0.051 0.950 0.0460 [0.864, 1.045] 1.11 0.2918 
Model 3: Documented OFU 
     Time 0.076* 1.079* 0.0213 [1.038, 1.122] 14.93 0.0001 
   BBW       
      Immediate 0.199 1.220 0.5823 [0.479, 3.109] 0.17 0.6774 
      Level Change -0.165* 0.848* 0.0526 [0.751, 0.958] 7.05 0.0079 
   NCD       
      Immediate 0.113 1.120 0.3500 [0.607, 2.066] 0.13 0.7180 
      Level Change 0.024 1.025 0.0645 [0.906, 1.159] 0.15 0.7004 
   REMS       
      Immediate 0.277 1.319 0.6838 [0.477, 3.643] 0.28 0.5938 
      Level Change -0.051 0.950 0.0617 [0.837, 1.079] 0.62 0.4302 
*Statistically significance at α = 0.05 
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Aim 3b Associations of covariates and ESA On-label use 
The same binary logistic regressions using GEE used in Specific Aim 3a were fit to 
assess the  associations of patient demographics, clinical characteristics, hospital characteristics, 
and physician characteristics with ESA on-label and off-label prescribing.  The three models 
include: ESA-ONS, ESA-OFS, and ESA-Documented OFU.  We did not distinguish between the 
two erythropoietic drugs in these models.  The reference categories for each of the categorical 
independent variables in the model made up of White males aged 31-50 who had Medicare as 
their primary payer, admitted as emergent patients, discharged to home, by a non-specialist, to 
non-teaching hospitals located in the Northeast region which had between 200 and 299 beds.  
Results from each model were divided for ease of understanding into three parts: patient 
demographic, clinical condition, and hospital and physician characteristics. Associations of these 
variables and on-label, off-label supported, and off-label unsupported of ESAs in the inpatient 
settings are shown in Table 4.31-4.39. 
Part 1: On-label use of ESAs 
 The regression results of patient demographics as possible predictors of ESA on-label 
prescribing are summarized in Table 4.31.  Young adult (18-30 years) were 0.29 times less likely 
to be prescribed with ESA for on-label indications compared to the middle aged adult in the age 
range of 31 to 50 years (95% CI 0.658, 0.763, p < 0.0001).  The late middle-age (51-64 years), 
on the other hand, were 1.20 times more likely to be prescribed with ESAs (95% CI 1.119, 
1.296, p < 0.0001).  Being of aged 65 to 84 years, a patient was not found to be statistically more 
or less likely than the young adult to be prescribed with ESAs.  Lastly, being the oldest old 
(above 85 years) was associated with decreased odds of receiving ESAs on-label (0.31 times less 
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likely, 95% CI 0.597, 0.790, p < 0.0001).  The odds of receiving ESAs also depended on 
patient’s gender.  Female patients were 0.12 time less likely to receive ESAs on-label (95% 
0.857, 0.915, p < 0.0001).  Patient’s race was strongly associated with the odds of being 
prescribed with ESAs.  Compared to Caucasian, African-American were 1.715 times more likely 
to receive ESAs (95% CI 1.557, 1.889, p < 0.0001).  Similarly, patients of ‘Other’ race were 1.46 
times more likely than Caucasian to receive ESAs (95% CI 1.307, 1.621, p < 0.0001).  Finally, 
compared to Medicare patients, patients with other health insurance types were less likely to 
receive ESA on-label.  For example, private insurance patients were 0.40 times less likely than 
Medicare patients to be prescribed with ESAs.  Those who had to pay for the healthcare services 
out-of-pocket (the “Self-pay” group) were 0.48 times less likely to use ESAs, compared to 
Medicare patients.   
 The regression results of patient clinical conditions as possible predictors of ESA on-
label prescribing are shown in Table 4.32.  Compared to “Emergent” patients, patient who were 
admitted to the hospitals as elective cases were 0.60 times less likely to be prescribed ESAs on-
label (95% CI 0.322, 0.490, p < 0.0001).  The odds of receiving ESAs increased substantially 
with more complex patients measured through combined comorbidity score.  The odds of 
receiving ESAs increased 1.20 times with one unit increase in the comorbidity index (95% 
1.174, 1.232, p < 0.0001).  Lastly, discharge disposition was a strong predictor of ESA on-label 
prescribing.  Compared to the patients who were discharged to home, those who expired in the 
hospitals were 1.98 times more like to use ESAs (95% 1.784, 2.196, p < 0.0001).  Patients who 
needed to be transferred to hospice, institutionalized, or non-institutionalized care were all more 
likely to use ESAs compared to those who were discharged to home. 
  
  
194 
 
 No significant differences in the odds of ESA on-label prescribing were found among 
hospitals across geographic regions.  Being admitted to small hospitals of fewer than 99 beds 
reduced the odds of receiving ESAs 0.48 times compared to medium-sized hospitals (95% CI 
0.0036, 0.819, p < 0.0001).  On the other hand, the odds of receiving ESAs increased 1.59 times 
if a patient was being admitted to relatively larger hospitals (300-499 beds).  Finally, admitting 
physicians, whether be a non-specialist or specialist, was not associated with the odds of using 
ESA on-label.  Associations of hospital characteristics and physician specialty and ESA on-label 
prescribing can be found in Table 4.33. 
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Table 4.31 Associations of patient demographic and ESA ONS use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Demographics       
Age       
   18-30 -0.345* 0.709* 0.0269 [0.658, 0.763] 82.66 <.0001 
   31-50 (reference) - - - - - - 
   51-64  0.186* 1.204* 0.0450 [1.119, 1.296] 24.73 <.0001 
   65-74 0.053 1.054 0.0593 [0.944, 1.177] 0.89 0.3458 
   75-84 -0.055 0.946 0.0613 [0.834, 1.074] 0.73 0.3938 
   85+ -0.376* 0.687* 0.0492 [0.597, 0.790] 27.52 <.0001 
Gender       
   Male (reference) - - - - - - 
   Female -0.122* 0.885* 0.0148 [0.857, 0.915] 53.06 <.0001 
Race       
   Caucasian 
(reference) 
- - - - - - 
   African-American 0.539* 1.715* 0.0845 [1.557, 1.889] 119.99 <.0001 
   Other 0.375* 1.455* 0.0799 [1.307, 1.621] 46.62 <.0001 
   Missing 0.071 1.074 0.0624 [0.958, 1.203] 1.49 0.2218 
Source of Payment       
   Medicare 
(reference) 
- - - - - - 
   Medicaid -0.260* 0.771* 0.0599 [0.662, 0.898] 11.20 0.0008 
   Commercial/ 
Private/ HMO 
Managed Care 
-0.504* 0.604* 0.0386 [0.533, 0.684] 62.38 <.0001 
   Self-pay -0.654* 0.520* 0.0334 [0.459, 0.590] 103.93 <.0001 
   Other -0.274* 0.760* 0.0716 [0.632, 0.915] 8.46 0.0036 
   Missing -0.217* 0.805* 0.0589 [0.697, 0.929] 8.80 0.003 
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Table 4.32 Associations of clinical conditions and ESA ONS use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Clinical Conditions       
Admission type       
   Emergency 
(reference) 
- - - - - - 
   Urgent -0.037 0.964 0.0532 [0.865, 1.074] 0.45 0.5015 
   Elective -0.924* 0.397* 0.0426 [0.322, 0.490] 74.21 <.0001 
   Other/Missing -0.478* 0.620* 0.0604 [0.512, 0.751] 24.05 <.0001 
Average CCI (SD) 0.184* 1.203* 0.0147 [1.174, 1.232] 228.08 <.0001 
Discharge status       
   Discharged to 
home/self care 
(reference)  
- - - - - - 
   Expired 0.683* 1.979* 0.1050 [1.784, 2.196] 165.56 <.0001 
   Discharged to 
Hospice 
0.174* 1.191* 0.0767 [1.049, 1.351] 7.34 0.0068 
   Discharged/ 
transferred to 
institutionalized care 
0.658* 1.932* 0.0778 [1.785, 2.090] 267.43 <.0001 
   Discharged 
/transferred to 
noninstitutionalized 
care 
0.434* 1.543* 0.0528 [1.443, 1.650] 160.71 <.0001 
   Other/Missing -0.167 0.847 0.1032 [0.667, 1.075] 1.87 0.1715 
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Table 4.33 Associations of hospital and physician characteristics and ESA ONS use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Hospital Characteristics  
Geographic region       
   Northeast 
(reference) 
- - - - - - 
   Midwest 0.147 1.158 0.2375 [0.775, 1.731] 0.51 0.4739 
   South 0.112 1.119 0.2636 [0.705, 1.775] 0.23 0.6343 
   West 0.142 1.153 0.3265 [0.662, 2.008] 0.25 0.6158 
Bed size       
   <99  -0.646* 0.524* 0.1192 [0.336, 0.819] 8.07 0.0045 
   100-199 -0.032 0.968 0.2022 [0.643, 1.458] 0.02 0.8774 
   200-299 
(reference) 
- - - - - - 
   300-499 0.465* 1.592* 0.3635 [1.018, 2.490] 4.15 0.0418 
   ≥500 0.214 1.238 0.3184 [0.748, 2.049] 0.69 0.4063 
Teaching status       
   Non-teaching 
(reference) 
- - - - - - 
   Teaching -0.049 0.952 0.1904 [0.643, 1.409] 0.06 0.8061 
Physician Characteristics  
Physician Specialty       
   Non-specialist 
(reference) 
- - - - - - 
   Specialist -0.057 0.945 0.0976 [0.772, 1.157] 0.30 0.5835 
   Missing 0.020 1.020 0.1321 [0.792, 1.315] 0.02 0.8776 
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Part 2: Off-label supported of ESAs 
Results of binary logistic regression assessing association of patient demographics and 
the prescribing of ESAs for the off-label supported indications are shown in Table 4.34.  Older 
age appeared as a strong possible predictor of the off-label supported use of ESAs.  Being older 
was associated with the increased odds of receiving ESAs for the off-label supported indications.  
For example, the young old at age of 65 to 74 years old were 1.91 times more likely than the 
middle-aged patients to be prescribed with ESAs off-label (95% 1.494, 2.434, p < 0.0001) while 
the young adult (aged 18-30 years) were 0.65 times less likely than the reference group to 
receive ESAs for these indications.  Female patients were 0.20 times less likely to use ESAs for 
the off-label supported indications. Being and African-American remained a significant predictor 
of ESA off-label (OR 1.214, 95% CI 1.082, 1.362, p = 0.0010).  In general, patients with other 
type of health insurance were less likely than Medicare patients to received ESAs for off-label 
indications.  Having to pay for the services out-of-pocket reduced the odds of using the drug by 
0.46 times compared to using Medicare coverage (95% CI 0.402, 0.739, p <0.0001). 
Associations between clinical conditions and the odds of receiving ESAs for the off-label 
supported indications are shown in Table 4.35.  Neither patient’s admission type nor comorbidity 
index was associated with the odds of receiving ESAs in patients with ESAs off-label supported 
conditions.  Nonetheless, patients admitted as elective cases were marginally significant of being 
of greater odds of receiving the drugs compared to the emergent cases.  Lastly, discharge 
disposition remained as one of the strongest predictors of this type of ESA prescribing.  For 
instance, compared to those who were discharged to home, patients who expired had a 4.92 times 
greater odds of receiving the drug (95% CI 4.075, 5.932, p < 0.0001).  Likewise, those 
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discharged to hospice, institutionalized, or non-institutionalized care were approximately four 
times more likely to use ESAs off-label (all p-values < 0.0001). 
Similar logistic regression results were observed between ESA on-label and off-label 
supported prescribing, with regards to hospital and physician characteristics. Teaching status, 
hospital geographic region, or physician specialty was not associated with the increased odds of 
receiving the drug.  On the other hand, being admitted to smaller hospitals of less than 199 beds 
decreased the odds of using ESAs for these indications about half (OR<99 beds 0.504, 95% CI 
0.278, 0.912, p < 0.0236; OR100-199 beds 0.593, 95% CI 0.405, 0.868, p < 0.0072), while admission 
to larger hospitals with 300-499 beds was associated with 2.433 times increase in the odds of 
drug use (95% CI 1.630, 3.630, p < 0.0001).  Associations of hospital and physician 
characteristics and ESA off-label supported use are summarized in Table 4.36. 
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Table 4.34 Associations of patient demographic and ESA OFS use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Demographics       
Age       
   18-30 -1.032* 0.356* 0.0351 [0.294, 0.432] 109.90 <.0001 
   31-50 (reference) - - - - - - 
   51-64  0.588* 1.800* 0.1681 [1.499, 2.162] 39.65 <.0001 
   65-74 0.645* 1.907* 0.2373 [1.494, 2.434] 26.88 <.0001 
   75-84 0.397* 1.488* 0.2231 [1.109, 1.996] 7.02 0.0080 
   85+ 0.062 1.064 0.1626 [0.789, 1.436] 0.16 0.6849 
Gender       
   Male (reference)       
   Female -0.228* 0.796* 0.0324 [0.735, 0.862] 31.47 <.0001 
Race       
   Caucasian 
(reference) 
- - - - - - 
   African-American 0.194* 1.214* 0.0713 [1.082, 1.362 ] 10.88 0.0010 
   Other 0.055 1.056 0.0908 [0.892, 1.250] 0.40 0.5265 
   Missing 0.035 1.036 0.0982 [0.860, 1.248] 0.14 0.7096 
Source of Payment       
   Medicare 
(reference) 
- - - - - - 
   Medicaid -0.274* 0.760* 0.0645 [0.644, 0.898] 10.43 0.0012 
   Commercial/ 
Private/ HMO 
Managed Care 
-0.153 0.858 0.0680 [0.734, 1.002] 3.75 0.0528 
   Self-pay -0.607* 0.545* 0.0847 [0.402, 0.739] 15.27 <.0001 
   Other -0.298* 0.742* 0.0830 [0.596, 0.924] 7.10 0.0077 
   Missing -0.234* 0.791* 0.0910 [0.632, 0.992] 4.14 0.0419 
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Table 4.35 Associations of clinical conditions and ESA OFS use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Clinical Conditions       
Admission type       
   Emergency 
(reference) 
- - - - - - 
   Urgent 0.150 1.162 0.0902 [0.998, 1.613] 0.07 0.7936 
   Elective -0.179 0.836 0.0626 [0.722, 1.352] 3.72 0.0539 
   Other/Missing 0.056* 1.058* 0.2276 [0.694, 0.968] 5.72 0.0168 
Average CCI (SD) 0.010 1.010 0.0173 [0.977, 1.045] 0.35 0.5525 
Discharge status       
   Discharged to 
home/self care 
(reference)  
- - - - - - 
   Expired 1.593* 4.917* 0.4709 [4.075, 5.932] 276.43 <.0001 
   Discharged to 
Hospice 
1.434* 4.194* 0.5560 [3.234, 5.438] 116.94 <.0001 
   Discharged/ 
transferred to 
institutionalized care 
1.457* 4.291* 0.3494 [3.658, 5.034] 320.01 <.0001 
   Discharged/ 
transferred to 
noninstitutionalized 
care 
1.121* 3.067* 0.2029 [2.694, 3.492] 287.01 <.0001 
   Other/Missing -0.043 0.958 0.3291 [0.489, 1.878] 0.02 0.9009 
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Table 4.36 Associations of hospital and physician characteristics and ESA OFS use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Hospital Characteristics  
Geographic region       
   Northeast 
(reference) 
- - - - - - 
   Midwest -0.295 0.744 0.1893 [0.452, 1.226] 1.35 0.2458 
   South 0.140 1.150 0.2392 [0.765, 1.729] 0.45 0.5020 
   West -0.070 0.932 0.3249 [0.471, 1.846] 0.04 0.8402 
Bed size       
   <99  -0.686* 0.504* 0.1526 [0.278, 0.912] 5.12 0.0236 
   100-199 -0.522* 0.593* 0.1154 [0.405, 0.868] 7.21 0.0072 
   200-299 
(reference) 
- - - - - - 
   300-499 0.889* 2.433* 0.4968 [1.630, 3.630] 18.94 <.0001 
   ≥500 0.522 1.686 0.4588 [0.989, 2.874] 3.68 0.0551 
Teaching status       
   Non-teaching 
(reference) 
      
   Teaching -0.198 0.820 0.1849 [0.527, 1.276] 0.77 0.3789 
Physician Characteristics  
Physician Specialty       
   Non-specialist 
(reference) 
- - - - - - 
   Specialist -0.024 0.976 0.1227 [0.763, 1.249] 0.04 0.8479 
   Missing -0.118 0.889 0.1480 [0.642, 1.232] 0.50 0.4805 
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Part 3: Off-label unsupported use of ESAs 
Results from logistic regression of demographic domain and off-label unsupported 
indications are shown in Table 4.37.  Age was not predictor of ESA use in this case.  Being a 
female with off-label unsupported indications, opposite to other indications, increased the odds 
of receiving ESAs by 1.15 times. Race remained statistically associated with the increased odds 
of ESAs prescribing where African-American were 1.40 times more likely to use ESAs (95% CI 
1.222, 1.610, p < 0.0001), and patient with “Other” race were 1.24 times more likely (95% CI 
1.088, 1.417, p = 0.0013), compared to Caucasian.  The effect of primary payer on ESA 
prescribing was also less prominent for the off-label unsupported indications.  Compared to 
Medicare patients, no other insurance type but “Self-pay” was associated with the decreased 
odds of receiving ESAs for such indications.  Patients with off-label unsupported indications 
who paid for the care by themselves were 0.24 times less likely than Medicare patients to use the 
drugs. 
Patients with off-label unsupported indications admitted to the hospital as urgent cases 
were 1.41 times more likely to be prescribed ESAs as compared to patients admitted to the 
hospital as emergency cases.  With one unit increase in patient’s comorbidity index measuring 
clinical complexity, the odds of being prescribed ESAs for off-label unsupported indications 
increased 1.23 times (95% CI 1.168, 1.289, p < 0.0001).  Similar results as other type of ESA 
prescribing were observed for discharge disposition, with the odds of receiving the drugs being 
increased as a patient was discharged to anywhere else but home.  For instance, the odds of using 
the drugs for an admitted patient with off-label unsupported indications who were discharged to 
institutionalized care increased by 3.58 times compared to patients who were discharged home 
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(95% CI 2.981, 4.309, p < 0.0001).  Associations of patient clinical conditions and ESA off-label 
unsupported use are summarized in Table 4.38. 
Finally, hospital size was the only significant predictor of ESA off-label unsupported 
prescribing.  Patients admitted to smaller hospitals with fewer than 99 beds were 0.57 times less 
likely to be prescribed ESAs (95% CI 0.209, 0.875, p = 0.0200) compared to those admitted to 
“200-299 beds” category.  On the other hand, patients in 300-499 and ≥ 500 beds hospitals were 
2.19 times (95% CI 1.334, 3.609, p = 0.0020) and 1.91 times (95% CI 1.143, 3.193, p = 0.0136) 
more likely to use ESAs for off-label unsupported indications.  Associations of hospital and 
physician characteristics and ESA off-label unsupported use are summarized in Table 4.39. 
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Table 4.37 Associations of patient demographic and ESA OFU use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Demographics       
Age       
   18-30 0.007 1.007 0.1197 [0.798, 1.271] 0.00 0.9529 
   31-50 (reference) - - - - - - 
   51-64  0.062 1.064 0.0501 [0.971, 1.167] 1.75 0.1859 
   65-74 0.131 1.140 0.0817 [0.991, 1.312] 3.36 0.0667 
   75-84 0.045 1.046 0.0911 [0.882, 1.241] 0.27 0.6049 
   85+ -0.176 0.838 0.0887 [0.681, 1.032] 2.77 0.0958 
Gender       
   Male (reference) - - - - - - 
   Female 0.137* 1.147* 0.0344 [1.081, 1.216] 20.80 <.0001 
Race       
   Caucasian 
(reference) 
- - - - - - 
   African-American 0.339* 1.403* 0.0987 [1.222, 1.610] 23.17 <.0001 
   Other 0.217* 1.242* 0.0837 [1.088, 1.417] 10.35 0.0013 
   Missing -0.156 0.855 0.0934 [0.690, 1.059] 2.05 0.1521 
Source of Payment       
   Medicare 
(reference) 
- - - - - - 
   Medicaid 0.096 1.101 0.1056 [0.912, 1.329] 1.00 0.3166 
   Commercial/ 
Private/ HMO 
Managed Care 
-0.058 0.944 0.0772 [0.804, 1.108] 0.50 0.4795 
   Self-pay -0.278* 0.758* 0.0557 [0.656, 0.875] 14.26 0.0002 
   Other -0.092 0.912 0.0978 [0.739, 1.125] 0.74 0.3899 
   Missing 0.013 1.013 0.1422 [0.769, 1.333] 0.01 0.9287 
 
  
  
  
206 
 
Table 4.38 Associations of clinical conditions and ESA OFU use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Clinical Conditions       
Admission type       
   Emergency 
(reference) 
- - - - - - 
   Urgent 0.341* 1.406* 0.0978 [1.224, 1.611] 23.94 <.0001 
   Elective -0.019 0.981 0.0794 [0.837, 1.150] 0.06 0.8139 
   Other/Missing 0.549* 1.732* 0.2885 [1.249, 2.401] 10.86 0.0010 
Average CCI (SD) 0.205* 1.227* 0.0309 [1.168, 1.289] 66.15 <.0001 
Discharge status       
   Discharged to 
home/self care 
(reference)  
- - - - - - 
   Expired 1.011* 2.747* 0.4199 [2.036, 3.706] 43.70 <.0001 
   Discharged to 
Hospice 
0.713* 2.040* 0.3243 [1.494, 2.786] 20.10 <.0001 
   Discharged/ 
transferred to 
institutionalized care 
1.277* 3.584* 0.3367 [2.981, 4.309] 184.63 <.0001 
   Discharged/ 
transferred to 
noninstitutionalized 
care 
0.981* 2.666* 0.2833 [2.165, 3.283] 85.12 <.0001 
   Other/Missing -0.651 0.521 0.1528 [0.293, 0.926] 4.94 0.0263 
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Table 4.39 Associations of hospital characteristics and ESA OFU use 
Variable Parameters  
 β Exp (β) SE 95% Confidence 
Interval 
Chi-Sq p-value 
Hospital Characteristics  
Geographic region       
   Northeast 
(reference) 
- - - - - - 
   Midwest -0.244 0.784 0.2048 [0.470, 1.308] 0.87 0.3511 
   South 0.137 1.147 0.3079 [0.678, 1.941] 0.26 0.6098 
   West -0.265 0.768 0.2907 [0.365, 1.613] 0.49 0.4849 
Bed size       
   <99  -0.851* 0.427* 0.1562 [0.209, 0.875] 5.41 0.0200 
   100-199 -0.452 0.637 0.1624 [0.386, 1.049] 3.14 0.0766 
   200-299 
(reference) 
- - - - - - 
   300-499 0.786* 2.194* 0.5571 [1.334, 3.609] 9.57 0.0020 
   ≥500 0.647* 1.910* 0.5007 [1.143, 3.193] 6.10 0.0136 
Teaching status       
   Non-teaching 
(reference) 
- - - - - - 
   Teaching -0.2674 0.7654 0.2211 [0.4344, 1.3484 0.86 0.3547 
Physician Characteristics  
Physician Specialty       
   Non-specialist 
(reference) 
- - - - - - 
   Specialist 0.206 1.229 0.1541 [0.961, 1.572] 2.71 0.0998 
   Missing 0.296 1.344 0.1403 [1.095, 1.649] 8.02 0.0046 
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CHAPTER 5 
Discussion and Conclusions 
This chapter summarizes the findings and provides discussion of the results by specific 
aims.  Limitations of the database and study design are described, and their effects on the internal 
and external validity of the study results are acknowledged.  Practical implications of the study 
finding and suggestions of possible future direction of the research are also discussed in this final 
chapter.  
Summary of Findings 
In this research, we examined demographics, clinical conditions, hospital characteristics, 
and physician specialty of epoetin alfa and darbepoetin alfa users who were admitted to Cerner 
hospitals.  Differences in such characteristics between the three patient groups were also 
described and statistically tested.  Descriptive results indicated that users of epoetin alfa and 
darbepoetin alfa were statistically different with respect to demographics, clinical conditions, 
hospital characteristics, and physician specialty.  Additionally, significant differences were also 
found among ONS, OFS, and OFU users of epoetin alfa and darbepoetin alfa.   
The first primary objective of this study was to determine if the three major safety 
interventions implemented during the study period had significant impacts on these three types 
of ESA prescribing.  Prior to the first black box warning in 2007, ESA prescribing in all three 
labeling categories showed increasing use trends (Figure 4.14).  Black box warning significantly 
reduced the level of ESA ONS use.  This reduction in ONS use was driven by darbepoetin alfa 
use (0.6% decrease in use), not epoetin alfa.  OFS use, on the other hand, was affected only by 
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the change in reimbursement policy (NCD) in April 2008.  In contrast to the effect of black box 
warning on ONS use, this reduction in the level of OFS use was driven by epoetin alfa (0.3% 
reduction) and not darbepoetin.  Lastly, we did not find that any safety interventions significantly 
affected the level of ESA use for OFU indications.  However, we found that when OFU use of 
ESAs was reanalyzed by specific drugs, there were insignificant reductions in the level of 
epoetin alfa OFU use following all three interventions.  Nonetheless, the level of OFU 
darbepoetin alfa use instead significantly increased after black box warning and NCD, causing 
the overall non-significant effects of the interventions when the two drugs were analyzed 
collectively.  REMS, on the other hand, significantly reduced the level of OFU darbepoetin use.  
In order to determine if the interventions were associated with the reduction in the 
likelihood of the receiving ESAs, three patients groups eligible to receive ESAs were defined a 
priori based on an evidence-based medicine framework.  The ONS eligible cohort included any 
patients admitted to Cerner hospitals with ICD-9-CM diagnoses and procedure codes, and drug 
codes indicated the presence of CKD, chemotherapy-induced anemia, HIV, and major surgical 
procedures.  The OFS cohorts included patients with non-chronic kidney disease, hepatitis C, 
congestive heart failure, radiotherapy, anemia due to puerperium, multiple myeloma, 
myelodysplastic syndrome, myelofibrosis, rheumatoid arthritis, beta thalassemia, and 
autotransfusion.  The known OFU cohort included only patients with conditions known to be 
treated with ESAs, but did not have sufficient scientific evidence supporting its use.  These 
conditions were anemia of neoplasm diseases without the use of concurrent chemotherapy, 
chronic anemia, bleeding, injury, cardiac surgeries, blood transfusion, and other OFU use such as 
irritable bowel syndromes (IBS) and Crohns’ disease.  We found that NCD significantly reduced 
the odds of using ESAs for patients with on-label, off-label supported, and off-label unsupported 
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conditions.  Black box warning and REMS, on the other hand, did not significantly affect ESA 
prescribing patterns.   
In the final specific aim, we used the same logistic regression models to assess 
associations of patient demographics, clinical conditions, and hospital and physician 
characteristics with ESA on-label and off-label prescribing.  A few predominant characteristics 
of patients receiving ESA therapy suggested by the binary logistic regression results included 
age, gender, race, source of payment admission type, discharge status, bed size, and teaching 
status of the hospitals.   
The odds of receiving ESAs in patients with ONS and OFS conditions increased with 
age, up until the older old age of 75 years old was reached.  After this age, a patient became less 
likely to receive the drug.  Female patients with ONS and OFS conditions were less likely to use 
ESAs compared to male. The opposite gender effect was found in OFU use.  In this use category, 
female patients with OFU conditions were more likely to use ESAs compared to male patients.  
African-American and patients with Medicare were more likely to receive the drugs compared to 
their counterparts, for all three conditions.  
Clinical conditions, especially places of discharge, were strongly associated with the odds 
of receiving ESAs for all indications. Compared to those discharged to home, patients who 
needed to be transferred, or discharged to other units/care settings were much more likely to be 
prescribed with ESAs.  Patients admitted as elective cases were less likely to use ESAs compared 
to those admitted as emergent cases, though the results were marginally significant in OFU 
prescribing.  More complex patients with ONS and OFU conditions were more likely to use 
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ESAs.  Nonetheless, associations of patient’s clinical complexity and the increased odds of using 
ESAs were not observed in patients with OFS conditions. 
Finally, our finding suggested that hospital size was strongly associated with the ESA 
use.  Being admitted to larger hospitals increased the odds of receiving ESAs for on-label, off-
label supported, and off-label unsupported indications.  No significant associations between 
hospital geographic regions or teaching status, and ESA use were found for any use category.   
Discussion of Results by Aim 
Specific Aim 1 
Previous studies focused on the impact of safety interventions on the use of 
erythropoiesis-stimulating agents in the outpatient settings,
184, 185
 thus very little was known 
regarding its use in patient admitted to the hospitals.  Additionally, most studies collectively 
analyzed darbepoetin alfa and epoetin alfa as ESAs and rarely distinguish between the two 
drugs.
181-184, 187
   Our descriptive findings shows that the two erythropoietic drugs were used 
differently in the inpatient settings.  Darbepoetin alfa was used to a greater extent for on-label 
indications (52.8%) compared to epoetin alfa (47.4%).  Greater proportion of darbepoetin alfa 
users was prescribed the drug for chronic kidney disease (93.9% darbepoetin alfa vs 83.8% 
epoetin alfa), while the use of the two drugs for chemotherapy-induced anemia, zidovudine-
induced anemia, and surgical procedures was similar.  These findings were consistent with the 
growth in popularity of darbepoetin alfa use in CKD due to its superiority over epoetin alfa in 
hemoglobin control, 
202, 203
dosing efficacy,
 204-206 
and cost efficacy
207 
claimed in many reports 
since the approval of darbepoetin alfa in 2001.
208 
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Differences in the characteristics of users of epoetin alfa and darbepoetin alfa were also 
observed in our sample. Greater proportion of patients older than 65 years of age used epoetin 
alfa compared to darbepoetin alfa (59.4% vs. 52.8%).  It is possible that physicians were more 
comfortable prescribing epoetin alfa which has been in the market longer to the older and frailer 
patients.  Greater proportion of Medicare patients used darbepoetin alfa compared to epoetin alfa 
(65.7% vs. 58.5%).  This was likely due to the fact that darbepoetin alfa was used extensively in 
the population with CKD usually covered by Medicare in our sample.  Greater proportion of 
patient admitted as emergency or urgent cases used epoetin alfa rather than darbepoetin alfa 
(emergency+urgent: 83.9% epoetin alfa vs. 75.2% darbepoetin alfa).  Lastly, more patients who 
used darbepoetin alfa were prescribed by specialists while the use of epoetin alfa was to a greater 
extent, initiated by non-specialists.  We believe that this finding was also due to familiarity of the 
two ESA drugs.  The study by Patkar et al, 2007, reported that almost all of the ESAs used in the 
hospitals from 2002 to 2004 were epoetin alfa.
15
 Specialists, especially nephrologists, are likely 
to be more familiar with the newer darbepoetin alfa compared to the non-specialists who might 
be more familiar with epoetin alfa since it has been in the market since 1989.  It is important to 
note that the findings on certain variables such as primary payer, admission type, and physician 
specialty may be tempered because as many as 50% of the hospitals did not report such 
information.   
Descriptive statistics, bar chart, and graphs were used to understand the prevalence of 
ESA therapy for on-label, off-label supported, and off-label unsupported indications among 
patients seen in the inpatient settings.  The results of this study revealed that off-label prescribing 
of ESAs constituted more than half of the utilization of the drugs in the hospitals.  The use of 
epoetin alfa and darbepoetin alfa for off-label treatment (both supported and unsupported) was 
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52.6% and 47.2%, respectively, between 2005 and 2011.  Our findings were consistent with 
previous study investigating off-label use of ESAs in the hospital settings between 2002 and 
2004.
15
   
However, in contrary to the similar study which found the majority of the off-label use to 
be supported with evidence, our results indicated that as high as 83% of the off-label use in our 
sample was for indications unsupported by strong scientific evidence.  These OFU use included 
chronic anemia and neoplastic diseases without concurrent chemotherapy.  This high level of off-
label unsupported use was however consistent with the study assessing off-label drug use in the 
physician’s office which found that most off-label drug mentions in 2001 (73%) had little or no 
scientific support.
190
 It is possible that contradicting results between Patkar’s finding and ours 
were due to the differences in the inclusion of patient population and the identification of the on-
label and off-label use with ICD-9-CM codes.  First, we only included adult patients in this study 
while they included the pediatric population. The study then found that off-label use was highly 
prevalent in pediatric population.  Second, in addition to ICD-9-CM diagnoses codes, we 
identified additional patients underwent major surgery with ICD-9-CM procedures codes.  We 
also strictly classified ESA use as for chemotherapy-induced anemia (on-label) only if a patient 
presented with cancer had procedures codes or drug records indicated the use of 
chemotherapeutic agents during that visits.  Patients who had cancer diagnoses but did not 
receive concurrent chemotherapy were categorized into the off-label unsupported group.  We 
believe that our on-label and off-label classification was a conservation approach that accurately 
captured all patients.   
 Differences in characteristics of ESA users for the on-label, off-label supported, and off-
label unsupported indications were observed in our sample.  Patients who used ESAs for OFS 
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indications were oldest compared to than patients in the ONS or OFU groups.   There were a 
greater proportion of patients in the OFS group who expired in the hospitals.  This was likely due 
to the high prevalence of acute renal failure (ARF) which contributed the highest off-label 
supported use of ESAs in very old hospitalized patients.
209, 210 
  In addition to the high 
prevalence, death rates among hospitalized patients with ARF was reported to be as high as 25 to 
>70%.
211 
Chronic kidney disease, on the other hand, began relatively earlier in life, progressed 
slowly, and rarely the main cause of inpatient death.
2
 Lastly, OFU patients appeared to be the 
“least sick” patients among the three users groups with comorbidity index of 0.29 compared to 
that of the ONS (2.72) and OFS (2.00).  With such low level of clinical complexity, it is possible 
that OFU use seen in our study truly reflected inappropriate use of ESAs in patients who may not 
need the drug.  However, it was also possible these patients were identified as OFU only because 
of the inadequate records of their diagnoses.   
Specific Aim 2 
Segmented ordinary regression with interrupted time-series technique was used to 
quantify the impacts of safety interventions.  Our initial hypothesis was that we could detect the 
impacts of black box warning, national coverage determination, and REMS as a decline in the 
proportion of visits that a patient was prescribed ESAs for on-label, off-label supported, and off-
label unsupported indications.  However, this hypothesis was proven to be partially correct.  
When the use of epoetin alfa and darbepoetin alfa was analyzed collectively as ESAs, we found 
only two significant immediate drop related to the safety interventions.  These significant 
impacts of the interventions included a significant immediate 1.2% drop in ONS use in the 
month after the implementation of black box warning, and a 0.3% drop in ESA OFS use after 
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NCD.  The decrease in the proportion of visits with ESA use on-label was consistent with the 
study by Vadhan-Raj et al, 2010 that found a 26% reduction in the use of ESAs in cancer 
patients concurrently on chemotherapy in 2007 from that in 2006.
183
   
Despite the downward trends in ONS, OFS, and OFU use, the decline after the 
interventions did not reach a statistically significant level.  After the analysis of ESAs was 
broken down by specific drugs, we found that only epoetin alfa OFS use was only affected by 
NCD (0.3% decrease).  The use of darbepoetin alfa on-label, on the other hand, was sensitive to 
several safety interventions.  We found that black box warning led to a 0.6% rise in darbepoetin 
alfa ONS use.  NCD and REMS were associated with 0.4% and 0.5% drop in darbepoetin alfa 
ONS use, respectively. Finally, REMS reduced darbepoetin alfa OFU use by 0.5%.  
Contradictorily to our hypotheses, we found that darbepoetin alfa OFS and OFU use increased 
immediately after the release of black box warning and NCD, though slight decreasing trends 
were observed after such interventions took place.  It is possible that some of these spurious 
results were due to the delay in the effect of the interventions that would be discussed in the 
section below. 
Our aggregate time-series technique used a small number of data points to detect changes 
in the proportion of ESA use at the time point which an intervention started; these time points 
were specified a priori.  As a results, our findings were sensitive to noises, impact of other 
possible intervention unspecified in our time-series models, and time lags in the change in the 
utilization patterns.  These confounding factors may have created spurious statistical results.  
Therefore, the following discussion was based on the actual graphical representation of the 
proportion of visits with ESA use rather the results from the specified time-series models.  The 
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graphical representations of ESA, epoetin alfa, and darbepoetin alfa utilization patterns are 
shown in Figure 4.12, 4.13, and 4.14, respectively. 
The use of epoetin alfa in our sample hospitals increased from 2005 to October 2006, 
after which drug utilization started to decline.  The only exception was found in the OFS use of 
epoetin alfa that showed a decreasing trend throughout study period.  The increase in epoetin alfa 
use on-label (ONS) and off-label unsupported (OFU) before 2007 was consistent with many 
studies.
182, 183
   Since the time of approval, ESAs had been promoted rigorously by their 
manufacturers as an alternative to blood transfusion.  No safety warning attempts were present 
before the release of negative clinical trial results that led to a release of public health advisory in 
November 2006.
28
   The results of the clinical trials published in late 2006 later revealed the 
increased risk of mortality in cancer patients who use ESAs.
19-23
   
As a result of these published trials, declining trends in epoetin alfa use were observed 
even before the release of a black box warning.  The decline in the proportion of visits with 
epoetin alfa use after the release of negative results from the clinical trials and public health 
advisory in November 2006 was confirmed in a separate time-series analysis (data not shown).  
In that analysis, we specified the first intervention as the negative results from the clinical trials 
and public health advisory in November 2006 as the first intervention, instead of a black box 
warning in March 2007.  We found a significant immediate drop of 0.8% in the proportion of 
visits with on-label epoetin alfa use. This drop was followed by a non-significant decreasing 
trend in epoetin alfa ONS use after the intervention.   
Since declining trends in epoetin alfa use existed even before the institution of a black 
warning, no significant reduction in utilization was detected at the release of the FDA black box 
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warning or NCD though non-significant declining slopes were observed.  However, a noticeable 
drop in the proportion of visits which epoetin alfa was used for on-label and off-label was seen in 
December 2008 (month 48).  This sharp decline coincided with the FDA revision of epoetin alfa 
label in August 2008 (month 44) to strengthen the safety information for healthcare 
professionals.  Changes in the labeling included a statement that ESAs were not indicated for 
patients receiving myelosuppressive therapy when the anticipated outcome is cure.
212 
  The FDA 
later approved the use a Medication Guide and Patient Instruction for Use in place of the old 
patient package insert in November 2008.  The Medication Guide which was created to disclose 
possible side effects of ESAs were to be distributed to all patients who were dispensed ESAs.  
This medication guide, alone with physician’s judgment, can affect patients’ decision to use the 
drug.  At the same time, Amgen and J&J Ortho Biotech, the manufacturers of epoetin alfa and 
darbepoetin alfa released a Dear Health Care Professional Letter to emphasize the content of the 
labeling change.
 213  
 In addition to the labeling revision in August 2008, several published 
clinical trials started reporting negative results of epoetin alfa could have led to a reduction in 
epoetin alfa use at the end of 2008.  One of the largest impacts could have resulted from the 
German Stroke Study.  In September 2008, results from a large German trial investigating 
effectiveness of ESAs as an aid to improve the ability of patients to care for themselves after 
their strokes.  Results of the trial revealed the increased risk of death in post-stroke patients 
receiving high dose epoetin alfa.  Among 522 post-stroke patients involved in the trial, 16 
percent of the patients who received epoetin alfa 40,000 units daily for 3 days died, compared to 
only 9 percent of patients in the placebo group.
214 
 
Interestingly, we found a slow rebound in the level of epoetin alfa use one year after the 
decline.  This gradual increase in ESA use was likely to be due to prescribers being comfortable 
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with ESAs again after a long period of the absence of alerts since there were no published alerts 
in the FDA website that year.  This increase in the epoetin alfa use continued from August 2009 
to February 2010, after which we observed a non-statistically significant decline in epoetin alfa 
on-label and off-label use.  This decline coincided with the implementation of REMS in March 
2010.  Despite it being officially implemented on March 24, 2010, the creation of REMS was 
announced by the FDA on February 16, 2010 to mitigate the risk of decreased survival in 
patients with cancer.  REMS restricted prescribing of ESAs in cancer patients only to physicians 
who underwent a manufacturer-created risk management and training program which 
emphasized the FDA-approved indications and the increased risks of using the drugs off-label.  
We believe that this decline was a true reduction in inappropriate use of epoetin alfa related to 
REMS restriction.  However, because our ONS, OFS, and OFU cohorts did not consist entirely 
of cancer patients, but instead a mixture of cancer patients and other conditions which were not 
directly affected by REMS, the reduction was not sufficient to reach a statistically significant 
level. 
Similar to epoetin alfa, the use of darbepoetin alfa on-label and off-label grew rapidly 
from 2005 to the beginning of the last quarter of 2006.  However, unlike epoetin alfa where an 
immediate drop was observed after the release of negative results trials and the first public health 
advisory in November 2006 November 2006, the use of darbepoetin continued to grow, but at a 
decreasing rate.  This slow increase in the use of darbepoetin alfa despite the warning may due to 
Amgen’s illegal promotion of Aranesp® off-label.  From 2001 to 2007, Amgen was found guilty 
of promoting off-label use of darbepoetin alfa by marketing dosing information not approved by 
the FDA as being an advantage to that of epoetin alfa.
 215 
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According to the actual use of darbepoetin alfa shown Figure 4.14, the addition of a black 
box warning onto the label significantly reduced the proportion of visits which darbepoetin alfa 
was use on-label and off-label.  ESA labeling was revised in March 2007 to include a black box 
warning which highlighted the negative results several completed cancer trials.  Though the 
warning applies to all products in this drug class: darbepoetin alfa, Aranesp®, Amgen, Inc) and 
epoetin alfa (Epogen® and Procrit®, Amgen), the fact the most of trials were based on the use of 
darbepoetin alfa and the possibility that physicians were less comfortable with using the newer 
darbepoetin alfa in cancer patients, a stronger impact of the black box warning on darbepoetin 
alfa compared to epoetin alfa was observed. 
The strongest reduction in darbepoetin alfa use was observed after the change in 
Medicare reimbursement policy.  NCD was announced effective in July 2007 and officially 
implemented in April 2008 to restrict payment of Medicare to only on-label use of ESAs.  With 
NCD, use of ESAs for unapproved indications to Medicare beneficiaries seen in the outpatient 
settings were no longer reimbursed under Medicare Part B.  Previous studies showed strong 
impact of NCD on ESA prescribing patterns in both Medicare and non-Medicare patients in the 
outpatient settings.
187
  Strictly speaking, NCD did not financially affect payment of Medicare to 
ESA use in the hospitals because charges for inpatient drug use were bundled as total hospital 
charges and were covered under Medicare Part A.   Our study was the first to show its significant 
impact in the inpatient settings which NCD was not directly applied.  Such strong impact that 
was observed in both on-label and off-label ESA utilization merits further investigation.  We 
believe that the coverage change sent out a strong message about inappropriate use of ESAs to 
prescribers tending all patients in all settings.  A decline in use may also due to the fact that 
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physicians who worked in the hospitals also worked concurrently in the outpatient settings and 
were familiar with the coverage change.   
 Lastly we observed a significant reduction in the proportion of visits with darbepoetin 
alfa on-label and off-label use after the implementation of REMS in March 2010.  This was a 
similar reduction was observed with epoetin alfa use that did not reach a statistically significant 
level.  It was likely to be due to the true effect of REMS. 
Specific Aim 3 
Binary logistic regression using generalized estimating equations (GEE), clustered by 
hospitals was used to identify the impacts of safety interventions on the odds of receiving ESA 
therapy.  Studies highlighting changes in prescribing patterns were important to measure the 
relative impact of various safety communications put in place to promote safe drug use.  The use 
of patient-level information in the logistic regression allowed for the inclusion of demographic, 
clinical condition, physician and hospital characteristics, all of which had been proposed to 
influence prescribing patterns.  This inclusion adjusted for the confounding effects these 
covariates may have imposed onto the effect of safety interventions on ESA utilization patterns.  
The use of GEE model therefore offered superiority to the aggregated time-series technique.  
Our results indicated that black box warning had low impact on all three ESA use 
categories.  These findings were consistent with previous literature investigating the impact of 
black box warning on ESA therapy for CKD and cancer patients in the outpatient settings.
182, 183
 
Interestingly, we again found strong impact of national coverage determination (NCD) on ESA 
use, both on-label and off-label, despite the fact that this coverage change did not directly apply 
to our population.  As mentioned earlier, NCD implemented in April 2008 restricted 
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reimbursement only to on-label use of ESAs for patients covered under Medicare Part B seen the 
outpatient settings.  Our results highlight such strong safety messages sent from payers that could 
be seen in the care settings not financially affected.  Finally, we did not observe any significant 
impact of REMS in our sample.  It is possible that oncologists have adjusted to ESA guidelines 
after the black box warning and NCD that no change was observed after the implementation of 
REMS. 
 Using the same logistic regression models with GEE to assess associations between 
patient, clinical, hospital, and physician characteristics, we observed apparent differences in 
patient, clinical, hospital, and physician characteristics between the users and non-users of ESAs 
for all the three use categories.  Characteristics of ESA on-label and off-label supported recipient 
were found to be similar, but very different from those of the off-label unsupported group. 
Among patients with ONS, and OFS conditions, the odds of receiving the drugs increased 
with age.  The relationship was flipped when a patient was in oldest age group; the oldest old 
patients were less likely to receive ESAs.  This age relationship may also be due to the fact that 
older patients were sicker and naturally needed ESAs more than the younger and healthier 
patients.  However, physicians may become more conscious to prescribe the drug the very 
patients (85+).  Interestingly, such age relationship was not found in the off-label unsupported 
(OFU) ESA prescribing.  We believe that because there was no consensus guidelines on the off-
label unsupported prescribing of ESAs, physicians would tend to prescribe the drugs to those 
patients with very low Hb, regardless of their age.  Additionally, we found that gender and racial 
differences exists in ESA use.  Female patients with ONS and OFS conditions were less likely to 
use the drugs.  On the other hand, female patients with OFU conditions were more likely to 
receive ESAs.  The associations of higher odds of female gender and ESA OFU prescribing 
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shown in our study were uniform with the finding by Patkar et al.
15
   It is possible these female 
patients with OFU conditions in our sample, despite having similar comorbidity scores, were 
more anemic than their male counterparts.  The very low Hb level of these patients could have 
led physicians to be more inclined to prescribe ESAs.  African-American were more likely to 
receive ESAs for any indications. This finding contradicts many published studies of racial 
disparities in prescription drug use.
164, 165
   Results of our study led us to believe that there were 
differences in prescribing behaviors between the inpatient and outpatient/office-based settings.  
In the case of critical care like in the treatment of anemia, patient’s socioeconomic status, to a 
lesser extent, influenced physician’s decision to prescribe.  This might partially resulted from the 
fact that, opposite to the outpatient care where patients were fully responsible for paying for their 
medications, drug use in the hospitals was included as one charge.  This mechanism could help 
mask the price of the drugs from the ordering physicians.  Also, the situation where charges were 
paid off by the hospital as a charity care if patients were not able to pay for the services was not 
at all uncommon.  Lastly, our results indicated that financial resources were a key determinant of 
ESA prescribing.  Compared to Medicare patients, ONS and OFS patients with other type of 
payment were less likely to use ESAs.  The findings were unsurprising as Medicare pledged to 
pay for the health care of the patients with end-stage renal disease (ESRD) - the conditions which 
ESAs were approved for use.  Moreover, Medicare was the largest payer of ESAs with 
approximately three billion ESA spending in 2011.
216 
  However, this relationship was not 
observed in the OFU group.  We believe that this finding reflects in part from Medicare’s strict 
off-label reimbursement policy after 2008.  Nonetheless, other results indicated that for all three 
use categories, self-pay patients were the least likely to use the drugs.  This is truly intuitive 
since listed price of one dose of 10,000 IU of epoetin alfa could cost a patient over $100.
217 
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Other predictors of ESA ONS and OFS use were patient clinical conditions and hospital 
size.  The greater severity of illness as measured through combined comorbidity scores, 
admission type, and discharge status, may have influenced physicians to prescribe ESAs.   
Finally, consistent with our hypothesis, we found that patients admitted to larger hospitals were 
more likely that any other patients to receive ESAs.  This might due to the fact that larger 
hospitals, to a greater extent, admitted more severely anemic patients.  Physicians working the 
larger hospitals should have seen more anemic patients and were more familiar with using ESAs 
compared to those in the smaller hospitals.   
Practical Implications 
Our results confirm previous research of a strong impact of national coverage 
determination and moderate impact of black box warning and REMS on ESA prescribing.  
Despite extensive effort of risk communications, the FDA should be concerned as more than half 
of ESAs was used for off-label purposes.  Our findings indicate that as high as 43% of all ESA 
use in the hospitals between January 2005 and June 2011 were for off-label unsupported 
indications.  The use of the drug off-label without strong supporting scientific evidence could 
pose threats to patient’s health.  Though no causal relationship could be established, it is 
noteworthy to mention the distinguishably longer length of stay and high inpatient mortality in 
patients who used the drug for off-label label unsupported indications compared to patients in 
other groups. 
Results of our study highlight the importance of different means of communicating drug 
risks to the health care community.  Off-label drug use can have serious safety implications.  The 
FDA needs to regulate prescribing of high-risk drugs more strictly.  Patient characteristics 
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associated with ESA off-label drug use identified in this study show that physicians were more 
likely to administer the drugs to the sicker patients.  Another area of intervention could be in 
large hospitals with more than 200 beds where ESAs were prescribed significantly to a greater 
extent.  Efforts from the safety regulatory authority should be emphasized on the sickest 
population of admitted patients, and in large hospitals to promote appropriate use of ESAs.  
This research adds incremental knowledge to ESA off-label prescribing and Cerner 
hospital database of electronic health records.  The Cerner database is a rich source of 
information on patient characteristics, diagnoses and procedures codes, drug administration, and 
clinical outcomes new to most researchers. The use of electronic health records in observational 
study can offer insight into clinical conditions, detailed drug administration, and timing of the 
treatments unavailable in surveyed, publicly-available, or government-provided database such as 
National Ambulatory Medical Care Survey (NAMCS) and Medicare Provider and Analysis 
Review (MedPAR) Files.  Additionally, Cerner data has a good mix of teaching and non-
teaching hospitals as well as small and large sized hospitals across different geographic regions 
in the United States.    
We developed a novel systematic algorithm to identify two types of off-label drug use 
from the domain of strength of evidence, level of recommendation, and efficacy provided in a 
reputable compendium, DRUGDEX.   Furthermore, we extensively provide all possible ICD-9-
CM diagnoses and procedures codes that could be used to identify on-label, off-label supported, 
and off-label unsupported use of ESAs from any electronic health records.  This knowledge can 
be useful to any researcher interested in assessing ESA off-label use. 
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Limitations 
Our study offers insights into the impacts safety interventions had on the on-label and 
off-label use of ESAs, but limitations of the study must be noted.  The first limitation was the 
possibility of other interventions not being captured in our study.  Our study design did not allow 
for the determination of the impacts of any other interventions that may have occurred during the 
same period as the interventions of interest such as news articles, and publication of large clinical 
trials.  In this study, those external factors were considered as a part of the respective 
intervention of interest.  In addition, we were not able to separate the effect of the updated black 
box warning in March 2008 from the implementation of NCD in April 2008.  Nonetheless, the 
implementation of NCD is chosen as an intervention instead of the black box warning update 
because we believed that the reimbursement change would have a greater impact on prescribing 
pattern than updating the already-exist black box warning.   
One of the possible limitations of the study included threats to internal validity relating to 
any longitudinal study designs that did not include the use of a control group.  Instrumental 
threat refer to the fact that aspects of the record keeping procedures in the database may have 
changed at the same time as the intervention and thus any changes observed could not be 
concluded whether they were related to the intervention.
 218 
  Moreover, this study relied heavily 
on the ICD-9-CM classification system; coding misclassification may lead to false estimations of 
the effects.  However, ICD-9-CM classification has been use in the use in studies identifying off-
label prescribing including ESAs.
15
   The use of ICD-9-CM classification for various health 
conditions in hospital data has also been validated.
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Even though we were able to identify the off-label use of ESAs for indications other than 
the ones approved by the FDA using ICD-9-CM codes, their doses and use in targeting a 
hemoglobin level exceeding the suggested level could not be readily determined from the 
database.  This was because the dosing information could only was provided by Cerner with a 
low level of confidence.  Utilizing the dosing information in our case would therefore add errors 
into the analyses and should be avoided.  As a result of this data issue, identification of the ESA 
off-label usage in terms of dose and target hemoglobin level was not undertaken in this study.  
This may lead to an underestimation of the off-label usage in our study findings.     
Another limitation was that physicians may be more inclined to prescribe ESAs to 
patients who have had encounters with the medications even though it was for the indication 
lacking supporting evidence.  Since patient medication history in the non-participating outpatient 
and inpatient hospitals were not captured in our data, it could have posed a potential confounding 
effect on the off-label ESA use in the analysis.  It was also important to note that the physician 
specialties information included in the GEE models was based specifically to attending 
physicians and not ordering physicians.  For example, a patient with CKD could be admitted by a 
generalist, developed anemia during his stay, referred to a nephrologist within the same hospital 
who prescribed him with an ESA.  In this specific case, a generalist was recorded under 
physician specialty and not nephrologist.    
Only inpatients of participating Cerner hospitals were included for analyses.  Thus, any 
changes in prescribing trends found in this study may not be generalized to patients in the 
outpatient setting or patients hospitalized at other hospitals.  However, we believe that there is 
good external validity of our findings.  This was a multi-hospital study that included 128 
hospitals of various sizes from different geographical regions across the nation.  As mentioned 
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earlier, Cerner database was a rich source of information on patient characteristics, diagnoses 
and procedures codes, drug records, and clinical outcomes.  More importantly, their electric 
health records accurately captured dates and times of admission, discharge, and drug 
administration most crucial in this study.  Hence, in spite of some limitations of existing database 
and retrospective analysis, Cerner database served as a very insightful resource in studying 
impacts of safety interventions on ESA utilization patterns in the inpatients settings. 
Last but not least we recognized that there could have been errors created from the way 
we dealt with outliers in our data.  We were certain that spurious data points observed in the third 
and fourth quarter of 2007, and the last two quarters of our study period in 2011 were due to data 
recording system that could not be corrected on our end.  We used a conservative method of 
forecasting missing values from the continual trends in utilization if the intervention has not 
occurred.  We were confident that our data manipulation method produced accurate predictions 
of values that could be used in place of the outliers. 
Future Research 
 Our study methods, database, and results provide basis to future research in off-label drug 
use.  We developed a categorization scheme of ESA off-label use with drug records, and 
diagnoses, and procedures codes of patients admitted to the Cerner Health System inpatient 
settings rarely known exists to researchers.  We found that while REMS had little to no impact 
on the on-label and off-label utilization patterns of ESAs in our sample hospitals, black box 
warning could potentially have affected off-label unsupported use of epoetin alfa, and both off-
label supported and unsupported use of darbepoetin alfa.  Interestingly, we found that a 
significant decline in the on-label, off-label supported, and off-label unsupported use of ESAs 
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after the month Medicare national coverage determination was implemented.  This impact of 
NCD was similar for both epoetin alfa and darbepoetin alfa prescribing patterns.   
  Despite the exciting findings, this study focused mainly on the impacts of the safety 
interventions on the likelihood of receiving ESAs, without looking into other aspect of treatment 
such as ESA doses and days of therapy.   Moreover, patient clinical outcomes such as length-of-
stay, inpatient mortality, and blood transfusion were beyond the scope of this investigation. 
Further analysis of such outcomes can provide insight into the impacts of different risk 
communication tools attempted to reduce inappropriate drug use.   
We quantified relatively few ESA users in our Cerner database.  There were on average 
130 patients who used ESAs per hospital in 2010 who used ESAs.   Future study should consider 
using larger database such as Marketscan® commercially provided by Thompson Reuters.  With 
a larger sample size, future study could focus on individual indications of ESA use instead of a 
collective on-label, off-label supported, or off-label unsupported use to determine which 
conditions was the main driver of the change in ESA utilization.  Additionally, with sufficient 
sample size, future study can focus on assessing the impact of REMS on ESA prescribing and 
utilization among the target cancer population.  Finally, pharmaceutical marketing efforts in 
counteracting the decline in the prescribing of ESAs resulted from these warning messages merit 
further exploration.  
  
  
  
229 
 
Conclusions 
 This study was the first to determine the impacts of safety interventions on ESA on-label 
and off-label utilization patterns in the inpatient settings using Cerner database.  In this study we 
attempted to quantify the impacts of the three types of safety interventions: black box warning, 
national coverage determination, and risk evaluation and mitigation strategy (REMS) program on 
ESA prescribing and utilization patterns.  Analysis of data collected from 128 hospitals from 
2005 to 2011 highlights the decreasing trend in ESA on-label use after the last quarter of 2006, 
increasing trend in ESA use for unsupported indications, and overall very low and decreasing 
prevalence of off-label supported use of ESAs (8.6%).  From 2005 to 2010, the proportion of 
visits with ESA ONS and OFS use decreased 53.2% and 81.9%, while ESA OFU increased 
112.6%.  The trends were similar for both epoetin alfa and darbepoetin alfa.  ESAs were used to 
the greatest extent to treat anemia in patients with chronic kidney disease (41.1%).  Almost all of 
ESA use classified as off-label supported (60.4% OFS) in our sample were for non-chronic 
kidney disease patients.  Lastly, a total of 42.7% of ESA use in our sample was for the 
unsupported indications.  The greatest unsupported use of ESAs was for the treatment of chronic 
anemia (31.8%).   
Differences in the impacts of risk communication techniques were observed in the ESA 
inpatient prescribing patterns.  Black box warning and REMS appeared to have little effect on 
physician’s prescribing patterns compared to Medicare national coverage determination.  Despite 
the intention of reducing inappropriate (off-label unsupported use of ESAs), we found that these 
three risk communication techniques were as likely to affect appropriate on-label and off-label 
supported use of the drug rather the potentially inappropriate off-label unsupported use.   
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Results from binary logistic regression using GEE model showed that REMS had no 
impact on the odds of receiving ESAs among patients with on-label and off-label conditions.  
Black box warning reduced the odds of being prescribed with epoetin alfa in patients with off-
label unsupported conditions by 40%.  It was also associated with 4% and 15% per month 
reduction in the odds of using darbepoetin alfa in patients with off-label supported and 
unsupported conditions.  Finally, we found a significant decline in the on-label, off-label 
supported, and off-label unsupported use of ESAs after the month Medicare national coverage 
determination was implemented.  The impact of NCD ranged from 20% reduction in odds of off-
label supported use, to 37% in the on-label use.  Patient demographic, clinical condition, and 
hospital and physician characteristics associated with ESA on-label and off-label drug use 
included age, gender, race, source of payment, admission type, clinical complexity, discharge 
disposition, and hospital size.  
We demonstrated lag time between these interventions and the observed change in 
clinical practice and also the relative impacts the three types of safety interventions had on the 
on-label and off-label ESA use in the hospital settings.  The indirect impacts of NCD may have 
unintended consequences of reducing ESA use in patients with indicated conditions that could 
have otherwise benefited from the drugs.  Policymakers should keep in mind of the lag time 
between the intervention and changes in clinical practice, their relative effectiveness, and 
potential unintended consequences of these safety interventions.   
  
  
  
231 
 
Bibliography 
(1) Kraai IH, Luttik ML, Johansson P, De Jong RM, Van Veldhuisen DJ, Hillege HL, 
Jaarsma T. Health-related quality of life and anemia in hospitalized patients with 
heart failure. Int J Cardiol 2012;161:151-155. 
(2) DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy A Pathophysiologic 
Approach. 7
th
 ed. McGraw-Hill Medical; 2008. 
(3) Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 
2001;28(2 Suppl. 8):1-6. 
(4) Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and 
treatment. J Natl Cancer Inst 1999;91:1616-1634. 
(5) McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients 
with chronic kidney disease. Curr Med Res Opin 2004;20:1501-1510. 
(6) Robinson B. Cost of anemia in the elderly. J Am Geriatr Soc 2003;51(3S):14-17. 
(7) Goodnough LT and Shander A. Risks and complications of blood transfusions: 
optimizing outcomes for patients with chemotherapy-induced anemia. Adv Stud Med 
2008;8(10):357-362. 
(8) Nissenson AR, Wade S, Goodnough T, Knight K, Duboise RW. Economic burden of 
anemia in an insured population. J Manag Care Pharm 2005;11(7):565-574. 
(9) Food & Drug Administration. Epoetin alfa package labeling. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5122lbl.pdf. 
Accessed June 24, 2011. 
  
  
232 
 
(10) Food & Drug Administration. Darbepoetin alfa package labeling. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5139lbl.pdf. 
Accessed June 24, 2011. 
(11) Blau CA. Erythropoietin in cancer: presumption of innocence? Stem Cells 
2007;25(8):2094-2097. 
(12) Food & Drug Administration. Center for Drug Evaluation and Research. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/125164s000_LBL.pdf . 
Accessed July 14, 2011. 
(13) Gray N. Changing landscapes. A special report on the world’s top 50 pharma 
companies. 2006. Available at 
http://www.pharmexec.com/pharmexec/data/articlestandard//pharmexec/272006/3541
38/article.pdf. Accessed March 24, 2012. 
(14) Stafford RS. Regulating Off-Label Drug Use — Rethinking the Role of the FDA. N 
Engl J Med  2008;358:1427-1429. 
(15) Patkar A, Holdford DA, Brophy DF, Pyles M. Off-label prescribing of erythropoiesis-
stimulating proteins in US hospitals. Drug Inf J 2007;41:437-440. 
(16) Lefebvre R, Duh MS, Mody SH, Bookhart B, Piech CT. The economic impact of 
epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic 
kidney disease. Dis Manag 2007;10(1):37-45. 
(17) Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for 
survival in patients with cancer: a systematic, quantitative review. Cancer 
2001;91:2214-2221. 
  
  
233 
 
(18) Besarab A, Bolton WK, BrowneJK et al. The effects of normal as compared with low 
hematocrit values in patients with cardiac disease who are receiving hemodialysis and 
Epoetin. N Engl J Med 1998;339:584-590. 
(19) Singh AK, Szczech L, Tang KL, et. al. Correction of Anemia with Epoetin Alfa in 
Chronic Kidney Disease. N Engl J Med 2006; 355:2085-2098. 
(20) Drueke TB, Locatelli F, Clyne N, et. al. Normalization of hemoglobin level in 
patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084. 
(21) Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin 
levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer 
receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972. 
(22) Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer 
patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-
controlled trial. Lancet 2003:362:1255-1260 
(23) Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and 
cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl 
Cancer Inst 2006;98:708-714. 
(24) DAHANCA.dk. Danish Head and Neck Cancer Group. Interim Analysis of 
DAHANCA 10. Available at: 
http://www.dahanca.dk/get_media_file.php?mediaid=125 . Accessed June 27, 2011. 
(25) Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo controlled 
trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J 
Clin Oncol 2007;25:1027-1032. 
  
  
234 
 
(26) Amgen. New Release Detail April 19, 2007. Aranesp “145 study” shows no 
difference in survival in patients with small-cell lung cancer. Available at 
http://www.amgen.com/media/media_pr_detail.jsp?releaseID=987476. Accessed 
January 3, 2013. 
(27) Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells 
explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713. 
(28) Food & Drug Administration. Safety alerts for human medical product. Aranesp 
(darbepoetin alfa) February 2007. Available at: 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedi
calProducts/ucm150817.htm . Accessed June 25, 2011. 
(29) Food & Drug Administration. Erythropoiesis Stimulating Agents (ESA) [Aranesp 
(darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)] – (11/2006) - 
Healthcare Professional Sheet text version. Available at: 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
ndProviders/ucm126488.htm. Accessed October 25, 2011. 
(30) Food & Drug Administration. Safety alerts for human medical product. Aranesp 
(darbepoetin alfa) January 2007. Available at: 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedi
calProducts/ucm150816.htm . Accessed June 25, 2011. 
(31) Food & Drug Administration. Drugs safety and availability. Information for 
Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp 
(darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)] (3/2007). Available 
at: 
  
  
235 
 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
ndProviders/ucm126485.htm . Accessed June 25, 2011. 
(32) Food & Drug Administration. Epoetin alfa package labeling. Available at:  
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103234s5164lbl.pdf . 
Accessed August 5, 2011. 
(33) Food & Drug Administration. Darbepoetin alfa package labeling. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103951s5170lbl.pdf . 
Accessed August 5, 2011. 
(34) Thomas G, Ali S, Hoebers FJP et al. Phase III trial to evaluate the efficacy of 
maintaining hemoglobin level above 12.0 g/dl with erythropoietin vs above 10.0 g/dl 
without erythropoietin in anemic patients receiving concurrent radiation and cisplatin 
for cervical cancer. Gynecol Oncol 2008;108:317-325. 
(35) Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials 
in oncology. The Oncologist 2009;14(Suppl 1):6-15. 
(36) Food & Drug Administration. REMS for epoetin alfa. Available at: 
http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation
forPatientsandProviders/UCM200105.pdf. Accessed July 14, 2011.  
(37) Food & Drug Administration. REMS for Aranesp. Available at: 
http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformation
forPatientsandProviders/UCM200104.pdf. Accessed July 14, 2011.  
(38) Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin 
usage and patient outcomes. Am J Kidney Dis 1998;32(6 Suppl 4):S133-41. 
  
  
236 
 
(39) Powe NR, Eggers PW, Johnson CB. Early adoption of cyclosporine and recombinant 
human erythropoietin: clinical, economic, and policy issues with emergence of hig-
cost drugs. Am J Kidney Dis 1994;24(1):33-41. 
(40) Powe NR, Griffiths RI, Anderson GF, de Lissovoy G, Watson AJ, Greer JW, Herbert 
RJ, Whelton PK. Medicare payment policy and recombinant erythropoietin 
prescribing for dialysis patients. Am J Kidney Dis 1993;22(4):557-567. 
(41) Berns JS, Fishbane S, Elzein H et al. The effect of a change in epoetin alfa 
reimbursement policy on anemia outcomes in hemodialysis patients. Hemodialysis 
International 2005; 9: 255–263. 
(42) National Kidney Foundation. NKF-DOQI clinical practice guidelines for the 
treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997; 30(Suppl 
3):S192–S240. 
(43) Steinbrook R. Medicare and erythropoietin. N Engl JMed. 2007;356(1):4–6. 
(44) Ofsthun NJ, Lazarus JM. Impact of the Change in CMS Billing Rules for 
Erythropoietin on Hemoglobin Outcomes in Dialysis Patients. Blood Purif 
2007;25:31–35. 
(45) US Department of Health and Human Services. Center for Medicare and Medicaid 
Services. Medicare Coverage Determination Process Overview. Available at:  
http://www.cms.gov/DeterminationProcess/ . Accessed June 25, 2011. 
(46) Fatodu. Evolving Regulatory Landscape with Erythropoiesis-Stimulating Agents and 
Impact on Managed Care. Am J Manag Care 2010;16:S74-S79. 
  
  
237 
 
(47) Goldberg R. The impact of Medicare’s anemia drug coverage decision on cancer 
patients: comparative effectiveness vs. patient centered-care. The center for medicine 
in the public interest. 2008. 
(48) US Department of Health and Human Services. Center for Medicare and Medicaid 
Services. National Coverage Determination (NCD) for Erythropoiesis Stimulating 
Agents (ESAs) in Cancer and Related Neoplastic Conditions (110.21). Available at:    
https://www.cms.gov/medicare-coverage-database/details/ncd-
details.aspx?NCDId=322&ncdver=1&bc=AAAAQAAAAAAA& . Accessed June 
25, 2011. 
(49) Arbuckle RB, Griffoth NL, Iacovelli LM, et. al. Continued challenges with the use of 
erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on 
policy-guided health care. Pharmacotherapy 2008;28(5 pt 2):1S-15S. 
(50) American Society of Clinical Oncology. Available at 
http://www.esafacts.org/ASCO.pdf . Accessed November 16, 2012. 
(51) Roger E. Diffusion of Innovations. 5th ed. Free Press. New York. 2003. 
(52) Berwick DM. Disseminating innovations in health care. JAMA 2003;289;1969-1975. 
(53) Craig JC, Irwig LM, Stockler MR.  Evidence-based medicine: useful tools for 
decision making. Med J Australia 2001;174:248-253. 
(54) Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment 
in pre-dialysis patients. Ann Intern Med 1989;110:108-114. 
(55) Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes 
from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). 
Am J Kidney Dis 2004;44:94-111. 
  
  
238 
 
(56) Healthcare Series MICROMEDEX. MICROMEDEX Healthcare Series. Greenwood 
Village, Colo: MICROMEDEX; 2011. 
(57) Food & Drug Administration. Epoetin alfa package labeling. Available at:  
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103234s5164lbl.pdf. 
Accessed April 6, 2012. 
(58) Marsh WA & Rascati KL: Meta-analyses of the effectiveness of erythropoietin for 
end-stage renal disease and cancer. Clin Ther 1999; 21(9):1443-1455. 
(59) Conlon P, Kovalik E, Schumm D, et al: Normalization of hematocrit in hemodialysis 
patients with cardiac disease does not increase blood pressure. Ren Fail 2000; 
22(4):435-444. 
(60) Provenzano R, Garcia-Mayol L, Suchinda P, et al: Once-weekly epoetin alfa for 
treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61(6):392-405. 
(61) Joy MS: Novel erythropoiesis-stimulating protein: An erythropoietin analogue with 
an extended half-life and less frequent dosing. Formulary 2001; 36:19-25. 
(62) Macdougall IC: An overview of the efficacy and safety of novel erythropoiesis 
stimulating protein (NESP). Nephrol Dial Transplant 2001; 16:14-21. 
(63) Jadoul M, Vanrenterghem Y, Foret M, et al: Darbepoetin alfa administered once 
monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial 
Transplant 2004; 19(4):898-903. 
(64) Agarwal AK, Silver MR, Reed JE, et al: An open-label study of darbepoetin alfa 
administered once monthly for the maintenance of haemoglobin concentrations in 
patients with chronic kidney disease not receiving dialysis. J Intern Med 2006; 
260(6):577-585. 
  
  
239 
 
(65) Phrommintikul A, Haas SJ, Elsik M, et al: Mortality and target haemoglobin 
concentrations in anaemic patients with chronic kidney disease treated with 
erythropoietin: a meta-analysis. Lancet 2007; 369(9559):381-388. 
(66) National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical 
Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of 
Hemoglobin Target. CPG and CPR 2.1 Hemoglobin Target. Available at 
http://www.kidney.org/professionals/kdoqi/guidelines_anemiaUP/guide1.htm. 
Accessed April 6, 2012. 
(67) National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical 
Practice Recommendations for Anemia in Chronic Kidney Disease (2006). CPR 3.1. 
Using ESAs. Available at 
http://www.kidney.org/professionals/KDOQI/guidelines_anemia/cpr31.htm. 
Accessed April 6, 2012. 
(68) Food & Drug Administration. Darbepoetin alfa package labeling. Available at: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103951s5170lbl.pdf . 
Accessed April 6, 2012. 
(69) Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly 
dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and 
quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 
19(11):2875-2882. 
(70) Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients 
treated with epoetin alfa is independent of disease response in tumor type: results 
  
  
240 
 
from a prospective community oncology study. J Clin Oncol 1998; 16(10):3412-
3425. 
(71) Schwartzberg L, Burkes R, Mirtsching B, et al: Comparison of darbepoetin alfa dosed 
weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in 
patients receiving multicycle chemotherapy in a randomized, phase 2, open-label 
trial. BMC Cancer 2010; 10:581. 
(72) Canon JL, Vansteenkiste J, Bodoky G, et al: Randomized, double-blind, active-
controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-
induced anemia. J Natl Cancer Inst 2006; 98(4):273-284. 
(73) Kotasek D, Albertsson M, Mackey J et al: Randomized, double-blind, placebo-
controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) 
or 4 (Q4W) weeks in patients with solid tumors (abstract). Presented at the 38th 
Annual Meeting of the American Society of Clinical Oncology; Orlando, FL, USA, 
May 18-21, 2002. 
(74) Hedenus M, Hansen S, Dewey C et al: A randomized, blinded, placebo=controlled, 
phase II, dose-finding study of novel erythropoiesis stimulating protein (NESP) in 
patients with lymphoproliferative malignancies (abstract). Presented at the 37th 
Annual Meeting of the American Society of Clinical Oncology; San Francisco, CA, 
USA, May 12-15, 2001. 
(75) Rodgers GM. Guidelines for the use of erythropoietic growth factors in patients with 
chemotherapy-induced anemia. Oncology 2006;20(8).  
(76) National Comprehensive Cancer Network. NCCN Clinical practice guidelines in 
oncology. Cancer- and Chemotherapy-induced anemia. Version 2.2011. 
  
  
241 
 
(77) Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence 
of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J 
Med Res 2010;132:386-389. 
(78) Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleeval B, 4. Lai AR, Saghayam S, 
et al. Spectrum of adverse events after generic HAART in Southern Indian HIV-
infected patients. AIDS Patients Care STDS 2008; 22: 337-344. 
(79) Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga 5. A, et al. Haematological 
changes in adults receiving a zidovudine-containing HAART regimen in combination 
with cotrimoxazole in Côte d’Ivoire. Antiviral Therapy 2005; 10: 615-624. 
(80) The US Recombinant Human Erythropoietin Predialysis Study Group. Double-Blind, 
Placebo-Controlled Study of the Therapeutic Use of Recombinant Human 
Erythropoietin for Anemia Associated with Chronic Renal Failure in Predialysis 
Patients. Am J Kid Dis. 1991;18:50-59. 
(81) Ortho Biologics, Inc., data on file. 
(82) Danna RP, Rudnick SA, Abels RI. Erythropoietin Therapy for the Anemia Associated 
with AIDS and AIDS Therapy and Cancer. In: MB Garnick, ed. Erythropoietin in 
Clinical Applications – An International Perspective. New York, NY: Marcel 
Dekker; 1990:301-324. 
(83) Fischl M, Galpin JE, Levine JD, et al. Recombinant Human Erythropoietin for 
Patients with AIDS Treated with Zidovudine. N Eng J Med. 1990;322:1488-1493. 
(84) deAndrade JR and Jove M. Baseline hemoglobin as a predictor of risk of transfusion 
and response to epoetin alfa in orthopedic surgery pateitns. Am J of Orthoped 
1996;25(8):533-542. 
  
  
242 
 
(85) Ezekowitz JA, McAlister FA, Armstrong PW. Anemia Is Common in Heart Failure 
and Is Associated With Poor Outcomes Insights From a Cohort of 12 065 Patients 
With New-Onset Heart Failure. Circulation. 2003;107:223-225. 
(86) Paul S. Paul R. Anemia in health failure. Journal of cardiovascular nursing 
2004;19:557-566. 
(87) Silverberg D, Wexler D, Blum M, et al: The use of subcutaneous erythropoietin and 
intravenous iron for the treatment of the anemia of severe, resistant congestive heart 
failure improves cardiac and renal function and functional cardiac class, and 
markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35(7):1737-1744. 
(88) Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R.  Prevalence of 
anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28(2 S 
8):54-593. 
(89) Sweeney PJ, Nicolae D, Ignaciao L, et al: Effect of subcutaneous recombinant human 
erythropoetin in cancer patients receiving radiotherapy: final report of a randomized, 
open-labelled, phase II trial. Br J Cancer 1998; 77(11):1996-2002. 
(90) Milman N. Postpartum anemia I: definition, prevalence, causes, and consequences. 
Ann Hematol (2011) 90:1247–1253. 
(91) Somdatta P, Reddaiah VP, Singh B. Prevalence of anaemia in the postpartum period: 
a study of a North Indian village. TROPICAL DOCTOR 2009; 39: 211–215. 
(92) Breymann C, Richter C, Huttner C, et al: Effectiveness of recombinant erythropoietin 
and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and 
blunted erythropoiesis. Eur J Clin Invest 2000; 30:154-161. 
  
  
243 
 
(93) VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical 
Advisory Panel. Recombinant Erythropoietin Criteria for Use for Hepatitis C 
Treatment-Related Anemia. Available at 
http://www.pbm.va.gov/Clinical%20Guidance/Criteria%20For%20Use/Erythropoieti
n%20Criteria%20for%20Formulary%20Use%20for%20Hepatitis%20C,%20Criteria
%20for%20Use.pdf. Accessed April 8, 2012. 
(94) Ludwig H, Pohl G, Osterborg A. Anemia in multiple myeloma. Clin Adv Hematol 
Oncol 2004;2(4):233-241. 
(95) Marsh WA & Rascati KL: Meta-analyses of the effectiveness of erythropoietin for 
end-stage renal disease and cancer. Clin Ther 1999; 21(9):1443-1455. 
(96) Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated 
with multiple myeloma. N Engl J Med 1990; 322:1693-1699. 
(97) International Myeloma Workshop (IMW). Consensus guidelines for the management 
of anemia with erythropoiesis-stimulating agents ESAs in multiple myeloma. 
Available at http://www.myeloma-
paris2011.com/files/files/ConsensusPanel1AnemiaTheFinal.pdf. Accessed April 8, 
2012. 
(98) American Cancer Association. Myelodysplatic Syndrome Detailed Guide. Available 
at http://www.cancer.org/Cancer/MyelodysplasticSyndrome/DetailedGuide/index . 
Accessed August 15, 2012. 
(99) Greenberg PL, Sun Z, Miller KB, et al: Treatment of myelodysplastic syndrome 
patients with erythropoietin with or without granulocyte colony-stimulating factor: 
  
  
244 
 
results of a prospective randomized phase 3 trial by the Eastern Cooperative 
Oncology Group (E1996). Blood 2009; 114(12):2393-2400. 
(100) Casadevall N, Durieux P, DuBois S, et al: Health, economic, and quality-of-life 
effects of erythropoietin and granulocyte colony-stimulating factor for the treatment 
of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 
104(2):321-327. 
(101) Terpos E, Mougiou A, Kouraklis A, et al: Prolonged administration of erythropoietin 
increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 
patients. Br J Haematol 2002; 118(1):174-180. 
(102) Spiriti MA, Latagliata R, Niscola P, et al: Impact of a new dosing regimen of epoetin 
alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. 
Ann Hematol 2005; 84(3):167-176. 
(103) Italian Cooperative Study Group for rHuEpo in Myelodyplastic Syndromes: A 
randomized double-blind placebo-controlled study with subcutaneous recombinant 
human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J 
Haematol 1998; 103(4):1070-1074. 
(104) Gabrilove J, Paquette R, Lyons RM, et al: Phase 2, single-arm trial to evaluate the 
effectiveness of darbepoetin alfa for correcting anaemia in patients with 
myelodysplastic syndromes. Br J Haematol 2008. 
(105) Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in 
patients with cancer: 2007 American Society of Clinical Oncology/American Society 
of Hematology clinical practice guideline update. J Clin Oncol 2008; 26(1):132-149. 
  
  
245 
 
(106) National Cancer Institute at the National Institutes of Health. Chronic 
Myeloproliferative Disorders Treatment (PDQ®). Primary Myelofibrosis.  Available 
at 
http://www.cancer.gov/cancertopics/pdq/treatment/myeloproliferative/Patient/page4 . 
Accessed August 15, 2012. 
(107) Hasselbalch HC, Clausen NT, & Jensen BA: Successful treatment of anemia in 
idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 
2002; 70(2):92-99. 
(108) AloeSpiriti M, Latagliata R, Avvisati G, et al: Erythropoietin treatment of idiopathic 
myelofibrosis. Haematologica 1993; 78(6):371-373. 
(109) Rodriguez JN, Martino ML, Dieguez JC, et al: rHuEpo for the treatment of anemia in 
myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical 
approach. Haematologica 1998; 83(7):616-621. 
(110) Bourantas KL, Tsiara S, Christou L, et al: Combination therapy with recombinant 
human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-
stimulating factor in idiopathic myelofibrosis. Acta Haematol 1996; 96(2):79-82. 
(111) Benetatos L, Chaidos A, Alymara V, et al: Combined treatment with thalidomide, 
corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. Eur J 
Haematol 2005; 74(3):273-274. 
(112) Cervantes F, Varez-Larran A, Hernandez-Boluda JC, et al: Erythropoietin treatment 
of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and 
review of the literature. Br J Haematol 2004; 127(4):399-403. 
  
  
246 
 
(113) Tsiara SN, Chaidos A, Bourantas LK, et al: Recombinant human erythropoietin for 
the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta 
Haematol 2007; 117(3):156-161. 
(114) Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and Outcomes of 
Anemia in Rheumatoid Arthritis: A Systematic Review of the Literature. Am J Med 
2004;116(7A):50S–57S.  
(115) Fitzsimons EJ, Sturrock RD. The chronic anaemia of rheumatoid arthritis: iron 
banking or blocking? Lancet. 2002;360:1713–1714. 
(116) Means RT Jr, Olsen NJ, Krantz SB, et al: Treatment of the anemia of rheumatoid 
arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arth 
Rheum 1989; 32:638-642. 
(117) Pubmed Health. Thalassemia. Available at 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001613/. Accessed April 8, 2012. 
(118) Chaidos A, Makis A, Hatzimichael E, et al: Treatment of beta-thalassemia patients 
with recombinant human erythropoietin: effect on transfusion requirements and 
soluble adhesion molecules. Acta Haematol 2004; 111(4):189-195. 
(119) Bourantas K, Makrydimas G, Georgiou J, et al: Preliminary results with 
administration of recombinant human erythropoietin in sickle cell/b-thalassemia 
patients during pregnancy (letter). Eur J Haematol 1996; 56:326-328. 
(120) Busuttil D & Copplestone A: Management of blood loss in Jehovah's Witnesses 
(editorial). BMJ 1995; 311(7013):1115-1116. 
(121) Atabek U, Alvarez R, Pello MJ, et al: Erythropoetin accelerates hematocrit recovery 
in post-surgical anemia. Am Surg 1995; 61(1):74-77. 
  
  
247 
 
(122) Kraus P & Lipman J: Erythropoietin in a patient following multiple trauma. 
Anaesthesia 1992; 47(11):962-964. 
(123) Moghtader JC, Edlich RF, Mintz PD, et al: The use of recombinant human 
erythropoietin and cultured epithelial autografts in a Jehovah's Witness with a major 
thermal injury. Burns 1994; 20(2):176-177. 
(124) Atabek U, Alvarez R, Pello MJ, et al: Erythropoetin accelerates hematocrit recovery 
in post-surgical anemia. Am Surg 1995; 61(1):74-77. 
(125) Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human 
erythropoietin in critically ill patients: a randomized controlled trial.. JAMA 2002; 
288:2827-35. 
(126) Silver M, Corwin MJ, Bazan A, et al: Efficacy of recombinant human erythropoietin 
in critically ill patients admitted to a long-term acute care facility: a randomized, 
double-blind, placebo-controlled trial. Crit Care Med 2006; 34(9):2310-2316. 
(127) van Iperen C, Gaillard C, Kraaijenhagen R, et al: Response of erythropoiesis and iron 
metabolism to recombinant human erythropoietin in intensive care unit patients. Crit 
Care Med 2000; 28(8):2773-2778. 
(128) Corwin HL, Gettinger A, Fabian TC, et al: Efficacy and safety of epoetin alfa in 
critically ill patients. N Engl J Med 2007; 357(10):965-976. 
(129) Quirt I, Robeson C, Lau CY, et al: Epoetin alfa therapy increases hemoglobin levels 
and improves quality of life in patients with cancer-related anemia who are not 
receiving chemotherapy and patients with anemia who are receiving chemotherapy. J 
Clin Oncol 2001; 19(21):4126-4134. 
  
  
248 
 
(130) Henry DH & Abels RI: Recombinant human erythropoietin in the treatment of cancer 
and chemotherapy-induced anemia: results of double-blind and open-label follow-up 
studies. Semin Oncol 1994; 21(2 Suppl 3):21-28. 
(131) Wright JR, Ung YC, Julian JA, et al: Randomized, Double-Blind, Placebo-Controlled 
Trial of Erythropoietin in Non-Small-Cell Lung Cancer With Disease-Related 
Anemia. J Clin Oncol 2007. 
(132) Smith RE, Aapro MS, Ludwig H, et al: Darbepoetin alfa for the treatment of anemia 
in patients with active cancer not receiving chemotherapy or radiotherapy: results of a 
phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin 
Oncol 2008. 
(133) Smith RE, Tchekmedyian NS, Chan D, et al: A dose- and schedule-finding study of 
darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 
88(12):1851-1858. 
(134) Smith RE, Jaiyesimi IA, Meza LA, et al: Novel erythropoiesis stimulating protein 
(NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J 
Cancer 2001; 84 Suppl 1:24-30. 
(135) Charu V, Belani CP, Gill AN, et al: Efficacy and safety of every-2-week darbepoetin 
alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II 
trial. Oncologist 2007; 12(6):727-737. 
(136) American Porphyria Foundation. Porphyria Cutanea Tarda (PCT). Available at 
http://www.porphyriafoundation.com/about-porphyria/types-of-porphyria/PCT. 
Accessed April 8, 2012. 
  
  
249 
 
(137) The Porphyrias Consortium. Information for Patients and Families. Available at 
http://rarediseasesnetwork.epi.usf.edu/porphyrias/patients/PCT/. Accessed April 8, 
2012. 
(138) The Merck Manual Home Health Handbook for patients and caregivers.  Porphyria 
Cutanea Tarda.  Available at 
http://www.merckmanuals.com/home/hormonal_and_metabolic_disorders/porphyrias
/porphyria_cutanea_tarda.html?qt=&sc=&alt=. Accessed August 20, 2012. 
(139) Anderson KE, Goeger DE, Carson RW, et al: Erythropoietin for the treatment of 
porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 1990; 
322:315-317. 
(140) Horina J & Wolf P: Epoetin for severe anemia in hepatoerythropoietic porphyria. N 
Engl J Med 2000; 342(17):1294-1295. 
(141) Scott WC: The abuse of erythropoietin to enhance athletic performance (letter). 
JAMA 1990; 264:1660. 
(142) Robinson N, Mangin P, Saugy M. Erythropoietin abuse in sport. Sysmex J Int 
2003;13:75-77. 
(143) Sheth S. Transfusional iron overload. In Rossi's Principles of Transfusion Medicine, 
4th Edition, Edited by Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, 
Petrides M. 2009 Blackwell Publishing Ltd. ISBN: 978-1-405-17588-3 
(144) McCarthy JT, Johnson WJ, Nixon DE, et al: Transfusional iron overload in patients 
undergoing dialysis: treatment with erythropoietin and phlebotomy. J Lab Clin Med 
1989; 114:193-199. 
  
  
250 
 
(145) Imagawa A, Kawanishi Y, & Numata A: Is erythropoietin effective for impotence in 
dialysis patients?. Nephron 1990; 54:95-96. 
(146) Bilenker JH, Demers R, Porter DL, Wasserstein AG, Peters E, Manaker S. 
Recombinant human erythropoietin usage in a large academic medical center.  Am J 
Manag Care 2002;8:742-747. 
(147) U.S. Department of Health & Human Services. U.S. Food and Drug Administration. 
About FDA. Available at 
http://www.fda.gov/aboutfda/transparency/basics/ucm194877.htm. Accessed April 2, 
2012. 
(148) Dranove D and Meltzer D. Do important drugs reach the market sooner? RAND 
Journal of Economics 1994:402-423. 
(149) Virginia Commonwealth University Office of Research. Policy for the conduct of 
human subject research. 21 Code of Federal Regulations 14.171 (2000) Available at 
http://www.research.vcu.edu/p_and_g/human_subjects.htm. Accessed January 2013. 
(150) Murphy S, Roberts R. “Black box” 101: how the Food and Drug Administration 
evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 
2006;117:34-39. 
(151) O’Connor NR. FDA boxed warnings: How to prescribe drug safely? Am Fam 
Physician 2010;81(3):298-303. 
(152) Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 
Timing of new black box warnings and withdrawals for prescription medications. 
JAMA 2002;287(17):2215-2220. 
  
  
251 
 
(153) Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription 
drug labeling: results of a survey of 206 drugs. Food and Drug Law 1998;53:403-
411. 
(154) Generali JA. The continuiting dilemma of drugs with black box warnings. Hospital 
Pharmacy 2008;43:7. 
(155) Lasser KE, Seger DL, Yu DT et al. Adherence to black box warnings for prescription 
medications in outpatients. Arch Intern Med 2006;166(3):338-344. 
(156) Chen DT, Wynia MK, Moloney RM, Alexander GC. U.S. physician knowledge of the 
FDA-approved indications and evidence base for commonly prescribed drugs: results 
of a national survey. Pharmacoepidemiology and drug safety 2009; 18: 1094–1100. 
(157) Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, 
Alexander GC. Impact of FDA Drug Risk Communications on Health Care 
Utilization and Health Behaviors A Systematic Review. Med Care 2012;50(6):466-
478. 
(158) Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings 
on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65:94–101. 
(159) Gallen AS. Factors that influence physicians’ prescribing of pharmaceuticals: a 
literature review. J Pharmaceutical Marketing & Mgt 2004;16(4). 
(160) Feldmann JE. Off-Label Use of Anticancer Therapies: Physician Prescribing Trends 
and the Impact of Payer Coverage Policy. Available at: 
http://www.bio.org/speeches/pubs/CovanceReport.pdf . Accessed July 6, 2011. 
(161) Dresser R and Frader J. Off-Label Prescribing: A Call for Heightened Professional 
and Government Oversight. J Law Med Ethics 2009; 37(3):476-486. 
  
  
252 
 
(162) Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and 
Pharmacodynamic Changes in the Elderly: Clinical Implications. Clin Pharmacokinet 
1998; 35(1): 49-64(16). 
(163) Lubitz J, Riley GF. Trends in Medicare payments in the last year of life. N Engl J 
Med 1993;328:1092-1096. 
(164) Sequist TD, Adams A, Zhang F, Ross-Degnan D, Ayanian JZ. Effect of Quality 
Improvement on Racial Disparities in Diabetic Care. Arch Intern Med 2006; 166: 
675-81. 
(165) Busch AB, Lehman AF, Goldman H, Frank RG. Changes over time and disparities in 
schizophrenia treatment quality. Med Care 2009;47(2):199-207.  
(166) Council on Ethical and Judicial Affairs of the American Medical Association. Gender 
disparities in clinical decision making. JAMA 266, 559, 1991. 
(167) Kjellstrand CM, Logan GM. Racial, sexual and age inequalities in chronic dialysis. 
Nephron 1987;45:257-263. 
(168) Held PJ, Pauly MV, Bovbjerg RR, et al. Access to kidney transplantation. Arch Intern 
Med 1988;148:2594-2600. 
(169) Kjellstrand CM. Age, sex, and race inequality in renal transplantation. Arch Intern 
Med 1988;148:1305-1309. 
(170) Anderson RM. Revisiting the Behavioral Model and Access to Medical Care: Does it 
Matter? J Health Soc Behav 1995;36(1):1-10. 
(171) Meyers DS, Mishori R, McCann J, Delgado J, O’Malley AS, Fryer E. Primary care 
physicians’ perceptions of the effect of insurance status on clinical decision making. 
Ann Fam Med. 2006; 4:399-042. 
  
  
253 
 
(172) Chin MH, Zhang JX, Merrell K. Specialty Differences in the Care of Older Patients 
with Diabetes. Med Care 2000; 38(2):131-40. 
(173) Kozyskyj A, Raymond C, Racher A. Characterizing early prescribers of newly 
marketed drugs in Canada: a population-based study. Eur J Clin Pharmacol 
2007;63:579-604. 
(174) Greving JP, Denig, van der Veen Wj, Beltman FW, Sturkenboom M, Haaijer-
Ruskamp FM. Determinants for the adopt of angiotensin II receptor blockers by 
general practitioners. Soc Sci Med 2006;63:2890-2898. 
(175) Coleman J, Katz E, Menzel. The diffusion of an innovation among physicians. 
Sociometry 1957;20(4):253-270. 
(176) Centers for Disease Control and Prevention. National Centers for Health Statistics. 
Health, United States 2011 With Special Feature on Socioeconomic Status and 
Health. Available at http://www.cdc.gov/nchs/data/hus/hus11.pdf#glance. Accessed 
August 16, 2012. 
(177) Folland S, Goodman AC, Stano M. Chapter 15 They Physician’s Practice. The 
economics of health and health care. 5
th
 ed. Pearson Education Internation. P 321-
325. 
(178) Phelps CE. Health Economics. 5th ed. Addison Wesley. 2002. 
(179) Freiman MP. The rate of adoption of new procedures among physicians: the impact 
of specialty and practice characteristics. Med Care 1985;23(8):939-945. 
(180) Fischer MA, Vogeli C, Stedman MR, Ferris TG, Weissman JS. Uptake of electronic 
prescribing in community-based practices. Gen Intern Med 2008 Apr;23(4):358-363. 
  
  
254 
 
(181) McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D. 
International trends in erythropoietin use and hemoglobin levels in hemodialysis 
patients. Kidney international 2010;78:215-223. 
(182) Regidor D, McClellean WM, Kewalramani R, Sharma A, Bradbury BD. Changes in 
erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-
dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial 
Transplant 2011;26:1583-1591. 
(183) Vadhan-raj s, Zhou X, Sizer K, Lai L, Wang, Roquemore J, Shi W, Benjamin RS, 
Litchiger B. Impact of safety concerns and regulatory changes on the usage of 
erythropoiesis-stimulating agents and RBC transfusions. The Oncologist 
2010;15:1359-1369. 
(184) Hess G, Nordyke RJ, Hill J, Hulnick S. Effect of reimbursement changes on 
reythropoiesis-stimulating agent utilization and transfusions. Am J Hematol 
2010;85:838-843. 
(185) Henry DH, Langer CJ, McKenzie RS, Piech CT, Senbetta M, Schulman KL, 
Stepanski EJ. Hematologic outcomes and blood utilization in cancer patients with 
chemotherapy-induced anemia (CIA) pre- and post-national coverage determination 
(NCD): results from a multicenter chart review. Support Care Cancer 2012;20:2089–
2096. 
(186) Feinberg BA, Bruno AS, Haislip S, Cilmore J, Jain G, Whyte JL. Hemoglobin trends 
and anemia treatment resulting from concomitant chemotherapy in community 
oncology clinics. Journal of oncology practice 2012;8(1):18-23. 
  
  
255 
 
(187) Arneson TJ, Li S, Gilbertson DT, Bridges KR, Acquavella JF, Collins AJ. Impact of 
Centers for Medicare & Medicaid Services national coverage determination on 
erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer 
patients. Pharmacoepidemiology and drug safety 2012;21(8):857-864. 
(188) Chan Q and Chan A. Impact of erythropoiesis-stimulating agent prescribing at an 
Asian cancer center, after release of safety advisories. J Oncol Pharm Practice 
2010;17(4):350-359. 
(189) Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. 
Prioritizing future research on off-label prescribing: results of a quantitative 
evaluation. Pharmacotherapy 2008;28(12):1443-1452. 
(190) Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based 
physicians. Arch Intern Med 2006;166:1021-1026. 
(191) Sikora K, Advani S, Koroltchouk V, et al. Essential drugs for cancer therapy: a World 
Health Organization consultation. Ann Oncol 1999 Apr;10(4): 385-390. 
(192) Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis 
of interrupted time series studies in medication use research. J Clin Pharm Ther 
2002;27(4):299-309. 
(193) Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity 
score predicted mortality in elderly patients better than existing scores. Journal of 
Clinical Epidemiology 2011;64(7):749-759. 
(194) Division of Pharmacoepidemiology and Pharmacoeconmics, Department of 
Medicine, Brigham and Women’s Hospital, Harvard Medical School. Available at: 
http://www.drugepi.org/dope-downloads/ Accessed December 16, 2012. 
  
  
256 
 
(195) Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous 
outcomes. Biometrics 1986;42:121-130. 
(196) Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated 
data using generalized estimating equations: an orientation. Am J Epidemiol 
2003;157:364-375. 
(197) Allison PD. Logistic Regression Using SAS® Theory and Application. 2nd Ed.Cary, 
NC: SAS Institute Inc. 2012. 
(198) Virginia Commonwealth University. Institutional Review Board. Available at: 
http://www.research.vcu.edu/irb/wpp/flash/II-2.htm . Accessed June 28, 2011. 
(199) SAS/ETS(R) 9.2 User's Guide.  The Arima Procedure. Identification Stage. Available 
at:http://support.sas.com/documentation/cdl/en/etsug/60372/HTML/default/viewer.ht
m#etsug_arima_sect004.htm . Accessed December 17, 2012. 
(200) Box-Jerkins Time Series Analysis. Available at http://www.statistical-solutions-
software.com/BMDP-documents/BMDP-2T.pdf . Accessed December 17, 2012. 
(201) Wooldridge JM. Introductory Econometrics A Modern Approach. 4th Ed. South-
Estern Cengage Learning, Canada, 2009. 
(202) Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous 
darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients 
on haemodialysis. Nephrol Dial Transplant 2006;21:2846–2850. 
(203) Rutkowski B, Bitterova Z, Ferenczi S, et al. Effectiveness of converting from 
itravenous (iv) or subcutaneous (sc) recombinant human erythropoietin (rHuEPO) to 
iv darbepoetin alfa (DA) in end stage renal disease (ESRD) patients (Pts) on 
  
  
257 
 
hemodialysis (HD) [abstract] Presented at American Society of Nephrology Annual 
Congress, 14–19 November 2006, San Diego, CA, USA. 
(204) Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients 
with unit dosing of darbepoetin alfa at a reduced dose frequency relative to 
recombinant human erythropoietin (rHuEpo) Nephrol Dial Transplant 2003;18:362–
369. 
(205) Bock HA, Hirt-Minkowski P, Brunisholz M, et al. Darbepoetin alpha in lower-than-
equimolar doses maintains haemoglobin levels in stable haemodialysis patients 
converting from epoetin alpha/beta. Nephrol Dial Transplant 2008;23:301–308. 
(206) Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains 
haemoglobin concentrations at extended dose intervals relative to intravenous or 
subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial 
Transplant  2004;19:1224–1230. 
(207) Ardevol M, Fontseré N, Casals M, et al. A feasibility cost-analysis study of 
recombinant human erythropoietin and darbepoetin alfa in ambulatory haemodialysis 
patients during current clinical practice. Eur J Hosp Pharm Sci 2006;12:47–51. 
(208) Carrera F and Burnier M. Use of darbepoetin alfa in the treatment of anaemia of 
chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus 
2009;2(supp 1):i9-i17. 
(209) Obialo CI, Crowell AK, Okonofua EC. Acute renal failure mortality in hospitalized 
African Americans: age and gender considerations. J Natl Med Assoc 
2002;94(3):127-134. 
  
  
258 
 
(210) Acute renal failure in patients over 80 years old: 25-years' experience. Akposso K, 
Hertiq A, Couprie R, et al. Intensive Care Med 2000;26(4):400-406. 
(211) Mittalhenkle A, Stehman-Breen CO, Shilpak MG, et al. Cardiovascular Risk Factors 
and Incident Acute Renal Failure in Older Adults: The Cardiovascular Health Study. 
Clin J Am Soc Nephrol 2008;3(2):450-456. 
(212) Epogen [package insert labeling changes]. Amgen, Inc. Thousand Oaks, CA, August 
2008. Approved by the US Food and Drug Administration November 19, 2008. 
Available at 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103234s5195sPI.pdf. 
(213) Dear Health Care Professional Letter. Amgen, Inc, Thousand Oaks, CA, August 
2008. Available at: 
http://www.procrit.com/sites/default/files/pdf/DHCP0808.pdf#zoom=100. Accessed 
December 29, 2012. 
(214) U.S Food and Drug Administration. Early communication about ongoing safety 
review of epoetin alfa. Available at 
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsa
ndProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136211.htm. 
Access December 31, 2012. 
(215) The United States Department of Justice. Office of Public Affairs. Justice News. 
Available at http://www.justice.gov/opa/pr/2012/December/12-civ-1523.html. 
Accessed December 31, 2012. 
  
  
259 
 
(216) The Washington Post. Medicare overspending on anemia drug. Available at: 
http://articles.washingtonpost.com/2012-08-09/business/35490064_1_epogen-
anemia-drug-amgen. Accessed December 31, 2012. 
(217) Kruep EJ, Basskin LE. Cost-Minimization Analysis of Darbepoetin Alpha vs Epoetin 
Alpha. Am J Health Syst Pharm. 2005;62(24):2597-2603.  
(218) Schafermeyer KW, Hurd PD. Research Methodology: Designing a Research Study. J 
Managed Care Pharm 1998; 4(5): 504-514. 
(219) Roumie CL, Mitchel E,  Gideon PS,  Varas-Lorenzo C, Castellsague J, Griffin MR. 
Validation of ICD-9 codes with a high positive predictive value for incident strokes 
resulting in hospitalization using Medicaid health data. Pharmacoepidem Dr S 2008; 
17: 20–26. 
(220) MacIntyre CR, Ackland MJ, Chandraraj EJ, et al. Accuracy of ICD-9-CM codes in 
hospital morbidity data, Victoria: implications for public health research. Austr NZ J 
Public Health. 1997;21:477– 482. 
(221) Raiford DS, Gutthann SP, Garcia Rodriguez LA. Positive Predictive Value of ICD-9 
codes in the identification of cases of complicated peptic ulcer disease in the 
Saskatchewan hospital automated database. Epidemiology 1996;7:101-104. 
(222) Waikar SS, Wald R, Chertow GM, et. al. Validity of International Classification of 
Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am 
Soc Nephrol 17: 1688–1694, 2006. 
 
  
  
  
260 
 
Vita 
Arpamas Seetasith was born on February 9
th
, 1983 in Bangkok, Thailand. She graduated 
from Anglo-Chinese Junior College, Singapore in 2002 and received her Bachelor of Sciences in 
Pharmacy from Chulalongkorn University, Bangkok, Thailand in 2008. 
  
  
  
261 
 
Arpamas Seetasith 
25/19 Soi Ladphrao 35 
Chatujak, Bangkok, 10900 Thailand 
Email: seetasitha@vcu.edu 
 Mobile: (757) 581-1767 
Education 
August 2008 - February 2013: 
Doctor of Philosophy 
Virginia Commonwealth University, School of Pharmacy, Richmond, VA 
(in the tradition of the Medical College of Virginia) 
 Dissertation: “Impacts of Safety Warnings, National Coverage Determination, and Risk 
Evaluation and Mitigation Strategies  on the Inpatient On-label and Off-label use of 
Erythropoiesis-Stimulation Agents” 
 Quantified impacts of safety interventions on inpatient drug use using time-series 
technique and logistic regression with generalized estimating equation 
May 2003 – March 2008: 
Bachelor of Science in Pharmacy (First Class Honors) 
Chulalongkorn University, Bangkok, Thailand 
January 2001 – December 2002: 
Singapore-Cambridge General Certificate of Education Advanced Level 
Anglo-Chinese Junior College, Singapore 
Work/Research Experience 
May 2012 – August 2012: 
Healthcare Consulting Intern 
IHS Global Insight, Washington DC 
 Assisted various international pricing, reimbursement, and market access consulting 
projects.   
- Gathered pricing information; reviewed clinical guidelines, market landscapes,  
and Health Technology  Assessment (HTA) documents; and produced 
deliverables for clients 
 Demonstrated “Values of Pharmaceutical Interventions in Mexico” through the 
development of a cost-effectiveness analysis.   
  
  
262 
 
- Led the team on conceptual planning, model inputs gathering, and data 
manipulating 
 Initiated “Disease Prevention Micro-simulation Model” to forecast disease burden 
- Preliminarily explored and analyzed NHANES data using regression techniques 
August 2009 – May 2012: 
Teaching Assistant 
School of Pharmacy, Virginia Commonwealth University 
 Delivered lectures on health insurance, managed care, and pharmacy benefit management 
to Class of 2014-2015 pharmacy students  
 Supervised pharmacy lab counseling and case presentations 
May 2008 - August 2008: 
Research Assistant 
Pharmaceutical System Research & Intelligence Center (PSyRIC), Thailand 
 Assisted the development of educational drug information website for patients 
and healthcare providers: yaandyou.net 
January 2007 - December 2007: 
Pharmaceutics Research Principle Investigator                     
Chulalongkorn University, Thailand 
 Senior Project: “Formulation of Andrographolide Oral Fast-Dissolving Strips” 
November 2003 - March 2008: 
English Tutor 
Wayama Tuition Center, Bangkok, Thailand           
 Tutored English to students in grades 5-11 and to 12th grade students 
for preparation to take the national entrance examination (classes of 10-15 students) 
Publications & Presentation 
Inocencio TJ. Seetasith A, Newland A, Bose P, Holdford DA. International Society for 
Pharmacoeconomics and Outcome Research 17
th
 Annual International Research Meeting, 
Washington DC, June 4-6, 2012 
 Poster Presentation: Cost-effective Analysis of Nilotinib compared to Imatinib for Newly 
Diagnosed Chronic Myeloid Leukemia (CLM) in Chronic Phase 
  
  
263 
 
Zhang JX, Seetasith A, Szymanski KA. AcademyHealth Annual Research Meeting, Seattle, 
WA, June 12-13, 2011 
 Poster Presentation: Insurance Mix and Quality of Care in Elderly Medicare Beneficiaries 
with Diabetes: What are the Opportunities and Challenges for Improvement? 
Seetasith A, Zhang JX. International Society for Pharmacoeconomics and Outcome Research 4
th
 
Asia-Pacific Conference, Phuket, Thailand, September 6-7, 2010  
 Poster Presentation: A Difference-in-Differences Analysis of the Offsetting Effect of 
Statins on Non-Pharmacy Medical Resource Utilization among Patients with Diabetes in 
the US.  
Zhang JX, Seetasith A. International Health Economics Association 6
th
 World Congress, 
Beijing, China, July 12-15, 2009  
 Podium Presentation: Insurance Status, Out-of-Pocket Payment, and Drug Utilization in 
patients with Diabetes in the US.  
Seetasith A, Zhang JX. AcademyHealth Annual Research Meeting, Chicago, IL, June 28-30, 
2009  
 Poster Presentation: Racial Disparities and Out-of-Pocket Payment in Drug Utilization in 
Patients with Diabetes in the United States. 
 Developed a manuscript for publication in a peer-review journals (work-in-progress) 
Seetasith A, Zhang JX. International Society for Pharmacoeconomics and Outcomes Research 
14
th
 Annual International Meeting, Orlando, FL, May 16-20, 2009  
 Podium Presentation: Racial Disparities and Barriers to Drug Utilization in Patients with 
Diabetes in the United States. 
Professional Honors 
August 2012 – December 2012: 
Dissertation Assistantship Award Recipient                 
Graduate School, Virginia Commonwealth University 
May 2011: 
Annual Student Research Competition Champion              
International Society for Pharmacoeconomics and Outcomes Research, 16
th
 Annual International 
Meeting, Baltimore, Maryland 
  
  
  
264 
 
September 2010: 
Best Student Research Poster Award Finalist                   
International Society for Pharmacoeconomics and Outcome Research, 4
th
 Asia-Pacific 
Conference, Phuket, Thailand 
August 2008 - May 2009: 
Pharmaceutical Economics and Policy (PEP) Program Graduate Fellowship Recipient             
School of Pharmacy, Virginia Commonwealth University 
June 2009: 
AcademyHealth Disparities Interest Group Emerging Scholar Award Recipient 
The Robert Wood Johnson Foundation, AcademyHealth Annual Research Meeting, Chicago, 
Illinois 
May 2009: 
Best Student Research Podium Presentation Award Recipient 
International Society for Pharmacoeconomics and Outcomes Research, 14
th
 Annual International 
Meeting, Orlando, Florida 
Pharmacy Profession Training 
January 2008 – February 2008: 
Cosmetic R&D and Regulatory Affairs trainee                         
Beiersdorf (Thailand) Co., Ltd., Samutprakarn, Thailand       
 Prepared product claim documents for FDA approval submission 
April 2007 – May 2007: 
Production, R&D, and Quality Assurance trainee                  
Greater Pharma Manufacturing Co., Ltd., Nakhon Pathom, Thailand 
 Collaborated with industrial pharmacists and scientists in formulation development, 
production, and quality control of drug products 
March 2007 – April 2007: 
Clinical Pharmacist trainee                  
Phetchaboon Hospital, Phetchaboon, Thailand 
 Assisted clinical pharmacists on their rounds, counseling, dispensing, and in-house drug 
product compounding  
  
  
265 
 
2004 – 2006: 
Community Pharmacist trainee 
Huay Kwang Community Health Center, Osot Sala at Chulalongkorn University, Keew Makok 
Drug Store, and Drug Mart, Bangkok, Thailand 
 Help community pharmacists in diagnosing and drug dispensing 
 Learned about independent pharmacies’ business models and strategies  
Leadership 
October 2005 – September 2006: 
Vice President                
Pharmacy Volunteer Club, Chulalongkorn University, Bangkok, Thailand 
January 2002 – December 2002: 
Funding Director 
Interact Club, Anglo-Chinese Junior College, Singapore                   
Professional Organization 
Member since 2008: 
The Pharmacy Council of Thailand                  
International Society for Pharmacoeconomics and Outcome Research (ISPOR)         
Research Knowledge & Skill 
International pharmaceutical P&R and policy analysis 
 Experienced in international regulatory and pricing and reimbursement process including 
HTA reviews in US, UK, EU5, and BRIC-MT 
 Well-versed in clinical guidelines and landscape assessment of various disease areas 
including mental health, neurology, oncology, and cardiovascular disease 
 Familiarized with advocacy strategic planning and primer development  
Pharmacoepidemiology  
 Expert in the analysis of prevalence using ICD-9-CM codes, cost estimations, drug 
utilization, and quality of care 
 Skilled in Medicare Physician Fee Schedules and Facility Fees calculation 
  
  
  
266 
 
Pharmacoeconomics  
 Proficient in MS Excel-based Markov and semi-Markov modeling of cost-effectiveness 
analysis  
Databases 
 Competent user of claims data, electronic medical records datasets, and large and 
nationally representative databases including Medical Expenditure Panel Survey (MEPS), 
Medicare Current Beneficiaries Survey (MCBS), Medicare claims data, National 
Ambulatory Medical Care Survey  (NAMCS, NHAMCS), National Health and Nutrition 
Examination Survey (NHANES), Cerner Health Solution’s ERM  
Statistical Software 
 Experienced user of SAS, Stata, JMP, SPSS, and Microsoft Office Excel 
Statistical Methods 
 Knowledgeable in various statistical modeling such as linear regression, logistic 
regression, generalized linear model, difference-in-differences analysis 
Systematic Literature Review 
 Trained in targeted literature search and network meta-analysis 
Others 
 Familiarized with healthcare micro-simulation modeling  
 Strong commanding in deliverable development and professional conference presentation 
skills            
Languages 
Fluent in English and Thai 
 
 
